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Abstract
(1) The potent vasoconstrictor endothelin-1 (ET-1) Is thought to regulate pulmonary 
blood flow and play a role in the aetiology of pulmonaiy hypertension (PHT), as well as 
in the transition of the pulmonary circulation from fetal to neonatal life. Responses to 
ET-1, and the receptor subtypes involved, were studied in isolated pulmonary resistance 
arteries (PRAs) from a rabbit coronary ligation model of left ventricular dysfunction 
(LVD), and also from fetal and neonatal rabbits.
(2) The rabbit coronaiy ligation model of LVD displayed right ventricular hypertrophy 
and significant increase in lung weight in animals with coronary artery ligation for 8 
weeks compared to age matched sham-operated animals. Also consistent with the 
development of PHT was significant structural alteration demonstrated in the pulmonary 
vasculature of the LVD group animals. Small muscular pulmonary arteries were studied 
8, 16 and 32 weeks after coronary artery ligation or sham operation.
(3) In the rabbit coronary-ligation model, investigation of ET-receptor mediated 
responses showed an agonist potency profile, according to ^EC^o values, of SXS6c > 
ET-3 = ET-1 in all PRAs from all 8, 16 and 32 week procedure groups. This is 
indicative of a predominant role of contractile ETb receptor subtypes in these vessels.
(4) ET receptor subtypes in this preparation were examined further with the use of 
several selective antagonists. The results demonstrated a biphasic response to ET-1 in all 
vessels. In sham-operated rabbit PRAs, the shallow component of the response at lower 
ET-1 concentrations was resistant to the effects of the non-selective ETa/ETb receptor 
antagonist SB209670 but sensitive to BQ788, a selective ETg receptor antagonist. The 
steeper component of the ET-1 response, obseiwed at higher peptide concentrations, was 
resistant to BQ788 but sensitive to SB209670. These differential effects of the 
antagonists may provide evidence for a heterogeneous population of ET g -like-receptors. 
Furthermore, competition radioligand binding studies in rabbit pulmonary artery 
membranes provided a best fit for a two-site model, thus indicating the existence of two 
distinct ET receptor populations in this preparation. Ki values of 6.43 x10"14m and 4.43
in
x10-10m  were calculated for the first ultra-high affinity site and the second high affinity 
site respectively.
In PRAs from 8 week coronary-ligated animals, responses to ET-1 
concentrations less than InM were potentiated iii the presence of BQ788 and SB209670. 
This suggests that, with the development of PHT secondary to LVD, the BQ788- 
sensitive-receptor-mediated response has changed in that it is now potentiated by both 
BQ788 and SB209670; thus may indicate an alteration in the contribution of ETb 
receptor subtypes in this model. FR139317 did not inhibit ET-1-induced responses in 
any PRAs. Indeed this selective ETa antagonist tended to augment the ET-1 responses; 
this was apparent at higher ET-1 concentrations in sham-operated rabbit PRAs and was 
also obseiwed at lower ET-1 concentrations in vessels from LVD animals. Hence ET-1 
does not appear to be acting at a typical ETa receptor and suggests the presence of a 
putative inhibitory ETa receptor, which may have a greater role at lower, 
pathophysiologically relevant ET-1 concentrations in PRAs from coronary-ligated 
animals.
(5) The role of intracellular cyclic nucleotides was examined in pulmonary arteries from 
the rabbit coronary ligation model. Basal levels and ET-1-induced levels of cGMP 
tended to be greater in 8 week coronary-ligated preparations compared to sham-operated 
vessels. Similarly, basal and forskolin-stimulated levels of cAMP tended to be greater in 
arteries from LVD animals compared to control preparations. Unfortunately however, 
due to the variability noted between tissues in individual groups and lack of statistical 
significance, no definite conclusions can be made regarding the involvement of cAMP 
and cGMP in this preparation.
(6) The influence of NO on ET-receptor mediated responses was examined in PRAs 
from the rabbit coronary-ligation model. The nitric oxide synthase inhibitor L-NAME 
caused a marked potentiation in responses to ET-1 and SXS6c in PRAs from rabbits 
with LVD but not in vessels from age-matched control animals. The increase in 
sensitivity to these peptides was most pronounced in the 8 week group, was still evident 
in vessels from 16 week coronary-ligated rabbits whereas in the 32 week LVD group,
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was no longer evident. These results suggest an increase in NO production associated 
with the development PHT in these animals. This may represent an early compensatory 
mechanism in response to elevation in pulmonary pressure with LVD. In addition, the 
potency of SNP, the endothelium-independent relaxatory agent, was significantly 
reduced following 8 week of coronary-artery ligation. This may be related to reduced 
NO sensitivity of the vascular smooth muscle in the face of increased NO production.
(7) KCl-induced responses were similar in all isolated pulmonary resistance arteries 
(PRAs) from 8, 16 and 32 week control and experimental groups, indicated the integrity 
and contractility of the vascular smooth muscle. 5-HT had a similar potency in 
stock/sham-operated rabbit PRAs and in preparations from LVD rabbits both after 8 and 
32 weeks of coronary artery ligation. However, the magnitude of the maximal response 
to 5-HT and the 5-HTid  receptor agonist sumatriptan was decreased in the 8 week 
ligated compared to sham-operated group, whilst the non-selective 5-HTi receptor 
agonist 5-CT evoked similar responses in both groups. These findings indicate a 
functional population of 5-HTi-like receptors in this preparation, and a possible 
alteration in 5-HTiD-like receptors which may occur in the PHT state secondary to LVD 
in these animals.
(8) The potency of ET receptor agonists was altered with developmental age in isolated 
rabbit PRAs. In particular, there was a hypersensitivity to contractile ETg-receptor 
stimulation in PRAs from newborn rabbits. The potency of ET-1 was similar (pECso 
-8.7) in fetal, 0-24 hour and 4 day old rabbit PRAs. These were all significantly more 
sensitive to ET-1 than vessels from 7 day old rabbits, which in turn, had similar 
sensitivity to adult rabbit PRAs (pECgo ~8.0). According to y^ECjo values, the order of 
potency for SXS6c was 7 days = 4 days > 0-24 hours > fetal rabbit PRAs. The ^ECso 
for SXS6c in 7 day vessels was -11.1 and this was markedly greater than that noted in 
adult PRAs, -8.6. The magnitude of SXS6c-induced vasoconstriction was significantly 
greater at 0-24 hours and 4 days after birth, compared to other age points studied.
(9) BQ788 inhibited ET-1-induced responses in PRAs from fetal, 0-24 hour and 4 day 
old rabbits but, as was noted in the adult vessels from the rabbit coronary ligation model.
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was ineffective against ET-1 responses of 7 day old preparations. FR139317, inhibited 
ET-1 induced responses of 0-24 hour and 4 day old rabbit PRAs, however was 
ineffective against these responses in fetal and 7 day old vessels, thus similar to that 
noted in adult PRAs. These differential antagonist results indicate that in the fetus and 
newborn less than 7 days old, antagonism of either ETa or ETb receptor alone is 
sufficient to inhibit ET-1 mediated responses, whereas with increasing age, blockade of 
both receptors is necessary. Thus "crosstalk" between ET-receptor subtypes may 
develop in this preparation later than 4 days after birth.
(10) In rabbit PRAs, the ability of noradrenaline (NA) to evoke vasoconstriction was 
greatest 0-24 hours after birth, it then decreased during the first week of life and was 
non-existent in adulthood. Alterations in vasodilator responses to acetylcholine (ACh) 
were also obsei*ved. These increased with the transition from fetal to newborn state and 
maximal endothelium-dependent relaxatory responses were evident in PRAs from 4 and 
7 day old rabbits. In comparison, ACh evoked a vasoconstrictor response in adult PRAs.
(11) The influence of L-NAME on ET-receptor mediated responses was also examined 
in PRAs from fetal and neonatal rabbits. The most pronounced effects were shown in 
vessels from 7 day old rabbits, where L-NAME potentiated responses to ET-1. This 
finding, together with the greatest vasodilator response to ACh being obseiwed in the 7 
day vessels, suggests increased NO level in the 7 day old compared to the newborn 
preparation, and suggests that sensitivity to ET-1 is normally reduced by NO in these 
neonatal vessels. In comparison, the lack of effect of L-NAME on ET-1- and SXS6c- 
induced responses of fetal PRAs provides evidence for diminished NO levels in the 
pulmonary vasculature in fetal compared with neonatal life.
(12) ET-1 was equipotent in human PRAs and in adult rabbit PRAs of a similar internal 
diameter. The response to lower ET-1 concentrations were inhibited by BQ788, 
indicating the involvement of vasoconstrictor ETb receptors. A markedly greater 
antagonism of ET-1-induced contraction was evident with SB209670. This suggests that 
ETB2“like receptors of human PRAs are not as sensitive to the prototypical ETb receptor 
antagonist BQ788 as they are to the non-selective antagonist SB209670.
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Chapter 1 
Introduction and Literature Review
Introduction to Research
Extensive morphological and functional studies of the pulmonary circulation 
over the last five decades have demonstrated the strikingly complex systems for the 
regulation of blood flow in the lung and its numerous important non-respiratory 
functions. This refutes earlier notions which regarded the pulmonary circulation as 
merely a passive conduit for the purpose of gas exchange of the continual flow of blood. 
Likewise, the vascular endothelium can no longer be regarded as only a selective barrier. 
The vast amount of evidence for the endothelium's paracrine and autocrine function, by 
its ability to release vasoactive agents, highlights a ciucial role in the understanding of 
local mechanisms of vascular tone in both the systemic and pulmonary circulation, and 
in both health and disease.
My research has focused on the vascular reactivity of pulmonary resistance 
arteries and in particular on the role of endothelin, a potent endothelium-derived peptide. 
Of the vast amount of previous in vitro studies already carried out on the pulmonary 
circulation, the majority of these have been on relatively large calibre pulmonary 
vessels. There has been comparatively little investigation of the small pulmonary 
arteries yet indirect evidence suggests that they may have an important role in the 
control of pulmonary vascular tone (e.g. Leach, et al, 1989; Leher & Bevan, 1985). In 
addition, Leach et al (1992) demonstrated a number of important differences between 
the responses of large (1-2 mm internal diameter) and small (100-300|_im internal 
diameter) pulmonary arteries to various agents. Thus it may be unwise to extrapolate 
from results obtained in either large pulmonary artery preparations or in perfused lungs 
to what may occur in the functionally important resistance arteries. In addition, using a 
vascular occlusion technique ET-1 has been shown to preferentially increase small 
artery resistance in the intact lung, and ET-receptor mediated responses have been 
demonstrated to vary depending on the pulmonary artery size in vitro (Barnard, et a l, 
1991; MacLean, et a l ,  1994). Hence taking these findings into consideration, 
characterisation of vascular reactivity in pulmonary resistance arteries is of great 
importance.
The physiology and pharmacology of endothelin and its role in the pulmonary 
circulation is reviewed in sections 1.4 and 1.5, respectively, of this introduction. The 
vascular responsiveness of pulmonary resistance arteries was investigated under two 
different states; (i) in the transition from fetal to neonatal life and (ii) secondary to left 
ventricular dysfunction and in the transition to right ventricular dysfunction. Before we 
can examine the pulmonary vasculature in transitional states it is important to 
understand the pulmonary circulation which exists under normal conditions.
1.1 The Pulmonary Circulation
The adult pulmonary circulation is characterised as a low pressure, low 
resistance vascular bed that accommodates the entire cardiac output of the right ventricle 
to the gas exchanging surface at less than 20% of the systemic vascular pressure. 
Vasodilators have little or no effect on the pulmonary vascular pressures suggesting that 
under nonnal conditions, there is little or no resting vascular tone (Fishman, 1985). The 
pulmonary vasculature is highly compliant and this prime feature, along with capillary 
recruitment, ensures maintenance of low pressure even in the face of increased flow rate, 
such as increased cardiac output during exercise. This ensures that the perfusion 
pressure of the lungs always remains low and that the thin walled right ventricle is not 
stressed.
From the extensive studies of the pulmonary circulation of many species 
including man over numerous decades, a vast amount of information is now available on 
its various aspects. However, since I primarily examined the pulmonaiy resistance 
arteries of the rabbit in this thesis, I will focus this literature review on the pulmonary 
vasculature of this species where appropriate.
1.1.1 Functions of the Pulmonarv Circulation
The continual flow of the cardiac output through the lungs is essential for the 
purpose of gas exchange. Deoxygenated blood is delivered, via the pulmonary arterial 
system, to sheets of pulmonary capillaries in the alveoli to allow gas exchange to occur.
The oxygenated blood returns to the left side of the heart via the pulmonaty venous 
system. Moreover, it has become more clear in recent years that the pulmonaiy vascular 
bed is the site also of many non-respiratory functions including vital metabolic 
processes. The pulmonary microvasculature represents an enormous surface area for 
processing of circulating vasoactive substances (Vane, 1969). Several mediators 
including noradrenaline (NA), 5-hydroxytryptamine (5-HT) and endothelin (ET) are 
removed from the blood upon passing through the pulmonary vasculature (Albaster & 
Bakhle, 1970; Said, 1982; De Nucci, et a l, 1988). In addition, pulmonary endothelial 
cells contain angiotensin converting enzyme, which catalyses formation of AIT and 
degrades bradykinin (Johnson & Erdos, 1977; Said, 1982).
1.1.2 Structure of the pulmonarv arterial system
The main pulmonary trunk leaving the right ventricle passes upwards through the 
heart and rapidly divides into two daughter branches. The left pulmonary artery extends 
to the hiium of the left lung where it divides into two branches, one passing to each lobe. 
The right pulmonary artery divides into two branches also, the larger of which extends 
to the middle and lower lobes, and the smaller to the upper lobe of the right lung. The 
pulmonary arteries form a rapidly branching structure with daughter branches occurring 
generally at the distal end of the parent vessels although an arteiy may have a number of 
side branches often coming off at right angles to the parent branch. Most of the 
pulmonaiy arteries follow the branching pattern of the airways. Singhal et al. (1973) 
estimated 17 orders in the human pulmonary arterial tree. The pulmonary arteries from 
the main trunk down to a diameter of approximately 1 mm have the stmcture of typical 
conducting arteries with a media consisting of several elastic laminae with a small 
quantity of interposed smooth muscle, a thin intima and a thick adventitia. These have 
been defined as elastic pulmonary arteries. With continued branching of the human 
pulmonary arterial tree, the number of elastic fibrils gradually decreases and as the 
arteries diminish in size the proportion of muscle in the media and its thickness relative 
to diameter increases (Daly & Hebb, 1966). The predominantly muscular arteries (100
iam-1 mm internal diameter (i.d.)) accompanying the terminal bronchioles have four to 
six layers of obliquely arranged smooth muscle cells bound by distinct internal and 
external elastic laminae (Brenner, et al, 1935; Heath & Edwards, 1958). At the level of 
the respiratory bronchioles, this layer is abruptly reduced and the more distal branches 
are only partially muscular or non muscular (Heath & Edwards, 1958; Meynick & Reid, 
1983). In the human lung, pulmonary arterioles can generally be classed as arterial 
vessels less than lOOqm i.d. (Brenner, 1935). These vessels consist of a single elastic 
lamina, with extremely sparse smooth muscle (Heath & Edwards, 1958); this is the 
region most significantly affected in pulmonary hypertension and this is discussed in 
section 1.3.1 of this introduction. At the level of the respiratory bronchioles, the 
arterioles give off one branch to each alveolar duct and this divides into an number of 
smaller arterioles which supply capillaries to the alveolar sac in which the duct 
terminates.
Considerable variation in the structure of the pulmonary vessels exists not only 
between species (Kay, 1983) but also within species (Heath & Williams, 1981). In 
general the stmcture of the pulmonary arteries is similar in man, monkey and ferret with 
most other mammals demonstrating more muscular pulmonary arteries (Kay, 1983). In 
the human pulmonary vasculature, vessels below 100 jam i.d. are normally non 
muscular, whereas in some animals muscular pulmonaiy arteries can extend to vessels 
smaller than 100 |_im i.d.. The pulmonary arteries of the rabbit have a consistently thick 
muscle coat although in some places it is much thicker than in others (Daly & Hebb, 
1966).
1.1.3 Pulmonarv Pressures and Vascular Resistance
The pulmonary circulation is a low pressure system. In humans, the systolic 
pulmonary arterial pressure averages approximately 22 mmHg, the diastolic pulmonary 
arterial pressure approximately 8 mmHg and the mean arterial pressure 13mmHg. This 
low pressure condition is associated with the stmctural characteristics of the pulmonary 
arteries, which have a luminal diameter significantly larger than systemic arteries of the
same size. Despite equal blood flow rates, the mean pulmonaiy arteri al -to -v enou s 
pressure difference is about one-tenth that in the systemic circulation, hence the 
pulmonary vascular resistance (PVR) is approximately one-tenth of the total (systemic) 
peripheral resistance (Fishman, 1985). In the systemic circulation the arterioles represent 
70% of the resistance to blood flow. In contrast an even distribution of PVR throughout 
the lung is indicated by the similar pressure drop occurring across the arterial, capillary 
and venous beds. However, evidence from morphometric studies in human lung 
suggests small muscular pulmonary arteries (100 p.m-1 mm i.d.) and arterioles (<100 
pm i.d.) as being the major sites of PVR (Horsefield, 1978; Singhal, 1973), particularly 
in PHT.
1.1.4 Regulation of low pressure vascular tone
The pulmonary circulation is under the control of both active and passive factors 
(Daly & Hebb, 1966). Active factors alter pulmonaiy vascular resistance and tone by 
causing contraction or relaxation of vascular smooth muscle. These factors include 
autonomic nerves, humoral factors, and gasses. Passive factors include changes in 
airway and interstitial pressure, gravitational force, and vascular obstmction or 
reciuitment. Alterations in cardiac output and left atrial pressure are also passive factors 
that influence pulmonary vascular pressure. These variables in particular are of 
important consideration in the pulmonary circulation in conditions of heart 
abnormalities; this is discussed in section 1.3.2.2. Passive factors change pulmonary 
vascular resistance and/or blood flow independently of the changes in vascular tone. I 
study both active and passive factors. Active regulation by oxygen is studied at birth and 
the passive effect of left atrial pressure is studied in the rabbit model of left ventricular 
dysfunction.
1.1.4.1 Neural regulation
The autonomic nervous system may modify the pulmonary blood flow under 
physiological conditions and may be involved in the pathophysiology of pulmonary
vascular diseases. The pulmonary vasculature is innervated primarily from the anterior 
and posterior pulmonary plexi (Downing & Lee, 1980). The density and type of 
innervation appears to be strongly species dependent and varies with the location and 
size of the vessel (Downing & Lee, 1980, Barnes & Liu, 1995). In general it would 
appear that extrapulmonary arteries and large muscular pulmonary arteries are more 
densely innervated, whereas the smaller pulmonary arteries and arterioles tend to have 
sparse innervation. However, some species including rabbit (Cech & Dolezel, 1967) and 
man (McLean, 1986), have an extensive and dense adrenergic innervation, which 
extends to arteries < 70p.m and < 60f,im outer diameter, respectively. The pulmonary 
circulation receives little cholinergic input compared with adrenergic innervation. Again 
there is a marked species-dependent variation in the distribution of cholinergic neiwe 
fibres. Pulmonary arteries of the rabbit are extensively inneiwated with AChE-positive 
nerve fibres which extend down to arterioles (Barnes & Liu, 1995). Stimulation of 
sympathetic (adrenergic) nerve fibres in the pulmonary vasculature mediates 
predominantly vasoconstrictor responses, whereas stimulation of parasympathetic 
(cholinergic) nerve fibres mediates vasodilation (Downing & Lee, 1980; Barnes & Liu, 
1995). Muscarinic and adrenergic receptors are heterogeneous and the receptor subtypes 
on vascular smooth muscle seem to have a variable regional distribution, this factor 
along with the level of pre-existing tone will determine the overall effect, i.e. 
vasoconstriction or vasodilation (Hyman & Kadowitz, 1988; 1989). The contribution of 
autonomic innervation to basal tone is uncertain, but may be involved during conditions 
of stress (Fishman, 1985).
1.1.4.2 Humoral regulation
Many circulating mediators and hormones have effects on pulmonaiy vascular 
tone that are mediated via multiple receptors, and vary with species, age, and pre­
existing tone (Barnes & Liu, 1995). To name a few agents, in general. All, 
thromboxane, and prostaglandins (PGs) Dz, Eg and Fga? are pulmonary vasoconstrictors, 
whereas ANP and PGs E% and Ig are pulmonary vasodilators. Mediators such as
bradykinin, histamine, substance P, 5-HT, arachadonic acid and endothelins have dual 
effects on the pulmonaiy vascular tone, generally causing contraction when vascular 
tone is low but relaxation when vascular tone is high.
1.1.4.3 Endothelial regulation
Despite intensive research carried out over many years, the factors that maintain 
low pulmonaiy vascular tone remain enigmatic. It seems increasingly likely, however, 
that the state of tone of vascular smooth muscle depends on endothelial factors.
It has been widely demonstrated that the endothelium plays an important role in 
both short- and long-term regulation of vascular homeostasis as well as in the 
modulation of several physiological functions, including inflammation, platelet 
aggregation, fibrinolysis and angiogenesis. The vascular endothelium also participates in 
the metabolism of blood-borne compounds such as 5-HT. Endothelial cells synthesise 
and release a great variety of paracrine substances which have vasoactive properties. 
Among these are the vasoconstrictor factor endothelin, endothelium-derived relaxing 
factor (EDRF), endothelium-derived hyperpolarising factor (EDHF), arachadonic acid 
(AA) metabolites, the prostaglandins and leucotrienes. Endothelium-derived factors can 
have profound influences on vascular tone in both the systemic and pulmonary 
vasculature (Luscher, et al,  1989). In keeping with the nature of the studies shown in 
this thesis, I will focus on the role of EDRF and endothelin in particular. This latter 
endothelial derived peptide and its role in the pulmonary circulation is introduced in 
sections 1.4 and 1.5.
EDRF is a diffusible factor discovered by Furchgott and Zawadski in 1980 when 
they demonstrated acetylcholine (ACh)-induced relaxations in rabbit isolated aortic 
strips were dependent upon an intact vascular endothelium. Ignarro et a l  (1987a) 
suggested that EDRF is nitric oxide (NO), based on pharmacological similarities 
between EDRF and NO generated from either acidified NOg“ or NO gas. Evidence now 
strongly supports the identification of EDRF as NO (Moncada, et al, 1991; Nathan, 
1992). Many substances including bradykinin, substance P, 5-HT and histamine were
also shown to mediate vasodilation via the release of EDRF (NO) (Luscher, 1989; 
Furchgott, 1990).
NO is synthesised by a number of cells from the terminal guanidino nitrogen 
atom of L-arginine in the presence of molecular oxygen to yield L-citrulline and NO, by 
means of either constitutive (cNOS) or inducible (iNOS) NO synthases (Palmer, et al, 
1987; Angus & Cocks, 1089; Palmer & Moncada, 1989). Three isoforms of this enzyme 
have been identified and named isoform I, II, and III; I and III are constitutively 
expressed, whilst II is induced by bacterial lipopolysaccaride and cytokines (Marin & 
Rodriguez-Martinez, 1995). cNOS was first described in vascular endothelium and in 
neurones but has also been detected in other cell types (Palmer & Moncada, 1989; 
Mayer, et al, 1989), whilst iNOS is primarily located in macrophages and neutrophils 
(Marietta, et al, 1988; Moncada, et a l ,  1991). cNOS is strongly regulated by 
calcium/calmodulin, is continually expressed, and once activated will produce picomolar 
amounts of NO until calcium levels decrease (Moncada, et al, 1991). In contrast, iNOS 
is regulated at the level of transcription, requiring the action of inducers such as 
cytokines for expression, and is calcium independent (Moncada, e ta l ,  1991). After 
induction iNOS remains active for 4-24 hours, yielding nanomolar concentrations of 
NO, 100 fold greater than those of cNOS. The synthesis of NO is stereo-specifically 
inhibited by various L-arginine analogues which act as competitive inhibitors of NOS, 
such as L-N®-arginine methyl ester (L-NAME) (Rees, e ta l ,  1990). In addition to 
chemical activation, physical forces such as pulsatile flow and sheer stress mediate 
EDRF production (Tesfamariam & Halpern, 1987; Tesfamariam & Cohen, 1988).
Figure 1.1 schematically summarises endogenous NO production and illustrates 
the interaction between endothelial cell and smooth muscle cell in effecting 
vasorelaxation. Upon release NO diffuses freely through the endothelial cell to the 
smooth muscle where it activates soluble guanylate cyclase, stimulating the production 
of cyclic 3*, 5' guanosine monophosphate (cGMP) from guanosine-5'-triphosphate (GTP) 
(Ignarro, 1989). cGMP is hydrolysed by cGMP-specific phosphodiesterase enzymes 
(PDEs) to inactive metabolite 5'GMP (see also section 1.1.4.4). Moreover, recent work
has demonstrated that NO may have a direct effect on the smooth muscle cell, 
independent of guanylate cyclase activation (Bolotina, et al, 1994).
agonistSheer stress
Endothelial Cell
L-citr. + NOL-arg + 20
GC > -  VASODILATIONcGMP
PDE
5'GMP,GTP
Smooth muscle cell
Figure 1.1 Simplified illustration of formation of endogenous NO and mechanism of 
action. See text for details. R=receptor; L-arg=L-arginine; L-citr.=L-citrilline; 
cNOS=constitutive NOS; GTP=guanosine-5'-triphosphate; GC=soluble guanylate 
cyclase enzyme; cGMP-cyclic 3' 5' guanosine monophosphate; PDE=phosphodieterase 
enzyme(s); X=see section 1,1.4.4 for possible mechanisms of action.
The activity of NO is short lived, approximately 3-30 seconds, and decomposes 
rapidly to form mixtures of nitrate and nitrite in oxygenated solutions (Tolins, et al,
1991). The short half life of NO in plasma is reflective of the existence of several 
reactants in the plasma milieu that causes inactivation, including haemoglobin and 
superoxide anions (Moncada, et al, 1991). In accordance with the interaction between 
NO and superoxide anion, Rubanyi and Vanhoutte (1986) demonstrated that the half life 
of NO was prolonged in the presence of superoxide dismutase (SOD), a scavenger of 
superoxide anions.
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1.1.4.4 Intracellular cyclic nucleotides
Cyclic nucleotides are important in the regulation of pulmonary vascular tone. 
Vasoactive compounds can stimulate or inhibit the activity of the enzymes adenylate 
cyclase or guanylate cyclase, there by altering intracellular concentrations of cAMP and 
cGMP, respectively, and these second messengers in turn can regulate pulmonary 
vascular tone. cGMP is the key second messenger of NO-induced pulmonary 
vasodilation (see section 1.1.4.3), whereas cAMP plays a central role in the pulmonary 
vasodilator response to many direct acting vasodilator agents, including P-adrenoceptor 
agonists, PG1% and vasoactive intestinal polypeptide (VIP). Exogenous cGMP and 
cAMP themselves are potent pulmonary .vasodilators (Haynes, e ta l ,  1992; McMahon, 
et a i ,  1992; 1993). Ignarro et al  (1987b) demonstrated a basal level of cGMP in 
isolated bovine endothelium-denuded pulmonary artery rings.
The mechanisms underlying cGMP- and cAMP-induced vasodilations are 
incompletely understood. Nevertheless, evidence suggests that cGMP mediated 
relaxations are related to activation of protein kinase G, inhibition of IP3 , 
dephosphorylation of myosin light chain kinase, stimulation of Ca^'^'-ATPase, opening 
of K+ channels, and inhibition of Ca^+ influx (Lincoln, 1989). Likewise several 
mediators may mediate cAMP-induced vasorelaxations, including activation of cAMP- 
dependent protein kinase, thus resulting in a reduced myosin light chain kinase activity, 
inhibition of Ca^ "*" influx, stimulation of Ca^ "*" efflux, and opening of Ca^+-dependent K+ 
channels (Murray, 1990). Cells inactivate cyclic nucleotides by the action of the 
enzymes phosphodiesterases (PDEs). At present there are over 30 recognised PDE 
isoforms which, on the basis of their amino acid sequence, substrate specificity and 
sensitivity to phaimacological agents, can be classified into seven main families (Beavo, 
et al,  1994). cAMP and cGMP are degraded by PDE-mediated hydrolysis to the 
corresponding 5' nucleotide.
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1.1.4.5 Regulation by respiratory gasses
The relative composition of the respiratory gas has a profound effect on 
pulmonary vascular tone, with both hypoxia and hypercapnia inducing pulmonary 
vasoconstriction (Fishman, 1961). The phenomenon of hypoxic pulmonary 
vasoconstriction (HPV) was first described by Von Euler and Liljestrand (1947) and is 
unique to the pulmonary vasculature; a vasodilator response to hypoxia is noted in the 
systemic circulation. This pulmonary response is of great physiological importance in 
both fetal and adult life. In the fetus HPV, which exists due to the relatively hypoxic 
conditions in utero, acts to divert blood away from the as yet non functioning lungs (see 
section 1.2.1). Whilst in the adult lung, HPV functions to redirect circulating blood away 
from less well ventilated (hypoxic) alveoli toward better ventilated areas of the lung, 
thus optimising the matching of ventilation and perfusion and maximising arterial 
oxygenation. Mixed venous PO2 contributes to HPV however, the main stimulus seems 
to be alveolar hypoxia (Marshall & Marshall, 1983). Pulmonaiy arteries of different 
sizes exert HPV though most investigators have concluded that the small muscular 
pulmonary arteries are the major site of HPV. For example, Nagasaka et al  (1984) 
demonstrated by direct micropuncture measurements of intrapulmonary vascular 
pressure, that the predominant site of HPV is the precapillary arteries in the hypoxic cat. 
Despite many years of investigation, the mechanism(s) responsible for HPV remains 
controversial, with evidence both for and against (i) reduced release of relaxants from 
endothelial cells, (ii) via release of mediators from other cells and (iii) by a direct effect 
of hypoxia on the smooth muscle cell, being reported (Voelkel, 1986).
An acute hypoxia produces a HPV which is maintained only for the duration of 
the stimulus. However, the HPV reflex appears to be malign following a chronic 
exposure to hypoxia as it is maintained even upon return to normoxia (see also section 
1.3.4 (i)).
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t .2 The pulmonary circulation of the fetus and neonate
1.2.1 Fetal pulmonarv circulation
The fetal pulmonary circulation exists as a high-resistance, low-flow circuit, 
accepting less than 10% of the combined ventricular output. This unique physiologic 
state ensures sufficient pulmonary blood flow to provide for lung growth and 
development, yet allows blood to shunt right to left to perfuse the placenta, the fetal 
organ of gas exchange. The lungs do not have a physiological role apart from possible 
metabolic functions which include secretion and activation of hormones and degradation 
of active agents. Most of the systemic and venous and umbilical venous blood returning 
to the heart is shunted through the foramen ovale to the left atrium and ventricle, and 
approximately 85-90% of the blood ejected by the right ventricle flows through the 
ductus arterious directly from the pulmonary trunk to the descending aorta, thus 
diverting the lungs (Rudolph, 1979). The low fetal pulmonary blood flow has been 
explained on the basis of a high pulmonaiy vascular resistance. In fetal lambs, calculated 
pulmonary vascular resistance was shown to be extremely high at 6 mmHg/ml/min at 
0.4 gestation and fell progressively to 0.3-0.35 mmHg/ml/min at term (Rudolph, 1977). 
This decrease in pulmonary vascular resistance presents a 17-20 fold increase in the 
cross sectional area of the pulmonary vascular bed. This appears to result from a 
decrease in the resting vascular vasoconstriction and an increase in individual vessel 
diameter and growth of new vessels.
The mechanisms that maintain vasoconstriction in utero and permit vasodilation 
after birth are not fully understood. The pulmonary vasoconstriction in the fetal lung has 
been related to the phenomenon of hypoxic pulmonary vasoconstriction, due to the low 
p0 2  of blood perfusing the lungs (see section 1.1.4.5), autonomic nervous influences, 
and circulating hormones (Randolph, 1979). Maintenance of high resting tone also 
reflects a different "balance", compared with the postnatal lung, between vasoconstrictor 
and vasodilator mediators. As already stated the vascular endothelium is able to 
influence vascular tone via the release of several vasoactive agents. Amongst these are 
NO (see section 1.1.4.3) and the potent vasoconstrictor ET-1. The potential role of this
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latter peptide in the transitional pulmonary circulation is reviewed in section 1.5.3.1. 
The high pulmonary vascular resistance during fetal life and the greater responsiveness 
in the lung as compared with adult animals have been explained by greater muscularity 
of the arteries (O'Neal, et al, 1957).
1.2.2 Transition of the pulmonarv circulation at birth
At birth, normal transition of gas exchange from the placenta to the lungs 
depends on a 10-fold increase in the pulmonary blood flow and a sharp decline in the 
pulmonary arterial pressure. These events are dependent on a dramatic decrease in 
pulmonary vasculai* resistance within the first few hours after birth, due to structural 
(Haworth & Hislop, 1981; Hall & Haworth, 1986) and functional (Zellers & Vanhoutte, 
1991; Liu, e ta l,  1992)remodelling.
Haworth and Hislop (1981) examined the normal adaptation of the pulmonary 
circulation in the pig, from fetal to six months of age and the following was shown. 
Associated with the rapid fall in pulmonary arterial pressure is dilatation and recruitment 
of small arteries within the acinar region. This was observed during the first 5 minutes 
and continued during the first 24 hours, associated with a loss of arterial smooth muscle. 
Muscularity also decreases in the hilar and lobar elastic arteries during the first week of 
life. This structural change is associated with a reduction in arterial elasticity, 
compatible with the reduced pressure at which the vessels are now operating. The 
significant reduction in the amount of arterial smooth muscle was related to a reduction 
in the pulmonary : systemic vascular resistance ratio from 0.58-0.18, observed between 
24 hours and 2  weeks after birth. Growth and development of the lung continued until 
an adult pattern was reached by 6 months of age. Furthermore, the haemodynamic and 
structural adaptation of the pulmonary occurring in the first two weeks of life were 
shown to follow a similar time course to those in the human infant.
Although the processes occurring in the transition of the pulmonary circulation at 
birth involve multiple factors, growing evidence suggests that NO may be, at least in 
part, a mediator for these processes (Xue, et al, 1994) and that NO may also play a role
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in angiogenesis during lung development (Halbower, et al., 1994). The vasodilatory 
response to birth-related stimuli for the postnatal decline in pulmonary vascular 
resistance, such as increased oxygenation and shear stress, have been shown to be 
markedly attenuated by pretreatment with the NOS inhibitor L-NN (Shaul, et al, 1992; 
Cornfield, et al, 1992). Xue et al. (1996), using immunohistochemical labelling in fetal 
and neonatal rat lung, demonstrated endothelial NOS (eNOS) immunoreactivity 14 -day 
fetal lung cells and the quantity of immunopositive cells increased as gestation 
proceeded, to coalesce to form an inner (endothelial) layer of pulmonary vessels. This 
progress of angiogenesis was seen from 15 days of gestation to at least 7 days 
postnatally. Levy and co-workers (1995) examined the influence of the endothelium in 
the contractility of newborn pig intrapulmonaiy arteries. It was found that at birth, when 
measured plasma ET-1 levels were shown to be at their greatest, the endothelium 
enhanced the contractile response to KCl and PGF2a. Whilst these responses were 
inhibited by the endothelium from 10 day onwards. However the NOS inhibitor L- 
NMMA augmented the contractile response at all ages. This suggests a complex change 
in the functional properties of both pulmonaiy arterial endothelial and smooth muscle 
cells, and the interaction between these cell types during development.
Numerous lines of evidence implicate the possible involvement of ET-1 in the 
extrauterine adaptation of the pulmonary circulation and this is reviewed in section
1.5.3.1. A third vasoactive endothelial-derived mediator with a possible role is the 
eicosanoids. It appears that the cyclooygenase pathway is the predominant pathway for 
arachadonic acid (AA) metabolism in the fetal and transitional pulmonary circulations, 
producing prostaglandins. Prostacyclin causes a potent vasodilation when infused in the 
fetal lung in vivo (Cassin, et al, 1981). Davidson (1988) demonstrated that acute 
cyclooxygenase inhibition attenuated the drop in pulmonaiy vascular resistance at birth 
in term animals. However this attenuation was modest and postnatal adaptation was not 
changed significantly, suggesting that, although prostacyclin contributes to the 
pulmonary vascular changes during the transition, it does not appear to be essential for 
the postnatal adaptation.
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1.3 Pulmonary Hypertension
Pulmonary hypertension (PHT) is a condition which exists when mean 
pulmonaiy arterial pressure increases by 10-15 mmHg (Fishman, 1985). This condition 
can arise as a primary phenomenon (idiopathic PFIT) where the cause is unknown. 
Primary PHT is a rare disease, it occurs most frequently in women of 30-40 years of age 
and after the onset of the symptoms, has an average sumval rate of 2-3 years (Rich,
1988). More commonly, PHT occurs as a secondary phenomenon to other disease states. 
There are many mechanisms that appear to cause or contribute to the pathogenesis of 
PHT (Rich, et al, 1987). The principal causes have 3 basic mechanisms; (i) passive 
type, produced by disease which increase pulmonary venous pressure, e.g. chronic left 
ventricular failure, and mitral stenosis, (ii) Reactive or hyperkinetic type, produced by 
congenital heart defects that cause an increased blood blow through the pulmonary 
vasculature; e.g. persistent pulmonary hypertension of the newborn caused by a patent 
ductus arteriosus (see section 1.3.2) and atrial or ventricular septal defects, (iii) Vaso- 
occiusive type, which can be: obstructive e.g. multiple emboli, thrombosis and chronic 
obstructive lung disease (COLD); obliterative, due to a reduction in vascular bed by 
chronic parenchymal disease such as emphysema or advanced fibrosis; and 
vasoconstrictive which is usually related to hypoxia. The form of secondary PHT occurs 
most commonly in response to hypoxic lung disease, but can also develop as a result of 
exposure to low inspired O2 such as displayed in people with long term residence at 
altitudes over 2500m above sea level (Aldashev, et a l,  1989). Hence the main 
distinction is between those that cause a direct physical change in the pulmonary 
vascular bed due to structural or functional alterations, and those which affect other 
determinants of the pulmonaiy vascular resistance, such as flow and airway pressure, 
and contribute to exacerbate the process. Despite the differential aetiologies of PHT, this 
condition is often progressive and is characterised by a relentless increase in pulmonary 
vascular resistance which eventually leads to right heart failure and death.
The low pulmonary arteiy pressure sustained in a normal subject depends on two 
components: firstly, the high compliance of the major pulmonary blood vessels and.
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secondly, the state of tone of the peripheral precapillary resistance vessels. With disease 
the structure of the pulmonary circulation may change markedly. In pulmonary 
hypertension there is thickening of the major vessels and a narrowing of the peripheral 
vessels (see section 1.3.1). Constriction of the pulmonary arteries results in elevated 
pulmonary artery pressure, which increases the pressure on the right side of the heart, 
whereas constriction of the pulmonary veins increases pulmonary capillaiy pressure, and 
this could result in pulmonary oedema. The association of vasoconstriction and 
anatomical restriction results in PHT.
The mechanism(s) underlying the development of PHT has not yet been 
clarified, although some evidence suggests an important role of the endothelium in its 
pathogenesis (Reid, 1986). The importance of the vascular endothelium in the regulation 
of pulmonary vascular tone is introduced in section 1.1.4.3. The role of the ET-1 (and 
NO) in the pulmonary circulation and its putative involvement in PHT is introduced in 
section 1.5.
Recent studies have shown that inhalation of nitric oxide (NO) in patients with 
chronic lung disease and PHT relieves the hypertension by a selective effect on the 
pulmonary circulation (Adnot, et al,  1992). Nitric oxide was also shown to reverse PHT 
in children with neonatal PHT and may provide permanent benefit (Kinsella, et al., 
1992). Inhaled NO therapy was subsequently applied to the treatment of various PHT 
states including secondary to congenital heart disease (Roberts, et al, 1993) and 
acquired heart disease (Girard, et al, 1992). This success eased a major problem facing 
clinicians caused by the lack of selectivity of most vasodilators used in the treatment of 
PHT. Due to the pulmonary vascular remodelling (see section 1.3.1), diseased lungs are 
relatively resistant to vasodilator therapy and the standard vasodilators exert greater 
effects on the systemic circulation hence leading to unwanted systemic hypotension. At 
present oxygen is the only generally available selective pulmonary vasodilator but NO is 
likely to become more commonly used. Moreover, from the many studies of ET- 
receptor mediated responses in the pulmonary circulation under both normal and 
abnormal conditions, an increasing amount of evidence indicates a possible therapeutic
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use of ET-receptor antagonists in the treatment of PHT; this is discussed in section
1.5.3.2. In addition, 5-HT receptor antagonists present another possible therapeutic 
intervention. For example, Herve et al. (1990) reported the case of a patient with 
primary PHT in the presence of familial platelet storage pool disease and elevated 
plasma 5-HT levels. Administration of a 5-HT2 receptor antagonist, ketanserin, was 
shown to substantially reduce the PHT.
1.3.1 Pulmonarv vascular remodelling
Despite the differences in the origin of PHT states, there are many common 
features of vascular remodelling which are present in all forms of hypertensive 
pulmonary vascular disease, whatever the aetiology. Functionally, the important changes 
are those in the muscular arteries, which can undergo progressive medial hypertrophy 
until there is virtually no lumen. Generally the thickness of the media of the muscular 
pulmonary arteries is proportional to the level of the pulmonary arterial pressure 
(Yamaki & Wagenvoort, 1981). In the early stages of both primary and secondaiy PHT, 
a progression of muscularisation into the non-muscular terminal portion of the 
pulmonary arteriole tree is observed (Heath, et al, 1987, 1993). This occurs as a result 
of hypeiplasia of vascular smooth muscle cells which extend distally in a layer internal 
to the original internal elastic lamina (Heath, et al, 1987), thus forming an inner layer of 
longitudinal smooth muscle. The media also extends peripherally along the arterial tree 
to the elastic arteries. In the latter stages of remodelling the pattern of cell migration and 
proliferation depends on the type of PHT. For example, in secondary PHT the muscular 
artery hyperplasia is not so advanced and'dilatation lesions which occur in primary PHT 
are not seen. Plexogenic pulmonary hypertension in which distinct plexiform lesioning 
develops is typical of the primary form and Eisenmenger's syndrome. In this latter 
mentioned condition, the contributing factor leading to PHT is increased pulmonary 
flow due to intracardiac shunt.
Although a vast amount of attention has focused on the medial hypertrophy and 
hyperplasia, in PHT, the pulmonary arteries respond with thickening of all three
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vascular layers, namely intima, media and adventitia, but the pattern of thickening varies 
depending on the size of the artery (Peacock, et al,  1993). In the smallest arteries the 
dominant change is in the media. Whilst in the major arteries, the dominant change is in 
the adventitia with collagen deposition and contraction (Reid, 1990). With a chronic 
increase in pulmonaiy vascular pressure, there is structural remodelling with fibrosis, 
particularly in the intima layer. Smooth muscle cells migrate from the tunica media 
through fenestra in the internal elastic lamina into the intima where they proliferate and 
secrete proteoglycans and matrix proteins; this cellular intima eventually matures into a 
less collagenous layer (Edwards, 1957). Endothelial cell disruption has been observed in 
experimental monocrotaline PHT and in patients with congenital heart defects and PHT 
(Rosenberg & Rabinovitch, 1986; Rabinovitch, eta l,  1986). The resulting intimai and 
medial hypertrophy may reduce the calibre of the resistance arteries and occlude small 
vascular channels, resulting in increased vascular resistance. Once PHT has developed, 
the associated structural vascular changes renders the pulmonary circulation relatively 
resistant to standard vasodilators (see section 1.3).
1.3.2 Persistent pulmonarv hvpertension of the newborn
Failure of the pulmonary circulation to adapt normally to extrauterine life is a 
common cause of mortality and morbidity in the newborn (Hageman, 1984). Pulmonary 
vascular resistance remains high after birth and a right to left shunt persists across the 
ductus arteriosus and foramen ovale. Persistence of the fetal circulation is most 
commonly associated with asphyxia, is often seen in premature infants suffering from 
the respiratory distress syndrome, and is occasionally found in term babies following a 
normal delivery (Gersony, 1973).
The vascular remodelling associated with pulmonary hypertensive states has 
been introduced in the previous section (1.3.1). A stained section of lung from a human 
female baby born nine weeks premature is shown in figure 1.2. This newborn suiwived 
for only two days and suffered from PHT resulting from infantile respiratory distress 
syndrome. A persistence of morphological structure associated with fetal pulmonary
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&Figure 1.2
Section of lung (E. V.G. stain) from human female bom 9 weeks premature with pulmonary hypertension resulting from Infantile Respiratory Distress Syndrome. (Newborn also suffered from bronchopneumonia and pleuré effusions and died at 2 days old). Morphologically, this section shows persistence of fetal pulmonary vascular structure. See text for details.
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vasculature is evident. The definitive histologic features lie in the pulmonary arterioles 
and the muscular pulmonary arteries (Heath & Edwards, 1958). Brenner (1935) defined 
pulmomary arterioles as arterial vessels in the lung less than 100  p.m in diameter, but 
obviously this is only an approximation. In particular, figure 1.2 shows transverse 
section of pulmonary arterioles ~ 50 p,m i.d. with muscular media and internal and 
external elastic lamina. The media is relatively thicker than found in muscular arteries. 
The thickened arterioles also bear a striking resemblance to the intralobar pulmonary 
arteries of the fetus (Heath & Edwards, 1958).
1.3.3 Pulmonarv hvpertension secondarv to left heart disease
The heart and lungs function as an integrated unit and, consequently, heart 
disease frequently affects the lungs and vice versa. The pulmonary circulation acts as a 
passive system in most situations. In systemic hypertension, a proportional rise in blood 
pressure and vascular resistance in the pulmonaiy circulation are probable (Kobayashi & 
Amenta, 1994). Left sided heart failure interferes with pulmonary venous drainage and 
results in acquired congestive pulmonary vascular disease. Oedema is a frequent sequela 
and occurs not only since the alveolar capillaries are over-extended, but they also suffer 
from hypoxia and increased pressure, which promote escape of fluid across the vascular 
endothelium. In more severe cases of left-sided heart failure PHT results, leading to 
failure of the right side of the heart. Severe PHT may debar surgical correction of the 
cardiac defect since such procedures when the pulmonary vascular bed is in this "high 
resistance, low reseiwe" state may be fatal (Edwards, 1957).
Cardiac failure can be chronic or acute, with the latter being caused by such 
conditions as myocardial injury due to coronary occlusion. The rabbit coronaiy arteiy 
ligation model of left ventricular dysfunction (LVD) was first characterised by Pye et al
(1996) and is described in section 2.1.1 of this thesis. Recently, Deuchar et a l  (1997) 
reported a marked elevation in pulmonary arterial pressure, pulmonary vascular 
remodelling and right ventricular hypertrophy in animals with LVD compared to sham- 
operated rabbits, thus providing evidence for the existence of PHT in this model.
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Several other animal models of various forms of heart disease have been 
reported. These include a rat model of cardiac hypertrophy which was produced by 
placing a constricting clip around the suprarenal abdominal aorta (Arai, et al,  1995); 
acute myocardial infarction using a rabbit model of regional myocardial ischaemia and 
reperfusion (Vitola, et a l,  1996); and a rat model of myocardial infarction produced by 
permanent ligation of left coronary artery (Stassen, et al, 1997). However the majority 
of the studies in these models have been to examine alterations in the myocardium, 
coronary and systemic circulations.
1.3.4 Other animal models of pulmonarv hvpertension
(i) Chronic hypoxic animals (mainly rat and mice) is a well studied model of 
hypoxic PHT. Rats exposed to chronic (hypobaric or normobaric) hypoxia exhibit 
significant PHT, and develop similar morphological changes in the pulmonary vascular 
bed that are observed in human PHT (Hislop & Reid, 1976; Rabonitch, et a l ,  1979). 
Chronic hypoxic animals also exhibit polycythaemia which exacerbates the development 
of PHT and right ventricular hypertrophy (Naeye, 1965; Hunter, 1974).
(ii) The leguminous plants Crotalaria are toxic due to their content of the alkolid 
monocrotoline. Ingestion of the seeds of this plant causes severe damage to the liver, 
lungs and central nervous system m in man (Fishman, 1985). However, in animals such 
as the rat, ingestion of Crotolaria or subcutaneous injection of monocrotoline results in 
the development of PHT within several days (Fishman, 1985; Olson, et a l,  1984). 
Monocrotoline has an indirect effect on the pulmonary circulation; it is converted by the 
liver to dehydromonocrotoline which is a substance highly toxic to the pulmonary 
circulation. Monocrotoline-induced PHT is characterised by early vascular endothelial 
damage, followed by increased vascular muscularisation, a rise in pulmonary arterial 
pressure and right ventricular hypertrophy (Rosenberg & Rabinovitch, 1988). This 
model is considered useful for studying both primaiy PHT and PHT associated with 
lung disease (Wanstall & O'Donnell, 1990).
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(iii) The fawn hooded rat has an hereditary tendency to bleed due to platelet 
storage pool disease and has been shown to develop idiopathic PHT (Stelzner, et al,
1992). Hence this may present a possible model of primary PHT.
1.4 Endothelin
1.4.1 Discoverv
In 1985, Hickey et al demonstrated that the culture medium of bovine aortic 
endothelial cells triggered a slowly developing and long lasting contraction of isolated 
pig coronary arteries, which could not be attributed to any known vasoconstrictor 
mediators and was shown to be peptidergic in nature. Subsequent studies confirmed this 
pioneering observation (Gillespie, e ta l ,  1986). By 1988, this potent endothelial derived 
constrictor factor (EDCF) had been isolated, purified, sequenced and cloned, and was 
named endothelin (ET) (Yanagisawa, et al, 1988). Soon after its discovery, isotypes of 
ET ware identified. Analysis of human genomic sequences revealed the existence of 
three distinct ET genes for ET which encoded three distinct ET peptides, named 
endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3) (Inoue, et al., 1989).
1.4.2 Structure of the endothelins
The newly identified 21 amino acid peptide, ET, had no similarity in its sequence 
to the known peptides of mammalian origin. However in 1989, Kloog and Sokolovsky 
reported that the sequence of another family of peptides the sarafotoxins (SXS6 a, 
SXS6 b, SXS6 c), found in the snake venom of the Atractaspis engadennsis, should a 
very similar sequence and structure to that of the ET family. The amino acid stmctural 
sequences of the ET isopeptides and that of SXS6 c, a member of the SX family, are 
illustrated in figure 1.3. All family members contain 21 amino acid residues and show 
complete identity at 10 positions, including all four cysteine residues; these participate 
in two intrachain disulphide bridges formed by the bonding cysl-cysl^ and cys^-cysH. 
Human ET-2 and ET-3 have 2 and 6 substitutions, respectively, relative to ET-1. Human 
and porcine ET-1 have identical sequences, whilst the ET-3 sequence is
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His X Leu U Asp ï lie X He X Trp jCOOH
Endothelin-1 
(porcine / human / rat / 
canine)
Endothelin-2
(human)
Asp X lie I lie X Trp 1 COOH
Endothelin-3 
(human / rat)cys)ili»rcys)NH
Asp
Lys Glu XGysY Val)(Tyr Cys
Met Asn Sarafotoxin S6 c 
(A. engaddenis)C y s } | | i ( c y s )  NH 2
Asp
Glu X Cys Cys
Figure 1.3 The amino acid sequences of the three isoforms of endothelin from different 
species and the related peptide sarafotoxin S6 c. The dotted circles represent amino acid 
changes compared with the endothelin-1 sequence. Bold black lines indicate disulphide 
bonds between Cys^ - Cys and Cys^ - Cys^k
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identical in both human and rat. The sequence of the COOH-terminal hexapeptide 
region is conserved throughout the ET family, is greatly hydrophobic, and has been 
shown to have its own biological activity (Rovero, et ai, 1990). Numerous studies 
indicate that ETs exist in solution as highly compacted structures. The structures which 
have defined however differ depending on the technique used, although a good deal of 
consensus about certain structural elements does exist.
1.4.3 Endothelin genes: Regulation and tissue expression
The distinct genes for human ET-1, ET-2 and ET-3 have been mapped to 
chromosome 6 , 1 and 2 0 , respectively (Arinami, etal., 1991). Each gene encodes for a 
large preproendothelin (preproET) mRNA from which the ET isotype is the product (see 
section 1.4.4). ET isoforms are now known to be produced in a variety of tissue and cell 
types and there are tissue-specific patterns of isoform expression. Endothelial cells 
regardless of their origin appear to express ET-1 mRNA; for example, umbilical vein 
(Inoue, e ta l ,  1989a; b) and aorta (Tokunaga, et al,  1992). Evidence also indicates that 
vascular smooth muscle cells are capable of ET-1 mRNA expression (Yanagisawa, et 
al., 1988; Tokunaga, et al,  1992). Northern analysis has suggested that ET-2 and ET-3 
are not expressed in either vascular endothelium or smooth muscle (Bloch, et al., 1989a; 
b). ET-1 expression also occurs in many other non-vascular cell types such as 
macrophages (Ehrenreich, et al,  1990), cardiac myocytes (Suzuki, et a l,  1993) and 
neurones (Giaid, e ta l,  1989).
Regulation of the transcription of ET mRNA plays an important role in the 
production of mature ET isoforms. Numerous studies show that several important 
stimuli enhance expression on the preproET-1 gene and de novo ET-1 synthesis. 
Increased message levels have been observed after treatment of endothelial cell with 
various growth factors, such as thrombin (Emori, et a l,  1992), and vasoactive 
substances such as angiotensin II (Dohi, et al, 1992) and bradykinin (Marsden, et al,
1991). Exposure of endothelial cells to physiologically low oxygen tension has also been 
shown to increase ET-1 mRNA expression (Kourembanas, et a l,  1991). Fluid sheer
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stress may also influence expression and release of ET-1, however opposing findings 
have been reported. For example, Malek and Izumo (1992) demonstrated a dose 
dependent decrease in ET-1 expression with increasing sheer stress in bovine aortic 
endothelial cells. Whereas in cultured porcine aortic cells, low sheer stress was shown to 
increase ET-1 expression, whilst higher sheer rates had no effect (Yoshizumi, et al.,
1989). In addition, atrial natriuretic peptide (ANP) and NO have also been shown to 
inhibit ET-1 synthesis and release (Hu, e ta l,  1992; Boulanger & Luscher, 1991).
1.4.4 Endothelin biosvnthesis
All the ETs are derived from preproET precursors comprised of between 160 and 
238 amino acid residues, depending on the isopeptide and the species; I will focus on 
ET-1. The amino acid sequences of prepro-, pro(big)-, and mature ET-1 predicted 
hypothetical biosynthetic pathway for the production of the mature 21  amino acid 
mature ET-1 (Yanagisawa, e ta l ,  1988); the proposed proteolytic pathway is shown in 
figure 1.4. The 203 residue prepro-form is initially processed by dibasic pair-specific 
endopeptidases and carboxypeptidases to yield a 39 amino acid intermediate, pro-ET-1 
(or big ET-1), which is secreted and circulates in the plasma. In the final stage, big ET-1 
is converted to the mature form via an unusual proteolytic processing between Trp^l and 
VaP2 by specific endothelin converting enzymes (ECE) (Yanagisawa, et al., 1988; 
Inoue, et al, 1988a). This hypothesis was supported by the presence of big ET-1, and its 
carboxyl (COOH)-terminal fragment, in the conditioned medium of endothelial cells, 
also indicating that all of the biosynthetic stages can occur within the endothelial cell 
(Emori, e ta l ,  1989).
As the vasoconstrictor activity of-big ET-1 is about 100-fold lower than that of 
ET-1 (Kimura, et a l,  1989), this step in the biosynthesis appears to be important for the 
biological significance of ET-1. Intravenous injection of big ET-1 in rats evoked a 
pressor effect with a potency similar to ET-1 (Sawamura, et a l,  1989), suggesting a 
rapid and efficient conversion of exogenous big ET-1 to biologically active ET-1 in 
vivo. ET-1 is not stored in secretory granules within endothelial cells (Nakamura, et al.
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1990), therefore active control of ET-1 release appears to depend upon de novo 
synthesis of the peptide.
1.4.4.1 Endothelin converting enzvmes ÆCE1
Early studies to characterise ECE activity revealed that the enzyme may be a 
membrane bound neutral metalloprotease, as the production of ET-1 or conversion of 
big ET-1 by cultured bovine carotid artery endothelial cells displayed a narrow pH
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Figure 1.4 Biosvnthetic pathway for ET-1 production.
optimum (pH 7.1) and could be selectively inhibited by phosphoramidon (Okada, et al,
1990). Initial evidence suggested that the conversion of big ET-1 to ET-1 in vivo occurs 
by an ECE present on the vascular endothelium. For example, Fukuroda et al  (1990) 
showed that the conversion of big ET-1 to ET-1 in isolated blood vessels was dependent 
on the presence of an intact endothelium. Advances in ECE research demonstrated the
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existence of more than one isoform of the enzyme. The first ECE isoform to be 
identified and cloned was termed ECE-1, this was described as a type H metalloprotease 
that processed endogenously produced ET-1 intracellularly and exogenously supplied 
big ET-1 on the cell surface (Xu, et al, 1994). ECE-2 is structurally similar to ECE-1 
but was found to have an unusually acidic pH 5.5 optimum, suggesting that the enzyme 
acts intracellularly in acidified compartments and not on the cell surface (Emoto & 
Yanagisawa, 1995). ECE-1 was found to be abundantly expressed in endothelial cells in 
vivo, but could not be detected in neurones (Xu, et al, 1994). In contrast, ECE-2 is 
strongly expressed in neuronal cells (Emoto & Yanagisawa, 1995). Two isoenzymes of 
ECE-1 which are derived from the same gene have been described (Shimada, et al, 
1995); these were subsequently termed ECE-la and ECE-lb. Recently, Emoto et a l
(1997) demonstrated that ECE-la, the predominant isoform in cultured vascular 
endothelial cell, resided strictly within intracellular secretory compartments. In contrast, 
ECE-lb, the isoform found in cultured smooth muscle cells, was expressed on the 
plasma membrane. The authors proposed the model that cleavage of big ET-1 by the 
"generator" cells takes place mostly inside the cell, provided that those cells express 
sufficient levels of ECE-1, as in the case of vascular endothelial cell. Whilst 
extracellular big ET-1 can be cleaved by cell-surface ECE-1 expressed by the "target" 
cells, with the resultant mature peptide acting locally on cell surface receptors.
1.4.5 Molecular cloning and characterisation of endothelin receptor subtypes
The discovery of various ET isoforms and the diverse biological functions 
exerted by them predicted the existence of more than one ET receptor. In 1990, two 
groups independently reported the cloning and sequencing of two different ET receptors. 
Arai et al.. (1990) isolated a receptor from bovine lung cDNA library; when this 
receptor was expressed in Xenopus oocytes, it showed extremely high selectivity for ET 
and SXS6 peptides. The second cloned receptor was isolated from rat lung cDNA 
library, and showed equal affinity for ET-1, ET-2 and ET-1 (Sakurai, et a l,  1990). 
These two cloned receptors are members of the rhodopsin superfamily, which have
28
seven transmembrane-spanning hydrophobic regions, an extracellular N terminus and a 
cytosolic C terminus. These receptors are coupled with guanine-nucleotide-binding (G) 
proteins and range from 45000 to 50000 daltons in size in various tissues.
1.4.5.1 Endothelin A receptors
The cloned receptor which showed selectivity for ETs in the following order, 
ET-1 = ET-2>ET-3, was subsequently named ETa (Aral, et al, 1990; Masaki, et a i,
1991). Cloned ETa receptors show 1000 fold selectivity for ET-1 over ET-3. However, 
a selectivity for ET-1 in the range 10-100 fold is indicated by radioligand and functional 
studies of ETa receptors. These discrepancies may be related to the tissues examined 
having a mixture of receptor subtypes.
The involvement of E T a receptors in ET-1 mediated responses is generally 
classed by (i) the relative potencies of ET-1 over ET-1, (ii) the inability of selective ETb 
receptor agonists to elicit equivalent responses, and (iii) effectiveness of selective ETa 
receptor antagonists. In some tissues where agonist potencies indicated a role of ETa 
receptors, it was found that the E T a receptor antagonist was more effective against ET- 
3-induced compared with ET-1-induced responses (Sumner, et al., 1992). Contractile 
responses in the rabbit saphenous vein are mediated by both E T a &nd ETg receptors, 
however the E T a receptor mediated response could be subdivided into a BQ-123 
sensitive and a BQ-123 insensitive component (Sudjarwo, et a l,  1994; Nishiyama, et 
al., 1995). Thus E T a receptors are occasionally subtyped with regard to there sensitivity 
to a selective antagonist. For example, E T ai (BQ-123 sensitive) and ETa2 (BQ-123 
insensitive) (Sudjarwo, eta l,  1994).
1.4.5.2 Endothelin B receptors
The ETb receptor is non-isopeptide selective and therefore has the following 
rank order of sensitivity, ET-l=ET-2=ET-3 (Sakurai, etal., 1990; Masaki, et a l,  1991). 
Considerable homologies exist between ETa and ETb receptors in a given species.
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approximately 50% identity at the amino acid level, and between individual subtypes 
across mammalian species (85%-90%).
Numerous lines of evidence now indicate ET g receptors to be present on the 
endothelium, evoking vasodilator responses (refeiTed to as ETbi receptors), and also on 
the vascular smooth muscle, inducing vasoconstriction on activation (referred to as 
ETb2 receptors) (see section 1.4.8 .3). Although ETg receptors are anatomically and 
functionally distinct, it is still uncertain as to whether these receptors are structurally 
distinct subtypes. Radioligand binding studies in canine coronary arteiy membranes 
indicated possible ET g receptor subtypes, exhibiting either high or low affinity for ET-1 
and ET-3 (Teerlink, et ai, 1994b). A functional correlate could be identified for the high 
affinity site however, none could be found for the low affinity site. Like the ETa 
receptor, ETg receptors have also been proposed to be subtyped with reference to 
antagonist sensitivity. The nonselective ET receptor antagonist PD 142893 may 
selectively inhibit ETgi receptor mediated vasodilation but be ineffective against ETb2 
receptor mediated vasoconstrictions (Warner, eta l,  1993; Douglas, eta l,  1995).
Recently, Mizuguchi, et al (1997) performed a study to clarify whether the ET 
receptor subtypes mediating the two pharmacologically heterogeneous responses were 
the products of a single ETg receptor gene. This clever experiment used isolated aorta 
and gastric fundus from ETg receptor gene knockout mice and control mice, and the 
results indicated that the vasodilator and vasoconstrictor responses to SXS6 c, selective 
ETg receptor agonist, was derived from the same gene.
1.4.5.3 Endothelin C receptors
Numerous studies revealed that vascular endothelial cells were particularly 
sensitive to the action of ET-3. Emori et al  (1991) showed that an ET receptor on 
bovine endothelial cells was functionally selective for ET-3 over ET-1. Whilst Warner et 
al (1992) demonstrated that release of NO by endothelial cells was particularly sensitive 
to ET-3 compared to ET-1. These findings may suggest a further receptor subtype. 
Recently, a cDNA was cloned from dermal melanphores of the frog Xenopus laevis
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(Karne, et a l,  1993). This cDNA encoded a protein predicted to have a seven- 
transmembrane domain stmcture, thus typical of the superfamily to which ETa ^iid ETg 
receptors belong. However, to date no putative third (ETc) receptor has been cloned by 
screening cDNA libraries prepared from mammalian cells. Thus the existence of a 
mammalian ETc-like receptor remains to be determined.
Possible non ET^/non ETn receptors
An increasing number of studies in vascular preparations have observed atypical 
ET receptor mediated responses and this has led to the proposal of possible novel 
subtypes of ETa or ETg receptors, or non ET A/non ETg receptors in these preparations. 
In human saphenous vein contractile responses to ET-1 were resistant to the actions of 
the ETa receptor antagonist BQ 123 , whereas SXS6b-induced responses were partially 
inhibited by BQ 123 (Bax, et al, 1993). From these observations the authors proposed 
that ET-1 evoked vasoconstriction via activation of a non ETA/non ETg receptor. As 
another example, the vasoconstrictor response of guinea-pig bronchus was shown to be 
mediated predominantly by ETg receptors, yet these responses appeared to be 
insensitive to selective ETg receptor antagonists (Hay & Luttman, 1997). Thus the ET- 
receptor mediated responses in this preparation seems not to be mediated by the classical 
ETg receptor, but rather an atypical population.
In vivo studies have also suggested possible further ET receptors. Recently, 
Cirino et a l  (1997) demonstrated that the haemodynamic and renal effects of ET-1 in 
the anaesthetised pig could not be blocked by BQ-123 or BQ-788, however BQ788 
inhibited SXS6 c-induced effects. The authors hypothesised the existence of an 
additional ET-receptor or a subtype of the ETg receptor, activated by ET-1 but not 
SXS6 c, which is insensitive to BQ788. Although no strong conclusions can be made 
concerning possible ET receptor subtypes, from the ever growing number of studies the
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considerable heterogeneity in ET-receptor mediated responses between various tissues 
and species is becoming increasingly apparent (see sections 1.4.8 and 1.5.2).
1.4.5.4 Regulation of expression of endothelin receptors
Hirata e ta l  (1988) demonstrated that ET-1 pretreatment caused a substantial 
decrease in [1^^I]-ET-1 binding sites in vascular smooth muscle cells. Subsequently, 
numerous studies have demonstrated that ET receptors, like many other cell surface 
peptide receptors, are subject to ligand-induced downregulation (e.g. Sakurai et a l,
1992). The regulation of the production of ET-receptors often parallels that of the ETs. 
For instance, hypoxia or cyclosporine rapidly stimulates the production of ET-1 and 
ETa receptors in endothelial cells and vascular smooth muscle cells, respectively 
(Simonson, 1993). Epidermal growth factor, basic fibroblast growth factor, cAMP and 
oestrogen upregulate ETa receptors in some tissues. Whilst a down regulation of ETa 
receptors to angiotensin II, platelet derived growth factors, and transforming growth 
factor p, has been shown in various tissues (Levin, 1995). Upregulation of ETg receptor 
subtype inRNA by angiotensin II and (dibutyiyl) cAMP has also been reported (Kanno, 
et al, 1993; Hama, et a l,  1992). However other studies suggest that cAMP and also 
catecholamines downregulate ETg receptors (Levin, 1995).
1.4.5.5 Tissue-specific expression of endothelin receptors
A variety of different techniques and approaches have been used to localise ET 
receptors which appear to demonstrate tissue-specific expression. Variable results have 
been reported fro the various studies however, in general, ET A receptor mRNA appears 
to be strongly associated with vascular tissue, and is particularly expressed in the heart 
and lungs (Arai, et a l ,  1990). Whilst ETg receptors appear to be more widely 
distributed on many different tissue types, e.g. brain, liver, kidney and uterus (Sakurai, 
et al., 1990; Simonson, 1993). Hori et al. (1992) showed that in the brain, ETa receptors 
appeared to be associated with blood vessels, and ETg receptors with glial and epithelial 
cells. Regarding the vasculature in general, the majority of evidence suggests that ETa
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receptors are located on smooth muscle cells, whereas ETg receptors have been shown 
to be expressed in endothelial cells. However ETg receptor mRNA has been detected in 
vascular smooth cells of various vessels from several species; including human 
coronaiy, pulmonary and intermammary arteiy (Davenport, etal., 1995a; b). Stimulation 
of vascular ETa receptors mediates a slowly developing, long-lasting contraction 
(Rubanyi & Parker-Boteiho, 1991). Activation of endothelial ETgi receptors appears to 
mediate vasodilation, whereas stimulation of ETg2 receptors present on the vascular 
smooth muscle is generally thought to mediate vasoconstriction (Rubanyi & Polokoff, 
1994). The vascular effects of ET-receptor agonists is discussed more in section 1.4.8.3- 
5.
1.4.6 Agonists and antagonists for endothelin receptor subtypes
1.4.6.1 Selective agonists for endothelin receptors
ET-2 appears to be approximately equipotent with ET-1 at most ETg receptor 
binding sites or functional receptors and only slightly less potent than ET-1 at ETg 
receptors. Since relatively little data is available for ET-2, only ET-3 could be 
considered a selective agent with preference for ETg receptors. However it is important 
to consider that in some cases, ET-3 has a potency in the low nanomolar range for ETa 
receptors. In addition, as stated in section 1.4.5.3, there is evidence for a putative ETc 
receptor with selectivity for ET-3. Hence determination of the ET-l:ET-3 potency ratio 
is required to reliably identify the ET receptor subtype(s) in a given preparation. In 
addition to ET-3, SXS6 c has become accepted as a selective ligand at ETg receptors. 
Williams et al (1991) showed that in rat aorta and atrium, tissues rich in ETa receptors, 
SXS6 c was at least 50000 times less potent than ET-1 at inhibiting the binding of [l^^I]- 
ET-1. BQ-3020 is also a potent agonist of ETg receptors, this was shown to have an 
ETg;ETA selectivity ratio of 4700 (Saeki, et al, 1991). [AlaE 1^]ET-1 (Hiley, et 
al., 1990) and IRE 1620 (Takai, et al., 1992) are other compounds which are also used 
as selective ETg receptor agonists. However, a selective agonist for the ETa receptor 
site remains elusive.
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1.4.6 .2 Peptide endothelin receptor antagonists
The first ET receptor antagonists to be described were peptide derivatives of the 
ETs or stmcturally related analogues. ETa receptor antagonists include BQ-123 (Ihara, 
et al., 1992) and PD 151242 (Davenport, et a l,  1994). This latter compound was 
initially used in an iodinated form as a selective radioligand of ET a  receptors in human 
tissue. In the studies shown in chapters 5 and 9 of this thesis, I used FR139317 as a 
selective ETa receptor antagonist. This compound was shown to have approximately 
90-fold selectivity for ETa receptors, with a pA2 value of 7.2 against ET-1-induced 
contractions of rabbit aorta (Sogabe, et al,  1993).
Selective ETg receptor antagonists described include RES-701-1 (Morishita, et 
al  1994). This peptide is less potent than BQ788, a selective ETg receptor antagonist 
which I used in my own studies (chapters 5 and 9). BQ788 was characterised by 
Ishikawa et a l  (1994) who showed this compound to have a pAa against BQ-3020- 
induced contraction of rabbit pulmonaiy artery of 8.4. Non-selective peptide ET receptor 
antagonists include PD 142893 and the more potent PD 145065 (Doherty, e ta l ,  1993).
1.4.6.3 Non-peptide endothelin receptor antagonists
The first non-peptide ET receptor antagonists were described in 1993 and 1994; 
these represented possible therapeutic advantage over those of a peptide nature since 
they would be orally active. Bosentan (Ro-46-2005) (Clozel, et a l ,  1994) was among 
the first examples of non-selective non-peptide antagonists. Although this compound 
inhibits both ETa ETg receptors, it demonstrates approximately 2 0 -fold selectivity 
for the ETa receptor subtype. BMS 182894 is a selective non-peptide ETa receptor 
antagonist; the pA2 was 6.3 for ETa receptor-mediated contraction of rabbit carotid 
artery (Stein, e ta l,  1994).
The most potent of the non-peptide ET receptor antagonists classed as non- 
selective is SB 209670 (Ohlstein, et a l,  1994); this was a compound I utilised in my 
own studies. SB 209670 was shown to antagonise ET-1-induced contraction of rat aorta
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(ETa receptors) and rabbit pulmonary artery (ETg receptors) with pA2 values of 9,39 
and 6.1, respectively. At least a 90 fold selectivity for ETa receptor subtype was 
indicated by the comparative Ki values of 0 .2  nM (ETa receptors) and 18 nM (ETg 
receptors). In addition to presenting possible therapeutic agents in the treatment of 
various disease states in which ET-1 is implicated, this continually increasing list of 
highly effective antagonists should assist in the further elucidation of the role of ET-1 in 
both physiology and pathophysiology.
1.4.7 Signal transduction mechanisms
Several receptor signal transduction mechanisms are suggested to be involved in 
ET-1-induced vasoconstriction. Generally, in most vascular preparations ET-1 mediates 
increases in cytosolic free Ca '^  ^in two distinct phases; a transient initial phase, which is 
the result of Ca '^*' mobilisation from intracellular stores (see section 1.4.7.1), and a 
sustained phase which is dependent on extracellular Ca "^  ^(see section 1.4.7.2) (Rubanyi 
& Polokoff, 1994).
1.4.7.1 Activation of phospholipase C (PEC) protein kinase C (PKC).
Both subtypes of ET receptors are coupled to PEC via a G-protein (Takuwa, et 
a l,  1989; Sakamoto, et al, 1993). PEC catalyses the generation of inositol phosphate 
(IP3) and diacylglycerol (DAG) via the hydrolysis of phosphotidylinositol (4, 5) 
biphosphate (PIP2). The intracellular cascade of events triggered by PEC activation by 
vascular ET receptors is shown in figure 1.5. IP 3 acts upon specific receptors to release 
intracellularly stored Ca^ "^ . The increase in intracellular Ca^’*' activates the enzyme 
myosin light-chain kinase (MECK), which leads to phosphorylation of myosin light- 
chain (MEC) protein, thus triggering contractile events. The second product DAG may 
in turn activate PKC (Emori, et a l,  1990). PKC was shown to be involved in ET- 
receptor mediated vasoconstriction of rabbit saphenous vein (Sujarwo & Karaki, 1995). 
From a study in isolated small branches of rabbit pulmonary artery, Yoshida et al, 
(1995) proposed that in this preparation ET-1 activates both ETa and ETg receptor
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subtypes to enhance Ca^'^ influx and to release Ca '^  ^from intracellular storage sites, and 
that stimulation of ETa receptor subtype by ET-1 induces contraction mainly through 
PKC activation. In cultured rabbit vascular smooth muscle cells, ET-1 induced a rapid 
(15 sec) transient formation of IP3, suggesting that the PIP2 pathway is an initial event 
following ET-receptor activation (Marsden, et. al., 1989). The in eversibility of the ET-1- 
induced responses is due to a late signalling event for which PKC may be partly 
responsible (Marsault, e ta l, 1991). PKC activation also stimulates DNA synthesis, gene 
transcription and mitogenesis (Simonson, 1993), thus appears to mediate the long term 
effects of ET-receptor activation.
|ET- l lV
ETR
Cell membrane
PIPCa^ "*" channel
DAG
MLC
MLC-P
Contraction Proliferation
Figure 1.5 ET-1 intracellular signalling pathways. Main intracellular signalling events 
due to activation of ETa and ETg receptors. Refer to text for explanation. ET R = ET 
receptor; G = G-protein; PLC = phospholipase C; PIP2 = phosphotidyl inositol 
bisphosphate; DAG = diacylglycerol; IP3 = 1,4,5-inositol triphosphate; PKC = protein 
kinase C; MLCK = myosin light-chain kinase; MLC = myosin light-chain; MLC-P = 
phosphorylated myosin light-chain; ? = link between ET receptor and activation of Ca^ "*" 
channel still uncertain.
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1.4.7.2 Increase of cvtosolic calcium concentration
The first demonstration of the involvement of extracellular Ca^+ in ET-induced 
vasoconstriction was carried out by Hickey et a l (1995), who found that EDCF-induced 
coronary artery contraction was attenuated by removal of Ca^+ from the medium and by 
the L-type Ca^+ channel antagonist verapimil. Since then numerous studies have 
demonstrated that the many effects, vascular and non-vascular, of ET-1 to be dependent 
on extracellular Ca2+ and inhibited by Ca '^*' channel antagonists, suggesting the 
importance of Ca^+ influx in the mechanism of action of ET-1 (Hirata, et a l, 1988b; 
Yoshida, et a l, 1995). The originally proposal that ET-1 was a possible endogenous 
direct activator of L-type Ca^+ channels (Yanagisawa, et a l, 1988), has since been 
discounted. Thus the obseiwed activation of Ca^+ entry via VOC channels in some 
tissues must be the consequence of indirect gating by ET-1; several possible 
mechanisms have been proposed. Activation of VOC may be secondary to ET-1-ET-1- 
induced membrane depolarisation (Takenaka, et a l, 1992); however other reports 
indicate this to be unlikely (Wallnofer,. et a l, 1989). The most convincing indirect 
mechanism to date is the involvement of CL channels. Cl" channel antagonists have 
been shown to inhibit the ET-1-induced sustained phase of [Ca2+]i increase and 
membrane depolarisation of cultured vascular smooth muscle cells (Takenaka, et a l,
1992).
1.4.7.3 Other intracellular pathwavs: ET-receptor mediated vasorelaxation
ET-1 may activate phospholipase A2 in certain tissues to mediate the release of 
PGI2 and TXA2 through the metabolism of arachadonic acid (AA); this may be one of 
the mechanisms by which ETs evoke vasodilations. Numerous studies indicate that 
ETg-receptor mediated vasodilator response involves activation of NO. (The mechanism 
of action of NO is discussed in section 1.1.4.3). For example. De Nucci et a l (1988) 
demonstrated the ability of ET to induce the release of EDRF (NO) from isolated 
perfused mesentery and PGI2 and TXA2 from isolated perfused lung. Cultured bovine
37
endothelial cells were shown to possess specific receptors coupled to PLC, which 
mediate vasodilation via the release of NO (Emori, et al, 1990). Other studies in this 
preparation also indicate ETg receptors to be functionally coupled PLC, and also to 
adenylate cyclase, possibly via an inhibitoiy G (Gi) protein (Eguchi, et a l,  1993). 
Activation of these receptors would result in a reduction in intracellular cAMP levels 
and hence a rise in intracellular free Ca^+, and perhaps stimulate NOS activity resulting 
in NO production. In general, data suggests that in addition to coupling to PLC via Gq 
protein, ETa ETg receptors subtypes are coupled to adenylate cyclase via Gg in 
smooth muscle cells and via Gj in endothelial cells (ETg receptor).
The involvement of ATP-sensitive K"** channels has also been indicated in ETg- 
receptor mediated vasodilation, such as the vasodilator response to ET isopeptides in 
adult lung (Hasunma, et a l, 1990; Lippton, et al, 1991). Distinct K+ channels in vitro 
are coupled to pertussis toxin-sensitive G proteins. Other electrophysiological effects of 
ET-1 have recently been reported. Salter & Kozlowski (1996) demonstrated that in 
pulmonary arterial myocytes, ETa receptor stimulation caused activation of Ca^+ 
activated Cl" and currents, whereas stimulation of the ETg receptor mediated a 
gradual inhibition of the delayed rectifier current.
A further mechanism for ET-induced vasorelaxation was suggested recently by 
the demonstration that activation of ETg receptors can release adrenomedullin in canine 
aortic cells (Jougasaki, e ta l,  1997). Adrenomedullin is a recently discovered natriuretic 
peptide which mediates vasorelaxations in various tissues including pulmonary vessels, 
and is of vascular smooth muscle and endothelial origin (Shirai, et a l,  1997). This 
finding suggests another important vasoactive system regulated by the ETg receptor.
1.4.8 Endothelin and the cardiovascular svstem
1.4.8.1 Haemodvnamic actions
Intravenous infusion of ET-1 into conscious, anaesthetised or pithed rats causes a 
biphasic response, comprising a rapid and transient vasodilation, followed by a profound 
and long lasting increase in blood pressure (Yanagisawa, et a l, 1988; Gardiner, et a l.
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1990; MacLean, et a l, 1989). The initial transient depressor response has since been 
demonstrated to be mediated via the activation of ETg receptors, due to the ability of 
ETg receptor antagonists such as BQ788 to abolish the response (Ishikawa, et a l, 1994), 
and the ability of SXS6 c and ET-3 to mediate the depressor response (Gardiner, et a l, 
1990; Clozel, et a l, 1992). The depressor action of ET-receptor agonists may be due to 
release of prostacyclin and/or NO (De Nucci, et a l, 1988; Gardiner, et a l, 1990). The 
sustained pressor response in the pithed rat occurred with no alteration in cardiac output 
or heart rate, indicating an increase in total peripheral resistance (MacLean, et a l, 1989). 
Pressor responses in intact animals were initially thought to be mediated via ET A 
receptor activation, however it is now known that vascular ETg receptors contribute to 
the constrictor response in vivo (Clozel, et al, 1992). More recent studies of the ET- 
receptor subtypes has provided further insight into the biphasic nature of the 
haemodynamic ET-1-induced response. The ETg receptor has been shown to be 
strongly tachyphylactic (Henry, 1993; Sudjarwo, et a l, 1994). In addition, Schroeder et 
a l  (1997) demonstrated in CHO cells that the ETg receptor deactivated much more 
rapidly that the ETa receptor subtype. Thus the transient vasodilator response noted in 
vivo may be due to rapid ETg receptor desensitisation, with the sustained activation of 
ETa receptors being responsible for the prolonged vasoconstrictor response. 
Furthermore, the interaction of ETs with their receptors is essentially irreversible 
(Marsault, et a l,  1991); this in part explains the well maintained vasoconstrictor 
response observed in vivo and in isolated vascular preparations (see section 1.4.8 .3). The 
binding of ET-1 to its receptor is rapidly followed by internalisation (Resink, et a l 
1990) and this may also be important for the protracted action of the peptide.
1.4.8.2  Cardiac actions
High affinity ET-binding sites are present in cardiac tissue (Nayler, 1990). 
Russell et a l (1997) demonstrated the existence of ETa and ETg receptors on the media 
and at the subcellular level of human coronary epicardial arteries, with the ETa subtype 
being predominant, however no ET-receptors were detected on the endothelial cells..
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These receptors are likely to mediate the well established vasoconstrictor response to 
ET-1. ET-1 can evoke both inotropic and chronotropic effects on the heart. In isolated 
electrically driven rat and human cardiac myocytes, ET was shown to induce positive 
inotropic effects (Moravec, et a l, 1989). In anaesthetised pigs, ET-1 evoked the 
characteristic biphasic haemodynamic response, and reduced cardiac output and 
myocardial contractility (Cirino, et a l, 1997). SXS6 c produced a marked transient 
reduction in MAP, cardiac output and myocardial contractility. From studying the 
effects of BQ788 on these responses, the results suggested the involvement of ETg 
receptors in the initial transient depressor response and, due to the marked enhancement 
of the second sustained phase, it appears that ETg receptors may also act to oppose the 
vasoconstrictor effects of ETa receptor activation. Studies in other species such as the 
rat, however imply that ETg receptors are not involved in the central cardiovascular 
actions of ET (Gulati, et a l, 1995); these differences in findings may be species related. 
In addition, both positive and negative chronotropic effects have been obseiwed, which 
may be due to differences in experimental preparations and the site of ET-1 application 
(Rubanyi & Polokoff, 1994).
1.4.8 .3 Vascular actions
This characteristic slowly developing and well maintained ET-1 induced 
vasoconstriction first reported by Hickey .g/ al (1955) and Yanagisawa et a l  (1988), has 
since been obseived in vascular preparations of various anatomical origin isolated from 
a variety of animals and humans. Due to my interest in ET-1 being primarily in the 
pulmonary circulation, the pulmonary vasculature in particular is discussed in section 
1.5.2.
In the majority of preparations the vasoconstrictor response could be attributed to 
the activation of ETa receptors on the vascular smooth muscle. This was indicated by (i) 
the presence of ET A receptors on these blood vessels (Arai, et al, 1990), (ii) the order of 
potency of the isoforms (ET-1 =ET-2>ET-3) (Masaki, et a l, 1994) and (iii) the ability of 
selective ETa receptor antagonists to prevent or reverse the response (Cardell, et al,
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1993). However in some vascular preparations the ET-1-induced response was only 
partially inhibited or resistant to ET A receptor antagonism and vasoconstrictor responses 
to selective ETg receptor antagonists were observed; for example, saphenous vein 
(Sudjaiwo, et a l, 1994), jugular vein (Sumner, et al, 1992) and pulmonary artery 
(Warner, et a l, 1993) of the rabbit. In vivo studies confirmed in vitro observations, 
these included the demonstration of ETg-mediated vasoconstriction in the pulmonaiy 
circulation of the rabbit (Clozel, et a l, 1992) and in the systemic circulation of the 
guinea-pig (Noguchi, e ta l,  1993).
From studies comparing the effects of ETs on large systemic arteries and 
corresponding veins, it was generally found that ET-1 was 3- to 10-fold more potent in 
venous compared to the arterial preparations (e.g. Cocks, et a l, 1988a; b). It has been 
postulated that the greater sensitivity of the venous preparations may be due to 
activation of different receptor populations, as evidence for vascular ETg receptors is 
commonly detected in systemic venous preparations, i.e. the low pressure side of the 
circulation (Moreland, et al., 1994). Moreover the pulmonary circulation is also a low 
pressure system (see section 1.5.1). In addition, ET-1 has been shown to be a potent 
vasoconstrictor of systemic resistance arteries and the microcirculation (Rubanyi & 
Polakoff, 1994) and these vascular beds are important determinants of the total 
peripheral resistance.
1.4.8.4 Morphological effects on the vasculature
Substantial evidence indicates that ET-1 may also regulate growth and 
proliferation of vascular cell types. ET-1 stimulates DNA synthesis and cell proliferation 
of cultured pulmonary vascular smooth muscle cells (Janakidevi, et al, 1992), and 
replication of pulmonaiy artery fibroblasts at high concentrations (Peacock, et a l, 1992). 
This response seems to be mediated by ETa receptors, as BQ123 (a selective ETa 
receptor antagonist) inhibits ET-1 mediated proliferation (Zamora, et a l, 1993). The 
mitogenic effects of ET-1 can be ascribed to its ability to stimulate PIP2 pathway (see 
section 1.4.7.1) (Takuwa, et a l,  1989). It has been proposed that the growth and
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migration of endothelial cells are the prerequisites for vascular remodelling. Morbidelli 
e ta l  (1995) demonstrated that ET-1 and ET-3 dose-dependently increased proliferation 
and migration of endothelial cells isolated from bovine adrenal capillaries and human 
umbilical veins. Furthermore this effect was inhibited by IRL-1038 whereas BQ-123 
was ineffective, indicating ETg receptor activation. In addition, treatment of vascular 
smooth muscle cells with ET-1 has been shown to induce the expression of other growth 
factors, suggesting that ET-1 can act by paracrine/autocrine regulatory mechanisms and 
thereby contribute to remodelling of surrounding tissues.
1.4.9 Clearance and metabolism of endothelin
The importance of pulmonary clearance of circulating ET-1 was initially 
reported by De Nucci et a l (1988). This group demonstrated that ET-1 was substantially 
removed by the pulmonary circulation in the rat in vitro and in vivo and by guinea-pig 
lungs in vitro. (-40% of infused amount detected in effluent). In 1994, Fukuroda et al 
(1994b) reported that in isolated perfused rat lung, -80% of bolus injected [l^^IjET-l 
was retained by the lungs after one passage. Moreover, the importance of ETg receptors 
in ET-1 clearance by the lungs and kidneys, but not liver, was demonstrated in this later 
study. More recently, ETg receptors were shown to be completely and exclusively 
responsible for pulmonary ET-1 removal in the dog in vivo. (Dupius, et a l, 1996).
The binding of ET-1 to its receptor has been shown to be rapidly followed by an 
internalisation of the peptide (Resink, et al 1990). Receptor internalisation may have an 
obvious function for clearance of ET-1 from the circulation (Ângaard, et al., 1989). 
Mature ETs may be degraded by the actions of neutral endopeptidases (NEP), as 
infusion of the NEP inhibitor SQ-29072 significantly increased plasma levels and 
urinary excretion of ET-1 in the anaesthetised rat (Agassi, et al, 1992).
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1.4.10 Potential physiological and pathological role of endothelin in
cardiovascular regulation
Several lines of evidence support the view that central ET plays an important 
role in cardiovascular regulation. ET receptors were shown to be present in high density 
in the cardiovascular regulatory areas of the brain in the rat, and these were down 
regulated in the hypothalamus and ventrolateral medulla of spontaneously hypertensive 
rats (Gulati & Rub ell o, 1992). Reports such as this and the evidence previously 
reviewed indicates a speculative role for ETs in the homeostasis of the cardiovascular 
system. ET-1 may act in a paracrine or autocrine fashion to regulate vascular tone via its 
direct effect on vascular smooth muscle or indirect interaction with the vascular 
endothelium. The ability of ET to induce release of the endothelial-derived relaxing 
factors NO and prostacyclin has been demonstrated (De Nucci, et a l, 1988). It may be 
postulated that the potent effects of ET-1 on the vasculature is modulated by the 
concomitant release of relaxing factors, with such interaction providing a feedback 
mechanism in the control of vascular tone. Indeed, previous studies indicate an 
attenuation of ET-1-induced arterial vasoconstrictions by NO (Raffestin, et a l, 1991). In 
addition, growth and migration of endothelial cells controls vascular remodelling 
necessary for the healing process and during vascular diseases. ET-1 induced endothelial 
cell proliferation and migration has been demonstrated (Morbidelli, et a l, 1995). The 
ability of ET-1 to stimulate proliferation of vascular smooth muscle cells and fibroblasts 
may contribute to the vascular remodelling associated with hypertension and 
atherosclerosis.
However a pathophysiological role of ETs has been postulated for numerous 
disease states including those of the cardiovascular system of various aetiologies; e.g. 
hypertension, myocardial ischaemia, congestive heart failure, stroke and atherosclerosis 
(Rubanyi & Polokoff, 1994). Thus selective ET-receptor antagonists or inhibitors of 
ECE may represent future therapeutic agents to alleviate or indeed prevent these 
conditions. The effect of several antagonists have been examined in various animal 
models. In a rabbit arterial-occlusion model, the administration of the selective ETa
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receptor antagonist FR139317 prior to but not after the coronary artery occlusion 
significantly reduced the infarct size (Burke & Nelson, 1997). Vitola et al. (1996) 
reported that exogenous ET-1 caused an elevation in coronary and systemic vascular 
resistance in a rabbit model of acute myocardial infarction,; these effects were 
significantly blocked by antagonism of the ET A receptor with FR139317, however 
blockade of both ETa and ETg receptors, using the non-selective antagonist PD 145065, 
was required to significantly reduce infarct size.
Yoshimoto, et al. (1991) reported that as much as 75% of ET-1 secretion from 
cultured porcine cerebral endothelial cells was toward the vascular smooth muscle 
(abluminal) side. It is thought to be unlikely that this pool contributes to plasma ET-1 
concentration, thus ET-1 may be regarded more as a paracrine than an autocrine 
hormone. Until the factors that regulate gene expression are fully elucidated it may be 
premature to link changes in the plasma ET-1 levels with the progress of a particular 
pathological disorder, as local regional ET-1 production is perhaps more responsible for 
the manifestation of effects. Plasma ET-1 levels are nevertheless useful, since plasma 
concentrations have been shown to correlate well with the severity of disease, such as 
chronic heart failure and pulmonary hypertension (Kiowski, et a l, 1995; Cody, et a l, 
1992; Yoshibayashi, eta l, 1991), and may have prognostic and diagnostic value.
1.5 Endothelin in the pulmonary circulation
1.5.1 Pulmonary actions of endothelin
1.5.1.1 Tri vivo studies
In the pulmonary circulation, complex patterns of responses to ETs have been 
described. In conscious rats, an increase in pulmonary vascular resistance was detected 
only after high doses of ET-1 (Raffestin, e ta l,  1991). Similarly, mild vasoconstriction 
of the pulmonary vascular bed was observed following i.v. infusion of ET-1 in the 
anaesthetised dog (Miller, et a l, 1989). Whilst in the anaesthetised cat, exogenous ET-1 
has been shown to cause both mild (Lippton, et a l, 1989) and potent (Minkes, et a l,
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1990) pulmonary vasoconstrictions. These differences may be due to the dose of ET-1 
administered.
In some studies where pulmonary vascular tone was elevated experimentally/ 
such as by increased airway hypoxia in the conscious rat and administration of U46619 
in the rat in vivo, administration of ET-1 produced pulmonary vasodilation (Hasunma, et 
ai, 1990; Lippton, et al., 1991). The relative potencies of ET isopeptides and the effects 
of the channel inhibitor glib end amide, have indicated a role of ETg receptors and 
K+ Channel activation in the vasodilatory response (Lippton, et a l, 1991).
1.5.1.2 Tri vitro studies
ET-1 is a potent constrictor of animal and human pulmonary arteries in vitro 
(Hay, et a l, 1993; McKay, et al, 1991; Hay, et a l, 1996), and is particularly potent in 
small pulmonary resistance arteries (Leach, et al., 1989; 1992). Similarly, ET-1 and ET- 
3 has a vasoconstrictor activity in lungs perfused under constant blood flow conditions 
(Raffestin, et al, 1991; Lipton, et al, 1991). As observed in the systemic vasculature 
(see section 1.4.7), ET-1 causes a slowly developing and prolonged vasoconstriction, 
and the vasoconstrictor response of pulmonary vessels is thought to be partly mediated 
via an influx in Ca^+ ions via dihydropyridine-sensitive channels and partly via a 
mechanism that involves protein kinase C activation (Leach, et a l, 1990).
ET binding sites in human lung parenchyma have been shown to be localised to 
pulmonary vascular smooth muscle, particularly in arteries (Brink, et a l, 1991; McKay, 
et a l, 1991). The use of selective ET receptor agonists and antagonists has aided the 
progressive elucidation of ET receptor subtypes involved in the vascular effects. In 
guinea-pig pulmonary arteries functional responses to ET-1 were more potent than those 
to ET-2 and ET-3, and the selective ETa receptor antagonists FR139317 and BQ-123 
inhibited the ET-1-induced vasoconstriction, thus indicating ETa receptor activation 
(Cardell, et a l, 1993). However, other studies indicate the involvement of 
vasoconstrictor ETg receptors, such as in the isolated rabbit pulmonary artery (La
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Douceur, et a l, 1993; Fukuroda, et a l,  1994a). In human pulmonary resistance 
(McCulloch & MacLean, 1995) SXS6 c was shown to be more potent that ET-1. The 
selective ETa receptor antagonist FR139317 was ineffective against ET-1-induced 
vasoconstrictions, whilst BMS 182874, another selective antagonist for the ET a 
receptor, inhibited responses to only high ET-1 concentrations. These results may 
indicate a role for ETg receptors in ET-1-mediated vasoconstriction in human 
pulmonary resistance arteries.
Evidence for a role endothelial ETg receptors has also been reported in 
pulmonaiy vessels in vitro. For example, Fukuroda and co-workers (1992) showed that 
ET isopeptides evoked relaxation of isolated preconstricted porcine pulmonary arteries. 
(The possible mechanism of action of a vasorelaxatory response have been reviewed in 
section 1.4.7.3.) Furthermore, in several pulmonary vessels, including human and 
guinea-pig pulmonary artery and swine pulmonary vein, there is also evidence for an 
atypical receptor at which ET-3 is most active (Cardell, et a l, 1992; Hay, et a l, 1993; 
Sudjarwo, et a l, 1993). These findings have lead to the proposal of a possible existence 
of a novel atypical ETg receptor subtype in these preparations; the possible existence of 
non ETa / ETg receptors is reviewed in section 1.4.5.3.
Alteration in ET-1-induced responses have been observed relative to the calibre 
of the pulmonary vessel examined (Leach, et al, 1989; 1992). In rat pulmonaiy arteries, 
evidence has been shown for ETa receptors mediating the vasoconstriction in the larger 
elastic pulmonary arteries whilst ETg receptor activation appeared responsible for 
vasoconstriction in the pulmonary resistance arteries (Mac Lean, et al, 1994). A similar 
situation is thought to occur in piglet pulmonaiy arteries (Perreault & Baribeau, 1995). 
In contrast to the large blood vessels of the systemic circulation (see section 1.4.8.3), 
arteries appear to be more sensitive than veins in the pulmonary circulation; this was 
demonstrated in the guinea pig by Cardell et a l (1990). These studies suggested that the 
increased sensitivity may be due to the differences in blood composition, i.e. 
comparatively low p0 2  of systemic venous and pulmonaiy arterial blood. Indeed 
hypoxia has been shown to increase ET-1 sensitivity in isolated rat mesenteric arterial
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bed (Douglas, et a l, 1991) and in isolated rat perfused lungs (Eddahibi, et a l, 1991). All 
the aforementioned studies indicate apparent species- and preparation- related 
differences in the functional effects of ET-receptor agonists on the pulmonary 
vasculature, and also distinct differences compared to the systemic circulation.
As previously mentioned in section 1.4.8.4 , ET-1 is also a potent mitogenic and 
proliferative agent, and has also been shown to be a potent stimulus for DNA synthesis 
and proliferation of bovine, pig and human pulmonary vascular smooth muscle cells in 
culture (Hassoun, e ta l,  1992; Janakiden, et a l, 1992; Zamora, et al, 1993). In cultured 
human pulmonary artery smooth muscle cells, ET-1 was considerably more potent than 
ET-1 and SXS6 c, and its effects were blocked by BQ-123, indicating the involvement of 
ETa receptors. This receptor subtype has also been suggested to be involved in the 
chemotactic and mitogenic effects of ETs on rat pulmonary artery fibroblasts (Peacock, 
e ta l,  1992).
1.5.2 Phvsiological role for endothelin in the pulmonary circulation
Besides the effects of ETs on the cardiovascular system, several lines of 
evidence suggest an important role for these peptides in regulating pulmonary 
circulatoiy function. From the marked vascular effects of ET-1 alluded to above, the 
influence of this peptide in the physiological regulation of pulmonary vascular tone 
seems plausible, Due to the variation in ET-1 mediated effects from the various studies 
which have been reported, the actual physiological role is difficult to determine. The 
vasodilator action of ET-1 could be implicated in the maintenance of low pulmonary 
vascular tone through interaction with the vascular endothelium, or through direct 
actions on vascular smooth muscle. However what may be of more physiological 
importance is that the pulmonary circulation appears to be an important site for ET-1 
biosynthesis. ET-1 has been shown to be produced by a number of pulmonary cell types 
including vascular endothelium (Giaid, et a l, 1991), parenchymal cells (Marciniak, et 
a l ,  1992), airway epithelial cells (Giaid, et al.., 1991) and tissue macrophages 
(Ehrenreich, et a l, 1990). Clearance of ET-1 from the plasma by the lungs may also be
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of more physiological importance (see section 1.4.9) and this has been proposed to limit 
the pressor effects of circulating ET-1 in animal models (e.g. De Nucci, et a l,  1988). 
Furthermore, Stewart et a l (1991) demonstrated in normal humans that the arterial to 
venous ratio of ET-1 was less than unity, suggesting pulmonary clearance of ET-1 in the 
healthy human lung.
1.5.2.1 Extrauterine adaptation of the pulmonaiy circulation
Numerous studies provide physiologic support for a role of ET-1 in the 
maintenance of high pulmonary vascular resistance in the fetus and in the transition of 
the circulation at birth. Circulating immunoreactive levels of ET-1 are very high in the 
fetal and transitional circulations (Endo, et al., 1996; Malamitsi Puchner, et al, 1993). 
However variable haemodynamic and in vitro effects of ET-1 have been reported in the 
perinatal circulation. ET-1 has been demonstrated as a potent vasoconstrictor of isolated 
small pulmonaiy vessels from the fetal lamb (Wang & Coceani, 1992). In the ovine fetal 
pulmonary circulation in vivo, a dose-dependent increase in pulmonaiy blood flow and 
decrease in pulmonary vascular resistance was observed during blockade of the ETa 
receptor with BQ-123 and also with stimulation of the ETg receptor with SXS6 c; both 
of these vasodilatory responses were inhibited by L-NNA (Ivy, et a l, 1994). These 
findings may suggest that selective ETa receptor inhibition within the fetal lung allows 
for preferential binding of ET-1 to the endothelial ETg receptor, resulting in 
vasodilation through the NO pathway. Cassin et al (1991) demonstrated that a potent 
pulmonary vasodilation in response to a brief infusion of ET-1 in the sheep fetus, which 
has a very high pulmonary vascular resistance. Thus exogenous ET appears to have a 
complex effects on the perinatal pulmonary vasculature, which may be site, time and 
tone dependent.
1.5.3 Pulmonaiy hypertension fPHTf
ET-1 levels have been reported to be increased in several experimental and 
clinical settings, including enhanced pulmonaiy preproET-1 mRNA expression and
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increased intrapulmonary ET-1 production in rats with idiopathic PHT (Stelzner, et a l, 
1992), and increased pulmonary gene expression for ET-1 after chronic hypoxia in rats 
(Elton, et al., 1992). Also, increased plasma ET-1 levels have been found in the 
pulmonary circulation of patients with primary and secondary PHT (Stewart, et a l, 
1991; Yoshibayashi, et a l, 1991) and in infants with persistent pulmonaiy hypertension 
of the newborn (Rosenberg, et a l, 1993: Kumar, et a l, 1996). These findings and the 
marked effects of ET-1 on the pulmonaiy circulation (section 1.5.1) suggests that ET-1 
may contribute to the elevated pulmonaiy vascular resistance of this condition. The 
reported ability of ET-1 to stimulate proliferation of pulmonary vascular smooth muscle 
and fibroblasts suggests that it may also play role in the concomitant vascular 
remodelling (Hassoun, et al, 1992; Janakiden, et al, 1992). It is still unclear, however, 
if ET-1 is a mediator or modulator of PHT (Stewart, e ta l, 1991).
Numerous investigations of the effects of ET-receptor antagonists in the 
pulmonary vasculature of animal and human models has brought about the prospective 
use of such compounds as possible therapeutic agents. For example, Chen and co­
workers (1995; 1997) showed that both bosentan and the novel non-peptide ETa 
receptor antagonist A-127722 were effective in preventing the pulmonaiy hypertensive 
effect of short-term hypoxia and attenuated the development of PHT. However, of 
important consideration was the significant elevation in systemic arterial pressure also 
observed. Due to these differential findings between the various experimental 
approaches in examining ET-1 in the pulmonary circulation, the question as to whether a 
selective ETa or nonselective ETa/ETb receptor antagonist would provide a more 
effective treatment in pulmonary hypertensive diseases is a current topic of great debate. 
Moreover, the possible effectiveness of the various ET receptor antagonists in man will 
depend not only on their efficacy in the pulmonary circulation but also on a desirable 
influence on the systemic circulation.
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L6 Aims of pro ject
In this thesis, I studied the pulmonary vasculature of the rabbit in two differing 
states; one being secondary to left ventricular dysfunction and hence involving "passive" 
regulation of the pulmonary vascular tone. In the other, the effect of the transition from 
fetal to extrauterine existence and during the early stages of neonatal life was studied, 
i.e. a study of "active" regulation due to changes in O2 . (These states have previously 
been introduced in this chapter.). These two paradigms in particular were examined 
since in both situations, the pulmonary vasculature undergoes marked alterations in 
similar aspects of structure and function. For example, the pulmonary circulation is 
normally a low pressure system, with low vascular resistance compared to that of the 
systemic circulation (see section 1.1.3). Whilst in iitero the lungs do not function and the 
cardiac output bypasses the fetal pulmonaiy circulation which is under high pressure and 
resistance (section 1.2 .1). At birth the lungs commence their functional role in life and 
this is accompanied by a marked reduction in the pulmonaiy pressure and thus resistance 
towards values of normal m vivo state (section 1.2.2). This variable is also altered but in 
the opposite direction in the disease state of pulmonary hypertension (PHT), such as 
secondary to left ventricular dysfunction (LVD), when a marked elevation of the 
pulmonary pressure/resistance occurs (section 1.3). Included in stiuctural changes in 
these two states are the loss of pulmonary arterial muscularisation observed in small 
arteries and also in the elastic vessels during perinatal life (section 1 .2 .2), whilst in the 
pulmonaiy hypertensive lung, stmctural changes involve medial hypertrophy in the large 
and small arteries and functional vascular smooth muscle cells become evident in more 
distal branches of arteries, at the level of the terminal bronchioles, which are normally 
only partially muscular or non-muscular (section 1.3.1). Hence, although these two 
models are quite different in nature, the aspects of the pulmonary circulation which are 
affected are comparable in both.
ET-1 is yet another factor which is common to both these models, since the 
involvement of ET-1 has also been implicated in numerous conditions including the 
transitional pulmonary circulation of perinatal life (section 1.5.3.1), and disease states
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such as heart failure (section 1.4.10) and PHT of various aetiologies including secondary 
to myocardial infarction and left heart failure and persistent pulmonary hypertension of 
the newborn (section 1.5.3.2). Thus it is of interest to examine ET-receptor mediated 
responsiveness of pulmonaiy vessels from the same species in these two states. Chapters 
3-7 show the results of the in vitro studies of pulmonaiy arteries in the rabbit coronaiy 
ligation model of left ventricular dysfunction, whilst the examination of the fetal and 
neonatal pulmonaiy resistance arteries are presented in chapters 8 and 9.
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Chapter 2 
Materials and Methods
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2.1. Animal models used in studies
2.1.1 Rabbit coronai'v ligated model of left ventricular dysfunction
2 .1.1.1 Introduction to model
Experimental pulmonary hypertension (PHT) can be induced by a variety of 
techniques, such as monocrotaline or chronic hypoxia. However, in the clinical setting 
the condition of the heart failure commonly occurs with associated PHT (Rabinovitch, et 
aL, 1978; Trell, 1973). Thus it is important to assess the structural and functional 
alterations of pulmonary vasculature which can arise from this source.
As with experimental models of PHT, experimental heart failure may also be 
induced by a variety of techniques (Smith & Nuttal, 1985; Eisner & Reiger, 1991). The 
rabbit coronaiy-ligated model of left ventricular dysfunction was first characterised by 
Pye et al (1996). The coronary artery ligations and sham-operations were performed by 
workers at The University's Department of Medical Cardiology at Glasgow Royal 
Infirmary. A brief description of this procedure is as follows. Adult male New Zealand 
White rabbit (2.5-3.5 kg body weight) received premedication using intramuscular 
fentanyl/fluanizone, 0.3-0.4 ml/kg (Hypnorm, Jansen). Anaesthesia was induced with 
midazolam (0 .2 -0 .4 ml/kg) and, following intubation of the rabbits, was maintained with 
a mixture of nitrous oxide, oxygen (1:1 ratio) and 1% halothane.
A left thorocotomy was performed through the 4th intercostal space to expose 
the heart. Quinidine hydrochloride (3-5 mg/kg) was administered intravenously prior to 
coronary artery ligation to reduce the incidence of ventricular fibrillation. The major 
branch of the left coronary arteiy was occluded approximately midway between the left 
atrial appendage and the cardiac apex. This gives rise to a large homogeneous infarct 
due to the poor collateral circulation of the rabbit coronary system. In cases where 
ventricular fibrillation occurred, defibrillation was undertaken with an 8 joule epicardial 
shock. When an acceptable area of infarction (approx. 20% of the left ventricle) had 
been produced and the animal was haemodynamically and electrically stable, the 
thoracotomy was closed. In sham operated controls, hearts were manipulated as in the 
coronary ligated animals but the artery was left unoccluded.
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Post-operative analgesia (buprenorphine 0.3 mg/kg) was administered every 8 
hours for the first 24-48 hours together with a broad spectrum of antibiotics. The 
investigation conformed with the Guide for care and. use o f laboratory animals (NEH 
Publication No. 85-23, revised 1985) and with the provisions of the Animals (scientific 
procedures) Act 1986.
2.1.1.2 Echocardiographv
The degree of left ventricular dysfunction in each animal was assessed using 
echocardiography as described by Pye et a l (1996). Briefly, measurements were made 
under light sedation (Hypnorm 0.3 mg/kg) using a 5 MHz focused paediatric transducer. 
M mode long axis measurements of left ventricular end diastolic and left atrial internal 
diameters were made. By rotating the transducer 90°, short axis end-diastolic and end- 
systolic frames were captured and traced onto the screen via an on-line cineloop 
computer analysis facility. The ejection fraction (EF) was calculated as;
end diastolic area - (end systolic area / end diastolic area)
Echocardiography was performed after the ligations / sham-operations and when 
the animals had been on procedure for the desired length of time, i.e. 8 , 16 or 32 weeks. 
They were then transported to the Physiology department of Glasgow University, where 
they were sacrificed by overdose of sodium pentobarbitone (1 0 0  mg/kg), the heart and 
lungs were promptly removed en bloc.
2.1.1.3 Assessment of pulmonary hypertension fPHTJ 
(i) Using ventricular weight ratios
In both clinical and experimental forms of pulmonary hypertension, thickening 
of the right ventricular wall is observed. The degree of right ventricular hypertrophy 
gives an index of the development and the degree of pulmonary hypertension (Hunter, et 
a l, 1974).
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Procedure for ventricular measurements
Rabbits from 8 week sham-operated and coronary-ligated groups were overdosed 
with sodium pentobarbitone (100 mg/kg). The thoracic cage was opened and the heart 
and lungs removed. Atria and associated large calibre vessels were dissected from the 
ventricular mass, and the heart was dissected so as to isolate the free wall of the right 
ventricle from the left ventricle plus septum as described by Fulton et. a l 1952. The 
ventricles were washed in Krebs solution, blotted dry on a tissue and then wet weight 
were measured on a Mettler AT261 balance. As the model used was one of left 
ventricular dysfunction, hypertrophy of the left ventricle in the ligated animals was 
observed, thus the commonly used ratio of right ventricular (RV) free wall weight to left 
ventricle plus septum was not suitable. The ratio of RV weight to body weight was used 
as an index of right ventricular hypertrophy. (No difference in body weight was 
observed between the two animal groups). This has been shown to be a reliable index of 
the degree of PHT present in experimental animals (Hunter, et a l, 1974; Wanstall & 
O'Donnell, 1990).
riri Histological analvsis of pulmonary vasculature
Pulmonary vascular remodelling can be assessed histologically, by estimation of 
the number of thick-walled peripheral pulmonary vessels. Thick walled peripheral 
vessels (TWPV) are generally characterised by their proximity to the alveolar ducts, 
their size, and the nature of their elastic coat.
Procedure for examination of TWPV
Lungs from the sham-operated and coronary-ligated rabbits were obtained as 
described in section (i) above. The lungs were washed in Krebs solution before being 
inflated and fixed in 10% formal saline. A transverse section of the middle right lobe 
was processed and embedded in paraffin wax under a vacuum. 5|um sections were cut 
using a microtome and mounted on slides. These sections were stained for elastic tissue 
and smooth muscle using elastic-Van Gieson (EVG) stain; this was as follows.
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Sections were returned to water, soaked in 0.25% potassium permanganate for 1-5 
minutes and then re-washed in water. The sections were then bleached in 1% oxalic acid 
for approximately 1 minute or until the tissue went white and again washed in water, 
before rinsing in 95% alcohol. Now rehydrated, the sections were soaked in Millers 
staining solution for 1 hour. Excess stain was removed by washing in 95% alcohol 
before being washed in water. Following this, sections were counter stained with van 
Gieson for 2  minutes and were then dehydrated, cleared and mounted.
The resulting sections were examined using a Zeiss Axiophot microscope. A 
double elastic lamina was said to be present when two laminae with a space between 
visible for at least half the diameter in cross section. The appearance of 100 vessels in 
sections obtained from an appropriate number of lungs was noted and quantified for the 
percentage of TWPV. Sections stained with EVG and also sections which were 
processed with a Haematoxylin/eison (H&E) stain, were photographed using Kodak 
Ektachrome 64 film.
Electron microscopv
This process was carried out by Dr Ian Montgomery, I.B.L.S.. Pulmonary 
resistance arteries were dissected from sham-operated and coronary-ligated rabbit lungs 
according to the methods stated in section 2.2.4.1. The vessels were fixed for 1 hour 
using 2 % glutaraldehyde in O.IM sodium cacodylate buffer at pH 7.2 (Sabatini, et a i, 
1963). the specimens were then given three times 20 minute washes in O.IM sodium 
cacodylate buffer at pH 7.2. Post fixation was carried out using 1% osmium tetroxide in 
O.IM sodium cacodylate buffer at pH 7.2 . Following fixation, the specimens were 
dehydrated with graded alcohol and embedded in araldite.
Ultrathin sections were cut with a diamond knife on a L.K.B.3. Ultrotome and 
mounted on Formvar coated 1000|Lim aperture grids. The ultrathin sections were double 
stained with uranyl acetate (Stempak & Ward, 1964) and lead citrate (Reynolds, 1963). 
The stained sections were examined using J.E.O.L. lOOS electron microscope at 80kV 
and electron micrographs taken on Kodak electron microscope film.
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Confocal Microscopy
This process was carried out by Craig Daly, I.B.L.S.. Pulmonary resistance 
arteries were dissected from the lungs of 8 week sham-operated and coronary-ligated 
rabbits as described in section 2.2.4.1 . Artery segments were incubated with the vital 
nuclear stain Hoechst 33342 (1 p,g/ml) for 60 minutes in the dark at room temperature. 
After 4 washes in fresh Krebs solution, segments were cut open and placed lumen side 
up in the well of a glass slide. The grease well was flooded with fresh Krebs solution 
and a coverslip was placed on top. Slide mounted artery segments were then visualised 
using laser scanning confocal microscopy (LSCM, Odyssey XL, Noran Instmments). 
The Odyssey scan module was fitted to a Nikon Optiphot microscope (objective; 40x 
oil, NA 1.3). Excitation of Hoechst was achieved with the 364 nm line of a UV argon 
ion laser (em 400). For image collection, identical levels of laser intensity (100%), AOD 
power, and levels of brightness and contrast were used. Digital images were collected 
using a 64 frame average to reduce noise. Smooth muscle cells were identified as being 
those cells whose nuclei lay beneath the (autofluorescent) internal elastic lamina and 
whose orientation was perpendicular to the axis of the blood flow, as indicated by the 
long axis of the endothelial cell nuclei. Images of smooth muscle cell and endothelial 
cell nuclei were collected at intervals of 0.5|um along the axial plane (Z-axis) to produce 
an image stack. A series of images (the stack) was then combined to produce an 
extended focus view of all nuclei in all planes.
fiiP Measurements of lung weight
When left heart failure causes a rise in pulmonary venous pressure, this can lead 
to lung congestion resulting from oedema (Coalson, et. a l, 1967; Kay & Edwards, 
1973). This was examined in the rabbit LVD model by comparing lung weights of 
control animals and those of animals with left ventricular dysfunction. Lungs were 
obtained from sham-operated and coronary-ligated rabbits as stated above. Prior to the 
dissection of pulmonary arteries for experimental studies, all connective tissue and fat 
were removed and associated large calibre vessels were dissected from the lung mass.
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This was to ensure that all lungs weighed only consisted of the actual lobes thus 
eliminating variability. Lungs were washed in Krebs solution, excess fluid was removed, 
and were weighed using a Mettler B3002 balance. The ratio of lung weight to body 
weight was assessed.
2.1.2 Fetal and neonatal rabbits
Female New Zealand White rabbits, pregnant with their first litter, were 
purchased from the credited commercial suppliers Harlan UK Ltd.. The animals were 
ordered in at approximately 23 days gestation, i.e. 7 days prior to their estimated date to 
litter down, and kept in the Central Animal Facility of the University of Glasgow. For 
the purpose of the experimental studies, the rabbit pups were used either 2  days preterm 
(fetal), 0-24 hours, 4 days or 7 days after birth. Animals were sacrificed with an 
overdose of sodium pentabarbitone (200 mg/kg). To obtain fetal pups, the mother was 
overdosed and a caesarean section was performed, fetal rabbits were then rapidly 
decapitated so as to ensure that a first breath was not taken. The lungs were then rapidly 
removed and placed in a beaker of ice cold Krebs solution. Pulmonary arteries were then 
dissected free, as described in section 2 .2 .4.2, for the experimental studies.
2.1.3 Human tissue
Whenever possible studies were carried out on human pulmonaiy arteries. As 
this tissue was only rarely available throughout my period of study, only limited 
investigation could be performed. Hence, I focused on key experimental results obtained 
in the animal models used. Macroscopically normal sections of lung tissue were 
obtained from patients undergoing surgeiy for bronchial carcinoma, who did not have 
evidence of any other chronic lung disease. Samples were supplied by the Royal and 
Western Infirmaries, Glasgow. Samples were refrigerated in fresh Krebs solution on 
site, collected and studied no longer than 12 hours post-operative. Details of individual 
patient histories are not known. The treatment provided for each patient is variable and 
depends strictly on individual needs.
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2.2 Functional nharmacological studies of isolated vessels using wire myography
2.2.1 Background to technique
Until the mid-1970s, most of the information about the mechanical and 
pharmacological properties of vascular smooth muscle was confined to large diameter 
vessels, with the rat tail artery being the smallest vessel studied in vitro. Information 
regarding small vessels could only be inferred from perfusion experiments and 
histological examination. However a technique first described by Bevan and Osher 
(1972) for investigating smaller vessels with internal diameters own to 100 jam was 
developed and the small vessel wire myograph was'first described by Mulvany and 
Halpern in 1976. This was an important advance in the investigations of blood vessels in 
vitro as it now allowed measurement of isometric responses of small resistance arteries. 
Measurements of pressures taken from various regions of the systemic vascular tree 
demonstrated that in some vascular beds, at least 50 % or more of the pre- capillary 
pressure drop occurs in vessels with diameter greater than 100 jam (Bohlen, 1986). 
Therefore vessels with internal diameters ranging from 100-400 jam must contribute 
substantially to peripheral vascular resistance. The technique which was developed is 
suited to vessels with internal diameters of 100-400 jam.
Initial studies involving wire myography concentrated on systemic resistance 
arteries, however the technique can be applied to any small tubular structures such as 
pulmonary vessels, small veins, bronchi or ureter (e.g. Leach et al., 1992; Chopra, et a l,
1994).
2.2.2 Mvograph equipment
Mulvany / Halpern small vessel wire myograph models 500A, 510A and 600M 
were used in the following experiments. The myographs consists of a stainless steel 
organ chamber, in models 500A and 510A, which can house 2  vessel preparations. 
Model 600M consists of 4 individual organ chambers and one vessel can be mounted in 
each. The vessels are mounted on the myograph by means wire (see mounting procedure 
section 2 .2 .5) to vessel support heads shown in figure 2 .1 .
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Figure 2.1 Illustration of Mulvany/Halpern wire myograph model 500A. An isolated 
vessel can be attached in between the vessel support heads by means of two wires 
inserted through vessel lumen, with either end secured around the top and bottom screw 
of the support head. Isometric tension is measured by the transducer.
One of the vessel supports is attached to a sensitive isometric force transducer. 
The other is attached to an adjustable support arm which is controlled by a micrometer. 
The micrometer allows the distance between the supporting heads to be accurately 
adjusted, allowing tension to be placed on the preparation.
The temperature of the chamber is electronically controlled via internal heating 
pads (within 0.1°C). A digital readout of force (all models) and temperature (models 
500A and 510A) is displayed on a separate myograph controller module. This in turn 
has an output connection to a Linseis 4 channel chart recorder (model 6514B), to allow a 
hard copy of the force readout from each transducer.
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2.2.3 Dissection of pulmonary resistance arteries
2.2.3.1 Adult rabbit
The left lung was cut free and pinned to the dissecting dish with its visceral 
surface exposed and parietal surface lying inferiorly. During the dissection, the 
preparation was frequently washed with ice cold Krebs solution. The dissection is 
illustrated in figure 2.2. An incision was made along the superficial aspect of the 
bronchus, cutting from the large proximal aiiway along the bronchial tree to the distal 
bronchus / bronchiole. Once completed, using a dissecting microscope, the associated 
pulmonary artery branching parallel to the bronchus in the bronchovascular bundle was 
then easily identified beneath the bronchiole wall. The bronchiole tissue was then gently 
dissected free and removed from the artery beneath. The lung tissue lateral to the artery 
was carefully dissected free, and the distal segment of the artery (-150 pm internal 
diameter) was removed. Isolated arteries were placed into a vial of ice cold Krebs 
solution, in preparation for mounting in the myograph.
2.2.3.2 Fetal and neonatal rabbit
This dissection was similar to that described for pulmonary arteries isolated from 
adult rabbit lung. However, due to the comparatively smaller size of the lung lobe and 
the associated arterial vascular tree, slight alterations were made. The left lung was 
prepared as for the adult preparation. Using a dissecting microscope, an incision was 
made along the superficial aspect of the bronchus and the lung tissue lateral to the 
associated pulmonary artery branching parallel to the bronchus was carefully dissected 
free, as previously described. This first branch of the main intrapulmonary artery 
(-3 00pm) was removed and placed into a vial of ice cold Krebs solution, in preparation 
for mounting in the myograph. Smaller vessels could not be used since the wall of these 
arteries were extremely delicate thus making them difficult to dissect free and clean of 
surrounding parenchymal tissue without damaging them.
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Figure 2.2 Diagram of dissection of pulmonary arteries. See text for details, (a) Distal 
segment (-150 pm) of pulmonary resistance arteries isolated from adult rabbit lungs, (b) 
Proximal segment (-300 pm) of first branch of main intrapulmonary artery isolated 
from fetal and neonatal rabbit lungs, (c) Main intrapulmonary artery and pulmonary 
resistance arteries were dissected free for biochemical studies (see section 2.3).
2.2.3.3 Human
Due to obvious differences in the surgery required for individual patients, the 
location of the area of lung removed during surgery, and the size of the section obtained 
varied between samples. However, great care was taken to ensure that vessels of the 
appropriate size were removed from each lung sample to minimise variation.
The lung samples were placed and pinned in a Krebs filled dissecting dish, and a 
large pulmonary artery segment was identified. The artery was followed along its
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branching pathway. As the branches decreased in size, using a dissection microscope, 
the artery was followed further along its branching network until pulmonary resistance 
arteries of appropriate size (-200 pm internal diameter) were located. The identification 
of a resistance artei-y was verified by the proximity of the accompanying bronchiole. 
This was found to be a useful tool when only small sections of lung were obtained. The 
arteries were cleaned of surrounding tissue, removed and placed in a vial of ice cold 
Krebs solution in preparation for mounting in the wire myograph.
2.2.4 Mounting procedure
Two different models of Mulvany/Halpern small vessel wire myograph (J.P. 
Trading) were used. Vessels were either mounted as pairs in the same bath of the 
myograph models 500A and 510A, or singularly in the individual baths of the 600M 
model. The mounting procedure is similar to that described by Mulvany & Halpern 
(1977) for small systemic arteries but with a slight modifications.
The mounting procedure for pulmonary vessels is shown in figure 2.3.. Isolated 
small muscular pulmonary arteries were placed in a petri dish containing Krebs, and 
whilst gently holding onto the cut end of the artery, a 40pM stainless steel wire was 
carefully passed through the vessel lumen. (1) This was then transferred to the bath of 
the myograph which contained Krebs solution. The wire was secured between the 
mounting heads, such that the artery segment was positioned in the gap between the 
mounting jaws. (2) The free ends of the wire were then secured to the left mounting jaw 
by winding clockwise around the top and bottom screws which were then tightened. (3) 
The heads were then separated and any excess vessel that lay outside the jaw was 
carefully cut away. The length of the arterial segment in the myograph was -2mm, the 
approximate length of the gap between the two heads. (4) A second 40pM wire was then 
carefully passed through the lumen of the vessel. (5) The mounting heads were then 
closed and the free ends of the second wire were secured around the screws of the right 
mounting head. (6) The mounting heads were then separated and, following adequate 
equilibration time period, the appropriate .tension could now be placed on the vessel.
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Figure 2.3 Mounting procedure for an isolated pulmonary resistance artery. Refer to text 
for description of points (1) to (6).
When the vessels were mounted, the Krebs was bubbled with the appropriate gas 
mixture (see section 2 .2 .8) and the heating system was activated to increase the 
temperature of the Krebs to 37°C.
2.2.5 Normalisation procedure
The normalisation procedure was' originally described by Mulvany and Halpern 
in 1977. This procedure allows vessels to be stretched to a required resting transmural 
pressure. The Laplace relationship (*) can derive the wall tension in a cylinder if it's 
radius and the pressure within it are known. It can therefore be modified to give the 
relationship between these three variables for a vessel mounted on the wire myograph. 
p. = ffraii tension /  (internal diameter / 2  k) (*)
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Where,
P i is the effective pressure. This is an estimate of the pressure which would be 
necessaiy to extend the vessel to the measured internal diameter.
Wall tension is the force divided by twice the vessel length (L). Twice the vessel length 
is used since there is both an "upper" and "lower" wall. i.e.
Wall tension = Force (F) / (L x 2)
Internal circumference (IC) can be calculated after a given amount of stretch (1) has 
been placed on the vessel, as follows,
ICi = (micrometer reading at 1 - micrometer reading at point B) x2  + (ICg)
Where point B is the point at which the two securing wires are just touching. When 
using 40pM diameter wires, ICb would equal 205.6 pm. The difference in the 
micrometer readings between the two points will be equivalent to the distance between 
the two wires.
Rearranging equation (*) gives,
Pi = (2%) X wall tension / IC 
Thus substituting values for wall tension and internal circumference gives.
Pi = (2tc) X F / 2 X L (205.6 + (2 x distance between wires))
Therefore by using this relationship vessels could be stretched to mimic a required 
equivalent transmural pressure.
2.2.6 Tension applied to vessels
The majority of systemic arteries are normalised to a pressure of 0.9 of L I00, 
where L I00  is the diameter which the vessel would have if relaxed and under a pressure 
of lOOmmHg. When set under these conditions the equivalent pressure of the vessel is 
normally in the range 60-70 mmHg, depending on the vessel type. As the pulmonary 
circulation normally operates under conditions of low pressure and resistance, it is 
clearly more suitable for these vessels to be set up under more appropriate conditions. It 
was therefore decided that arteries taken from the lungs would be tensioned to give an
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equivalent transmural pressure of ~16 mmHg. This is approximately the pulmonary 
pressure which would be experienced in vivo (Fishman, 1976).
Note
In the rabbit coronary-ligation model (8  week), in vivo measurements of pulmonary 
arterial pressure demonstrated a marked elevation in coronaiy-ligated rabbits compared 
to sham-operated. However, these measurements were not available until near the end of 
the functional studies shown in this thesis. Thus, although it may have been more 
appropriate to set up vessels isolated from coronary-ligated animals under comparatively 
greater tension, the in vivo evidence for this was only hypothetical at the time when the 
majority of the functional studies were carried out.
2.2.7 Gas mixtures
As the pulmonaiy vasculature is actively sensitive to O2 and CO2 concentrations, 
a gas mixture that would mimic physiological conditions was chosen. The contents of 
the gas mixture used for "bubbling" tissues in vitro was as follows: 16% O2, 5% CO2 
and balance N2 . Bubbling the Krebs bicarbonate solution with this mixture gives a final 
bath O2 tension of approximately 100- 110 mmHg and CO2 tension of 35- 36 mmHg, 
with pH 7.4 (measurements taken by oxygen electrode and blood gas analyser), which 
are values equivalent to those found in pulmonary arteriolar blood. This gas mixture was 
used when studying vessels from neonatal and adult rabbits, the rabbit coronary ligation 
model and those from human lung samples, thus minimising variables between the 
different groups.
Isolated arteries from fetal rabbits however were bubbled with a gas mixture 
containing 3% O2 , 5% CO2, balance N2, thus mimicking the hypoxic conditions which 
exist in utero. This is much more appropriate than the O2 level used in the other 
preparations, considering that a major factor instigating the structural and functional 
alterations in the pulmonary circulation at birth is the loss of the hypoxic pulmonary 
vasoconstrictor response, as the newborn inhales the comparatively hyperoxic 
atmospheric air.
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2 .2 .8  Calibration of equipment
The myograph equipment was calibrated on a regular basis using a calibration 
balance and 2g weight. The calibration device consists of a horizontal aim with a "pan" 
on each side and a vertical transducer arm attached to the mid point of the pan arm. This 
is carefully placed behind a wire which is secured to the mounting head which is 
connected to the isometric force transducer. The principle is that when a load W (e.g. 2 g 
weight) is placed on the appropriate load pan, the force transducer is subjected to a force 
(F) which is equal to
F = W X g X (pan arm / transducer arm) 
where, ( l)g  = 9.81 mN / gram and (2 ) pan arm / transducer arm = 2 cm /4 cm, thus "arm 
ratio" = 0.5.
Hence, calibration with a 2 gram weight gives
F =  2x9.81 X 0.5 = 9.81mN
Thus on calibrating the myographs, the magnitude of the deflection shown on the 
pen recorder readout was equivalent to 1 g weight or 9.81mN. This could then provide
(1) a calibration factor (a), which is the value of the force expressed in inN for a given 
deflection, to be used in the calculation of force in the normalisation procedure (see 
section 2 .2 .6), and (2) the force in mg weight tension for a given deflection, thereby 
allowing the absolute magnitude of the functional responses to be calculated in the 
experiments.
Little variation was observed in the readings from calibration to calibration.
2.2.9 General experimental procedure
The general procedure for in vitro wire myography experiments are listed as 
follows. Details may vary between individual experiments, therefore the precise details 
are given in the methods section of each results chapter.
(1) After the arterial segments were mounted in the myograph, prior to the addition of 
any dmgs, vessels were allowed to equilibrate for one hour in Krebs solution maintained 
at 37°C and bubbled with the appropriate gas mixture.
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(2) Vessels were then stimulated with 50mM KCl to verify tissue viability. Once the 
contractile response reached a plateau, the vessels were then washed at least 6 times 
with fresh Krebs solution and allowed to return to baseline tension. The stimulation with 
50mM KCl was repeated a second time and this provided a reference contractile 
response.
(3) The vessels were left for a further 30 minutes before the addition of any drugs.
(4) A cumulative concentration response curve (CCRC) was then constructed to the 
required agonist covering a range of concentrations which included a threshold and 
maximum response (if possible).
(5) For agonists which irreversibly bind to their receptor(s), only one CCRC could be 
conducted in each preparation. Therefore, separate vessels were used to perform 
experiments using inhibitors/ antagonists. In such experiments, the inhibitor or 
antagonist was left for it's required incubation period before the CCRC to the agonist 
was performed.
2.3 Measurement of intracellular cvclic nucleotide concentrations
2.3.1. Introduction
Intracellular cyclic AMP (cAMP) and cyclic GMP (cGMDP) concentrations were 
quantified by using a modified version of the technique described by Brown et a l  
(1972) and Cailla et a l (1976), respectively. The principal of the cAMP assay is based 
on competition between unlabelled cAMP to be quantified and a fixed, known amount 
of labelled nucleotide ([^HjcAMP) for a, binding protein which has a high affinity and 
specificity for the cyclic nucleotide. Whereas the cGMP assay is based on competition 
between the unlabelled cGMP and a fixed, known amount of [l^^IJcGMP for an 
antibody which has a high affinity and specificity for cGMP.
2.3.2 Preparation of samples
Lungs were obtained from 8 week coronary-ligated rabbits and age-matched 
sham-operated rabbits and were immediately placed in ice cold Krebs solution. Sections
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of arteiy from different locations in the pulmonary vascular tree were then dissected 
free; these were the main intrapulmonary arteiy and pulmonary resistance arteries (see 
figure 2.2). The isolated arteries were cleaned of surrounding parenchymal tissue, placed 
in a vial containing the reaction solution for the particular experiment, (see section 
2.3.3) and incubated for 15 minutes at 37®C. The tissues were then rapidly removed 
from the solutions and placed in pre-weighed eppendorf tubes. The eppendorfs were re­
weighed and the tissues were then rapidly frozen in liquid nitrogen and stored at -80°C 
for the second part of the protocol. The weight of intrapulmonary arteries for each 
sample were typically 1 0-1 2  mg, whilst samples of resistance arteries tended to weigh 
approximately 4-6 mg.
The frozen tissue was homogenised in 200p.l of 4% perchloric acid (PCA), 
briefly vortexed and left overnight at 4°C. The samples were sonicated on ice for 10 
minutes and centrifuged for 10 minutes at 12000 rpm. For each sample, ISOpl of the 
supernatant was removed into a fresh tube and 5|al of universal indicator was added, and 
This was neutralised by the addition of 1.5 M KOH and the final sample volume was 
noted. If the neutral pH point was passed, this was corrected by the addition of an 
appropriate volume of 0.04% PCA. All samples were then stored at -20°C for cAMP or 
cGMP determination.
2.3.3 Experimental conditions
Measurement of the intracellular cyclic nucleotides was made under various 
experimental conditions. Both cAMP and cGMP levels were determined under basal 
conditions. In this case, the arteries were incubated in Krebs solution containing ImM 
isobutylmethylxanthine (IBMX). The effect of BT-1 was examined via incubating the 
isolated arteries in Krebs solution containing O.lpM BT-1. For cAMP measurements, 
tissues were also incubated in a solution of lOpM forskolin, and the effect of BT-1 on 
forskolin-stimulated cAMP was investigated following incubation of tissues in Krebs 
containing lOpM forskolin plus 0.1 |aM BT-1. The general phosphodiesterase inhibitor 
IBMX (ImM) was present in all reaction solutions.
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2.3.4 Protocol for cAMP assay
The assay procedure for the measurement of intracellular cAMP concentration is 
given below. Using assay buffer, serial dilutions of stock solution of unlabelled cAMP 
(16 pmol/ 50111) were prepared giving corresponding values in the assay of 0.0625, 
0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 pmol / 50pl. These were used to prepare a standard 
cuiwe for unknown cAMP determination by incubating with a fixed concentration of 
labelled cAMP and binding protein, also used for unknown samples as shown below.
[5', 8-3H]-cAMP was diluted in assay buffer to give approximately 500 000 
c.p.m.ml. Binding protein was diluted 1:25 in assay buffer for use. Samples of 
unknowns were performed in duplicate and were set up as shown below:
Sample Buffer %-cAMP Binding
Background - 2 0 0  pi lOOpl -
Total bound - 100  pi 100 pi 100  pi
Standards 50 pi 50 pi 100 pi 100 pi
Unknowns 50 pi 50 pi 100 pi 100  pi
The assay tubes were set up in an ice sluriy bath. The incubation process was 
initiated by the addition of binding protein, hence this was added last. Tubes were 
briefly vortexed, and incubated for 2 hours at 4 to allow the reaction mixture to reach 
equilibrium. Following this, unbound cAMP was precipitated by the addition of 250 |_il 
of charcoal solution which was prepared 15 minutes prior to use and continuously stirred 
in an ice slurry bath. Tubes were rapidly vortexed then centrifuged at 12 0 0 0  g for 5 
minutes at 4 ^C, to sediment the charcoal containing cAMP which had not bound to 
binding protein during the incubation. A volume of 300 |.l1 of each supernatant was 
taken to which 3 ml of scintillation fluid was added and vials were briefly vortexed. 
cAMP concentration was assessed by liquid scintillation counting, incorporating a 
purpose-designed curve fitting programme.
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The results are expressed as pmol cAMP / mg weight of tissue. This was 
calculated as follows;
( [ (cAMP average / sample volume) x total vol. ] / 3 ) x 4 )  / mg weight tissue 
where, cAMP average = mean value of the duplicate sample expressed in pmol 
sample volume = 50 pi
total volume = 2 0 0  pi (PCA) + vol. added for neutralisation 
This value is divided by 3 and multiplied by 4 since in preparing the samples, tissues are 
originally in 200 pi of PCA however only 150 pi is removed for further processing, i.e. 
only counting 3/4 of sample. This is then divided by the mg weight of tissue for that 
particular sample, to give pmol cAMP / mg weight of tissue.
2.3.5 Protocol for cGMP assav
The assay procedure for the measurement of intracellular cGMP concentration 
was similar in only some respects as that described above for cAMP thus, details of 
important differences are given below. Using the acetate assay buffer, various dilutions 
of 2 mM stock solution of unlabelled cGMP (0.69 mg/ml) were prepared to give a stock 
solution of 40mM which contained 2 pmol/50pl and serial dilutions of this were made, 
giving corresponding values in the assay of 0.008, 0.0156, 0.03125, 0.0625, 0.125, 0.25, 
0.5, 1, 2  pmol / 50pi. These were used to prepare a standard cuiwe for unknown cGMP 
determination by incubating with a fixed concentration of labelled cGMP and binding 
protein, also used for unknown samples as shown below.
[125i]_qGMP was diluted in acetate buffer to give approximately 130 000 c.p.m. / 
ml (i.e. ~ 6500 cpm / assay tube). A 1:20 stock solution of anti-cGMP antibody was 
diluted in Tris buffer to give 1:5000 dilution per assay point. Samples of unknowns were 
performed in duplicate and were set up as shown below:
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Buffer Sample [*25i-|cGMP Antibo
Background 100  pi (acetate) - 50
100 pi (Tris)
Total bound 100  pi (acetate) - 50|j,l 100 nl
Standards 50 pi (acetate) 50|.a 50^1 100  111
Unknowns 50 pi (acetate) 50 |jl 50^1 100  111
Note The antibody dilutions were made using the Tris buffer and since the antibody is 
not added to the "background" tube, 100 pi of Tris buffer was added to this tube so that 
all tubes would contain Tris buffer.
The assay tubes were set up in an ice slurry bath. The various solutions were 
added to the tubes in the order shown, hence since the incubation process was initiated 
by the addition of antibody, this was added last. Tubes were briefly vortexed, and 
incubated overnight at 4 to allow the reaction mixture to reach equilibrium. 
Following this, unbound cGMP was precipitated by the addition of 1000 pi of charcoal- 
dextran solution which was continuously agitated to ensure complete mixing. Tubes 
were rapidly vortexed then centrifuged at 12 00 0  g for 15 minutes at 4 ^C. This was to 
sediment the charcoal containing cGMP which had not bound to binding protein during 
the incubation. The entire volume of each clear supernatant was removed using a clean 
glass pasteur pipette and placed into gamma counter tubes. [l^^IjcGMP concentration 
was assessed using a gamma counter, incorporating a purpose-designed curve fitting 
programme. The results are expressed as pmol cGMP / mg weight of tissue and this was 
calculated as described for cAMP in section 2.3.4..
2.4 Radioligand Binding
2.4.1 Introduction
Radioligand binding assay is a relatively simple but extremely powerful tool for 
studying receptors and therefore, is an important technique in many biological sciences. 
The principal of radioligand binding is incubation of a biologically active radioligand
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with a receptor preparation until a steady state has been reached. Bound radiolabel is 
then separated from free, either by centrifugation or filtration, and the bound fraction 
counted.
hi the studies of this thesis, ET-receptors of pulmonary arteries were primarily 
investigated using a functional pharmacological technique. In order to gain further 
information on the ET-receptor population.of this preparation, competition binding 
studies were performed using rabbit intrapulmonary arteiy membrane preparations. For 
a competition experiment, the receptor concentration, the radioligand ([l^^IJ-ET-l) 
concentration and the time are all constant, with the variable being the concentration of 
unlabelled competition dmg (ET-1). When the drug concentration is zero, only a small 
fraction of the receptors are bound as radioligand-receptor complex but as the 
concentration of drug increases, it competes with the radioligand for the receptor 
binding site. This decreases the concentration of free receptors and thus the 
concentration of radioligand-receptor complex is also reduced.
2.4.2 Membrane preparation
Lungs were obtained from 8 week sham-operated rabbits and placed 
immediately in ice cold Krebs solution. Intrapulmonaiy arteries were dissected free as 
described in section 2.2.4.1, except all arteries were isolated including the main (axial) 
artery located within the lung lobe. Isolated vessels were placed in an eppendorf, 
immediately frozen in liquid nitrogen, and stored at -SO^C for preparation of 
membranes. The procedure for the membrane preparations was as follows. Frozen 
arteries were pulverised under liquid nitrogen by hand using a stainless steel percusson 
mortar followed by a pestle and mortar. Powdered frozen tissue (from 3-4 lungs) were 
homogenised in 2  ml of ice cold assay buffer (see section 2 .6 .2  for details) on ice, using 
a precooled polytron for 3 times 5 second bursts at setting 4. The homogenate was 
filtered through a 100 jam gauze mesh and centrifuged at 600 x g for 5 minutes at 4 °C. 
The supernatant was centrifuged at 100 000 x g for 30 minutes at 4 °C and the resulting 
pellet was resuspended in 530 \xi of ice cold assay buffer. This suspension was then
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homogenised by hand using a needle and syringe, and separated into aliquots for use in 
ligand binding studies and a 30 |al volume was taken for protein assay. Preparations 
were stored at -80°C until needed.
2.4.3 Protein assav
Protein content of the membrane preparation was determined using Coomassie 
Plus protein assay reagent and bovine serum albumin (BSA) as standards. Stock solution 
of 10 mg/ml BSA was diluted, using buffer for membrane assay, to give corresponding 
values in the assay of 1, 0.75, 0.5, 0.25 and 0.1 mg/ml; these were used to prepare a 
standard curve. The assay was carried in a well plate which was set up as follows:
Sample , Buffer assav reagent
Background - lOp.1 200|.il
Standards lOpil - 2 0 0 p.1
Sample 5p.l 5 pi 2 0 0 pl
All standard and samples were done in triplicate. Thus in order to reduce the 
amount of membrane preparation used, thereby conserving a maximal amount for the 
ligand binding studies, a 5 pi volume was used in each well and the result obtained was 
multiplied by two. The plate was read immediately at 595 nm on a Dynatech plate 
reader; results were analysed using Protein Program on PC (DELL 425s/NP) and 
expressed as mg protein / ml.. In the competition assay, the membrane preparation was 
used at a concentration of approximately 10 pg protein per tube.
2.4.4 Competition studv
The protocol for the competition assays between unlabelled ET-1 and [1^^I]-ET- 
1 is described below. Stock solution of 50 nM [l^^Ij-ET-l was diluted in assay buffer 
(see section 2.6.2 for details) to give a 20 pM stock, thus a 25 pi volume of this in each 
assay tube with had a final volume of 250 pi, gave a final concentration of 2 pM.
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Various dilutions of unlabelled stock solution of O.lmM ET-1 were made to give final 
concentrations in the assay within the range 0.01 pM - 30nM; details of this are as 
follows:
Buffer fET-11 fpB =final tET-l] |-125ii_£T-1 Membrane
(*) 2 0 0  nl - - 25 pi 25 Ml
175 Ml 0.1pM(25 Ml) 0.01 pM 25 Ml 25 Ml
175 IpM (25 Ml) 0.1 pM 25 Ml 25 Ml
125 Ml IpM (75 Ml) 0.3 pM 25 Ml 25 Ml
175 Ml 10pM(25 Ml) 1 pM 25 Ml 25 Ml
125 Ml 10pM(75 Ml) 3pM 25 Ml 25 Ml
175 Ml 0.1 nM(25 Ml) 10 pM 25 Ml 25 Ml
125 Ml 0.1 nM(75 Ml) 30 pM 25 Ml 25 Ml
175 Ml 1 nM (25 Ml) 0.1 nM 25 Ml 25 Ml
125 Ml 1 nM (75 Ml) 0.3 nM 25 Ml 25 Ml
175 Ml 10 nM (25 Ml) 1 nM 25 Ml 25 Ml
125 Ml 10 nM (75 Ml) 3 nM 25 Ml 25 Ml
175 Ml 0.1 MM (25 Ml) ■ lOnM 25 Ml 25 Ml
125 Ml 0.1 MM (75 Ml) 30 nM 25 Ml 25 Ml
Non-specific binding was detemiined in the presence of 200 nM unlabelled ET-1 
and specific binding was defined as total binding (*) minus non-specific binding. All 
samples were performed in duplicate or triplicate.
The binding reaction was initiated by the addition of the membrane preparation 
hence this was added last. After a 2 hour incubation at 22°C, separation of bound from 
free ligand was carried out by rapid vacuum filtration through Whatman GF-B filters 
which had been presoaked for 2 hours in 0.3% PEI to reduce non-specific binding. 
Filters were washed 4 times with 4 ml of assay buffer. Radioactivity associated with the
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filters was determined with a gamma counter with a protocol for iodide cpm. Specific 
binding was defined as total binding minus non-specific binding.
2.5 Analysis of Data
2.5.1 Interpretation of results
For in vitro measurements of isometric tension, data from preparations 
undergoing the same protocol were grouped together and expressed as the mean value ± 
standard error of the mean (SEM). Functional data are expressed as absolute contraction 
(mg weight tension), percentage of the reference contraction to the second exposure to 
50mM KCl (% 50mM KCl), or expressed as a percentage of the own maximum 
response in each preparation (% own maximum) depending on the agonist used. For 
relaxatory responses, data is expressed as a percentage of the response relative to the 
pre-induced tone in each tissue (see individual results chapters).
Data for intracellular cyclic nucleotide levels are expressed as absolute pmol / 
mg weight of tissue. The correct cpm per sample was calculated by subtracting the blank 
value in each case. Details of the calculation to express these values as pmol / mg weight 
is given in section 2.2.3. The n numbers for each group are given in parenthesis and are 
expressed number of animals or n/ n = number of ring preparations from number of 
animals (lungs).
For the radioligand binding studies, data was analysed by non-linear least-square 
curve fitting, for a one-site or two-site model, using Graphpad Prism Program. The IC50 
defines the concentration of the competing drug that inhibits 50% of the specific 
binding. Kj is the inhibition constant and expresses the affinity of the inhibitor for the 
receptor. Ki values were calculated using IC50 values provided by the program and the 
Cheng Prussof relationship (Cheng & Prussof, 1973), defined as follows:
Kî = I C 5 o / ( 1 + F /K d )  
where F is the estimated free radioligand concentration. This calculation also requires a 
Kp) value which is the affinity of the radioligand for the receptor. The Kp) for this 
specific preparation was not available as this has to be determined by a saturation
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experiment and unfoitunately due to time and tissue constraints, these studies were not 
carried out. However, after referring to similar studies in other pulmonary artery 
preparations including human (Davenport, et al.^ 1995), an estimated value of 0.2 nM 
was used.
2.5.2 Calculation of agonist potency
As a measurement of agonist potency in arterial preparations ^EC^o values are 
given as standard; where EC50 is the concentration of an agonist that produces 50% of 
the maximal possible effect of that agonist, and ^ EC^o is equal to the -log of the EC50 . 
In order to compare potencies to lower concentrations of agonists, pECio andpEC25 
values were also calculated. These values were calculated by computer interpolation 
from individual concentration response curves in each vessel.
2.5.3 Calculation of antagonist potencv
To assess the effects of antagonists and give an estimation of affinity pKg values 
(where appropriate) have been calculated according to the methods described by 
Arunlakshana and Schild (1959). The /?Kb value is the -log of the Kb which is the 
dissociation equilibrium constant for an antagonist. This is defined as the molar 
concentration of ligand required to occupy 50 % of the receptor pool. An estimate of the 
/?Kb value was calculated using the following direct fit equation,
/?Kb = "log Kb and Kb= [antagonist] / r -1
Where (1) [antagonist] = concentration of antagonist used and (2) r = concentration ratio 
[A*] / [A], that is the concentration of agonist required to elicit an equal effect in the 
presence ([A^]) and absence ([A]) of antagonist. The common value chosen here in the 
EC50 .
Several assumptions have to be taken into account when estimating /?Kb values 
in the direct fit model. The equation used to calculate the />Kb value assumes that the 
antagonist interacts with the agonist for unoccupied receptors in a simple, reversible 
manner. As has been discussed in chapter 1, the nature of interaction of ET with
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receptors is thought to be essentially irreversible, and this factor therefore questions the 
validity of the />Kb calculations. For calculation of values, agonist response curves 
are normally with and without antagonist in the same tissue preparation. The fact that 
only a single response curve to ET and related peptides can be constmcted in isolated 
preparations will also increase the degree of error, However it was decided to include 
these values as estimates of antagonist potency, although these points must be taken into 
account when interpreting the data.
In some antagonists studies, a maximum response to the agonist was not attained 
within the concentration range of the peptide examined. Hence in these cases, pK.^ 
values could not be calculated. The reason that the peptide concentration was not 
extended beyond the normal maximum concentration of 0.3 pM was two fold. Firstly, 
the relative solubility of the peptide yields a stock concentration of 100 pM therefore a 
large volume of stock solution must be added to a 5 ml bath to give a final concentration 
of 1 pM. Secondly, ET-1 and related peptides are extremely expensive, it therefore was 
not financially feasible to use large volumes of stock solution when considering the 
large number of studies in which these compounds were to be used.
2.5.4 Statistical analvsis
Statistical comparisons between two groups of data were made using Students t- 
test. The nature of the studies were such that an unpaired t-test was appropriate. 
Comparisons between three or more groups of data were studied using one way analysis 
of variance (ANOVA) followed by the appropriate ad hoc post test to access which 
groups were statistically different. P < 0.05 was considered to be statistically significant. 
Where a significant difference was found, the test used is always stated. The statistic 
software package InStat P203 base on a Macintosh Classic computer was used.
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2.6 Solutions
Unless otherwise stated all solutions were stored at 4®C and used only for the 
duration of the recommended periods.
2.6.1 Functional phaiinacolosical and biochemical studies
The composition of the modified Krebs-Heinslet solution was as follows;
NaCl 118.4 mM, NaHCOa 25mM, KCl 4.7mM, KH2PO4 1.2mM, MgS0 4  0.6mM, 
CaCl2 2.5mM, glucose llmM.
Buffer for cAMP assay:
50mM Tris HCl, 4mM EDTA, pH 7.4 (with IM HCl) at 4^0 
Charcoal solution for cAMP assay:
1 g of 2% Norit GSX charcoal, 0.5 g of 1% (w/v) BSA, made up in 50ml assay buffer. 
cAMP binding protein:
preparation was essentially as described by Brown et al. (1972). Briefly, cortical tissue 
obtained from bovine adrenal glands was homogenised in 1.5 volumes of ice-cold 
homogenisation buffer (5mM MgCl2, 25mM KCl, 0.25mM sucrose, 50mM Tris HCl, 
pH7.4). Homogenate was centrifuged at 2000 x g for 5 minutes at 4°C. Supernatant 
decanted then re-centrifuged at 6000 x g for 15 minutes at 40C. Final supernatant was 
kept on ice and, while agitated, aliquoted into 1.5 ml eppendorf tubes and dropped into 
liquid nitrogen for rapid freezing. The binding protein was stored at -80°C until 
required.
Buffers for cGMP assay:
Tris HCl buffer- 50mM Tris-HCl, pH 7.4 (with IM HCl) at 4»C 
Acetate buffer- 50mM Na acetate, pH 6.2 (with IM acetic acid) at 4°C.
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Charcoal-dextran solution for cGMP assay:
(a) 50mM Tris, 5mM EDTA, pH 7.4. Dissolve 6.07g Tris in 500ml of autoclaved H2O. 
Add 250ml, lOOmM HCl and mix. Add 2g neomycin sulphate and 1.85g disodium 
EDTA and allow to dissolve. Sprinkle 5g BSA (fraction V) on the surface and leave to 
dissolve (do not stir). Adjust to pH 7.4 at 22°C with IM HCl and make up to 1 L with 
autoclaved H2O.
(b) To the above add 0.62g dextran T70 and dissolve. Add 6g Norit GSX charcoal and 
stir to ensure complete mixing.
2.6.2 Radioligand binding studies 
Buffer for membrane preparation:
150mM NaCl, 50mM Tris-HCl, 5mM EDTA, Ipg/ml leupetin, 500pg/ml soyabean 
trypsin inhibitor (SBTI), Img benzamidine, lOmM MgCl2, pH7.4 at 22°C.
Buffer for competition assay:
20mM HEPES, 135mM NaCl, 2.68mM KCl, 1.8mM CaC^, 2.05mM MgCl2 , IpM 
bautracin, Ipg/ ml leupetin, IpM SBTI, lOmM benzamidine, pH 7.4 at 22°C.
2.7 Drugs and chemical reagents
The following alphabetical list is of the dings and reagents used in the following 
experimental studies; the supplier is given in parenthesis.
Acetylcholine (Sigma);
Anti-cGMP antibody (Gift);
Bovine Serum Albumin (Sigma);
BQ788 (Peptide International)
(N-cis-2,6-dimethylpiperidinocarboxyl-L-g-methylleucyl-D-I-
methocarbonyltrypophanyl-D-norleucine);
Charcoal (Norit A) (Sigma);
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Endothélia-1 
Endothelin-3 
FR139317
(Thistle Peptides); 
(Peninsula laboratories); 
(Neosystems)
((R)2-[(R)-2-[(S)“2-[[l-(hexahydro-lH-azepinyl)]carbinyl]amino-4- 
methylpertanoyl]amino-3 -[3 -(1 -methyl-1 H-indoyl)]propionyl]amino-3 -(2- 
pyridyl)propionic acid);
L-NAME (N®-nitro-L-arginine methylester) (Sigma);
Millers staining solution (BDH);
Noradrenaline (Sigma);
Pentobarbitone Sodium (Uthetal) (Rhone);
Coomassie Plus Protein Assay Reagent (Pierce);
Sarafotoxin S6c (Sigma);
SB209670 (Gift)
( 1 S„2R„3 S)"3 -(2-carboxymethoxy-4-methoxyphenyl)-1 -(3,4-methyl eudioxy-pheny l)-5 - 
(prop-l-yloxylindane-2-carboxylic acid);
Sodium nitroprusside 
Sumatriptan (GR 43175) 
Superoxide dismutase 
U46619
(Sigma);
(Glaxo);
(Sigma);
(Upjohn)
(9,1 l-Dideoxy-lla,9a-epoxymethanoprostaglandin F2a);
5- carboximidotryptamine 
5 -Hydroxytiyptamine creatine sulphate 
3H cAMP 
[i25i] cGMP 
[1251] EX-1
(Research Biochemicals Int.); 
(Sigma);
(Amersham);
(NEN, Life Science Products) ; 
(Amersham).
Stock solutions of SXS6c were prepared in 0.1% acetic acid, those of BQ788 in 
0.1% DMSO and those U46619 in absolute alcohol. All other diugs and all subsequent 
dilutions were prepared in distilled water.
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Chapter 3
Rabbit coronary artery ligation model of left ventricular 
dysfunction: Vascular reactivity in pulmonary resistance
arteries
8 2
3.1 Introduction
The reasons for the changes in the systemic vasculature secondary to left-sided 
heart disease are incompletely understood (Cleland & Oakley, 1991; Habib, et a l, 1994) 
and this is even more the case for the alterations in the pulmonary circulation. An initial 
change in the pulmonary circulation secondary to left-sided cardiac disease is a passive 
response to a rise in pulmonaiy venous (left atrial) pressure. The increase in pulmonary 
venous pressure is transmitted through the pulmonary vascular bed to the pulmonary 
artery and the pulmonary artery pressures (PAP) rise "passively". As pressure rises in 
the pulmonary artery, dilation of the proximal arteries occurs while the distal arteries 
become attenuated and tortuous. The pathological aspects of pulmonary hypertension in 
left heart disease are described in chapter 1 of this thesis. Briefly however, pulmonary 
hypertension (PHT) is generally characterised by increased thickening of the walls of 
pulmonary arteries, narrowing of the pulmonary artery lumen, increased pulmonary 
vascular resistance, and right-sided heart failure (Heath & Edwards, 1958). The changes 
in the pulmonary circulation in response to left heart disease may not only contribute to 
the production of symptoms, but may also be important determinants of the response to 
treatment, the risk of surgery and ultimately prognosis.
The rabbit coronaiy-ligation model of left ventricular dysfunction (LVD) has 
been reported previously (Pye, et a l, 1996; Denvir, et a l, 1996) and is briefly described 
in section 2.1.1 of this thesis. The presence of pulmonary hypertension in this model has 
also been reported (Deuchar, et a l, 1997) and thus may act as an ideal model to examine 
pulmonary vascular changes occurring secondary to left ventricular dysfunction (LVD). 
In this chapter, I describe studies examining the morphology of the pulmonary 
vasculature in this model, and also alterations in ejection fraction and heart and lung 
weight from the cohort of animals used in my studies.
Various agents have been implicated in the condition of PHT, amongst these is 
the peptide endothelin-1 (ET-1) (Cody, et al, 1992; Kiowski, et a l, 1995). The role of 
ET-1 in the pulmonary vasculature of the rabbit coronary ligation model is extensively
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examined and discussed in chapters 4, 5, 6, and 7 of this thesis. 5-hydroxytiyptamine (5- 
HT) (or serotonin) has also been implicated in the aetiology of PHT, both clinical and 
experimental. 5-HT is produced by activated platelets and pulmonary neuroendocrine 
cells, and has been implicated in PHT in the presence of pulmonary thromboemboli 
(Comroe, et a l, 1953) and may be involved in PHT related to hypoxia in newborns 
(Johnson & Georgieff, 1989). Platelet release of 5-HT may also be involved in PHT 
secondary to cardiac surgery and in primary pulmonary hypertension (Johnson & 
Georgieff, 1989; Reneman & Starre, 1990; Herve, et a l, 1990; 1995). Responses to 5- 
HT are potentiated in the rat monocrotoliiie-induced model of PHT (Wanstall & 
O'Donnell, 1990) and has also been associated with the development of PHT in these 
animals (Kanai, et a l, 1993). The vascular effect of 5-HT in the pulmonary circulation 
appears to be dependent on both the species under study and on the degree of initial 
vascular tone. For example, 5-HT has been shown to act as a pulmonary vasoconstrictor 
(Wanstall & O'Donnell, 1990), but in some species such as the cat or sheep, 5-HT can 
also mediate vasodilation of the pulmonary vascular bed when the vascular tone is raised 
(Neely, et a l, 1993; Cocks & Arnold, 1992). In bovine isolated large intrapulmonaiy 
arteries, responses to the 5-HT}d receptor agonist sumatriptan were uncovered under 
conditions of raised vascular tone (MacLean, et a l, 1994b). In the pulmonary 
hypertensive state vessels are subjected to increased vascular tone which may therefore 
modulate responses to various spasmogens. Hence, in this study I examined 5-HT 
receptor mediated responses in isolated rabbit pulmonary arteries induced by the 
agonists 5-HT, 5-CT, a selective agonist for 5-HTi receptor subtypes, and sumatriptan 
(GR43175), a 5-HTi-like agonist which has been classified as a selective agonist for the 
5-HTid receptor subtype (Peroutka & McCarthy, 1989; Sumner & Humphrey, 1989; 
Humphrey, et a l, 1993). Muscular pulmonary arteries, referred to as pulmonary 
resistance arteries (PRAs), contribute most to the resistance to flow in PHT (Nagasaka, 
et a l, 1984). Indeed, previous reports indicate these arteries as being the most likely to 
have severe morphological abnormalities in patients with PHT (Heath & Edwards, 1958;
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Heath, 1993). Hence I examined functional responses of PRAs from the rabbit coronary 
ligation model of LVD.
Functional changes in the endothelium are known to occur in both experimental 
and clinical PHT. However, discordant results have been reported on the effect of 
disease on endothelium-dependent relaxations. For example, studies on isolated 
pulmonary artery rings from patients of Elsenmenger's syndrome (Dinh-Xuan, et al 
1990a) or chronic obstructive lung disease (Dinh-Xuan, et a l,  1991), showed 
diminished endothelium-dependent relaxations. In addition, the degree of impairment 
was shown to correlate well with intimai thickening. In vessels from chronic hypoxic 
rats, Adnot et a l,  (1991) reported that the ability of AGh to relax preconstricted 
pulmonary arteries was reduced compared with those from control animals, whilst 
MacLean et al. (1995) demonstrated an augmentation of ACh-induced relaxation in this 
model. Giaid and Saleh (1995) demonstrated that pulmonary hypertension in humans 
was associated with diminished expression of endothelial nitric oxide synthase. Whilst 
other studies in animal models of PHT have reported regional up-regulation of NOS 
(e.g. Xue, et a l 1994; MacLean et a/..,1995). Thus, in this chapter I also examined 
responses to various endothelium-dependent vasodilator agents and the endothelium- 
independent agent sodium nitroprusside (SNP) in isolated preconstricted PRAs from the 
rabbit coronaiy ligation model.
3.2 Methods
Measurement of ventricular and lung weight
The hearts from a proportion of the eight week sham-operated and coronary- 
ligated rabbits used in this study were dissected into right ventricle and left ventricle 
plus septum, blotted and weighed, according to the procedure described in chapter 2, 
section 2.1.1.3 (i).
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A proportion of all the lungs obtained during this study were weighed, according 
to the procedure described in section 2.1.1.3 (iii), before vessels were dissected out for 
in viti'o studies. The data from different experimental groups were compared.
Histological examination of lung sections
Light Microscopy
Preparation of lung sections from stock/sham-operated and coronary-ligated 
rabbits is described in the methods section 2.1.1.3 (ii). Separate sections from each lung 
were stained using haematoxilin and eosin stain and an elastic-Van gieson stain in order 
to examine the morphology and to detect the presence of increased muscularisation and 
changes in elastic tissue. Analysis of changes in the degree of muscularisation is also 
described in this section of chapter 2 of this thesis.
Electron andconfocal microscopy
Small muscular pulmonary arteries of the same size and anatomical location as 
used in in vitro studies were dissected from sham-operated and coronaiy-ligated rabbits 
by the procedure described in section 2.1.1.3 (ii). Vessels were then processed and 
examined using electron or confocal microscopy to access any structural changes in 
these vessels, according to the procedures described in chapter 2.
Functional studies: rabbit pulmonary resistance arteries
Lungs were obtained from the rabbit coronary ligation model of left ventricular 
dysfunction. In the 8 week and 16 week procedure period groups, age matched animals 
underwent the same methodology as the experimental animals (referred to in results and 
discussion as "ligated") except the ligatures placed around the coronaiy artery were not 
secured. These are subsequently referred to as "sham-operated". Also, age-matched 
animals in which no operational procedures were perfonned were used as controls in the
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16 week and 32 week procedure period groups These are subsequently referred to as 
"stock". Measurements of ejection fraction were made in all animals and animals were 
killed by sodium pentabarbitone 8, 16 or 32 weeks following the procedure. The lungs 
were promptly removed and small intralobar pulmonary resistance arteries (PRAs) of 
-150 |_im internal diameter (see table 3.3) were dissected out according to the methods 
stated in section 2.2.3.1. These were mounted as ring preparations (-2mm long) on a 
wire myograph, bathed in Krebs solution at 37°C. Using the normalisation process 
explained in section 2.2.5, vessels were tens!oned to an equivalent transmural pressure 
of -  16 mmHg (see table 3.3). This pressure was chosen as it is similar to in vivo 
pressures of rabbit pulmonary arterioles. Preliminary studies in our laboratory showed 
that bubbling with 95% O2  inhibits responses to vasoconstrictors in rabbit PRAs so we 
bubbled with 16% O2/ 5% CO2 balance N2 . These gas mixtures were chosen as they are 
similar to those which the vessels would be exposed to in vivo.
Experimental protocol
Vessels were allowed to equilibrate for 1 hour prior to the addition of any dmgs. 
The response of the PRAs to 50mM KCl was determined twice; once the contractile 
response had reached a plateau, the vessels were washed out at least 6 times with fresh 
Krebs solution. After a further equilibration of at least 20 minutes, vessels were then 
subjected to one of the following protocols.
(1) Cumulative concentration-response cuiwe (CCRC) to KCl (from 5mM-120mM)
(2) CCRC to 5-HT (lnM-30|iM).
(3) CCRC to 5CT (lnM-30|aM) and addition of 30|uM 5-HT at the end of the response 
(8 week group animals only).
(4) CCRC to sumatriptan (InM-O.lmM) and addition of 30|_iM 5-HT at the end of the 
response (8 week group animals only).
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(5) Preconstriction with 30nM U46619 or IjiiM 5-HT followed by CCRC to one of 
several endothelium-dependent relaxatory agents namely; ACh, substance P, bradykinin, 
histamine, and calcium ionophore A23177 (all at lnM-10|aM).
(6)Preconstriction with 30nM U46619, followed by CCRC to SNP (InM-O.lmM).
Data analvsis
Data for body and lung weight are expressed as g or kg, ventricular ratios were 
calculated for each individual heart, and lung to body weight ratios for each individual 
animal. Representative photographs from the histological studies are shown in the 
following results section. Morphological changes are expressed as percentage thick 
walled pulmonary vessels. For functional studies, pEC\Q,pEC2S and/?EC5o values 
(where appropriate) were calculated according to the methods stated in section 2.5.2, 
and expressed as -log M concentration. Responses to KCl are expressed graphically as 
percentage own maximum response or mg weight tension. CCRC to 5-HT receptor 
agonists are expressed as percentage reference contraction to second application of 
50mM KCl in each preparation. Relaxatory responses to SNP are expressed graphically 
as percentage level of preconstriction to U46619 in each preparation. Statistical 
comparison of the means of groups of data were made by one way analysis of variance 
(ANOVA) or Student's unpaired t test; J°<0,05 was considered statistically significant. 
Throughout, data are expressed as mean+ SBM, n= number of animals and n /n = 
number of ring preparations / number of animals.
3.3 Results
3.3.1 Rabbit coronary ligation model of left ventricular dvsfunction
Body and ventricular weights and ventricular ratios from 8 week sham-operated 
and coronary-ligated rabbits are shown in table 3.1. As a change in left ventricular
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weight was evident in this model, ventricular ratios are expressed relative to body 
weight, rather than total ventricular weight.
sham-operated
(n=17)
coronaiy -ligated 
(n=28)
RV/ body weight 0.42+0.01 0.51+0.02»**
LV+S/ body weight 1.36+0.04 1.48+0.04»
total ventricular weight (g) 6.14+0.11 6.99+0.16»»*
body weight (kg) 3.46+0.06 3.53+0.04
Table 3.1 Ventricular and body weights of 8 week sham-operated and coronary-ligated 
rabbits. Statistical comparisons were made by Students unpaired t test *P<0.05, 
***T><0.001. Data presented as mean ±SEM. RV, right ventricle; LV+S, left ventricle 
plus septum; n, number of animals.
Eight weeks of permanent coronary artery ligation resulted in a marked increase 
in the ratio of right ventricular to body weight and also in the ratio of left ventricle plus 
septum to body weight. Ventricular hypertrophy was also evident from the 
comparatively greater total ventricular weight of hearts from coronary-ligated compared 
to sham-operated rabbits. Animals from both experimental groups had similar body 
weights.
The lung and body weights of animals from the various experimental groups are 
shown in table 3.2. Lungs from 8 week coronary-ligated rabbits were comparatively 
heavier than those from age matched sham-operated rabbits. This marked increase was 
also evident in the ratio of lung to body weight. However, no significant difference was 
noted between groups in the 16 week and 32 week procedure animals. All animals had 
similar body weights.
89
n Lung weight 
(g)
Body weight 
(g)
lung /body 
(xlOO)
8 week
sham-operated 43 12.02+0.26 3670.8+48.7 0.328+0.01
coronary-ligated 64 13.13+0.32» 3565.4+32.1 0.370+0.01»
16 week
stock 3 11.53+0.59 3737.7+74.3 0.308+0.01
sham-operated 8 11.48+0.54 3817.2+154.9 0.303+0.02
coronary-ligated 8 13.25+0.81 3634.6+124.8 0.367+0.02
32 week
stock 6 13.81+0.96 3929.6+166.8 0.353+0.02
coronary-ligated 9 12.88+0.40 3996.6+171.1 0.327+0.02
Table 3.2 Lung and body weights of 8, 16 and 32 week stock/sham-operated and 
coronary-ligated rabbits. Statistical comparisons were made by one way analysis of 
variance (ANOVA), followed by Tukeys post test »T’<0.05. Data presented as mean 
±SEM. n, number of animals.
3.3.2 Morphological studies 
Light microscopy
Figures 3.1 and 3.2 show photographs taken from stained sections of lung 
viewed under the light microscope. Figure 3.2B shows a typical example of small 
pulmonary arteries from a sham-operated rabbit which comprise of a single elastic 
lamina and sparse traces of vascular smooth muscle. An EVG section obtained from an 
8 week coronary-ligated rabbit is shown in figure 3.2A. An arteriole of similar size to 
the sham-operated (control) examples has developed a relatively thick muscular media, 
bound by two distinct elastic laminae. Increased muscularisation of small muscular
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Figure 3.1 A
Lung section (H&E stain) from an 8 week coronary artery ligated rabbit. Section shows increased muscularisation of small pulmonary arteries. The prominent medial hypertrophy has decreased the pulmonary artery lumen.
lOOiim
Figure 3.1 B
Lung section (H&E stain) from an 8 week sham-operated rabbit. Section shows normal appearance of small pulmonary arteries; these are thin-walled with relatively sparse vascular smooth muscle.
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Figure 3.2 A
Lung section (E.V.G. stain) from an 8 week coronary artery ligated rabbit. Section shows a thick-walled small pulmonary artery, with double elastic laminae surrounding the newly developed smooth muscle layer.
Figure 3,2 B
'  \  4L. ' . ^
Lung section (E.V.G. stain) from an 8 week sham-ope rated rabbit. Section shows normal appearance of small pulmonary arteries, comprising of a single elastic laminae and sparse vascular smooth muscle.
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pulmonary arteries from 8 week ligated animals is evident from sections of lung stained 
with haematoxylin and eison shown in figure 3.1 A. This compares with section 
illustrated in figure 3.IB, showing the relatively little muscularisation of similar arteries 
in lung from sham-operated rabbits.
On viewing the sections obtained from rabbit lungs from both experimental 
groups, thick walled pulmonary vessels (TWPV) were abundant and easily detected in 
the ligated compared with the control preparations. Quantification of the percentage of 
TWPV in lungs from 8 week procedure animals, provided values of 8.5+0.4% (n=6 
lungs) for sham-operated rabbits and 21.0+0.4% (n=7 lungs) for coronary-ligated rabbits 
(T*<0.001). Similar percentages were noted in sections from 16 and 32 week procedure 
animals.
Electron microscopy
Figure 3.3A and B shows endothelial cells of pulmonary artery of -200 |.im 
internal diameter from 8 week sham-operated rabbit. These cells have a normal, intact 
appearance. In contrast, figure 3.4A and B is an example of an endothelium from 8 week 
coronary-ligated rabbit. In these sections the endothelium appears severely disrupted. 
Endothelial cells are in a defective state and debris from dying cells is evident in the 
lumen.
Confocal microscopy
Vessels of identical size and location to pulmonaiy resistance arteries used in in 
vitro studies were examined using confocal microscopy. An example of adventitia of 
sham-operated and coronary-ligated rabbit PRAs in shown in the picture of figure 3.5A 
and 3.5B, respectively. Adventitia from sham-operated preparation had a noiinal typical 
appearance, whilst that of pulmonary artery from coronary-ligated rabbit appeared 
disrupted.
Endothelial cells and underlying smooth cells in PRAs from 8 week sham- 
operated and coronary-ligated rabbits in shown in figure 3.5C and 3.5D, respectively.
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BFigure 3.3 A and B Endothelium of isolated pulmonary resistance arteries from an eight 
week sham-operated rabbit. Electron micrographs shows distinct endothelial cells with 
typical appearance. EC = endothelial cell; SM = smooth muscle cell; CT = connective 
tissue; L=lumen.
94
w%
B
Figure 3.4 A and B Endothelium of isolated pulmonary resistance arteries from an eight 
week coronary artery-ligated rabbit. Electron micrographs shows disrupted appearance of 
endothelial cells and visible cellular debris in the vessel lumen. EC = endothelial cell; 
SM = smooth muscle cell; CT = connective tissue; L = lumen.
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Figure 3.5
Example of the adventitia (A and B) and of endothelial cells 
and underlying smooth muscle cells (C and D) of pulmonary 
resistance arteries (~200|Lim intermal diameter) isolated from 
an eight week sham-operated (A and C) and coronary-ligated 
rabbit (B and D ). Bar = 20 |im.
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Figure 3.6
Example of endothelial cells of pulmonary resistance arteries 
(~200)im internal diameter) isolated from an 8 week sham - 
operated (A, B, and C) and coronary-ligated rabbit (D).
Bar = 20 |im.
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The smooth muscle cells of the example of a sham-operated preparation had a typical 
elongated appearance, running perpendicular to the longitudinally arranged endothelial 
cell layer. In some ligated rabbit artery preparations, smooth muscle cells were difficult 
to view and this may have been due to the thickness of the elastic lamina. In the example 
shown in figure 3.5B, the cells underlying the endothelial cells are presumed to be 
smooth muscle in nature due to their shape. However, these cells are running in the same 
direction as the endothelial layer and thus do not appear to have a typical circumferential 
orientation.
Figure 3.6 shows endothelial cells in PRAs from 8 week sham-operated (3.6 A, 
B, C) and coronary -ligated (3.6D) rabbits. These cells had an unsmooth appearance, 
indicated by the differences in intensity of nuclei staining. Intensity was either uneven 
throughout cell, or towards the outside of the nuclei, or veiy dark staining was evident 
around the perimeter of the endothelial cells. This indicates differences in the DNA 
concentration at different locations throughout the nuclei and thus possibly different 
states of activity. This appearance was evident in vessels from both sham-operated and 
coronary-ligated rabbits.
3.3.3 Vascular reactivitv of rabbit pulmonary resistance arteries
The ejection fraction of animals from the various experimental groups, from 
which lungs were obtained and PRAs dissected for the studies described in this chapter, 
are shown in table 3.1. The effective pressure to which these vessels were tensioned and 
the resulting estimate of internal diameter are also shown in table 3.1. The ejection 
fraction was markedly reduced in ligated animals compared with sham-operated/stock 
rabbits in 8 , 16 and 32 week procedure groups. Also, the reduced ejection fraction was 
significantly lower in 16 week ligated compared to 32 week ligated rabbits. Vessels 
from all experimental groups were tensioned to a similar effective pressure and internal 
diameter.
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Internal diameter Effective pressure Ejection fraction
(n/n) (liM) (mmHg) (%)
8 week
sham-operated(32/20) 148.9+5.4 19.7+0.9 72.94+1.6
ligated (33/22) 165.3±6,8 19.8+1.1 43.4+2.0***
16 week
stock (8/5) 135.8+3.3 17.7+2.0 78.2+2.4
sham-operated (20/19) 145.7±6.0 19.6+0.8 74.4+1.0
ligated (38/32) 161.2+7.5 18.4+0.7 38.8±1.2»»*a
32 week
stock (13/5) 152.4±8.5 • 16.5+1.2 75.0+1.3
ligated (13/7) 150,7+10.8 18.3+1.6 48.9+1.2***
Table 3.3 (1) Ejection fraction of animals from which PRAs were dissected and studied 
in this chapter and (2) internal diameter and effective pressure of PRAs from this cohort 
of rabbits. Statistical comparisons were made by one way analysis of variance 
(ANOVA), followed by Tukeys post test: ligated vs. age matched sham-operated/stock, 
*»»P<0.001; 16 wk. ligated vs. 32 wk ligated, ^f<0.01. Values are mean+SEM. n/n, 
number of ring preparations/ number of animals.
The vasoconstrictor response to cumulative concentrations of KCl in PRAs from 
8 week sham-operated and coronary-ligated rabbits is shown in figure 3.1 A. No 
difference in sensitivity was seen between the two experimental groups and a similar 
response was noted in all vessels examined from 16 and 32 week group animals (not 
shown). For all PRAs, a maximal vasoconstriction was noted at 50mM KCl. This 
concentration was subsequently used to preconstrict vessels at the beginning of each 
protocol for all functional studies carried out in this thesis. The magnitude of the 
response to the second application of 50mM KCl was used as a reference contraction to 
compare subsequent vasoconstrictor responses to other agents, in the same preparation. 
The absolute magnitude of the contractile response to 50mM KCl was similar in all
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Figure 3.7
Responses to KCl in rabbit PRAs.
A. CCRC's to KCl in PRAs from 8 week sham-operated (O, n=8/5) coronary ligated (#, 
11= 12/6) rabbits. Data are expressed as a percentage of their own maximum contraction.
B. Vasoconstriction to 50mM KCl in PRAs from: 8 week sham-operated (open- 
columns; n=73/63) and coronary-ligated (hatched columns; n=67/58) rabbits; 16 week 
stock (stippled columns; n=8/5), sham-operated (open-columns; n=20/19) and coronary- 
ligated (hatched columns; n=38/32) rabbits; and 32 week stock (stippled columns; 
11=29/5) and coronary-ligated (hatched columns; n=37/7) rabbits. Data are expressed as 
mg weight tension.
Each point represents meant SEM. n/n, number of vessels/ number of animals
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Figure 3.7
Responses to KCl in rabbit PRAs from 8 , 16 and 32 week experimental group animals.
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PRAs from both stock/sham-operated and coronary-ligated rabbits, regardless of the 
length of the procedure; this is shown in figure 3.7B.
Effect o f 5~HTreceptor agonists
The effect of 5-HT on PRAs from 8 week and 32 week procedure rabbits is 
shown in figure 3.8A and 3.8B, respectively. />ECio,y?BC25 andpECso values are 
summarised in table 3.4. 5-HT had similar potency in all PRAs from 8 week group 
rabbits (table 3.4). However, the magnitude of the maximal vasoconstriction was 
markedly reduced in coronary-ligated compared to age-matched sham-operated 
preparations (50.5+6.6% vs. 73.3+3.2%; / ’<0.05; figure 3.8A). Since the response of 
PRAs from 32 week stock rabbits did not reach a maximum, pEC values could not be 
calculated for this group. However, if the final response obtained is taken as a 
maximum, the vessels from stock rabbits appeared to have similar sensitivity to 5-HT as 
the coronaiy-ligated rabbit preparations. Comparing sensitivity between 8 and 32 week 
experimental groups, the potency of 5-HT was markedly reduced in the 32 week rabbit 
PRAs than in the 8 week procedure group arteries (pEC25 and pEC^O, P<0.05). The 
maximum response to 5HT tended to be smaller in the ligated preparation (47.5+10.1%) 
compared to age-matched stock rabbit vessels (76.2+12.6%) in the 32 week procedure 
group also, however, this was not statistically significant (figure 3.8B).
Responses to sumatriptan and 5-CT in PRAs from 8 week procedure group 
rabbits are shown in figures 3.9A and 3.9B, respectively. Vasoconstrictor response to 
sumatriptan were small and variable in magnitude. This was particularly the case in 
coronary-ligated rabbit PRAs where only a portion of vessels responded, whereas all 
sham-operated preparations examined showed a small response. The maximal 
contractile response to 30juM sumatriptan was markedly smaller in ligated rabbit PRAs 
compared to tliat of sham-operated rabbit vessels (P<0.05; figure 3.9A).
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Figure 3.8 Effect of 5-HT on rabbit PR As. Data are expressed as percentage reference 
contraction to 50mM KCl. A. PRAs from 8 week sham-operated (O, n=7/6) and 
coronary ligated rabbits (# , n=7/5). B. PRAs from 32 week stock (□, n=3/3) and 
coronary-ligated (■, n=6/6 ) rabbits. Each point represents mean ± SEM. n/n, number of 
vessels/ number of animals.
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Figure 3.9 Responses to 5-HT receptor agonists in PRAs from 8 week sham-operated 
(O) and coronary-ligated (# )  rabbits. Data are expressed as percentage reference 
contraction to 50mM KCl. A. Effect of sumatriptan (O, n=8/6 ; n=10/8). B. Effect of
5-CT (O, n=10/6 ; # , n=5/5). Each point represents mean ± SEM. n/n, number of 
vessels/ number of animals.
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pECio pEC25 pECsQ n/n
8 week
sham-operated 7.4+0.2 6 .8+0.1 6 .1+0 .2 7/6
coronary-ligated 7.2+0.3 6.7+0.1 6 .1+0.1 7/5
32 week
stock nc
coronary-ligated 6 .6+0 .2 6.0+0.3+ 5.3+0.2+ 6 /6
Table 3.4 Sensitivity to 5-HT in PRAs from 8 and 32 week procedure group animals. 
Results are expressed as mean+SEM. Statistical comparisons by ANOVA, ■^ T*<0.05, 32 
wk ligated vs. 8 wk ligated, n/n, number of ring preparations/ number of animals; nc, not 
calculated.
5-CT-induced responses were similar in PRAs from both experimental groups, eliciting 
a maximal response of -40% KCl -induced vasoconstriction (figure 3.9B). Since a 
plateau was not attained in the CCRCs to sumatriptan or 5-CT, pEC  values were not 
calculated. 30p,M 5-HT was added at the end of each sumatriptan and 5-CT CCRC and 
the amplitude of the vasoconstrictions to these agonists were significantly smaller 
compared to 5-HT in the same preparations. For example, the maximal response to 
(30|uM) sumatriptan, expressed as a percentage of the response to 30|uM 5-HT in the 
same preparations, was 22.3+3.3% and 13.6±4.3% for 8 week sham-operated and 
coronary “ligated rabbit PRAs, respectively. Whilst, the maximal response to 5-CT was 
62.2+5.1% and 58.6+6.6% of the response to 30p,M 5-HT in the same PRAs from 
control and LVD animals, respectively.
Responses to 5-HT receptor agonists at 30|iM were compared in 8 week group 
rabbit vessels. In PRAs from control animals, the vasoconstrictions to 5-HT (65.6+8.4% 
reference contraction to 50mM KCl) ,and 5-CT (42.6+10.7%) were of a similar 
magnitude, whereas the magnitude of the contractile response to sumatriptan was 
significantly smaller compared to that of 5-HT (20.2+4.0%, T’<0.001). In arteries from
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LVD animals, 5-HT and 5-CT responses did not significantly differ, however the 
vasoconstrictions to sumatriptan were markedly smaller compared to both these agonists 
(13.2+4.5%, vs. 44.3+5.8% (5-HT, P<0.001), vs. 37.9+6.9% (5-CT, P<0.01)).
Effect o f endothelium-dependent vasodilatory agents
There was no evidence for endothelial dependent relaxations using any of the 
agents tried in either the 8 week sham rabbit vessels or the coronary artery-ligated rabbit 
PRAs. ACh evoked a transient concentration-dependent contractile response in this 
preparation.
Effect o f endothelium-independent vasodilatory agent, SNP
The thromboxane mimetic U46619 (30nM) produced the same degree of 
preconstriction in the 8 week control group (54.0+7% of response to 50mM KCl) and in 
the LVD group (48.6+4.6%). However in PRAs from the 32 week group animals, 30nM 
U46619 induced a markedly greater preconstriction in the PRAs from the LVD group 
(121.6+17.8%) compared to vessels from age-matched stock animals (67.1+4.8%; 
P<0.01).
pECio . pEC25 pECso n/n
8 week
sham-operated 8.2+0.3 7.8+0.3 7.3+0.2 14/6
coronaiy-ligated 7.7+0.1 7.3+0.1 6 .8+0 .1* 14/7
32 week
stock 8.3+0.2 . 7.8+0.2 7.0+0.2 9/5
coronary-ligated 7.9+0.1 7.4+0.2 6.7+0.2 9/5
Table 3.5 Sensitivity to SNP in PRAs from 8 and 32 week procedure group animals. 
Statistical comparisons were made by Students unpaired t test; ligated vs. age-matched 
control, *P<0.05. Results are expressed as mean+SEM. n/n, number of ring 
preparations/ number of animals.
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Figure 3.10 Effect of SNP on rabbit PRAs. Data are expressed as percentage 30nM 
U46619-induced tone. A. PRAs from 8 week sham-operated (O, n=14/6) and coronary 
ligated rabbits (# , n=14/7). B. PRAs from 32 week stock (□, n=9/5) and coronary- 
ligated (■, n=9/5) rabbits. Each point represents mean ± SEM. n/n, number of vessels/ 
number of animals.
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Figure 3.10A and table 3.5 show that PRAs from the 8 week rabbits with LVD 
were less sensitive to the relaxant effects of SNP, although the maximum response to 
SNP was unaffected. In the 32 week group rabbits, no significant difference in 
sensitivity or maximum response was noted between stock and coronary-ligated rabbit 
vessels (figure 3.lOB; table 3.5).
3.4 Discussion
Rabbit coronary artery ligation model o f left ventricular dysfunction
The marked attenuation in the ejection fraction and the significant left ventricular 
hypertrophy of rabbits in which the left coronary artery was ligated indicated left 
ventricular dysfunction (LVD) in these animals. In this cohort of animals, the ejection 
fraction of animals ligated for 16 weeks was similar to that of animals ligated for 8 
weeks. However, the ejection fraction of 32 week ligated animals was significantly 
greater than that of 16 week coronary ligated rabbits. Thus, animals ligated for a longer 
duration do not appear to represent a more severe LVD condition but are more likely to 
be survivors in these groups.
Moreover, following 8 weeks of permanent coronary artery ligation, the rabbits 
exhibited a significant right ventricular hypertrophy, as demonstrated by the - 2 1 % 
increase in the right ventricular/body weight ratio, with no change occurring in body 
weight. Also, an -16 % increase was evident in lung/body weight ratio in the LVD 
rabbits This right ventricular hypertrophy and lung congestion indicate the development 
of PHT in the animals used in this study. These findings are similar to previous 
investigations using this model, where the marked reduction in cardiac output and 
increase in right ventricular and lung weight were also reported (Deuchar, et al., 1997). 
Furthermore, this previous in vivo study showed a 44% increase in pulmonary artery 
pressure in 8 week coronary-ligated rabbit, thus providing further evidence for the 
existence of PHT secondary to LVD in these animals.
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The results of several histological studies in this chapter provide yet more 
evidence for the development of PHT secondary to LVD in this model. The sections 
taken from control and experimental rabbit lungs showed that pulmonary vascular 
remodelling had taken place. Pulmonary arterioles of -50|_im are normally nonmuscular, 
thin walled and comprise of a single elastic lamina; this was demonstrated in lung 
sections from the cohort of animals examined in this study. However in lung sections 
from coronary-ligated rabbits , vessels of the same size and location were now muscular 
and comprised of two elastic laminae, surrounding the newly developed smooth muscle 
layer. The apparent progression of muscularisation occurs due to the pericytes normally 
present in nomnuscular vessels differentiating into a smooth muscle cell via an 
intermediate cell (Meyrick & Reid, 1978). The marked increase in the degree of 
muscularisation of small pulmonary arterioles was demonstrated further by the 
significant increase in the percentage of thick walled pulmonary vessels, compared to 
stock/sham-operated preparations. This prominent medial hypertrophy is indicative of 
considerable increase in the pulmonary arterial pressure, and therefore is consistent with 
previous haemodynamic findings in this model (Deuchar, et a l, 1997). Common to 
many forms of PHT is the proliferation of smooth muscle cells in the vascular media and 
frequently in the intima (Wagenvoort, 1981). The alterations in the medial layer shown 
in this present study are similar to previous reports in other animal models and in 
humans with PHT. For example. Hunter et al. (1974) described similar findings in 
hypoxic rat model, and Heath et al (1987) and Heath & Edwards (1958) reported 
pulmonary vascular pathology in the condition of primary PHT and PHT, of various 
degrees of severity, secondary to congenital heart defects. Results of a limited confocal 
microscopy study of isolated coronary-ligated rabbit PRAs showed that cells underlying 
endothelial cells ,which were presumed to be smooth muscle in nature, were not 
arranged in the typical circumferential manner but rather, appeared to be running in the 
same direction of the endothelial cells, i.e. longitudinally. Consistent with this, 
Wagenvoort & Wagenvoort (1984) reported the appearance of longitudinally orientated 
bundles of vascular smooth muscle cells in the remodelling of muscular pulmonary
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arteries. These were most common in the intima and in the adventia, but occasionally 
affected the media.
Another associated histological lesion occurring in severe pulmonary 
hypertension is concentric-laminar proliferation of cells ("onion-skin proliferation") in 
muscular pulmonary arteries and their branches; the cells which proliferated have been 
shown to be myofibroblasts (Smith & Heath, 1979). In PRAs (100-300qm internal 
•diameter) substantial medial thickening has been reported (Rabinovitch, et a l, 1981). 
The morphological studies of my own investigations are too limited to allow 
quantitative conclusions as to which components of the medial wall are altered 
secondaiy to left ventricular dysfunction. Previous studies in large diameter hilar 
pulmonary arteries of the chronic hypoxic rat demonstrated hypertrophy, rather than 
hyperplasia as being responsible for the medial thickening (Meyrick & Reid, 1978) but 
this remains controversial. Similarly, the factor(s) involved in pulmonary vascular 
remodelling are as yet unclear. Several growth factors are thought to play important 
roles in the proliferation of VSMCs. Numerous studies indicate ET-1 and/or NO in the 
vascular hypertrophy associated with the pathogenesis of hypertension (e.g. Janakidevi, 
et a l, 1992, Ferro & Webb, 1997).
In PHT, remodelling occurs in all three vascular layers but the pattern of 
thickening varies depending on the size of the artery. Electron microscopy of random 
samples from 8 week procedure groups showed that the endothelium was severely 
disrupted in sections from coronary-ligated animals. Rabinovitch et a l (1986) reported 
abnormalities in the pulmonaiy artery endothelium in patients with congenital heart 
defects and PHT. Nitric oxide (NO) also plays an important role in the in vitro 
destruction of endothelial cells by neutrophils (Fligel, et a l, 1984, Varani, et al, 1985; 
Warren & Ward, 1986). Activated neutrophils can generate superoxide anion that, 
together with NO, leads to hydroxyl radical formation. This highly reactive free radical 
appears to be ultimately responsible for the death of endothelial cells (Warren & Ward, 
1986). Moreover, the results of chapter 6 indicate an increase in NO in PRAs from 
coronaiy-ligated rabbits. In addition, it is known that in response to endothelial injuiy,
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the migration of vascular smooth muscle-cells (VSMCs) from the medial layer to intima 
triggers abnormal VSMC proliferation. Thus, this may play a role in the medial 
hypertrophy evident in these vessels. Disruption of the adventitia of isolated PRAs from 
ligated rabbits was evident from limited confocal microscopy studies. Increased matrix 
deposition is also well documented in PHT. Previous studies show a significant increase 
in the arterial adventitia due to increase in collagen deposition in the hypoxic rat model 
of PHT (Meyrick & Reid, 1978; Hi si op & Reid, 1976). Alterations in the adventitia have 
also been reported in various grades of severity of PHT induced by congenital cardiac 
defects (Heath & Edwards, 1958).
Many previous studies use increased right ventricular hypertrophy, vessel 
muscularisation, combined with pulmonary pressures as markers to confirm PHT in 
animal models (Wanstall & ODonnell, 1990; Sakai, et a l, 1996; Enriquez-Sarano, et 
a l, 1997). Thus, the results of this chapter indicate that the animals with LVD induced 
by permanent coronaiy artery ligation, exhibit similar alterations previously observed in 
other models of PHT.
5-HT receptor -mediated responses: effect o f left ventricular dysfunction
The comparable magnitudes of vasoconstrictions to KCl showed that the 
contractile ability was similar in vessels from both control and LVD rabbits, regardless 
of the duration of the coronary artery ligation. The response to KCl, which is mediated 
through if 8 effect on the membrane potential (Burnstock, et a l, 1963) and is therefore 
receptor independent, indicates the integrity of the smooth muscle present in the 
preparations examined from the various experimental groups.
5-HT, 5-CT and sumatriptan evoked cumulative concentration dependent 
vasoconstrictor responses in all rabbit PRAs. 5-HT had a similar potency in stock/sham- 
operated and coronary-ligated preparations from both 8 and 32 week procedure groups. 
However, various studies on other animal models have reported increased pulmonaiy 
artery sensitivity to 5-HT. For example, 5-HT has been associated with the development 
of PHT in the rat monocrotoline-induced model and responses to 5-HT were potentiated
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in these animals (Wanstall & O'Donnell, 1990; Kanai, et a l, 1993). In chronic hypoxic 
rat model, the sensitivity to, and the maximum response of, 5-HT was increased in the 
main, first branch and pulmonary resistance arteries removed from chronic hypoxic rats 
(MacLean, et al, 1996b). From the effects of various selective antagonists, the authors 
concluded that the augmentation in the 5-HT-induced response was due to the enhanced 
effect of 5-HT2A receptor stimulation combined with the increased influence of r5- 
HTiB-like receptor stimulation. In this previous report, rat PRAs had a similar 
sensitivity to 5-HT (pECso of -5.9) as was noted in rabbit PRAs (-6.1) in this present 
study. Similar pulmonary arterial hyperreactivity to 5-HT has been observed secondary 
to platelet 5-HT storage disorder in rats (Ashmore, et a l, 1991) and in isolated 
pulmonary arteries from patients with primary PHT (Brink, et al, 1988).
In this present study, the magnitude of the maximal 5-HT-induced 
vasoconstriction was reduced in ligated preparations compared with the age-matched 
controls; this attenuation was significant in the 8 week experimental group. Hence, this 
finding is in contrast to the other aforementioned studies, where an increase in 
magnitude of 5-HT responses were reported. Moreover, a previous in vivo study using 
this rabbit coronary ligation model demonstrated an increased pulmonary pressor 
response to i.v. administered 5-HT in 8 week ligated rabbits when compared to sham- 
operated animals (Deuchar, et al, 1997). Differences in findings between in vivo and in 
vitro studies have also been reported in humans; 5-HT was shown to contract human 
pulmonary arteries and veins in vitro (Raffestin, et a l, 1985), yet was shown to have no 
effect on pulmonary artery pressure in vivo (Harris, et al, 1960). This may be caused by 
the balancing between the vasoconstrictor and vasodilator effects of 5-HT. Also, when 
analysing the results of in vivo studies, a role of parenchymal and/or vascular agents 
cannot distinguished.
In humans and fawn hooded rat, hypersensitivity to 5-HT may be associated with 
abnormalities in platelet 5-HT storage (Heiwe, et a l, 1995; Ashmore, et a l, 1991). 
However, there is no evidence for abnormalities in platelet 5-HT storage in animal 
models or in humans with heart failure. In addition, in small systemic arteries dissected
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from gluteal skin biopsies, responses to 5-HT were similar in preparations obtained from 
normal and congestive heart failure patients (Angus, et at., 1993).The difference in 
findings between this present study and previous reports in other models may be due to 
differences in species or preparations and/or in the aetiology of the PHT state.
In pulmonaiy arteries and systemic arteries 5-HT is known to cause endothelium 
-dependent and endothelium-independent vasodilation via 5-HTiD-like and 5-HTy-like 
receptors, respectively (Schoeffter & Hoyer, 1990; Terron, 1996). Hence the overall 
effect of 5-HT will be determined by the balance between direct smooth muscle 
vasoconstriction and vasorelaxation. Since all 5-HT receptor agonist examined evoked a 
vasoconstrictor response in rabbit PRAs, it appears that the direct contractile effect 
overrides any vasodilator effect. This finding is consistent with the overall pressor 
response of the pulmonary circulation in vivo to 5-HT, which has previously been 
demonstrated in this rabbit model (Deuchar, et al., 1997). The decreased vasoconstrictor 
5-HT-induced response of isolated PRAs from LVD rabbits may therefore be due to 
decreased vasoconstriction and/or increased vasodilation via the 5-HT receptors.
The presence of contractile 5-HTid receptors in this preparation was indicated 
by the cumulative concentration dependent contractile response evoked to sumatriptan. 
However, the magnitude of the vasoconstriction to sumatriptan was markedly smaller 
compared to 5-HT in sham-operated rabbit PRAs, and both 5-CT and 5-HT in the 
coronary-ligated rabbit PRAs. The comparatively smaller response to sumatriptan could 
be due to the fact that both 5-HTj (MacIntyre, et al., 1993) and 5 -HT2 receptors 
(Raffestin, etal., 1985; McMahon, etal., 1993) are involved in the contractile response, 
whereas the relaxant response to 5-HT is mediated via 5-HTi receptors (Schoeffter & 
Hoyer, 1990; Terron, 1996). Thus activation of both contractile receptor subtypes by 5- 
HT would thereby elicit a comparatively greater response than the selective 5-HTid 
agonist sumatriptan. However, 5-CT evoked a similar response in PRAs from sham- 
operated and coronary-ligated rabbits and the magnitude of the response to this selective 
5-HTi receptor agonist was not significantly different from that of 5-HT. This finding 
suggests the predominance of 5-HT 1-like receptors mediating vasoconstriction in this
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preparation, however further studies using selective antagonists are required to confirm 
this. Since a maximum response was not reached in the 5-CT- and sumatriptan-evoked 
responses, EC50 values could not be calculated, however both agonists appeared less 
potent compared to 5-HT. These findings compare with a previous report in isolated 
larger pulmonary arteries from the adult rabbit. Morecroft & MacLean (1995b) 
demonstrated ^ EC^o values for 5-HT o f -7.4 and -7.1 in the extralob al and intralob al 
pulmonary arteries, respectively. Thus the value of -6.1 calculated for PRAs in this 
study suggests a lower potency of 5-HT in these smaller arteries. The disparity in 
sensitivities may be due to different anatomical location of the vessels studied. These 
finding are at odds with those of MacLean et al (1996b) in the chronic hypoxic rat 
model, who demonstrated that 5-HT was most potent in the PRAs compared with 
pulmonary branch and main pulmonary artery. This indicates yet again either species or 
model variation. In the rabbit larger pulmonary arteries 5-HT was shown to be more 
potent than 5-CT however sumatriptan was inactive (Morecroft and MacLean, 1995b). 
These findings suggested that .a "5-HT2 type" receptor is mainly involved in the 5-HT- 
induced vasoconstriction in larger pulmonary arteries of the adult rabbit but 5-HTib 
receptors appear not to be involved. 5-HT is also thought to constrict larger pulmonaiy 
arteries of the calf due to an action at 5-HT2A receptors (Frenkan & Kaumann, 1984). 
These findings are in contrast to the apparent role of contractile 5-HTid receptors in 
rabbit PRAs which is indicated by the contractile effect of sumatriptan in this 
preparation; and provides further evidence for regional differences in 5-HT receptor 
mediated responses.
As was noted with 5-HT responses, the maximal response to sumatriptan was 
markedly attenuated in 8 week LVD animals compared to control animals. This finding 
may indicate an alteration in 5-HTid  receptor subtype in the LVD animals. The reduced 
vasoconstriction to 5-HT and sumatriptan in PRAs from 8 week ligated rabbits may also 
be due to an increase in the production of endothelium-derived nitric oxide secondary to 
LVD; indeed this is indicated by the results shown in chapter 6 of this thesis.
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Other previous studies suggest the role of 5-HT j-like receptors in the contractile 
response to 5-HT in the pulmonaiy circulation. Templeton et al (1993; 1994) have 
previously shown that 5-CT Is more potent than 5-HT and sumatriptan is equipotent to 
5-HT in human pulmonary arteries, suggesting 5-HTiD-like activation in these vessels. 
Further evidence for this was reported more recently; GR55562 (5-HTid receptor 
antagonist) was shown to inhibit 5-HT and sumatriptan responses in a true competitive 
fashion, whereas ketanserin (selective 5-HT2A receptor antagonist) and methiothepin 
(non-selective 5-HT 1+2 receptor antagonist) had no effect on sensitivity to these agonists 
(MacLean, e ta l,  1996a). Furthennore, B.ard et al (1996) reported that rabbit and human 
recombinant 5-HTid receptors (a and|3) showed significant intraspecies and interspecies 
similarities in their ligand binding profiles, suggesting that 5-HTiD-mediated responses 
in rabbit preparations may provide information relevant to the pharmacology of the 5- 
HTid receptor subtypes in humans. The species homologues of the human 5-HTidoc and 
5-HTiDp receptors have recently been reclassified as the r5-HTio and r5-HTiB 
receptors, respectively (Hartig, et a l, 1996). In addition, McIntyre et al (1992) on 
studying the effect of and duration of action of sumatriptan on central haemodymnamics 
in humans, found that this selective 5-HTm  receptor agonist produced a more 
pronounced effect on the pulmonary pressure when compared with the overall systemic 
pressure. Indeed, the effect of 5-HT on systemic arteries is mainly due to activation of 5- 
HT2 receptors, more recently classified as 5 -HT2A receptors, which are antagonised by 
ketanserin (Humphrey, etal, 1993).
Although no difference in sensitivity was noted following coronary artery 
ligation, PRAs from 32 week procedure group were significantly less sensitive to 5-HT 
than the 8 week procedure group arteries. Since no change was noted with the presence 
of LVD, this difference may reflect an age-related reduction in potency. Such age- 
related alterations in agonist sensitivity have been reported previously. In rat mesenteric 
resistance arteries, Dohi and Luscher (1990) demonstrated that the sensitivity to ET-1- 
induced vasoconstrictions decreased with advancing age. Nakashima and Vanhoutte 
(1993) showed that in perfused larger mesenteric arteries of the rat, ageing decreased
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endothelium-dependent hyperpolarisations evoked by both ET-1 and ACh. The authors 
suggested that with ageing, a constant exposure to the ETs may result in the decreased 
sensitivity to ET-1 and ET-3. One can only speculate, however given the important role 
of the lungs in the metabolism of 5-HT which escapes being taken up by the platelets 
(Said, 1982), a possible overexposure may be related to the reduced 5-HT sensitivity 
observed in the 32 week procedure rabbit PRAs compared to those from 8 week 
animals.
In conclusion, this study suggests that the rabbit PRA has a functional population 
of 5-HT 1-like receptors, possibly rS-HTis-like, which may play a role in the contractile 
response to 5-HT. In particular, the attenuation of 5-HT- and sumatriptan-induced 
responses in coronaiy ligated rabbit PRAs suggests that an alteration in 5-HTiD-hke 
receptors may occur in PHT state secondary to LVD in these animals. These results 
suggest that further examination of the role of 5-HT in this model is warranted. Studies 
with selective antagonists and further selective agonists would provide more information 
on receptor subtypes involved and also in the possible alteration in 5-HT receptor 
subtypes, particularly 5-HTiD-like, in PRAs from rabbits exhibiting PHT secondary to 
LVD.
Endothelium dependent and independent relaxatory responses: effect o f left ventricular 
dysfunction
The PRAs from eight week procedure group animals were examined for 
endothelium dependent relaxations. Surprisingly, I could find no evidence for this 
despite trying a range of agonists known to induce endothelium dependent relaxations in 
pulmonary arteries (see chapter 1). In vessels from both sham-operated and coronary- 
ligated rabbits ACh evoked similar concentration-dependent, transient contractile 
responses. ACh-mediated vasoconstriction of rabbit small pulmonary vessels has 
previously been reported (Sada, et a l, 1987). Catravas et al (1984) also observed 
vasoconstrictor responses to ACh in the rabbit pulmonary circulation. The inability of 
ACh to induce a vasorelaxation is in contrast to the results of the studies in fetal and
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neonatal rabbit PRAs in chapter 8 of this thesis. In this latter study, ACh did induce a 
relaxatory response, however, in vessels from 7 day old rabbits, a contractile response 
was noted to higher concentrations of this agonist, thus similar to the responses observed 
in the adult vessels of this present study. These findings indicate an alteration in ACh- 
induced responses with age and this possibility is discussed in chapter 8 of this thesis.
However, endothelium-dependent relaxations have been reported in the larger 
pulmonary arteries of the rabbit (Morecroft & MacLean, 1995a). Such relaxations have 
also been demonstrated in isolated conduit pulmonaiy arteries from other animals 
(Chand & Altura, 1981) and man (Greenberg, Gt al,  1987; Dinh-Xuan, et al, 1990b), as 
well as in more distal muscular arteries and PRAs of the rat (Leach, et al,  1992; 
MacLean, et al.., 1994a). Similar results have been shown in isolated rabbit lung 
preparations (Hyman & Kadowitz, 1989) and in vivo In man (Fritts, et al, 1958). The 
differences between my own observations and those of other groups may lie in the 
preparations studied, i.e. pulmonary resistance arteries as opposed to isolated 
extrapulmonary arteries or isolated perfused lungs, and may also be species related. 
Alternatively, the endothelium derived factor(s) released from rabbit PRAs in response 
ACh may be contractile in nature, e.g. ET, superoxide anions (Vanhoutte & Kataustic, 
1988) . Another possibility is that contractile muscarinic receptors predominate in this 
preparation. Consistent with this is a previous study using autoradiographic mapping 
and in situ hybridisation which showed the predominance of muscarinic M^-receptors in 
pulmonary vessels of the rabbit lung (Mak, et al,  1993).
In addition, I also examined these adult preparation for relaxatory responses to 
ET-receptor agonists in chapter 4 of this thesis, as ET-1 itself is known to induce 
endothelium-dependent relaxations in the pulmonary circulation via the release of NO, 
and possibly adrenomedullin, following activation of endothelial ETg receptors. For 
example, previous studies have demonstrated this in the pig pulmonary artery (Namiki, 
et al,  1992), in the isolated perfused rat lung (Lai, et al,  1995) and the pulmonary 
vascular bed of the intact cat where it acts, in part, by activation of potassium channels 
and may act as an endothelium-derived hyperpolarising factor (Lippton, et al,  1991).
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The lack of relaxatory responses may be due to the absence of NO production by the 
endothelium or absence of the appropriate channels or receptors for the agents tested. 
However, the studies of chapter 6 of this thesis provides evidence for NOS in the 
endothelium of the PRAs, particularly in those vessels removed from the rabbits with 
LVD as L-NAME, evoked a marked potentiation of ET-1- and SXS6 c-induced 
responses in these vessels. Other reports in animal models of PHT also demonstrate an 
up-regulation of NOS (e.g. Xue, etal, 1994).
SNP evoked a concentration-dependent relaxation in all preconstricted PRAs 
examined. The PRAs removed from 8 week procedure animals with LVD demonstrated 
a decreased sensitivity to SNP, whereas maximum responses were unaffected. Whilst in 
PRAs from 32 week procedure animals, SNP evoked a similar response in vessels from 
stock and coronary-ligated rabbits. In contrast, Dinh-Xuan et al (1993) reported that 
relaxation with SNP was significantly greater, whereas endothelium-dependent 
relaxations to ACh were markedly reduced in isolated pulmonaiy arteries from patients 
with chronic obstructive lung disease compared to those from normal subjects. However - 
this condition is somewhat different from alterations in the pulmonary circulation which 
occur secondary to left-heart disease. For example, all the patients in this latter study 
were hypoxaemic whereas this condition is unlikely to exist in this model of LVD. In 
preconstricted small arteries (<300pM internal diameter) from gluteal skin biopsy 
specimens from patients with congestive heart failure, Angus et al (1993) reported that 
relaxatory responses to SNP were similar whereas those to ACh were reduced, 
compared to those in vessels from normal controls. The authors suggested that the 
release of EDRF (NO) is limited in congestive heart failure. Again, it is difficult to 
Compare these findings with my own as the systemic and pulmonary vasculatures differ 
in many respects both functionally and structurally. Several possibilities may account 
for my own observation. Firstly, this may reflect an increase in local levels of ET-1, 
indeed numerous studies show increased plasma levels in PHT of several etiologies 
including heart failure (Kiowski, et a l,  1995; Cody, et a l,  1992). This possible 
explanation extends from the findings of Yang et al (1989), who demonstrated that ET
inhibited SNP relaxations in human mammary veins. Also, ET-induced 
vasoconstrictions of rabbit pulmonary veins were shown to be resistant to isoproterenol 
or forskolin-induced relaxations (Russell & Roberts, 1991). These results reflect that the 
potent contractile endothelium derived substance ET-1 may modulate the actions of 
vasodilators in vascular preparations. Thus the reduced potency of SNP in the 8 week 
LVD animals may reflect increased local ET-1 levels. Unfortunately local ET-1 in 
pulmonary vasculature of this model are unknown. Nevertheless, a previous report 
demonstrated that thrombin stimulates production of ET in cultured endothelial cells 
(Schilli, et al, 1989), suggesting that activation of the coagulation cascade, which occurs 
upon endothelial damage, can ultimately result in ET-1 formation. This information, 
taken together with the endothelial damage in coronary-ligated rabbit pulmonary arteries 
and the pulmonary congestion indicated by the significant increase in lung weight in 8 
week animals, which were demonstrated in this chapter, provides further evidence for 
the possible role of local ET-1. Alternatively, from the findings of the studies of chapter 
6 , vessels from this same group of animals appeared to have increased NOS compared to 
age-matched sham-operated. Neddleman & Johnson (1973) reported that in man, a 
tolerance to the effects of nitrates was noted following an increase in stimulation by NO 
by long term nitrate administration. In the same line, another previous study reported 
that in rats chronically treated with L-NAME such that eNOS was depleted, the 
pulmonaiy arteries were hypersensitive to SNP (MacLean & MacMillan, 1993). These 
findings taken together suggest that when there is increased stimulation by NO either by 
upregulation of eNOS or administration of nitrates, the vascular smooth muscle 
compensates by a reduction in the sensitivity to NO. Whereas when eNOS is inhibited, 
the reverse case holds, with the smooth muscle becoming hypersensitive to NO. 
Furthermore, the findings of the studies in 32 week procedure group animals provide 
more evidence for this latter possibility. In PRAs from these animals, SNP evoked a 
similar response in vessels from coronaiy-ligated and age matched stock rabbits. In the 
studies of chapter 6 , L-NAME had no significant effect on responses to ET-1 and SXS6 c
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in PRAs from 32 week procedure rabbits. Thus these findings taken together are in 
keeping with the possible role of NOS in SNP-induced responses.
The thromboxane A% (TXA2) mimetic U46619 was used to preconstrict the 
PRAs. The contractile response to this agent was similar in all vessels from the 8 week 
procedure group, however was markedly augmented in PRAs from 32 week ligated 
rabbits compared to age-matched stock and 8 week preparations. Increased activity of 
the pulmonary vasoconstrictor TXA2 has been implicated in several forms of PHT. 
TXA2 has been shown to be responsible for the early phase of sepsis-induced PHT 
(Weitzberg, et ah, 1995). It has also been implicated in other experimental models of 
PHT induced by heparin/ protamine (Montalescot, et a l, 1990), leukotriene D4 (Noonan 
& Malik, 1986), microembolism (Garcia-Szabo, e ta l,  1988) and ischaemia-reperfusion 
(Zamora, e ta l, 1993). Furthermore, elevated levels of thromboxane B2 , the metabolite 
of TXA2 , has been found in neonatal PHT (Dodyns, et a l, 1994). The augmented 
contractile response to U46619 in 32 week ligated rabbit PRAs may indicate an 
alteration in receptors and /or intracellular pathway in this preparation. G-protein linked 
membrane TP receptors for TXA2 are coupled with phospholipase C (PLC) (Strader, et 
a l, 1995). Activated PLC catalyses the hydrolysis of PIP2 Into IP3, which releases Ca2+ 
from intracellular stores, and DAG, which activates PKC (see chapter 1). In addition, 
Sornik and Toro (1992) demonstrated that in pig coronary artery, U46619 inhibited Ca^+ 
activated-K+ channel activity; thus an alteration in K+ channel activity is another 
possibility for the augmented contractile response. Further investigations using agents 
which interfere which the underlying intracellular mechanism, such as PKC activators 
(e.g. phorbol myristate acetate (PMA)) or inhibitors (e.g. staurosporine), or selective K"^  
channel blockers would provide more insight into this obseiwation.
To summarise, following coronary artery ligation, rabbits exhibited a marked 
decrease in ejection fraction, left ventricular hypertrophy, right ventricular hypertrophy, 
augmentation in lung weight and pulmonary vascular remodelling. No functional 
differences to KCl in isolated PRAs were found between age-matched control rabbits
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and those which were ligated for 8 , 16 or 32 weeks. However, impaired contraction to 
sumatriptan and 5-HT, and relaxation to SNP was noted in PRAs from 8 week coronary 
artery ligated animals compared to sham-operated rabbit vessels. These results 
demonstrate the existence of PHT secondary to LVD in this model and show alterations 
in functional responsiveness of isolated PRAs which does not appear to be related to 
changes the integrity of the vascular smooth muscle.
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Chapter 4
ET-receptor mediated responses in rabbit pulmonary 
resistance arteries: Effect of pulmonary hypertension 
secondary to left ventricular dysfunction
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4.1 Introduction
The role of endothelin-1 (ET-1) in the pulmonary circulation, including 
biosynthesis, clearance, and the marked effects on the vasculature, both stmcturally and 
functionally, has been introduced in chapter 1 of this thesis. Increases in the plasma 
concentration of ET-1 has been described in patients with acute myocardial infarction 
(Miyauchi, et al., 1989) and in patients with pulmonaiy hypertension associated with 
congenital heart defects (Yoshibayashi, et al., 1991). In this latter study the authors 
indicated that this elevation is mainly'due to increased production of ET-1 in the 
pulmonary circulation. Kiowski et al (1995) and Cody et al (1992) reported that plasma 
levels of ET-1 are significantly elevated in patients with chronic heart failure and this 
correlated directly with several variables including the extent of pulmonary hypertension 
and pulmonary vascular resistance. After administration of ET-1 in man, pulmonary 
vascular resistance increased more than systemic vascular resistance (Weitzberg, et al,
1993). Sorensen et al (1994) also reported pronounced effects of exogenous ET-1 In 
human pulmonary circulation. Intravenous infusion of the non-selective ET-receptor 
antagonist bosentan was reported to decrease pulmonary vascular resistance in patients 
with chronic heart failure (Kiowski, et a l, 1995) and was reported to be effective in a rat 
model of chronic heart failure (Teerlink, et a l, 1994). ET antagonist have also been 
shown to reduce the PHT associated with coronary artery ligation in the rat (Sakai, et 
al., 1996). These observations provide more support for the notion that ET-1 is 
important in the regulation of pulmonary vascular tone and suggest the possible 
involvement of ET in the pathophysiology of PHT associated with heart abnonnalities.
Measurement of haemodynamic indices in these previous in vivo studies 
however reflects only the sum of responses. Furthermore, the control of PVR is not 
uniform throughout the pulmonary vasculature and arteries with a diameter greater than 
500|am are thought to relatively unimportant (Andersson, et a l, 1985). In addition PHT 
has been shown to be associated with increased expression of ET-1 in vascular 
endothelial cells and the greatest degree of immunostalning occurred in the endothelium
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of elastic and muscular pulmonary arteries (which also displayed severe medial 
thickening an intimai proliferation) compared with other pulmonaiy vessels (Giaid, et 
a l ,  1993). The majority of previous in vitro studies of ET-1 in the pulmonary 
vasculature were conducted in large pulmonary arteries with internal diameters ranging 
from 2-5mm, in situ location of these arteries were either main or branch 
extrapulmonary arteries or intrapulmonary arteries, depending on the species (Panek et 
al, 1992; LaDouceur et al, 1993; Watanabe, et al., 1991). Thus a greater understanding 
of the role of ET-1 in influencing the pulmonary vascular tone would be gained by 
examining the response of isolated small muscular arteries. I pursued this possibility by 
examining the functional responses in rabbit small muscular intrapulmonary arteries 
(referred to as pulmonary resistance arteries (PRAs)) throughout this study.
In this chapter I examined the vascular reactivity to ET-1 in PRAs obtained from 
rabbit coronaiy-ligation model of left ventricular dysfunction. The results in chapter 3 
showed evidence for the condition of PHT in these animals. ET-1 and ET-3 are 
isopeptides, encoded by distinct genes (Inoue et al, 1989). The ETa receptor shows 
selectivity of ET-1 over ET-3 (Arai, et a l, 1990; Masaki, et a l, 1991) whereas, the ETb 
receptor is non-isopeptide selective (Sakuri, et a l, 1990; Masaki, et a l, 1991). I used 
ET-1 as a non-selective agonist at ETa  and ETb receptors, and the peptides ET-3 and 
sarafotoxin S6 c (SXS6 c) as a selective- ligands for the ETb receptor subtype; these 
peptides have - 2 0 0 0 - and 300000 fold selectivity, respectively, for the ETb over the 
ETa receptor (Williams, e ta l, 1991a;b). The responses in coronary ligated preparations 
were compared with those in vessels from stock and sham-operated rabbits to examine 
the possible influence of PHT secondary to left ventricular dysfunction on ET-receptor 
mediated responses in PRAs. Furthermore, I investigated the effect of different durations 
of permanent coronary artery ligation using preparations from rabbits studied 8 , 16 and 
32 weeks after coronary ligation.
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4.2 Methods
Rabbit pulmonary resistance arteries
Lungs were obtained from the rabbit coronary ligation model of left ventricular 
dysfunction which has been extensively characterised (Pye ef al, 1996) and is described 
in detail in section 2.1.1 of this thesis. In the 8 week and 16 week procedure period 
groups, age matched animals underwent the same methodology as the experimental 
animals (referred to in results and discussion as "ligated") except the ligatures placed 
around the coronary artery were not secured. These are subsequently referred to as 
"sham-operated". Also, age matched animals in which no operational procedures were 
performed were used as controls in the 16 week and 32 week procedure period groups 
These are subsequently referred to as "stock". Measurements of ejection fraction were 
made in all animals and animals were killed by sodium pentabarbitone 8 , 16 or 32 weeks 
following the procedure. The lungs were promptly removed and small intralobar 
pulmonary resistance arteries (PRAs -150 pm i.d.) were dissected out according to the 
methods stated in section 2.2.4.1. These were mounted as ring preparations (-2mm 
long) on a wire myograph, bathed in Krebs solution at 37®C. Using the normalisation 
process explained in section 2 .2 .6 , vessels were tensioned to an equivalent transmural 
pressure of -  16 mmHg. This pressure was chosen as it is similar to in vivo pressures of 
rabbit pulmonary arterioles. Preliminary studies in our iaboratoiy showed that bubbling 
with 95% O2 inhibits responses to vasoconstrictors in rabbit PRAs so we bubbled with 
16% O2/ 5% CO2 balance N2 . These gas mixtures were chosen as they are similar to 
those which the vessels would be exposed to in vivo.
Experimental protocol
Vessels were allowed to equilibrate for 1 hour prior to the addition of any drugs. 
The response of the PRAs to 50mM KCl was determined twice; once the contractile
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response had reached a plateau, the vessels were washed out at least 6 times with fresh 
Krebs solution. Cumulative concentratlon-response curves (CCRCs) were then 
constructed to ET-1 or SXS6 c (lpM-0.3pM) in PRAs; ET-3 (lpM-0.3pM) responses 
were examined in 8 week procedure group only. In a proportion of SXS6 c experiments 
in vessels from 8 and 16 week procedure groups, 0.1 pM ET-1 was added to the bath at 
the end of the SXS6 c CCRC, before washing, so as to estimate the SXS6 c response as a 
percentage of response to a maximal ET-1 concentration.
The possibility of SXS6 c-induced vasorelaxations was studied in 8 week 
preparations only. After the second KCl response, following washout and appropriate 
rest period, vessels were preconstricted with IpM 5-HT or 30nM U46619 and SXS6 c 
(O.OlpM-O.lnM) was added cumulatively to the bath.
Note
(1) ET-receptor agonists are known to be slow acting in terms of production of 
functional responses (see chapter 1). Thus, in all studies involving these peptides, I left 
intervals of at least 5 minutes between each subsequent concentration in order to ensure 
that a plateau in the response had been reached.
(2) Due to the expense of ET-1 and the vast number of experiments in which it 
was to be utilised, cumulative responses were examined in the PRAs up to a 
concentration of 0.3 pM. In some results shown in this chapter it is not always evident if 
indeed a maximum response had been attained by 0.3pM ET-1. However in several 
studies, I constructed CCRCs up to IpM ET-1 in order to investigate this. At this 
financially feasible top concentration the contractile response was very similar to that 
evoked by 0.3pM ET-1. Hence I was satisfied that terminating the CCRCs at this 
concentration gave viable maximal responses of the vessels to this peptide.
(3) In order to examine the possibility that the actual procedures undertaken on 
the sham-operated rabbits had any affect on the functional responses of isolated tissues 
eventually obtained, age-matched stock animals were included in the 16 week procedure
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experimental group. This allowed comparisons to be made with age-matched sham- 
operated rabbit tissue.
Data analysis
Results are expressed graphically as percentage of their own maximum 
contraction, or percentage of reference contraction to second application of 50mM KCL, 
or percentage of contraction to 0.1 pM ET-1. t?ECio,/?EC25 and /^ECso values (where 
appropriate) were calculated according to the methods stated in section 2.5.2, and 
expressed as -log M concentration. Statistical analysis of the means of groups of data 
were made by Student's unpaired t-test when two groups of data were compared, and 
one-way analysis of variance (ANOVA) followed by Tukeys post test when three 
groups or more were compared; P<0.05 was considered statistically significant. 
Throughout, data are expressed as mean ± SEM and n in = number of ring prepaiations / 
number of animals.
4.3 Results
The ejection fraction of animals from the various experimental groups, from 
which lungs were obtained and PRAs dissected for the studies described in this chapter, 
are shown in table 4.1. The effective pressure to which these vessels were tensioned and 
the resulting estimate of internal diameter are also shown in table 4.1. The ejection 
fraction was markedly reduced in ligated animals compared with sham-operated/stock 
rabbits in 8 , 16 and 32 week procedure groups. Also, the reduced ejection fraction was 
significantly lower in 16 week ligated compared to 8 and 32 week ligated rabbits. 
Vessels from all experimental groups were tensioned to a similar effective pressure and 
internal diameter.
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(n)
Internal diameter Effective pressure 
(pM) (mmHg)
Ejection fraction 
(%)
8 week
sham-operated(29) 162.2+7.2 2 0 .8+1.2 72.8+1.0
ligated (34) 169.1+8.6 20.7+0.8 45.2+0.9
16 week
stock (12) 151.1+13.6 2 0 .2 +1.8 75.1+1.5
sham-operated(9) 135.8+3.3 17.7+1.8 77.8+1.9
ligated (36) 163.2+8.2 18.9+0.9 39.3+1.0***+
32 week
sham-op erated( 10) 151.7+9.5 15.7+1.2 75.0+1.3
ligated (12) 146.4+9.1 19.5+1.5 47.7+1.3***
Table 4.1 (1) Ejection fraction of animals from which PRAs were dissected and studied 
in this chapter and (2 ) internal diameter and effective pressure of PRAs from this cohort 
of rabbits. Statistical comparisons were made by Student's unpaired t-test, ligated vs. 
sham-operated/stock, ***P<0.001; ANOVA, 16 week ligated vs. 8 and 32 week ligated, 
+P<0.001. Values are mean+SEM. n, number of ring preparations.
8 week experimental group
Figure 4.1 demonstrates CCRC's to ET-1, SXS6 c and ET-3 in 8 week sham- 
operated and coronary-ligated rabbits. These peptides evoked phasic responses. For ET- 
1 and ET-3, the first component showed a gradual slope up to ~lnM  and a markedly 
steeper incline was evident at higher peptide concentrations. SXS6 c-evoked CCRC was 
of a different shape, reaching a maximum at lOnM and "dropping off" at higher 
concentrations (figure 4.1 A; 4 .IB). All three ET-receptor agonists were potent 
vasoconstrictors of rabbit PRAs from both experimental groups and pEC\Q^pEC25 and 
/>EC5o values are summarised in table 4.2. Considering the pECso values, the potency 
order for these peptides were SXS6c>ET-3=ET-l in vessels from both groups of 
animals. No difference in sensitivity were noted between sham-operated and coronaiy 
ligated rabbit vessels.
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Figure 4.1 Responses to ET-receptor agonists in PRAs from 8 week experimental group 
animals. Data are expressed as a percentage of their own maximum. A. CCRC's to ET-1 
(# , n=8/6 ), SXS6 c (□, n=10/9) and ET-3 (O, n==10/9) in PRAs from sham-operated 
rabbits. B. CCRC's to ET-1 (n=12/7), SXS6c (n=ll/7) and ET-3 (n=9/6) in PRAs from 
coronary ligated rabbits. Each point represents mean± s.e. mean.
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Figure 4.2 Responses to ET-receptor agonists in PRAs from 8 week experimental group 
animals. Data are expressed as a percentage reference contraction to 50mM KCl. A. 
CCRC's to ET-1 (# , n=8/6), SXS6c (□, n-10/9) and ET-3 (O, n=10/9) in PRAs from 
sham-operated rabbits. B. CCRC's to ET-1 (#, n=12/7), SXS6c (□, n-11/7) and ET-3 
(O, n=9/6) in PRAs from coronary ligated rabbits.
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Figure 4.3
A. ET-receptor mediated vasoconstriction in PRAs from sham-operated (open columns) 
and coronary-ligated (hatched columns) rabbits. Statistical comparisons by ANOVA: 
coronary-ligated vs. sham-operated response, **P<0.01; SXS6 c or ET-3 response vs. 
ET-1 response in same group, '^P<0.05, +'^'^P<0.001. Data are expressed as absolute 
contraction mg weight tension.
B. ET-3 response in PRAs from 8 week sham-operated (O, n=10/9) and coronary- 
ligated (# , n=9/6) rabbits. Data are expressed as a percentage reference contraction to 
50mM KCl. Each point represents mean+s.e. mean.
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Figure 4.3 Magnitude of ET-receptor mediated vasoconstriction in PRAs from 8 week 
sham-operated and coronary-ligated rabbits.
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The magnitude of responses to these ET-receptor agonists in PRAs from sham- 
operated and coronary ligated rabbits are shown in figures 4.2 and 4.3. The maximal 
responses to SXS6c and ET-3 were markedly less than that to ET-1 in the coronary- 
ligated rabbit vessels, both in teims of percentage reference contraction to 50mM KCl 
(110±8.3% (ET-1) vs. 78.4+12.1% (SXS6 c, P<0.05); vs. 5±9.2±5.9% (ET-3, f <0.001) ; 
figure 4.2B), and absolute contraction mg weight tension (308.9+47.6 (ET-1) vs. 
156.7+34.2 (SXS6 c, P<0.05); vs. 113.5+22.6 (ET-3, f<0.01) ; figure 4.3A). In PRAs 
from sham-operated animals, ET-1- and ET-3-induced maximal vasoconstrictions were 
similar (-90% / 300 mg wt. tension); SXS6 c responses tended to be comparatively 
smaller however this was not significant (figures 4.2A and 4.3A). The amplitude of 
responses to ET-1 and SXS6 c were similar in the two experimental groups however, the 
ET-3-evoked maximal vasoconstriction was significantly reduced in PRAs from 
coronary-ligated rabbits compared to the response from sham-operated vessels (f< 0 .0 1 , 
figure 4.3B). ET-1 (0.1 |aM) was added at the top of the SXS6 c CCRC to examine the 
amplitude of the response compared to ET-1 in the same tissue; this is illustrated in 
figure 4.4A. No difference was evident between the sham-operated and coronary ligated 
preparations, with both displaying SXS6c maximum of -65% response to 0.1 pM ET-1.
Other vessels from this group were preconstricted with either IpM 5-HT or 
30nM U46619, prior to the addition of SXS6 c (O.OlpM-O.lnM). In both sham-operated 
and coronary-ligated preparations no vasorelaxations were observed in either 5-HT or 
U46619 preconstricted vessels. However, significant constrictor responses were seen 
from 0. IpM onwards, compared with time controls (results are not shown; n/n=4/4).
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Figure 4.4 SXS6 c-evoked vasoconstrictions in rabbit PRAs. Data are expressed as a 
percentage contraction to 0.1 pM ET-1. A. CCRC's in vessels from sham-operated (□, 
11= 10/9 ) and coronary-ligated (■, n=ll/7) 8 week group animals. B. CCRC's in vessels 
from stock (O, n=3/3), sham-operated (□, n-6/6) and coronary-ligated (■, n=9/6) 16 
week group animals. Each point represents meani s.e. mean.
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16 week experimental group
Vasoconstrictor responses in 16 week stock, sham-operated and coronary ligated 
rabbit PRAs to ET-1 and SXS6c are displayed in figures 4.5A and 4.5B, respectively.
pECio pEC25 pECso n/n
sham-operated
ET-1 9.1+0.4 8.6+0.4 7.9+0.3 8 /6
SXS6 C 10.6+0.26** 9.9+0.3* 9.0+0.2** 10/9
ET-3 9.6+0.3+ . 8.9+0.2++ 8.4+0.2+ 10/9
ligated
ET-1 8.9+0.4 8.3+0.2 7.9+0.2 12/7
SXS6 c 10.4+0.3** 9.4+0.3** 8 .6+0 .2 * 11/7
ET-3 9.7+0.5 9.1+0.3* 8 .5+0.2 9/6
Table 4.2 Sensitivity to ET-receptor agonists in PRAs from 8 week procedure rabbits. 
Statistical comparisons were made by ANOVA followed by Tukey's post test: SXS6 c 
vs. ET-1, "^p<0.05, **p<0.01; ET-3 vs. SXS6 c, +p<0.05, ++p<0.01. Values are mean ± 
SEM. ET-1, endothelin-1; ET-3, endothelin-3; SXS6 c, sarafotoxin S6 c; n/n, number of 
ring preparations/number of animals.
ET-1 CCRCs were again seen to contain a relatively shallow component at the lower 
concentrations. Vessels from sham-operated rabbits appeared more sensitive in this 
lower portion of the ET-1 curve however this was not significant (figure 4.5A). The 
nature of the SXS6 c response was also similar to that exhibited in 8 week preparations 
(figure 4.5B). pEC\Q,pEC25 and ^ ECgo values are summarised in table 4.3. SXS6 c was 
markedly more potent than ET-1 in vessels from all 16 week animals, as was noted in all 
8 week rabbits. However, in contrast to findings between different groups after 8 weeks 
on procedure, both ET-1 and SXS6 c differed in sensitivity in 16 week ligated 
preparations compared to stock/sham -op erated rabbit vessels. ET-1 was signiEcantly
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Figure 4.5 Responses to ET-receptor agonists in PRAs from 16 week experimental 
group animals. Data are expressed as a percentage of their own maximum. A ET-1 
CCRC's in stock (□, n=6/5), sham-operated (O, n=5/5) and coronary-ligated (# , 
n=13/7) rabbit PRAs. B SXS6 c CCRC's in stock (□, n=3/3), sham-operated (O, n=6/6 ) 
and coronary-ligated ( • ,  n=9/6) rabbit PRAs. Each point represents meant s.e. mean.
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Figure 4.6 Responses to ET-receptor agonists in PRAs from 16 week experimental 
group animals. Data are expressed as a percentage reference contraction to 50mM KCL. 
A ET-1 CCRC's in stock (□, n=6/5), sham-operated (O, n=5/5) and coronary-ligated 
( • ,  n=13/7) rabbit PRAs. B SXS6 c CCRC's in stock (□, n=3/3), sham-operated (O, 
n=6/6) and coronary-ligated ( • ,  n=9/6) rabbit PRAs. Each point represents mean+SEM.
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Figure 4.7 ET-1- and SXS6 c-induced vasoconstrictions in PRAs from 16 and 32 week 
procedure rabbits. A. 16 week stock (open columns), sham-operated (hatched columns) 
and coronary-ligated rabbits (filled columns); n/n as figure 4.6. B. 32 week stock (open 
columns) and coronary-ligated rabbits (filled columns); n/n as figure 4.8. Data are 
expressed as absolute contraction mg weight tension. Each point represents mean+SEM.
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less potent in PRAs from coronary-ligated compared to sham-operated animals (table
4.3, figure 4.5A). The sensitivity to SXS6 c was also markedly reduced in coronary- 
ligated rabbit PRAs compared to vessels from stock and sham-operated animals (table
4.3, figure 4.5B). For both ET-1 and SXS6 c, no difference in sensitivity existed between 
the stock and sham-operated preparations.
The magnitude of responses to these peptides in PRAs from 16 week procedure 
rabbits are shown in figures 4.6 A, 4.6B and 4.7A. In PRAs from stock and sham- 
operated animals, both peptides evoked similar maximal vasoconstrictions, in terms of 
percentage reference contraction to KCl and absolute response (figure 4.7A). However, 
maximal responses to SXS6 c were markedly less than that to ET-1 in the coronary- 
ligated rabbit vessels; this attenuation was significant when analysed as percentage KCl 
response (89.6+4.8% vs. 57.5+11.5%, P<0.01). This is similar to situation noted 
following 8 weeks on procedure. No significant difference was noted in the absolute 
response to these peptides between the different experimental groups (figure 4.7A). 
Whereas on examining the vasoconstrictions relative to KCl response, the following was 
noted. ET-1 maximum was similar in stock and coronary ligated tissues (112.8+6.5% 
and 107.8+3.9%, respectively) but that noted in sham-operated animal PRAs was 
significantly lower (80.9+8.7%, f  <0 .0 1 ; figure 4.6A). In the case of SXS6 c, the 
maximum vasoconstriction was significantly attenuated in PRAs from coronary ligated 
rabbits (57.5+11.5%) compared to those from stock (82.5+15.1%) and sham-operated 
(82.6+8.0%) animals (7*<0.01). This marked difference in amplitude of response was 
evident at all SXS6 c concentrations up to lOnM (figure 4.6B). Furthermore, on 
examining the responses relative to the vasoconstriction to 0.1|,lM ET-1 in the same 
preparation, the magnitude was again evidently reduced in coronary-ligated rabbit 
vessels compared to those from sham-operated animals (52.8+9.5% vs. 90.3+8.8%, 
P<0.001, figure 4.4B). This is in contrast to the 8 week group where no difference 
existed (figure 4.4A). However, the response was significantly lower in sham-operated 
preparations from 8 week procedure compared to 16 week procedure animals (P<0.01).
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pECio pEC25 pECso n/n
stock
ET-1 8.9+0.3 8.4+0.2 7.8+0.2 6/5
SXS6 c 11.7+0.04+++ 10.2+0.4++ 9.3+0.4++ 3/3
sham-operated
ET-1 9.7+0.6 1 0 .1+1.0 8 .2+0 .2 5/5
SXS6 C 11.5+0.3+ 10.8+0.3 9.8+0.2+++ 6 /6
ligated
ET-1 9.0+0.3 8 .2 +0 .2 * 7.5+0.1** 13/7
SXS6 C 9.9±0.2***b 9 1+0 2***+++^ 8 .6+0.2**+++ 9/6
Table 4.3 Sensitivity to ET-1 and SXS6 c in PRAs from 16 week procedure rabbits.
Statistical comparisons were made by ANOVA: ligated vs sham-operated, *p<0.05.
**p<0 .0 1 , **=^p<0.001; ligated vs. stock, ^p<0.05, ^p<0.001; SXS6 c vs. ET-1, ^p<0.05.
■'■■*'p<0.01, +++p<0.001. Values are mean+SEM. ET-1, endothelin-1; SXS6 c,
sarafotoxin S6 c; n/n, number of ring preparations/number of animals.
pECio pEC25 pECso n/n
stock
ET-1 9.2+0.2 8.5+0.1 7.9+0.1 5/5
SXS6 C 10.0+0.3 9.4+0.2++ 8.7+0.15++ 5/5
heated
ET-1 9.3+0.5 8.7+0.4 7.7+0.15 5/5
SXS6 c 1 0 .8+0 .2 *+ 10.3+0.2**++ 9.4+0.2*+++ 6 /6
Table 4.4 Sensitivity to ET-1 and SXS6 c in PRAs from 32 week procedure rabbits. 
Statistical comparisons were made by Student's unpaired t-test: ligated vs. stock, 
*p<0.05, **p<0.01; SXS6 c vs. ET-1, +p<0.05, ++p<0.01, +++p<0.001. Values are 
mean+SEM. ET-1, endothelin-1; SXS6 c, sarafotoxin S6 c; n/n, number of ring 
preparations/number of animals.
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32 week experimental group
The only controls available for this group were 32 week stock animals. The 
vasoconstrictor responses to ET-1 and SXS6 c in PRAs from this group are displayed in 
figures 4.7B and 4.8. As described for the previous two experimental groups, a biphasic 
response was evident to ET-1 and the SXS6 c-evoked vasoconstriction reached a 
maximum by lOnM, with further increasing concentrations causing a "fall off" in 
tension. /?ECio,pEC25 and^ECgo values are summarised in table 4.4. PRAs from both 
32 week experimental groups were markedly more sensitive to the selective ETp- 
receptor agonist SXS6 c compared ET-1 (figure 4.8A), as was noted in all 8 and 16 week 
rabbit tissues. 32 week stock and coronary-ligated rabbit PRAs had similar sensitivity to 
ET-1 (figure 4.8A; table 4.4). Hence, this is the same as findings in the 8 week 
experimental group but differs from the 16 week group, where coronary-ligated 
preparations were comparatively less sensitive than the corresponding control vessels. 
Coronary-ligated vascular preparations were significantly more sensitive to SXS6 c, over 
the entire rising component of the CCRC, compared to vessels from stock animals in 
this group (figure 4.8A; table 4.4). This again differs from the previously described 
experimental groups since no difference was noted after 8 weeks, whereas reduced 
sensitivity was evident following coronary ligation after 16 weeks.
The magnitude of responses in PRAs from 32 week procedure rabbits to ET-1 
and SXS6 c are shown in figures 4.7B and 4.8B. Maximal vasoconstrictions to SXS6 c 
were markedly less than that to ET-1 in the coronary-ligated rabbit vessels in terms of 
percentage KCl (57.9+10.9% vs. 102.1+7.0%, f<0.01; figure 4.8B) but not absolute 
response (figure 4.8B). SXS6 c maximal responses tended to be relatively smaller than 
those to ET-1 in stock animal vessels but this was not significant. This is the same 
situation noted in preparations from 8 and. 16 week experimental groups. The magnitude 
of the responses to both ET-1 and SXS6 c in the PRAs did not differ significantly 
between the stock and coronary ligated groups.
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Figure 4.8 Responses to ET-receptor agonists in PRAs from 32 week experimental 
group animals. CCRC's to ET-1 / SXS6 c in stock (O / □, n=5/5 / n=5/5) and coronary- 
ligated ( #  / ■, n=5/5 / n=6/6 ) rabbit PRAs. A Data are expressed as a percentage of 
their own maximum. B Data are expressed as a percentage reference contraction to 
50mM. Each point represents mean± s.e. mean.
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When the results were analysed to compare the responses to ET-1 and SXS6 c in 
vessels from animals at different ages the following was evident. ET-1 had a similar 
potency in vessels from 8 , 16 and 32 week procedure period animals in both stock/sham- 
op erated and coronaiy-ligated groups. However, PRAs from 16 week sham-operated 
rabbits were more sensitive to SXS6 c compared to those from 8 week sham-operated 
{pEC\Q and^ECgo, E<0.05) and 32 week stock (pEC^a andj^EC^o P<0.01) animals. In 
addition, tissue from 32 week coronary-ligated rabbits had greater sensitivity to SXS6 c 
than vessels from 8 week (pECjo f<0.05) and 16 week (pECio andJ2EC25 T*<0 .0 1 ; 
pECsQ, P<0.05) coronary-ligated animals.
4.4 Discussion
In the groups of animals from which PRAs were studied in this chapter, the 
ejection fraction was markedly reduced in rabbits which had undergone coronary artery 
ligation compared to corresponding control animals. This provides evidence that 
coronary artery ligation in these rabbits produced left ventricular dysfunction (LVD); the 
depressed ejection fraction has also been shown in previous studies in this model (Pye, 
et al., 1996; Denvir, et al., 1996; Deuchar, et al., 1997). In addition, the results of 
chapter 3 provide evidence for the concomitant pulmonary hypertension in this model.
On examining the effect of different durations of permanent coronary artery 
ligation, in the cohort of animals used in this study, the ejection fraction of 16 week 
ligated animals was markedly lower than that of 8 week ligated rabbits. However, this 
progression of attenuation was not extended to the 32 week LVD group. Hence the 
rabbits ligated for a longer period do not appear to represent a more severe form of LVD 
but rather are "survivors" in this group.
ET -receptor mediated responses
In this chapter ET-1 and SXS6 c were potent vasoconstrictors of rabbit PRAs
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from both control and experimental animals regardless of the duration of the procedure 
period. Previous studies have shown ETs to be potent spasmogens of pulmonary artery 
isolated from humans (Brink, et a l, 1992; McKay, e ta l, 1991; Hay et ah, 1993; Buchan 
et al, 1994) and rabbits (Panek, et ah, 1992; White, et ah, 1993). In all vessels ET-1- 
evoked responses of a biphasic nature, comprising of an initial '"shallow component" at 
lower ET-1 concentrations and a steep rising incline at the higher concentration range. 
CCRC's to ET-1 of a biphasic nature have previously been demonstrated in rat 
(McCulloch & MacLean, 1995) and human PRAs (McCulloch et al, 1996; chapter 5 this 
thesis). These findings suggest a heterogeneous population of ET-receptors mediating 
the response. Indeed, radioligand binding studies of ET-1, described in chapter 7 of this 
thesis, supports this view. McCulloch & MacLean (1995) suggest that the biphasic 
nature of the rat PRA responses may be due to a heterogeneous population of ETp 
receptors or due to the presence of Inhibitory ETa receptors. In this study, SXS6 c 
induced potent vasoconstrictions which reached a maximum at -lOnM in all vessels 
from all three procedure period groups and then "dropped o ff  at higher concentrations. 
This was not observed in the CCRC's to ET-1. I also showed a similar '"drop o ff  in 
tension to high SXS6 c concentration in PRAs from fetal and neonatal rabbits (Chapter 8 
and 9, this thesis) and this has previously been shown in rat (McCulloch & MacLean, 
1995). The most likely reason for this is receptor desensitisation. I investigated the 
possible involvement of nitric oxide (NO) in this phenomenon by studying the effect of 
the nitric oxide synthase inhibitor L-NAME on SXS6 c-induced responses in 
preparations from both paradigms of the pulmonary circulation studied in this thesis; (1) 
PHT secondary to heart failure (chapter 6 ) and (2 ) the transitional perinatal pulmonary 
circulation (chapter 8). In both cases, this component of the SXS6 c curve did not appear 
to be due to NO production as it persisted in the presence of L-NAME. Similar findings 
have been shown in separate studies in rat PRAs in our laboratory. Thus the most likely 
reason for this drop off in tension is receptor desensitisation. Indeed, La Douceur et al 
(1993) demonstrated in rabbit pulmonary branches that the contractile activity mediated 
by the ET g receptor develops tachyphylaxis with prolonged exposure to SXS6 c.
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Given that both SXS6 c and ET-3 caused vasoconstriction of rabbit PRAs, these 
results suggest the presence of vasoconstrictor ETb receptors. SXS6 c was markedly 
more potent than ET-1 in vessels from all groups. Warner et al (1993) reported that ET- 
1 and SXS6 c were approximately equipotent in constricting rabbit pulmonary artery 
branch (-3mm ID). However in agreement with my findings in PRAs, La Douceur et al
(1993) reported that rabbit pulmonary aitery branches also showed a sevenfold greater 
sensitivity to SXS6c compared to ET-1; Panek et al (1992) reported similar results with 
SXS6c in this preparation. Furthermore, both these studies used endothelium denuded 
preparations thus making the vascular smooth muscle, as opposed to the endothelium, 
the likely site of action of SXS6c. Responses to ET-3 were studied in 8 week group 
animals only. In these vessels the potency order for the ET receptor agonists were 
SXS6c>ET-l=ET-3. Equipotency of ET-1 and ET-3 has also been shown in the larger 
pulmonaiy artery of the rabbit (White, et a l, 1994). Sakurai et al (1990) reported that 
the ETb receptor was non-isopeptide selective, thus the equipotency of ET-1 and ET-3 
provides further evidence for vasoconstriction being mediated ETB2"like receptors and 
is indicative of the predominance of this receptor in this vascular preparation. In chapter 
8 and 9, I also showed the predominance of vasoconstrictor ETb receptors in neonatal 
rabbit PRAs and this receptor subtype has also been reported to evoke vasoconstrictions 
in the larger PA of the rabbit (Fukuroda et al, 1994a; Hay et al, 1996) and human PRAs 
(McCulloch et al, 1996). The role of ETb receptors in vasoconstriction of the rabbit 
pulmonary arterial system has not only been demonstrated by functional 
pharmacological experiments; for example, Fukuroda and co-workers (1994b) reported 
that binding assays of membrane preparations from rabbit pulmonary arteries (l-5mm 
outer diameter) contained ET A and ETb receptors in the ratio 23:77. I investigated ET- 
receptor subtypes in rabbit PRAs from the coronary aiteiy- ligation model and in human 
PRAs using selective antagonists; the results are shown and discussed in chapter 5 of 
this thesis.
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Effects of left ventricular dysfunction secondary to coronaiy artery ligation
The results of this chapter show that the responsiveness of PRAs to ET-receptor 
agonists is altered in vessels from rabbits exhibiting pulmonary hypertension secondary 
to left ventricular dysfunction (LVD). In PRAs from animals in the 8 week procedure 
group no difference in the sensitivity or magnitude of responses to either ET-1 or SXS6 c 
was evident between corresponding control and experimental vessels. The period of 
coronary-artery ligation had differential effects on the resulting ET-1-induced responses 
in rabbit PRAs. Following 16 weeks of coronary artery ligation, PRAs were ~ 6  fold less 
sensitive to ET-1 than vessels from sham-operated rabbits and the magnitude of 
vasoconstriction was attenuated compared to age-matched stock animals. Whereas in the 
32 week procedure group, the ET-1 mediated response was similar in stock and 
"experimental" preparations, as was seen following ligation period of 8 weeks. The 
pBCso for ET-1 was -7.9 for all vessels from both these groups. This is similar to ET-1 
sensitivity previously reported in rat PRAs (McCulloch & MacLean, 1996) however, is 
comparatively less sensitive to previous reports in rabbit pulmonary artery branches 
wherepEC^oof - 8 .5-9.2 was reported (LaDouceur, et al., 1993; Warner, et a l, 1993). 
This difference may be due to variation in vessel size as ET-receptor mediated responses 
have been shown to differ in pulmonaiy of different sizes in the rat (MacLean, et al,
1994).
LVD also effected responses to SXS6 c in small muscular pulmonaiy arteries in 
this model. The sensitivity to SXS6 c was not altered in PRAs from 8 week procedure 
group however, the potency of this selective ETg-receptor agonist was significantly 
reduced as a result of ligation for a 16 week period. This was indicated by the -  eight 
fold reduction in sensitivity in these "experimental" vessels compared to corresponding 
sham-operated PRAs. Whilst following coronary artery ligation for 32 weeks, isolated 
PRAs were significantly more sensitive to SXS6 c than vessels from age-matched stock 
rabbits. The magnitude of the SXS6 c-induced vasoconstriction was not significantly 
altered in coronary-ligated rabbit PRAs from any of the three procedure groups
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examined. Thus the period of permanent coronary arteiy ligation effects the resulting 
responsiveness of PRAs to SXS6 c also. The finding that LVD had differential influences 
in ET-1- and SXS6c-evoked responses in PRAs suggests that ETa and ETb receptors 
may demonstrate different activity in pathological conditions. Differences in the 
response to SXS6 c and ET-1 following LVD have also been shown in patients with 
chronic heart failure. Infusion of peptides into the non dominant brachial arteiy with 
simultaneous measurement of forearm blood flow, using the technique of venous 
occlusion plethysmography, revealed that forearm vasoconstriction to ET-1 was 
significantly blunted whereas vasoconstriction to SXS6 c was markedly enhanced in 
CHF patients compared with control subjects (Love, et al., 1996). Similar results have 
also been reported in a dog model of experimental congestive heart failure (CHF). 
Thoracic inferior vena cava constriction is an experimental model of CHF which is 
characterised by a decrease in cardiac output and an increase in plasma ET-1. In this 
model intracoronary administration of peptides showed an attenuated coronary 
vasoconstrictor response to ET-1 with an enhanced vasoconstrictor response to SXS6 c 
in CHF dogs compared with controls (Cannan, et a l, 1996). In this present study the 
sensitivity to selective ETb receptor stimulation was also increased in PRAs from 32 
week LVD group compared with control vessels. Another investigation using pithed rats 
with congestive heart failure, induced by coronary arteiy ligation, showed a reduced 
pressor response to a bolus injection of ET-1, while the vasodilator response was 
unaltered as compared with sham-operated controls. This investigation also 
demonstrated a marked reduction in ET-receptor density in mesenteric arteries from this 
model compared with controls. These,authors concluded that there is a decreased 
vascular ET-receptor function due to a down-regulated ET-receptor and this may be 
impaired ETa but not ETb receptor function (Fu, et al, 1993). In another rat model of 
experimental congestive heart failure (CHF) which was produced by aortocaval fistula, 
the effects intravenous infusion of big ET-1 on mean arterial pressure and renal 
haemodynamics were blunted in CHF rats. This suggested that rats with CHF have 
reduced sensitivity to the vascular and renal action of ET (Gurbanov, et a l,  1995).
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Hence these previous studies in the systemic vasculature indicate reduced sensitivity to 
ET-1 secondary to CHF. The results of this chapter also indicate an attenuation in ET- 
receptor mediated responsiveness in pulmonary vasculature from 16 week ligated 
rabbits. An attenuation in ET-1 responses has not been found in all investigations; for 
example, Noll et al (1994) demonstrated that sensitivity to low concentrations of ET-1 
was also enhanced in aorta from cardiomyopathic hamsters with pulmonary congestion 
compared with control preparations.
Given that alterations are also evident in SXS6c-evoked response, as shown in 
this chapter and also in the studies of Love <3/ al (1996) and Cannan et al (1996), implies 
an upregulation of ETg-receptor subtype. However, from the results of their in vivo 
study, Fu and co-workers (1993) concluded that the impairment appeared to be in the 
ETa- rather than the ETg-receptor subtype. However this was inferred since the 
vasodilator response of the coronary vasculature to ET-1 was unaltered in CHF. The 
predominance of the ETa receptor subtype, with ETb receptors accounting for only 5% 
of the total ET-receptor population, has previously been demonstrated by binding 
studies of human coronary artery (Russell et al, 1997). In contrast, the results of this 
chapter demonstrate the predominance of vasoconstrictor ETb receptors in rabbit PRAs. 
Thus the differences in findings may be explained by heterogeneity in the ET-receptor 
subtypes of the different arterial preparations. Previous studies and the investigations of 
this chapter vary not only in terms of species but also in the manner in which ventricular 
dysfunction was created. The severity of the resulting alterations in the vasculature and 
thus the functional responsiveness of isolated arterial preparations may differ greatly and 
therefore cannot be realistically compared. Indeed even in non-pathophysiological 
conditions varying responses to ET-1 are evident in different arterial preparations. As 
already stated in chapter 1 of this thesis, the systemic and pulmonaiy circulation differ in 
many aspects therefore it is difficult to compare ET-receptor mediated effects in 
vascular preparation from both these circulations. Raffestin et al (1991) reported that 
circulating ET is a more potent constrictor of the systemic circulation than of the 
pulmonary vascular bed in the rat. Differences in ET-receptor mediated responses in
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various arterial preparations from six different species was demonstrated by Moreland et 
al (1994). From this extensive study, the authors concluded that ETa receptors were 
primarily located on the high pressure side of the circulation, whilst the vasoconstrictor 
ETg-like receptor appeared to be concentrated on the low pressure side. Nevertheless, 
these previous reports together with the results of this chapter, suggest that alterations of 
ET-receptor mediated vascular function in heart failure may depend on the experimental 
model, the duration and severity of the disease, and the type of preparation studied.
Numerous investigation have been undertaken to examine systemic vascular 
alterations in response to heart failure; this Is exemplified above. However, few reports 
exist examining the pulmonaiy circulation in vitro and the effects of experimental heart 
failure. This makes knowledge of changes in the pulmonary circulation in response to 
left heart disease very limited. Furthermore, the importance of the pulmonary circulation 
in the role of ET-1 in this condition should not be overlooked. Yang and co-workers
(1994) reported that the elevated plasma ET levels in patients with CHF were positively 
correlated with several pulmonary haemodynamic variables including pulmonary 
vascular resistance and also the severity of the impairment of cardiac function. However 
no such correlation was noted with systemic vascular resistance. This suggests that 
elevated circulating ET may participate in the pathophysiology of CHF, especially 
closely related to occurrence and development of PHT. Furthermore, associated PHT 
with heart failure, following various forms of LVD, is a common occurrence 
(Rabinovitch, et al, 1978; Trell, 1973). Hence the investigations of this chapter were an 
attempt to shed more light on pulmonary arterial alterations in this condition.
The maximum vasoconstrictions to SXS6 c and ET-3 was significantly lower 
than that to ET-1 in 8 , 16 and 32 week coronary ligated preparations. Smaller responses 
to ET-related peptides compared to ET-1 responses has also been demonstrated in vivo 
(Ciozel, et a l, 1992). Thus, although the relative potencies of these peptides indicate the 
predominance of vasoconstrictor ETb receptors, since the constriction to ETb agonists 
were less than that to the non-selective ETa/b receptor agonist ET-1, this implies that 
ETa receptors also contribute to vasoconstriction. In comparison no significant
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ETa receptors also contribute to vasoconstriction. In comparison no significant 
difference in the magnitude of the responses to the peptides was evident in control 
vessels; these differences were regardless of the duration of coronary ligation. This may 
indicate a greater involvement of ETa receptors in the pulmonary vasculature following 
left ventricular dysfunction. On the other hand, it may also imply a reduced contribution 
from ETb vasoconstrictor receptors in this model, as is also suggested by the marked 
reduction in sensitivity to ET-1 and SXS6 c in PRAs from 16 week coronary ligated 
rabbits compared with control vessels. Indeed, the maximum vasoconstrictions to ET-3 
was markedly reduced in 8 week coronary-ligated preparations compared with sham- 
operated preparations, and SXS6 c-induced constrictions were significantly smaller 
following 16 weeks of coronary artery ligation compared to responses of both stock and 
sham-op erated rabbit PRAs.
The observation that responses to ET-3 were reduced in PRAs from the LVD 
group may also be explained by an increase in endothelial ETs-mediated vasodilation as 
ET-3 is extremely potent at this receptor (Douglas, et a l,  1995). Endothelial ETb 
receptors have been shown to mediate pulmonary vasodilation in rats and lambs 
(Eddahibi, et a l, 1991; Wong, et a l, 1995a). However, in this chapter I also examined 
possible vasodilator responses to the ETb receptor agonist SXS6 c in 8 week 
preconstricted preparations but no relaxatory response was evident and a concentration- 
dependent increase in tone was again produced by this peptide. I used two different 
agonists, 5-HT or U46619, to preconstrict vessels as previous studies have shown that 
relaxatory responses can be influenced by the agent used to increase tone 
(Perezvizcaino, et a l, 1996); I also showed this in ACh-induced relaxations of newborn 
rabbit PRAs (chapter 8 this thesis). However, no relaxatoiy response was evident when 
either agent was used. Thus the presence of endothelial ETb receptors in not indicated 
by the results of this study. A lack of endothelium-dependent relaxation to SXS6 c has 
also been reported in rat PRAs; a preparation in which the involvement of 
vasoconstrictor ETb receptors have also been shown (MacLean, et a l, 1994a). 
However, recently Higashi et a l (1997) demonstrated ET-3- and ET-l-induved transient
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,vasodilations in rat larger pulmonary arteries. In this study the ETg receptor mediated 
vasodiiations were shown to vary depending on the pulmonary arterial region; the 
relaxatory response was more potent in extrapulmonary artery compared with the 
intrapulmonary artery. One possible explanation is that the population of functional 
endothelial ETb receptors is greater in extrapulmonary artery compared to the 
intrapulmonaiy arteiy. This hypothesis could be extended to explain the lack of ETb 
receptor mediated vasorelaxations in the PRAs of this species (MacLean, et a l, 1994a), 
i.e. Rmctional ETb receptors on the endothelium might gradually decrease in number on 
approaching the distal segment. In addition, it should be noted that some of the effects of 
ET-3 could have been mediated by a putative ETc receptor (ET-3-selective) receptor 
situated on endothelial cells. However, although there is evidence from binding 
(Yokokawa, et a l, 1991) and functional studies (Harrison, et a l,  1992) to support the 
existence of an ETc receptor in the vasculature, and a potential candidate has been
identified in Xenopus laevls melanpliores (Karne, et a l, 1993), it remains to be 
established if this amphibian ETc receptor has a mammalian counterpart.
Another possible explanation for altered ET-receptor mediated responses noted 
in PRAs from coronary-ligated rabbits and also in other vascular preparations from other 
models, may be an alteration in the clearance of ET-1. The pulmonary circulation has ;
been shown to be a major site of ET-1 clearance in some animal models including the 
guinea-pig, rat, and rabbit (De Nucci, et al., 1988; Sirvio, et a l, 1990; Shiba, et a l,
1989; Rimmar & Gillis, 1989). Infusion of the selective ETb receptor antagonist BQ788, 
reduced ET-1 removal in the rat. and completely abolished its removal by the lungs in 
the dog, whereas selective ET A-receptor antagonists were without effect (Fukuroda, et 
a l,  1994b; Dupuis, et a l, 1996). Hence the ETB-receptor appears to have a role as a 
clearance receptor in the pulmonary circulation and indeed appears completely and 
exclusively responsible for pulmonary ET-1 removal in the dog in vivo. There is 
normally no net arteriovenous differences in circulating ET-1 levels across the lung 
(Dupius, et a l, 1994; Stewart, et al, 1991); the lung consequently produces an amount of 
ET-1 equal to the amount to be extracted (Dupius, et a l, 1994). As already stated
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plasma ET-1 levels are elevated in heart failure and pulmonaiy hypertension of various 
etiologies. Thus it is possible that reduced clearance of this peptide contributes to the 
hyperendothelinemia of these pathologies. ETg clearance receptors may have a 
protective role by modulating the levels of this circulating potent vasoconstrictor. The 
expression of ETb receptor mRNA was shown to be reduced in the in the lungs of rats 
with monocrotaline-induced pulmonary hypertension and elevated plasma ET-1 levels 
(Yorikane, et a l, 1993). Hence it is plausible that alterations in the expression or 
function of this ETb receptor subtype may be involved in. changes in responses ET- 
receptor agonists in the pulmonary vasculature.
The possibility that surgery per se may affect the responses of isolated vessels 
was examined by including age-matched stock animals in the 16 week procedure group. 
Sham-operation did not effect the sensitivity of PRAs to either ET-1 or SXS6c as this 
was similar to that noted in PRAs from age-matched stock animals. However, the 
magnitude of the maximal ET-1-induced vasoconstriction was reduced in the sham- 
operated compared with the stock preparations. Onizuka et al (1991) investigated the 
involvement of ET-1 in the physiological response to surgical stress in patients 
undergoing op en-chest surgery. Plasma ET-1 levels from various sampling sites were 
reported to increase during pulmonary surgery however these values returned to baseline 
within 72 hours after surgery. ET-1 levels are unfortunately not available for during and 
shortly after surgery in the animals in this model. Sakurai et al (1992) and Yorikane et al 
(1993) suggested that the density of ETb receptors is down-regulated by circulating ET- 
1. Thus if ET-1 “levels were augmented in the pulmonary vasculature in this model, the 
possible down-regulation of ETb receptors may account for the reduction in 
vasoconstriction to ET-receptor agonists.
The results of this chapter show that LVD induced by coronary artery ligation 
has differential effects on ET-1 and SXS6c-mediated vasoconstriction of PRAs and 
furthermore, these effects are altered by the duration of coronary artery ligation. LVD 
produced by 8 week of coronaiy artery ligation produced no significant effect on 
responsiveness of rabbit PRAs to either ET-1 or SXS6c. Whereas sensitivity to both
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these peptides and the vasoconstriction to ET-1 was significantly reduced in 
preparations from the 16 week LVD group. The effect on ET-1-induced responses was 
no longer evident in PRAs from 32 week coronaiy artery ligated rabbits, whilst the 
alteration in SXS6c sensitivity now appeared as an augmentation rather than an 
attenuation. The finding that these alterations occurred particularly at low peptide 
concentrations suggests that it may be important in in vivo conditions. I can only 
speculate from the results of this study however, these findings may be due to alterations 
in ET-receptor subtypes, and/or the influence of other vasoactive factors, and/or 
mechanism of action of receptors. These possibilities are investigated further in chapters 
5, 6 and 7, respectively, of this thesis.
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Chapter 5
Endothelin-receptor subtypes in rabbit and human 
pulmonary resistance arteries; Effect of left ventricular
dysfunction
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5,1 IntrQductiQn
ET-1 has been shown to mediate both vasoconstriction and vasodilation of the 
pulmonary vasculature depending on the species, preparation and degree of initial 
vascular tone. In the rat, dog and guinea-pig isolated pulmonary arteries the 
vasoconstrictor response to ET-1 appears to be mediated solely via ETa receptors, due 
to relative potency of ET isopeptides and/or the ability of selective ETa receptor 
antagonists to inhibit the responses (Watanabae, et al,, 1991a; Douglas, et a l, 1993, 
Cardell, et a l,  1993). Previous studies in the rabbit pulmonary vasculature show 
vasoconstrictions to ET-1 to relatively resistant to the actions of BQ123 (selective ETa 
receptor antagonist) and potent vasoconstrictor responses are observed to selective ETg- 
receptor agonists. These findings suggest the role of ETg receptors in mediating 
vasoconstriction in this preparation (Panek, et a l, 1992; LaDouceur, et a l, 1993). The 
results of chapter 4 of this thesis, showing the vasoconstrictor action of SXS6c and the 
greater potency of this selective ETg receptor antagonist over the non-selective peptide 
ET-1, indicates that vasoconstrictor ETg receptors predominate in rabbit PRAs. Thus the 
aim of this chapter was to investigate further the ET receptor subtypes in small muscular 
pulmonary arteries of the rabbit with the use of several ET receptor antagonists.
Endothelins have been implicated in many pathophysiologic conditions 
including pulmonary hypertension (PHT). Elevated circulating ET-1 levels have been 
reported in patients with both primary and secondary PHT (Stewart, et a l, 1991), 
Increased plasma levels also occur secondary to left heart dysfunction, congenital heart 
defects and cardiac surgery, and are positively correlated with the degree of PHT and 
negatively correlated with prognosis (Cody, et a l, 1992; Yoshibayashi, et a l, 1991). 
The results of chapter 3, including those of the morphological study showing the 
muscularisation of pre-alveolar pulmonaiy arterioles, demonstrated the presence of PHT 
in the rabbit coronary ligation model of left ventricular dysfunction (LVD). A previous 
report in this model demonstrated a 44% increase in pulmonary arterial pressure (PAP) 
and a 64% increase in lung weight and right ventricular weight in rabbits after 8 weeks
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of coronary ligation (Denchar, et ah, 1997). Therefore this is an ideal model to use to 
examine pulmonary vascular changes occurring in LVD. Recently there has been much 
interest in ET receptor antagonists as possible therapeutic agents for the treatment of 
cardiovascular disease including PHT. Kiowski et al (1995) reported that the non- 
selective ETa/b receptor antagonist bosentan may decrease pulmonary vascular 
resistance in patients with heart failure. In a rabbit arterial-occlusion model of acute 
myocardial infarction treatment with the selective ETa receptor antagonist FR139317 
before coronary arteiy occlusion, significantly reduced infarct size (Burke & Nelson, 
1997). Similarly, Watanabe et a l (1991b) reported a reduction in infarct size on infusion 
of an antibody to ET-1 in a rat model of myocardial infarction. Furthermore, the 
development of PHT secondary to chronic heart failure, induced by coronary ligation in 
the rat, can be ameliorated by the long term treatment with an ETa receptor antagonist 
(Sakai, et al., 1996). In the search for therapeutics for PHT that are based on 
antagonising the effects of ET-1, it will be important to determine what ET receptor 
subtypes are responsible for the diverse effects of this proposed mediator in the 
pulmonary vasculature. A secondary aim of this study was, therefore, to examine if there 
were any changes in the effect of selective ET receptor antagonist on ET-receptor 
mediated responses in the pulmonary vasculature in this model of LVD.
Previous investigations have used isolated rabbit main pulmonaiy artery in their 
a studies of ET-1 (La Douceur, et a l, 1993; Fukuroda, et al, 1994a; Hay, et al.., 1996) 
As it is the pulmonary resistance arteries (PRAs) which are thought to be functionally 
important in the resistance changes which occur in PHT (Marshall & Marshall, 1983; 
Staub, 1985), I examined the functional responses to ET-receptor stimulation in PRAs 
from the rabbit model of LVD, induced by eight weeks of coronary artery ligation, using 
ET-1, ET-3 (ETa/b non-selective agonists) and sarafotoxin S6c (SXS6c; an ETb- 
selective agonist). The ET receptor antagonists used to characterise the endothelin 
receptors were the ETa -selective antagonist FR139317 (Sogabe, et a l, 1992), BQ788, a 
potent and selective ETg receptor antagonist (Ishikawa, et al, 1994) and the non-peptide 
non-selective ET-receptor antagonist SB209670 (Ohlstein, et a l, 1994a).
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A previous investigation by Fukuroda et al. (1994a) suggested interspecies 
differences in the ET receptor subtypes that mediate ET-1-induced vasoconstrictions.. 
ETa receptors appeared to be dominant in the human pulmonary artery whereas, as 
already stated, the predominance of ET# receptors was indicated in the rabbit pulmonary 
artery; arterial preparations from both species were ~lmm outer diameter. Hence, in 
addition, in this chapter, I also examined ET-receptor mediated responses in human 
PRAs with the use of the peptides ET-1 and ET-3 and the antagonist compounds BQ788 
and SB209670, and compared these with those of arterial segments of similar internal 
diameter from the rabbit.
Thus the main aims of this chapter was that the results of my own studies in 
small pulmonary arteries from both rabbit and human lung (along with the information 
available on larger pulmonary arteries, and with what others investigators have 
demonstrated in vivo and in the isolated perfused lung in vitro) would provide a more 
complete picture of ET-1-mediated vasoconstriction in the human and rabbit pulmonary 
arterial circulation and how such vasoconstriction may change in pulmonary 
hypertension.
5.2 Methods
Rabbit pulmonary resistance arteries
Lungs were obtained from the rabbit coronary ligation model of left ventricular 
dysfunction which has been extensively characterised (Pye, et al,. 1996) and is descried 
in detail in section 2.1.1 of this thesis. In the 8 week procedure period groups, age 
matched animals underwent the same methodology as the experimental animals 
(referred to in results and discussion as "coronary-ligated") except the ligatures placed 
around the coronary artery were not secured. These are subsequently referred to as 
"sham-operated". Measurements of ejection fraction were made in all animals and 
animals were killed by sodium pentabarbitone 8 weeks following the procedure. The
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lungs were promptly removed and small intralobar pulmonaiy resistance arteries (PRAs 
~170 |Lim internal diameter, see table 5.1) were dissected out according to the methods 
stated in section 2.2.3.1. These were mounted as ring preparations (-2mm long) on a 
wire myograph, bathed in Krebs solution at 37°C. Using the normalisation process 
explained in section 2.2.5, vessels were tensioned to an equivalent transmural pressure 
of ~ 16 mmHg. This pressure was chosen as it is similar to in vivo pressures of rabbit 
pulmonary arterioles. Preliminary studies in our laboratoiy showed that bubbling with 
95% O2 inhibits responses to vasoconstrictors in rabbit PRAs so we bubbled with 16% 
O2/ 5% CO2 balance N2. These gas mixtures were chosen as they are similar to those 
which the vessels would be exposed to in vivo.
Human pulmonarv resistance arteries
Human pulmonary arteries (~ 240 pM internal diameter, see table 5.1) were 
dissected from grossly normal sections of human lung removed from postoperative 
bronchial carcinoma tissue (as described in section 2.2.3.3). Samples were refrigerated 
in fresh Krebs' solution and were collected and studied no longer than 12 hours 
postoperative. As for the rabbit preparations, the human PRAs were mounted as ring 
preparations (-2mm long) on a wire myograph, bathed in Krebs solution at 37°C which 
was bubbled with gas mixture containing 16% O2/ 5% CO2 balance N2 . Using the 
normalisation process explained in chapter 2, vessels were tensioned to an equivalent 
transmural pressure o f - 16 mmHg, thus similar to in vivo pulmonaiy arterial pressures.
Experimental protocol
Vessels were allowed to equilibrate for 1 hour prior to the addition of any drugs. 
The response of the PRAs to 50mM KCl was determined twice; once the contractile 
response had reached a plateau, the vessels were washed out at least 6 times with fresh 
Krebs solution. Cumulative concentration-response curves (CCRCs) were then
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constructed in rabbit PRAs to ET-1, SXS6c or ET-3 (lpM-0.3pM) following either a 45 
minute "rest period" or 45 minute incubation period with the selected concentration of 
an ET receptor antagonist. The antagonists used were FR139317, BQ788 and SB209670
The following protocols were carried out in PRAs from the rabbit coronary 
arteiy ligation model. The effect of FR139317 (at IpM) was examined on ET-1-evoked 
responses only. Preincubation with BQ788 (at IpM) was performed preceding ET-1, 
SXS6c and ET-3 CCRCs whilst preincubation with FR139317 plus BQ788 (both at 
IpM) was performed preceding ET-1 responses only. The effect of SB209670 (at 0.1 
and lpM)was examined in both ET-1- and SXS6c-evoked responses.
In human PRAs, the effects of preincubation with BQ788 (IpM) was studied in 
ET-1- and ET-3 CCRCs (0.1pM-0.3pM). Whereas effects of SB209670 (lOnM, 0.1 pM 
and IpM) was examined in ET-1-responses only.
Note
In human PRAs, control responses to ET-1 were performed in vessels from the 
same lung sample when the effects of BQ788 and SB209670 were being examined; 
hence these antagonist results are displayed with their own control data. In the rabbit 
vessels, control responses to ET-1. ET-3 and SXS6c were carried out whenever possible 
in each lung preparation. However, due to limitation in equipment and time it was not 
always possible to run a control CCRC to the peptide whilst studying the different 
antagonists. However the control curves in this study have been updated with each 
group of experiments . No differences were found in the control ET-1, ET-3 or SXS6c 
responses when tested throughout the period of investigation, thus the data for the 
control curves which are shown have been pooled over many protocols. Due to the 
inhibitory effect of SB209670 which became apparent during this study, I attempted to 
examine the effects of this antagonist at several different concentrations. Unfortunately 
due to time constraints it was not possible to study a range of concentrations for all the
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antagonists in each tissue. The concentrations which were studied, were chosen due to 
t h e i r v a l u e s  in other vascular preparations.
Data analysis
Results are expressed graphically as percentage of their own maximum 
contraction, or percentage of reference contraction to second application of 50mM KCl. 
pECiÇ), pBC 25 and a>EC5o values were calculated according to the methods stated in 
chapter 2, and expressed as -log M concentration. Where ever possible, j^Kg values were 
estimated for single stated concentration of antagonist according to the methods stated in 
chapter 2. Statistical comparison of the means of groups of data were made by Student's 
unpaired t test or where appropriate, ANOVA followed by Tukeys post test ; P<0.05 
was considered statistically significant. Throughout, data are expressed as mean±SEM 
and n In -  number of ring preparations / number of animals.
5.3 Results
The ejection fraction of animals from the 8 week procedure group, from which 
lungs were obtained and PRAs dissected for the antagonist studies described in this 
chapter, are shown in table 5.1. The effective pressure to which these vessels and human 
PRAs were tensioned and the resulting estimate of internal diameter are also shown in 
table 5.1. Table 4.1 in chapter 4 shows these parameters for 8 week preparations in 
which control responses to ET-receptor agonists were examined. In the antagonist 
studies, vessels from both experimental groups were tensioned to a similar effective 
pressure and internal diameter and these values were similar to those in preparations in 
which control curves were constructed (table 4.1). The ejection fraction was markedly 
reduced in ligated animals compared with sham-operated in the 8 week procedure group 
(table 5.1).
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(n)
Internal diameter 
(rim)
Effective pressure 
(mmHg)
Ejection fraction 
(%)
Rabbit PRAs
sham-op erated(7 2) 165.0+5.9 19.2+0.6 72.7+0.8
ligated (62) 175.7+6.6 19.3+0.7 44.0+0.9 **»
Human PRAs f37l 241.6+14.4 16.4+0.6 -
Table 5.1 (1) Ejection fraction of 8 week procedure animals from which PRAs were 
dissected and studied in this chapter and (2) internal diameter and effective pressure of 
PRAs from this cohort of rabbits and also for human vessels studied in this chapter 
Statistical comparisons were made by Student's unpaired t-test: ligated vs. sham- 
operated, '*'**P<0.001. Values are meaniSEM. n, number of ring preparations.
Effect of antagonists on ET-receptor mediated contraction of rabbit pulmonarv 
resistance arteries
The effect of FR139317, BQ788 and a combination of both these antagonists on 
ET-1-induced vasoconstrictions in PRAs from 8 week sham-operated and coronary- 
ligated rabbits are shown in figures 5.1 and 5.2, respectively. />ECio,i?EC25 and^ECgo 
values are summarised in table 5.2.
FR139317rvsET-n
The selective ETa receptor antagonist FR139317 failed to inhibit the ET-1- 
evoked responses in PRAs from either sham-operated of coronary-ligated rabbits. In 
fact, there was a tendency for the response noted above InM ET-1 to be greater in the 
presence of FR139317 in control vessels (figure 5.1 A). A potentiation was also seen in 
preparations from the LVD group but at ET-1 concentrations below InM (figure 5.2A).
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n/n ^ECio /?EC5o
Sham-operated rabbit PRAs
ET-1 control 8/6 9.1+0.4 8.6+0.4 7.9+0.3
+lpMFR139317 7/6 10.0+0.3 9.1+0.1 8.2+0.1
+l|_iMBQ788 6/5 8.6+0.1 8.2+0.1 7.8+0.1
+ltiMFR139317 
plus l|i.MBQ788
7/6 8.2+0.1 8.0+0.1 7.7+0.1
+Q.l|aMSB209670 6/6 9.0+0.3 8.4+0.2 7.9+0.1
+lpM  SB209670 8/7 nc
Coronarv-lieated rabbit PRAs
ET-1 control 12./7 8.9+0.4 8.3+0.2 7.9+0.2
+HiMFR139317 9/6 8.4+0.2 8.0+0.1 7.6+0.1
+ lfiMBQ788 7/6 9.9+0.4 8.8+0.2 8.1+0.2
+lpMFR139317 plus l|.iMBQ788
9/6 8.4+0.2 8.0+0.1 7.6+0.1
+0.1|.iMSB209670 4/4 8.6+0.1 8.3+0.1 7.8+0.1
+1M,MSB209670 6/6 nc
Table 5.2 Effect of selective antagonists on the sensitivity to ET-1 in PRAs from sham- 
operated and coronary ligated rabbit PRAs. Values are mean ± SEM. ET-1, endothelin- 
1; n/n, number of ring preparations / number of animals; nc, not calculated.
The maximal contraction in PRAs from sham-operated rabbits was not affected 
but the response to lOnM ET-1 was increased from 49.3+11.6% (% reference 
contraction to 50mM KCl) to 75.7+3.5% (P<0.01; figure 5.IB). FR139317 did not effect 
the magnitude of the ET-1-evoked vasoconstrictions in vessels from the LVD group 
(figure 5.2B).
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Figure 5.1
Effect of selective antagonists on ET-1-induced responses in PRAs from sham-operated 
rabbits.
CCRCs to ET-1 (# , n=8/6) and in the presence of IjiM FR139317 (O, n=7/6), lp,M 
BQ788 (□, n=6/5), and l\xM FR139317 plus IgM BQ788 (A, n=7/6).
A Data are expressed as a percentage own maximum contraction.
B Data are expressed as a percentage reference contraction to 50mMKCl.
Each point represents mean ± s.e. mean.
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Figure 5.1
Effect of selective antagonists on ET-1-induced responses in pulmonary resistance 
arteries from 8 week sham-operated rabbits.
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Figure 5.2
Effect of selective antagonists on ET-1-induced responses in PRAs from coronary artery 
ligated rabbits.
CCRCs to ET-1 (# , n=12/7) and in the presence of l|iM  FR139317 (O, n=7/6), IpM 
BQ788 (□, n=7/6), and l|aMFR139317 plus l|xMBQ788 (A , n=9/6).
A Data are expressed as a percentage own maximum contraction.
B Data are expressed as a percentage reference contraction to SOmMKCl.
Each point represents mean ± s.e. mean.
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Figure 5.2
Effect of selective antagonists on ET-1-induced responses in pulmonary resistance 
arteries from 8 week coronary artery ligated rabbits.
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B0788 rvsE T-n
BQ788 failed to significantly inhibit ET-1 responses in PRAs from both 
experimental groups (table 5.2). However, in PRAs from sham-operated group, the 
threshold concentration of ET-1 was increased by BQ788 from 30pmol to 3nmol. 
Responses to higher concentrations were resistant to BQ788 (Figure 5.1 A). BQ788 
failed to inhibit responses to any concentration of ET-1 in arteries from the LVD group 
in fact a tendency for potentiation of the responses was noted at the lower concentration 
range. The threshold concentration of ET-1 was decreased from 300pmol to lOpmol. 
Maximum vasoconstriction to ET-1 was not effected by IpM BQ788 in PRAs sham- 
operated (93.3+9.5% cf. 112.2+4.7%, figure 5.IB) or coronary-ligated (105.5+9.5% cf. 
80.4+8.6%, figure 5.2B) rabbits.
B0788 + FR139317 fvs ET-D
Figures 5.1 also shows the effect of BQ788 in combination with FR139317 on 
responses to ET-1 in PRAs from sham-operated rabbits. In these vessels, BQ788 and 
FR139317 in combination increased the threshold concentrations of ET-1 which caused 
contraction from 30pM to lOnM (figure 5.1 A). Thus FR139317 did not markedly 
increase the effect of BQ788. Also the potentiation of the vasoconstrictor response at 
ET-1 concentrations >lnM  which was noted in the presence of FR139317, was not 
evident when BQ788 was present also. Due to the biphasic nature of the curve, this 
inhibitory effect was not reflected as a significant change in />ECio,/>EC25 or/^EC^o 
values (table 5.2). The maximum vasoconstriction was not effected. However, as was 
seen with BQ788 alone, the magnitude of vasoconstrictions to lower ET-1 
concentrations were attenuated; for example, response to InM ET-1 were reduced from 
24.2+9.6% to 2.1+1.0% by FR139317 plus BQ788 (f=0.05, figure 5.IB).
In PRAs from coronaiy-ligated rabbits, BQ788 plus FR139317 increased the 
threshold concentrations of ET-1 which caused contraction in vessels from 300pM to
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of BQ788 to inhibit responses to lower concentrations of ET-1, as seen in the sham- 
operated rabbit PRAs. This inhibitory effect was not reflected by a significant change in 
pECio, i?EC25 or7?EC5o values (table 5.2). The maximal responses were not affected by 
the combination of BQ788 and FR139317 (figure 5.2B).
B0788 fvs SXS6cl
The effect of IpM BQ788 on SXS6c-evoked vasoconstrictions in PRAs from 
sham-operated and coronary-ligated rabbits is shown in figure 5.3. pEC\Q, PEC25 and 
PEC 50 values are summarised in table 5.3. BQ788 had a marked inhibitory effect on 
SXS6c-induced vasoconstrictions in PRAs from both groups. The estimated /?Kb values 
were 7.1+0.2 and 7.0+0.1 for PRAs from sham-operated and coronary-ligated rabbits, 
respectively. BQ788 had its most profound effect on responses to the lower 
concentrations of SXS6c and removed the first component of a biphasic response to 
SXS6c. The magnitude of the maximum vasoconstriction to BQ788 was not 
significantly altered by BQ788 (figure 5.3B).
B0788 fvs ET-31
ET-3-induced responses were significantly inhibited by BQ788 in PRAs from 
both groups. This is shown in figure 5.4 and pECio,/>EC25 and pECso values are 
summarised in table 5,4. BQ788 had its most profound effect on responses to the lower 
concentrations of ET-3 and removed the first component of a biphasic response to ET-3 
The inliibitory effect on responses to SXS6c concentrations >3nM were more 
pronounced in coronary-ligated vessels. The estimated j!?Kb value was 6.6+0.1 for sham- 
operated vessels. For coronary-ligated preparations, a /?Kb value of 7.010.2 was 
calculated and this was significantly greater than the value obtained in the PRAs from
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Figure 5.3 Responses to SXS6c in PRAs from sham-operated (O, n=10/9) and coronaiy 
ligated ( • ,  n= ll/7) rabbits: Effect of l|aM BQ788 in sham-operated (□, n=7/7) and 
coronary ligated (■, n=12/8) vessels. A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
50mMKCl. Each point represents mean ± s.e. mean.
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Figure 5.4 Responses to ET-3 in PRAs from sham-operated (O, n=10/9) and coronaiy 
ligated ( • ,  n=9/6) rabbits: Effect of l|.iM BQ788 in sham-operated (□, n=10/9) and 
coronary ligated (■, n=5/5) vessels. A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
SOmMKCl. Each point represents mean ± s.e. mean.
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sham-operated rabbits (P<0.05). Maximal responses were not significantly affected by 
l|aMBQ788 (figure 5.4B).
n/n pECio pEC25 pECso
Sham-operated rabbit PRAs
SXS6c control 10/9 10.6+0.3 9.9+0.3 9.0+0.2 .
+ l|iMBQ788 7/7 9 1+0.2*** 8 4+0.1** 7.8+0.1***-
+0.1pMSB209670 7/6 9.6+0.4* 8.8+0.2* 8.2+0.1**
+ l|aMSB209670 7/6 7.9+0.3*** 74+0,2*** 7 1+0.1***
Coronarv-ligated rabbit PRAs
SXS6c control 11/7 10.4+0.3 9.4+0.3 8.6+0.2
+ltiMBQ788 12/8 8.7+0.3*** 8.3+0.1** 7.8+0.1**
+0.1nM SB209670 6/6 9.2+0.6 8.8+0.4 8.1+0.3
+HiM SB209670 6/6 8.9+0.5* 8.3+0.4* 7.8+0.2*
Table 5.3 Effect of selective antagonists on the sensitivity to SXS6c in PRAs from 
sham-operated and coronaiy ligated rabbit PRAs. Statistical comparisons were made by 
Students' unpaired t-test: antagonist vs. control *P<0.05, *^P<0.01, *=^*P<0.001. Values 
are mean ± SEM. SXS6c, sarafotoxin S6c; n/n, number of ring preparations / number of 
animals.
SB209670rvsET-n
The effect of SB209670 on ET-1 responses in rabbit PRAs from sham-operated 
and coronary-ligated rabbits is shown in figures 5,5 and 5.6, respectively. y?ECio,pEC25 
and pECgo values are summarised in table 5.2. O.lpM SB209670 did not effect 
sensitivity to ET-1 in PRAs from either control or LVD groups. However when present 
at IpM, it inhibited ET-1 responses in sham-operated rabbit PRAs. A maximum 
response to ET-1 was not reached within the concentration range studied, therefore ^ EC 
values and a /?Kb value for ET-1 in the presence of l|aM SB209670 could not be
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calculated. However using the maximal response which was attained, this would give an 
estimated/>Kb of 6.8+0.2.
As was noted in sham-operated rabbit PRAs, the ET-1 CCRC did not reach a 
maximum response within the concentration range studied when coronary-ligated PRAs 
had been preincubated with lp,M SB209670, thus pEC values could not be calculated. 
However, it is apparent from figure 5.6A that IpM SB209670 failed to reduce ET-1 
sensitivity in this preparation. In fact, a slight potentiation of responses to lower 
concentrations of ET-1 was noted, in that small responses were observed to O.OSnM and 
0.1 nM ET-1 (figure 5.6A). However, when the results are expressed to demonstrate the 
magnitude of the contractile responses, IpM SB209670 inhibited the responses to ET-1 
in that it caused a rightward shift in the upper component of the CCRC and markedly 
attenuated the responses to the maximal concentration of ET-1 it was financially viable 
to use (67.2+9.6% vs. 105.5+9.5%, P<0.05; figure 5.6B).
n/n yiECio ;?EC25 /^ECso
Sham-operated rabbit PRAs
ET-3 control 10/9 9.6+0.3 8.9+0.2 8.4+0.2
+lpMBQ788 10/9 8.5+0.1** 8.3+0.1* 8.0+0.1*
Coronarv-liaated rabbit PRAs
ET-3 control 9/6 9.7+0.5 9.1+0.3 8.5+0.2
+ l|aMBQ788 5/5 8.3+0.3 7.8+0.2* 7.5+0.2*
Table 5.4 Effect of BQ788 on the sensitivity to ET-3 in PRAs from sham-operated and 
coronaiy ligated rabbit PRAs. Statistical comparisons were made by Students' unpaired 
t-test; antagonist vs. control *P<0.05, **P<0.01. Values are mean ± SEM. ET-3, 
endothelin-3; n/n, number of ring preparations / number of animals.
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Figure 5.5 Effect of SB209670 on ET-1-induced responses in PRAs from sham-operated 
rabbits. CCRCs to ET-1 (O, n=8/6), and in the presence of 0.1 pM (A, n=6/6) and IpM 
( • ,  n=8/7) SB209670. A Data are expressed as a percentage own maximum contraction. 
B Data are expressed as a percentage reference contraction to 50mMKCl. Each point 
represents mean ± s.e. mean.
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Figure 5.6 Effect of SB209670 on ET-1-induced responses in PRAs from coronary 
ligated rabbits. CCRCs to ET-1 (O, n=12/7), and in the presence of 0.1|_iM (A , n=4/4) 
and HiM ( • ,  n=6/6) SB209670. A Data are expressed as a percentage own maximum 
contraction. B Data are expressed as a percentage reference contraction to 50mMKCl. 
Each point represents mean ± s.e. mean.
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SB209670 Tvs SXS6cl
The effect of SB209670 on SXS6c responses in rabbit PRAs from sham-operated 
rabbits is shown in figures 5,7. /?ECio, ^EC%5 andpECgo values are summarised in table 
5.3. In these vessels, SB209670 produced a concentration-dependent inhibition of 
responses to SXS6c and a profound effect as seen on the early component of the CCRC..
0.1 piM SB209670 produced a significant inhibition of the response. This inhibitory 
effect was even more pronounced in the presence of l^iM SB209670 and the threshold 
concentration was increased from 0.3pM to lOnM SXS6c (figure 5.7A, table 5.3). The 
estimatedpKs values was 7.8+0.2 (IgM  SB209670). 0.1|iM SB209670 did not effect 
the magnitude of the contractile response to SXS6c concentrations below lOnM 
however, the maximum response was significantly increased from 67.9+8.2% to 
105.0+11.7% (P<0.05) in ifs presence. The maximum SXS6c-induced vasoconstriction 
was not effected by IpM SB209670 (figure 5.7B).
Figure 5.8A shows that SB209670 also produced a concentration-dependent 
inhibition of responses to SXS6c in vessels from the LVD group. However the 
inhibitory effect of this non-selective ETa/b receptor antagonist was markedly less than 
that observed in PRAs from control vessels. This is demonstrated further by the 
estimated />Kb value of 6.7+0.1 (IjuM SB209670) in PRAs from coronary-ligated 
rabbits which was significantly less than that observed in the sham-operated rabbit 
vessels (P >0.001). This may be related to the lesser effect on the early component of 
the CCRC. SB209670 did not effect the magnitude of the maximum contractile response 
to SXS6c in PRAs from coronary-ligated rabbits (figure 5.8B).
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Figure 5.7 Effect of SB209670 on SXS6c-induced responses in PRAs from sham- 
operated rabbits. CCRCs to SXS6c (O, n=10/9), and in the presence of 0.1 p,M (A, 
11=7/6 and lp.M (# , n=7/6) SB209670. A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
SOmMKCl. Each point represents mean ± s.e. mean.
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Figure 5,8 Effect of SB209670 on SXS6c-induced responses in PRAs from coronary 
ligated rabbits. CCRCs to SXS6c (O, n=l 1/7), and in the presence of 0.1 |aM (A, n=6/6 
and l|iM  (# , n=6/6) SB209670. A Data are expressed as a percentage own maximum 
contraction. B Data are expressed as a percentage reference contraction to SOmMKCl. 
Each point represents mean ± s.e. mean.
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Effect of antagonists on ET-receptor mediated contraction of human pulmonary 
resistance arteries
Both ET-1 and ET-3 induced a concentration-dependent contraction of human 
PR As. The potency of ET-3 was significantly greater than that of ET-1 in these vessels 
and this is shown marked increases iny?EC values displayed in table 5.5. However, the 
maximal contraction evoked by ET-3 (103,54+5.7% reference contraction to 50mM 
KCl, n=5/5) was lower than that induced by ET-1 (183+24.4%, n=8/8; P<0.05).
n/n pECio pEC25 pECso
ET-1 8/8 9.5+0.2 8.8+0.2 8.1+0.2
ET-3 5/5 11.2+0.1*** 10.6+0.3*** 9.5+0.3**
Table 5.5 Sensitivity to ET-1 and ET-3 in human PR As. Statistical comparisons were 
made by Students’ unpaired t-test; ET-3 vs. ET-1 **P<0.01, '^ '‘''^^<0.001. Values are 
mean + SEM. ET-1, endothelin-1; ET-3, endothelin-3 ; n/n, number of ring preparations / 
number of animals.
B0788 tvs. ET-l/ET-31
Figure 5.9A shows that BQ788 inhibited responses to ET-1 up to InM but was 
without effect at higher ET-1 concentrations in human PR As. This is also shown by the 
marked inhibition at the level of the pECio (table 5.6). The maximum contraction to ET- 
1 was not altered in the presence of BQ788 (151.7+18.2% (control) and 211.0+38% (in 
the presence of lp,M BQ788); figure 5.9B).
BQ788 caused a marked rightward shift in the vasoconstrictor response to ET-3. 
This is shown in figure 5.10A and is further demonstrated by the marked decrease in 
y?ECio,pEC25 andpECgo values for ET-3 in the presence of l^iM BQ788 (table 5.6).. 
Assuming that a maximum response had been achieved, the estimated />Kb value for
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Figure 5.9 Effect of BQ788 on ET-1-induced responses in human PR As. CCRC's to ET- 
1 (O, n=4/4) and in the presence of l^iM BQ788 ( • ,  n=4/4). A Data are expressed as a 
percentage own maximum contraction. B Data are expressed as a percentage reference 
contraction to 50mMKCl. Each point represents mean ± s.e. mean.
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Figure 5.10 Effect of BQ788 on ET-3-induced responses in human PRAs. CCRC's to 
ET-3 (□, n=5/5) and in the presence of IjiiM BQ788 (■, n=5/5). A Data are expressed as 
a percentage own maximum contraction. B Data are expressed as a percentage reference 
contraction to 50mMKCl. Each point represents mean ± s.e. mean.
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n/n pECio pEC25 pECso
ET-1 4/4 11.1+0.3 9.6+0.4 8.3+0.2
ET-l+l|iM BQ788 4/4 9.6+0.2** 8 .9+0.2 8 .5+0.1
ET-3 5/5 1 1 .2 +0.1 10.6+0.3 9.5+0.3
ET-3+l|aMBQ7S8 5/5 9.6±0.5* 9.0+0.4* 7.7+0.2**
Table 5.6 Effect of BQ788 on sensitivity to ET-1 and ET-3 in human PRAs. Statistical 
comparisons were made by Students' unpaired t-test; BQ788 vs. control *P<0.05, 
**P<0.01. Values are mean ± SEM. ET-1, endothelin-1; ET-3, endothelin-3; n/n, 
number of ring preparations / number of animals.
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Figure 5.11 Effect of SB209670 on ET-1-induced responses in human PRAs. CCRC’s to 
ET-1 ( 0 , 11=8/8) and in the presence of lOnM (A, n=3/3), 0.1 p,M (□, n=7/6), and IpM 
(# , n=7/6) SB209670. Data are expressed as a percentage reference contraction to 
SOmMKCl. Each point represents mean ± s.e. mean.
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BQ788 against ET-3 was 7.9+0.1. This selective ET g receptor antagonist significantly 
reduced the magnitude of the contractile response to all ET-3 concentrations; the 
maximum vasoconstriction was decreased from 103.5+5.6% to 57.8+9.2% (P<0.01; 
figure 5.1 OB).
SB209670 tvs. ET-D
In small human pulmonary arteries, the presence of SB209670 resulted in a 
marked inhibition of the entire ET-1-induced CCRC. The antagonistic effect was 
concentration dependent. This non-selective ETa/b receptor antagonist SB209670 at a 
concentration of lOnM did not significantly effect the sensitivity of human PRAs to ET-
1. The calculated pEC  values in the absence / presence of lOnM SB209670 were as 
follows: /)ECio, 9.5+0.2 / 9.1+0.2; # C 25, 8.8+0.2 / 8.3+0.2; ;?EC50, 8.1+0.2 / 7.7+0.2. 
lOnM SB209670 did not effect the magnitude of ET-1-induced vasoconstrictions (figure
5.11). However a marked inhibition of the ET-1-induced vasoconstriction was evident in 
the presence of 0.1 and IpM SB209670. 0.1 tiM SB209670 shifted the threshold 
concentration from 3pM to InM ET-1, and IjaM SB209670 abolished ET-1-induced 
vasoconstrictions to all ET-1 concentrations up to 0.1 p,M. The control contractile 
response to 0.1 pM ET-1 of 166.8+21.4% was attenuated to 41.8+11.9% and 15.8+7.1% 
(both P<0.001) in the presence of 0. l|_iM and 1|liM  SB209670, respectively (figure
5.11). Hence the degree of inhibition was such that a maximum response was not 
attainable within the ET-1 concentration range which was financially feasible. Due to 
this, I was unable to calculate pEC or pKiQ values for these concentrations of antagonist. 
However, assuming that the maximum vasoconstriction would not be significantly 
altered by SB209670, one could estimate a/>Kb value o f-8  for IpM SB209670.
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5.4 Discussion
Endothelin-receptor subtypes in rabbit PRAs
The results of chapter 4 of this thesis showed that the potency order for the ET 
agonists in 8 week procedure animals, usingj^ECjo values as an index, was SXS6c>ET- 
3=ET-1. This is indicative of vasoconstriction being mediated by ETg receptors, as has 
been previously shown in the larger pulmonary arteiy of the rabbit (Fukuroda et al, 
1994a; Hay et al, 1996; Maggi, et al, 1989; Panek et a l, 1992). In the studies of this 
chapter, I investigated the ET-receptor subtypes in this preparation further with the use 
of several selective antagonists.
SB209670 had an estimated value of 7.8 against SXS6c in the sham rabbit 
muscular pulmonary arteries. An inhibitory effect of this antagonist was also evident 
against ET-1 responses in this preparation, but a value could not realistically be 
calculated since the response did not reach a maximum. However if it was assumed that 
a maximum was attained, this provided an estimated pKb value of 6.8. Hay et al (1996) 
and Beck et a l (1995) have shown that SB209670 has similar/>Kg values (6.7 and 7.7, 
6.6 and 7.8, respectively) against responses to ET-1 and SXS6c in large rabbit 
pulmonary arteries. Ohlstein et al (1994a;b) also showed a ^K g value of 6.7 for 
SB209670 against ET-1-mediated vasoconstrictions in large rabbit pulmonaiy arteries. 
In addition, these investigators reported that SB209670 has a j^Kg value of 9.4 against 
ET A- mediated responses in the rat aorta. This confirms that, in this study, SB209670 is 
acting as an antagonist against an ET g receptor in the rabbit pulmonary resistance artery 
and this SB209670-sensitive receptor has a similar pharmacological profile to that in the 
larger pulmonaiy arteries. As described in the results, the shallow component of the 
CCRC to ET-1 was resistant to SB209670. Since this antagonism occurred only at the 
higher concentration range of ET-1, this would suggest that this component of the ET-1 
response curve was mediated by SB209670-sensitive ETg receptors. This may indicate 
that responses to ET-1 are not mediated by a homogeneous population of ETg receptors.
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consistent with the observations of Hay et al (1996) and Beck et al (1995) in the large 
rabbit pulmonary artery and Hay and Luttman (1997) in the guinea-pig bronchus.
The selective ETg receptor antagonist BQ788 (lp,M) removed the initial 
"shallow component" of the ET-1 CCRC but failed to effect the rest of the CCRC. It did, 
however, competitively inhibit responses to both SXS6c and ET-3 with estimated />Kg 
values of 7.1 and 6.6 respectively. Again, this phenomenon was observed by Hay et al 
(1996) in the larger rabbit pulmonary arteries where thepKq values were 6.2 and 5.1 for 
SXS6c and ET-3, respectively, whilst there was no effect on ET-1. The authors 
concluded that the ETg receptors stimulated by ET-1 in rabbit large pulmonary arteries 
are not sensitive to BQ788. Similarly, Beck et al (1995) demonstrated in the larger 
rabbit pulmonary artery that BQ788 (lO^iM) was ineffective against ET-1-induced 
vasoconstriction, but inhibited SXS6c-elicited contractile responses, with a/^Kg value of 
5.8. It would appear, therefore, that on the basis of both agonist and antagonist 
interactions, that the ETg receptors stimulated by ET-1 in the large and small pulmonary 
arteries are pharmacologically similar.
Differential effects of BQ788 and SB209670 on the two components of the ET-1 
CCRC were evident. The results show that ET-1 responses include a "shallow" 
component at lower at lower concentrations of ET-1 and this did appear to be resistant to 
the effects of SB209670 but sensitive to BQ788. Thus there is evidence for 
heterogeneous populations of ETg receptors in the pulmonary resistance artery. One is 
sensitive to BQ788, but not SB209670 and mediates responses to lower concentrations 
of ET-1. The other is insensitive to BQ788, but sensitive to SB209670 and mediates 
responses to higher concentrations of ET-1. This resembles the profile of the receptor 
mediating responses in the large pulmonary artery of the rabbit (Hay, et a l, 1996). Thus 
the simplest explanation for the "shallow" component of the ET-1 CCRC in the rabbit 
PRAs is that there is a heterogeneous population of ETg receptors. This is suggested by 
the shape of the CCRC and the differential effects of BQ788 and SB209670 on the 
"shallow" component of the ET-1 CCRC. However, this interpretation of the data 
remains speculative. Curve fitting for a biphasic response is, unfortunately, not possible
180
where the first component of the curve is less than 30% of the maximum response. This 
theory cannot, therefore, be assessed mathematically. Nevertheless, competition 
radioligand binding studies with ET-1 described in chapter 7 of this thesis supports this 
hypothesis. Previous studies, on several different tissue preparations, have proposed 
differential ETg receptor subtypes based on the sensitivity of conventional ETg receptor 
antagonists (Sudjarwo, et al, 1993; 1994; Hori, et a l, 1994). Hay and Luttmann (1997) 
demonstrated in isolated guinea-pig bronchus, that the contractions induced by several 
ET-receptor agonists were mediated predominantly via stimulation of ETg receptors 
however, these receptors were also shown to be insensitive to selective ETg receptor 
antagonists. The authors concluded that ET-receptor mediated responses in the guinea- 
pig bronchus are not mediated by the classical ETg receptor, but rather an atypical 
receptor population. The existence of additional ETg receptors or a subtype of the ETg 
receptor that is insensitive to BQ788 has also been hypothesised in the systemic 
circulation in vivo. This was proposed by Çirino eta l (1997) following the observation 
that combined treatment with BQ123 and BQ788 revealed an action of ET-1 in the pig 
cardiovascular and renal system which could not be attributed to either ET A or ETg 
receptors blocked by these antagonists.
The results of this chapter also show that, in rabbit PRAs, BQ788 markedly 
inhibited vasoconstrictions elicited by both ET-3 and SXS6c, confirming that these 
peptides evoke their vasoconstrictor response via the activation of ETg receptors. Lower 
concentrations of both SXS6c and ET-3 were more sensitive to the effects of BQ788 
which removed the first component of a biphasic response to these agonists. The 
estimated />Kg for BQ788 against SXS6c was 7.1, whilst the lower value of 6.6 was 
estimated against ET-3, indeed, SXS6c has a higher affinity for this receptor. This 
suggests that SXS6c and ET-3 differentially activate the ETg receptors which may 
contribute to the possible heterogeneous population present in this preparation. That ET- 
1 is also acting at different receptors from SXS6c in rabbit PRAs is suggested by the 
selective effect of BQ788 on responses to SXS6c. In addition, in these results and those 
of chapter 4 ,1 showed desensitisation to higher concentration of SXS6c, as indicated by
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the "drop off’ in it's CCRC, which is not observed in the cumulative responses to ET-1. 
In addition the vasoconstrictor responses to individual applications of SXS6c were 
transient, whereas the increase in tone elicited by each ET-1 concentration was 
sustained. Similar findings have also been reported in other preparations in which the 
involvement of vasoconstrictor ETg receptors have also been described, namely rat 
PRAs (McCulloch & MacLean, 1995) and in rabbit saphenous vein (Sudjaiwo, et a l,
1994).
SXS6c-mediated responses were even more sensitive to the to the actions of the 
mixed receptor antagonist SB209670 compared to the selective ETg receptor antagonist 
BQ788. SB209670 also produced a greater inhibition of SXS6c-responses in this 
preparation compared with ET-1-induced vasoconstrictions, as was evident from the 10 
fold difference in pKg values. Ohlstein et al (1994a) also reported in the large rabbit 
pulmonary artery that SB209670 was approximately 4 fold more potent as an ETg 
receptor antagonist when SXS6c was the agonist rather than ET-1. Similarly, Beck et al 
(1995) demonstrated, also in the large rabbit pulmonary artery, that SB209670 produced 
10 fold greater shifts in the CCRCs produced by SXS6c than ET-1. These results and 
also the differential inhibitory effect of BQ788 on responses to SXS6c and ET-3 
demonstrated in this study, provide additional evidence that the potencies of ET receptor 
antagonists depend upon the specific ET agonist. This phenomenon has been reported 
previously by several investigators (Warner, e ta l,  1993b; Kizawa, etal, 1994; Ohlstein, 
et al, 1994a; Yoneyama, et a l, 1995; Hay & Luttmann, 1997) These results may be 
explained by the existence of heterogeneous populations of ET receptor subtypes, as I 
have previously suggested, for which different ET receptor antagonists have different 
affinities. This has also been proposed by Warner et al (1993a), who demonstrated in 
first branch rabbit pulmonary artery that PD142893, a nonselective ET-receptor 
antagonist, did not inhibit ET-1 mediated vasoconstrictions, but gave a 3 fold 
antagonism of constriction induced by SXS6c. These apparent differences in ETg 
receptors may correspond with the previous reports that different populations of high- 
and low- affinity ETg receptors are present in the brain; a novel subtype of the ETg
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receptor that binds ET in the picomolar range was identified and characterised in rat 
brain and atrium (Solovsky, et a l, 1992). Alternatively, the explanation for this 
difference may be that the different agonists ligands bind to different or multiple 
accessory binding domains on the ETg receptor, and receptor antagonists may have 
differential affinities for these domains (Hiley, et a l, 1992; Sakamoto, et a l, 1993). 
Another possibility is that a single population of ETg receptors exists but in two 
different conformational states, an active state coupled to contraction and an inactive 
state that is not coupled to contraction; this has been postulated by Robertson et a l
(1994) for the angiotensin II receptors.
SB209670 has also been shown to effectively antagonise ETg-mediated 
vasodilation (Ohlstein, et al, 1994b). The inhibition of these receptors in rabbit PRAs 
may account for the augmentation in the maximum SXS6c-induced vasoconstriction 
which was observed in the presence of (0.1 tiM) SB209670. Ohlstein et al (1994a) and 
Beck et al (1995) also demonstrated that the maximal contraction induced by SXS6c in 
the rabbit isolated large pulmonaiy artery was potentiated by several different non­
selective ET-receptor antagonists including SB209670. However in the studies of 
chapter 4 of this thesis, I was unable to show ETg-receptor mediated vasodilations in 
rabbit PRAs; this is discussed later.
Effect of pulmonarv hvpertension secondary to left ventricular dysfunction (LVD)
What happens in the rabbits exhibiting PHT secondary to LVD? In isolated 
PRAs from coronary-ligated rabbits, a potentiation of responses to lower concentrations 
of ET-1 was observed in the presence of BQ788 and SB209670. This suggests that, after 
eight weeks of coronary ligation and with the development of PHT, the BQ788-sensitive 
receptor-mediated response has changed in that it is now potentiated by both BQ788 and 
by SB209670. This may indicate an alteration in ETg receptor subtypes with the 
development of PHT. Both BQ788 and SB209670 inhibit the endothelial ETg receptor 
which mediates endothelium-dependent relaxation (Douglas et al, 1995; Ohlstein, et a l.
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1994b). Endothelial ETg receptors have been shown to mediate pulmonary 
vasodilatation in rats and lambs (Eddahibi, et al., 1991; Wong, et al, 1995). Fukuroda et 
al (1992) reported that ET isopeptides caused vasodilation in preconstricted isolated 
porcine pulmonary arteries. These results suggest, therefore, that there has been an 
upregulation of this receptor concurrent with the development of PHT. In chapter 4 
however, I failed to demonstrate ETg receptor-mediated vasodilation in this preparation.
I also examined the possibility of a relaxatory response to SXS6c in preconstricted 
rabbit PRAs in the presence of FR139317. However, despite the presence of this 
selective ET A receptor antagonist, no vasodilatoiy response was evident and again, 
SXS6c evoked a concentration-dependent contractile response. Nevertheless the 
possibility remains that the existence of this receptor in rabbit PRAs may be masked by 
the predominance of vasoconstrictor ETg receptor subtypes, thus preventing it from 
being identified functionally. Furthermore, the results of chapter 6 suggest an 
upregulation of basal nitric oxide synthase in eight week ligated rabbit pulmonary 
resistance arteries. In addition, on a few occasions throughout this study, I observed an 
increase in basal tone in response to BQ788 alone, this would suggest that endothelial 
ETg receptors are also involved in this preparation. The obseiwation that responses to 
ET-3 were reduced in the PRAs from the ligated rabbits (shown in chapter 4) may be 
explained by an increase in endothelial ETg-mediated vasodilatation as ET-3 is
extremely potent at this receptor (Douglas et al, 1995).
The question remains as to whether ETg receptors on the endothelium are 
functionally distinct from those present on the vascular smooth muscle. Conflicting 
views have been reported by several investigators. From the findings that the non­
selective antagonist PD 142893 displayed a markedly greater inhibitoiy effect against 
SXS6c-induced vasodilatory compared with vasoconstrictor responses, Warner et al 
(1993) concluded that the ETg receptor mediating vasoconstriction was most probably 
distinct from that on the endothelium mediating the release of nitric oxide. In contrast, 
from studies in rat tracheal rings, Clozel & Gray (1995) reported that the inability of 
ETg receptor blockade to inhibit ET-1-mediated vasoconstrictions could be accounted
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for by cross-talk between receptors that allows ET a  receptors to compensate for 
inhibition of ETg receptors. Thus these authors concluded that these ETg receptors may 
not represent two different subtype. More recently Mizuguchi e ta l  (1997) performed a 
study using the ETg receptor gene knockout mouse, to clarify whether the ET receptor 
subtypes mediating the vasoconstriction and vasodilation response to ETg receptor 
agonists were the products of a single ETg receptor gene. The results of this study 
demonstrated that the PD 142896 (non-selective ETA/ETg receptor antagonist)- sensitive 
vasodilator response of the aorta and the PD142896-resistant contractile response of the 
gastric fundus to SXS6c were completely absent in the ETg receptor gene knockout
mouse. Thus the authors concluded that the two pharmacological heterogeneous 
responses to SXS6c are mediated by receptors derived from the same ETg receptor
gene.
The />Kg value for BQ788 against ET-3 was increased from 6.6 to 7.0 in the 
vessels from the LVD rabbits whilst the pKg value for SB209670 against SXS6c was 
reduced from 7.8 to 6.7. In addition, SB209670 no longer evoked a significant inhibition 
of ET-1-induced vasoconstrictions. The reason for these changes are unclear but it is 
known that the actual phenotype of the pulmonary vascular smooth muscle is different 
throughout the pulmonary arterial tree and changes in phenotype are evident with the 
development of PHT (e.g. Meyrick & Reid, 1978; Frid et a l, 1994). Therefore, ligand- 
receptor interactions may well be influenced by changes in smooth muscle phenotype. In 
addition, there may also be an alteration in the ET-receptor subtypes present in the 
pulmonary vasculature in pathophysiological conditions. Indeed, previous investigators 
have reported an upregulation of smooth muscle ETg receptors in pathological states 
which are also associated with increased plasma ET-1 concentrations and an increase in 
peripheral vascular resistance. In particular, this was reported in heart failure in man 
(Love, et a l, 1996) and dogs (Cannan, et a l, 1996) and in systemic hypertension 
(Kanno, et a l, 1993; Batra, et a l, 1993). In studies on isolated renal artery from ageing 
spontaneously hypertensive rats, Seo & Luscher (1995) demonstrated that endothelial 
ETg receptor-mediated vasodilation was more efficient in control rat vessels, whilst
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ETg receptors in the vascular smooth muscle were unmasked in spontaneously 
hypertensive rats. Similarly, Clozel and Breu (1996) showed in rat models of systemic 
hypertension in vivo, the predominant influence of endothelial ETg receptors mediating 
vasorelaxation, whilst ETg receptors appeared to be mediating vasoconstrictor tone in 
normotensive rats. Such alteration in ETg-receptors may account for the results of 
chapter 4 of this thesis, showing alteration in ET-1- and SXS6c-elicited responses of 
PRAs from rabbits following 16 and 32 weeks of coronary arteiy ligation. The results of 
this chapter may indicate an upregulation of inhibitory ETg and ET A receptors in PRAs 
from LVD rabbits induced by eight weeks of coronary artery ligation. Altered 
expression of ETg-receptor mRNA has been reported in the lungs of rats with 
monocrotaline-induced PHT (Yorikane, e ta l,  1993). Although this study demonstrated 
a reduction in ETg-receptor mRNA, it was unclear which function, vasodilation or 
vasoconstriction, would be altered by this attenuation. Furthermore, the morphological 
results, shown in chapter 3 of this thesis, demonstrate structural changes in small 
pulmonary vessels from pulmonary hypertensive rabbits which are common to many 
form of PHT. The growth and migration of endothelial cells are the prerequisites for 
vascular remodelling. Morbidelli et al (1995) reported that proliferation and migration 
of endothelial cells is promoted by ETs via activation of ETg receptors; thus ETs can 
contribute to neovascularisation through an autocrine mechanism that requires ETg 
receptor activation. Furthermore, Azuma et al. (1995) demonstrated, in a preparation of 
angioplasty-induced lesion formation in the rabbit carotid arteiy, that an increase in ET- 
1 receptors, especially ETg and/or a putative non-ETA/non-ETg receptors, were evident 
in the hyperplastic vascular wall.
The studies with FR139317 suggest that the pharmacology of the ET receptor in 
rabbit pulmonary resistance arteries is even more complex. FR139317 did not inhibit 
responses in either sham-operated or coronary ligated rabbit vessels. Another selective 
ETa receptor antagonist, BQ123, was also shown to be ineffective in inhibiting ET-1- 
induced vasoconstrictions in the larger rabbit pulmonary arteiy (Warner, et a l, 1993). 
This is consistent with the suggestion that ETa receptors do not form the major
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population of ET receptors. This has also been demonstrated in binding assays of rabbit 
pulmonary artery membranes which showed that this preparation contained ETa and 
ETg receptors in the ratio 23:77 (Fukuroda, et al, 1994a). In contrast, Cardell et a l 
(1993) showed that ET-1 vasoconstrictor responses in guinea-pig main pulmonary artery 
were competitively antagonised by FR139317. This observation along with the 
decreased potency of ET-3 compared with ET-1, indicates the predominance of ETa 
receptors in this preparation. Thus, there appears to be both species and vessel-related 
differences in the ET-receptor subtypes of pulmonary arterial system. In this study, in 
both sham-operated and ligated rabbit vessels, FR139317 caused a tendency to 
potentiate the responses to ET-1 at higher ET-1 concentrations and this tendency was 
also observed for lower concentrations of ET-1 in the ligated rabbit vessels. This 
indicates that ET-1 is not acting through a typical interaction with ETa receptors and 
suggests the presence of a putative inhibitory ETa receptor, as first described by Gray 
and Clozel (1993) in the rat fundic strip. In this previous study, responses to ET-1 were 
potentiated in the presence of the selective ET A receptor BQ123. The presence of such a 
receptor has also previously been reported in the rat pulmonary resistance artery, where 
the selective ETa receptor antagonist, BMS 182874, potentiated ET-1 responses 
(McCulloch & MacLean, 1996).
The concept of this receptor "crosstalk" has previously been proposed to explain 
the observations that dual inhibition of ETa and ETg receptors is required to inhibit ET- 
1 induced vasoconstrictions in rabbit pulmonary artery (Fukuroda, et a l, 1994c) and in 
human bronchi and rat trachea (Fukuroda, et a l, 1996; Clozel & Gray, 1995). More 
recently, this postulate has been suggested by Mickley et a l (1997) to explain the 
requirement of dual inhibition of ETa and ETg receptors in order to expose ETg 
receptor mediated vasoconstriction of rat isolated small mesenteric arteries. In tliis 
hypothesis, the ETa receptor can compensate when the ETg receptor is inhibited and 
mediate responses to ET-1 and vice versa; thus explaining the decreased potency of 
antagonists from that which would be anticipated from results of previous binding and 
functional studies. For example, this hypothesis may be used to explain why a selective
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antagonist such as BQ788, which has been shown by numerous binding and 
pharmacological studies to be a selective antagonist for ETg receptors, is unable to 
inhibit ETg receptor mediated vasoconstrictor responses, in that interaction or 
"crosstalk" of the receptor subtypes occurs such that the ETa receptor subtype can 
compensate for the ETg receptor blockade and therefore the vasoconstrictor response 
can still be manifested. The inability of FR139317 and BQ788 to antagonise ET-1- 
mediated responses, which was shown in the results of this chapter, may also be 
explained by a possible "crosstalk" between ETa and ETg receptors. However, due to 
the apparent predominance of vasoconstrictor ETg receptors in rabbit pulmonary 
arteries, it seems unlikely that on inhibition of these receptors, that ETa receptors could 
evoke a similar CCRC; but, the possibility also remains that the vasoconstrictor ETg 
receptor predominantly responsible for this vasoconstriction may be insensitive to 
BQ788. In addition, Clozel & Gray, (1995) reported that this "crosstalk" does not take 
place when an ETg receptor agonist is used or when only ETg receptors mediate the 
response. This may explain the marked inhibition of SXS6c responses by BQ788 in this 
preparation but the comparative ineffectiveness against the non-selective agonist ET-1. 
The mechanism for the plausible receptor "crosstalk" is not fully understood. Fukuroda 
et al. (1996) suggested interactions at in the signal transduction systems between ETa 
and ETg receptors. This proposal was based on the observations by Ozaki et a l (1997) 
in human Giradi heart cells expressing ETa and ETg receptors. This study showed that 
stimulation of ET A receptors with ET-1 results in a lowering in the affinity of BQ3020 
and BQ788 for ETg receptors, thus suggesting conversion of the ETg receptor to a 
BQ788-insensitive form through ETA-mediated intracellular signalling. Allosteric 
interactions between ET receptors has been suggested to account for the results of 
radioligand binding in rat heart (Sokolovsky, 1993).
The ineffectiveness of FR139317 and BQ788 in antagonising ET-1-mediated 
responses in adult rabbit PRAs was also demonstrated in PRAs from 7 day old rabbits 
(chapter 9). However, these findings are in contrast to other results of chapter 9, which 
showed a significant inhibitory effect of FR139317 in the same preparation from
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newborn and 4 day old rabbits. Similarly, BQ788 produced a marked inhibition of 
responses to ET-1 in vessels from fetal to 4 day old rabbits. This suggests an alteration 
in the interaction of ET receptor subtypes with developmental age, and this is discussed 
in chapter 9 of this thesis.
In PRAs from sham-operated rabbits, FR139317 had no significant effect on the 
ability of BQ788 to inhibit responses to ET-1. However, the potentiation of the response 
to higher ET-1 concentrations which was noted in the presence of FR139317, was no 
longer evident when BQ788 was present also. This suggests either that ET-1 is acting on 
vasoconstrictor ETg receptors although this response is masked by the actions of 
possible inhibitory ETa receptors, or that ET-1 is not acting at typical ETa ^tid ETg 
receptors. The combined effects of FR139317 and BQ788 might be expected to be the 
same as the effect of SB209670. The differential results might be explained by 
SB209670 being a much more potent antagonist at an ETg receptor than BQ788 
(Ohlstein, et a l ,  1994b; Sogabe, et a l,  1993). Or it could be that the ETg 
vasoconstrictor receptor population is uniquely sensitive to SB209670. In coronary- 
ligated PRAs, the potentiation of the responses to lower ET-1 concentration which was 
noted in the presence of either FR139317 or BQ788 alone, was no longer evident when 
both these antagonists were present together. However, the decrease in sensitivity to 
lower ET-1 concentration still did not reach significance. As discussed previously, 
synergy between ETa and ETg receptors has been reported in larger rabbit pulmonaiy 
arteries where administration of both an ETa and ETg receptor antagonist is required to 
inhibit responses to ET-1 (Fukuroda et al, 1994c). Necessity of dual receptor blockade 
has also been demonstrated in human bronchi (Fukuroda et al, 1996). These findings 
suggest the presence of normally quiescent ETa receptors and receptor cross-talk 
between ETa and ETg receptors through intracellular signalling cascades (Fukuroda et 
al, 1994c; Fukuroda a/., 1996).
In conclusion, these results show that the pharmacology of the ET-1 receptor in 
rabbit pulmonary resistance arteries is extremely complex. There would appear to be a 
quiescent ETa receptor which synergises with a vasoconstrictor ETg receptor which is
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BQ788 sensitive (SB209670 insensitive) and mediates responses to lower concentrations 
of ET-1. There is also a BQ788-insensitive receptor which is sensitive to SB209670 and 
mediates responses to higher ET-1 concentrations. Furthermore, evidence is provided 
for inhibitoiy ETg and ETa receptors which may be upregulated in the vessels from the 
rabbits with LVD. This may be a physiological compensatory mechanism in response to 
the early elevation in pulmonary pressure to maintain responses to ET-1 constant, 
particularly at the lower physiologically relevant concentration range. Antagonism of 
ET-receptor mediated vasoconstriction may provide a possible therapy in established 
pulmonary hypertensive states, or prophylactic against pulmonary hypertension 
secondaiy to other pathologies such as heart failure. However, the effectiveness of ET- 
receptor antagonism therapeutically will depend on the level of endothelial ETg receptor 
stimulation and on the relative selectivity for endothelial and smooth muscle ETg 
receptor subtypes.
Endothelin-receptor subtvpes in human PRAs
ET-1 had similar sensitivity in human PRAs to that observed in rabbit vessels of 
a similar internal diameter (pECgo 8.1 and 7.9, respectively). The results show that the 
CCRCs to ET-1 are biphasic in human PRAs. This has also been shown by previous 
studies in human and rat PRAs (McCulloch & MacLean, 1995; McCulloch et al, 1996). 
I also demonstrated this in rabbit PRAs in chapter 4 of this thesis. In the previous report 
in rat PRAs, the authors suggest that the biphasic response may be due to a 
heterogeneous population of ETg receptors or due to the presence of inhibitory ETa 
receptors (McCulloch & MacLean, 1995). From the results in this chapter in rabbit 
PRAs, the initial component appears to be due to a heterogeneous population of ETg 
receptors. Furthermore, in human PRAs, the first component of the response to ET-1 
appears to be due to a population of ETg receptors mediating vasoconstriction, as was 
indicated by the inhibitory effect of the selective ETg receptor antagonist BQ788 at 
lower ET-1 concentrations (<lnM). The previous study by McCulloch & MacLean
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(1995) in human PRAs showed that the selective ETa receptor antagonist BMS 182874 
inhibited ET-1 concentrations greater than InM. This suggests that vasoconstriction 
evoked by higher ET-1 concentrations is mediated through stimulation of ETa 
receptors. A previous report in human pulmonary arteries (-1mm outer diameter), 
demonstrated that ET-1-induced contractions were competitively antagonised by BQ123 
(an ETa receptor antagonist) whereas the ETg receptor agonist BQ3020 was without 
effect (Fukuroda, et al., 1994a). Inhibition of ET-1-responses of human larger 
pulmonary arteries by BQ123 has also been reported by Hay eta l (1993). These findings 
indicate differential ET-receptor subtypes in human pulmonaiy arteries of different 
sizes. Davenport et al. (1995) reported from radioligand binding studies, that ETg 
receptors only represented less than 15% of the of the ET receptors in the larger human 
pulmonary artery. Fukuroda et al (1994a) showed from binding assays that human 
pulmonary arteries of -1mm outer diameter contained ETa and ETg receptors in the 
ratio 93:7; this compares with the ratio of 23:77 reported in rabbit pulmonary arteries of 
similar diameter. The influence of vessel size on ET-receptor mediated responses, in 
terms of antagonist effectiveness, has also been demonstrated in rat pulmonary arteries 
(MacLean, eta l, 1994a; Bonvallet, eta l, 1993).
Concentration-dependent contractile responses were also observed to ET-3. ET-1 
and ET-3 would be expected to be equipotent at a classical ETg receptor; the results of 
chapter 4 of this thesis demonstrated equipotency of these isopeptides in rabbit PRAs. 
However, from these results, it can be seen that ET-3 was -5 fold more potent than ET- 
1; this has also been reported in previous studies in isolated human PRAs (McCulloch, 
et a l, 1996). A receptor selective for ET-3 over ET-1 (denoted ETc) has been cloned in 
Xenopus laevis dermal melanphores (Karne, et a l, 1993). The relative potency of ET-3 
over in human PRAs may suggest the presence of such an ETc receptor. Indeed, there is 
pharmacological evidence for this receptor in other vascular tissue including rabbit 
saphenous vein (Douglas, et al., 1995). However, a mammalian vascular counterpart of 
this putative receptor has yet to be identified. The magnitude of the vasoconstriction 
evoked by ET-3 was markedly smaller than that of ET-1 in human PRAs; I also showed
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this in rabbit PRAs from coronary-ligated rabbits (chapter 4). As was noted in rabbit 
PRAs, the ability of BQ788 to antagonise ET-3-induced responses in human PRAs 
confirms that ET-3 is mediating its responses via ETg receptors. This provides further 
evidence for the involvement of ETg receptors in the contractile responses of human 
PRAs. In addition, the differential effect of BQ788 on ET-1 and ET-3 responses in this 
preparation provides additional evidence that the potency of BQ788 depends upon the 
ET-receptor antagonist (this is discussed earlier).
The involvement of both ETa ETg receptor subtypes was shown by the 
marked inhibitory effect of the non-selective antagonist SB209670. The degree of 
inhibition of ET-1-responses by SB209670 in human PRAs was markedly greater than 
that observed in rabbit PRAs. Of the previous studies using selective ET-receptor 
antagonist and the effect of BQ788 shown in these results, the most profound inhibitory 
effects on ET-1-induced vasoconstrictions of human pulmonary arteries were noted to 
this non-selective antagonist As was suggested in rabbit PRAs, this difference may be 
explained by a heterogeneous population of ETg receptors. The limited potency of 
BQ788, demonstrated in this study, suggests that ETg receptors in PRAs are not as 
sensitive to the prototypical ETg receptor antagonist BQ788 as they are to the non- 
selective antagonist SB209670. Support for this hypothesis requires molecular 
biological and further pharmacological evidence of the nature and location of ET- 
receptor subtypes on the human pulmonary vasculature.
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Chapter 6
Influence of nitrie oxide on ET-receptor-mediated 
responses in rabbit pulmonary resistance arteries: Effect of
left ventricular dysfunction
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6.1 Introduction
I have previously introduced in chapter 1 of this thesis, the physiological role of 
endothelium-derived nitric oxide (NO) and endothelin-1 (ET-1) in the pulmonary 
circulation and also the mechanisms of action and effects of this oxidant radical and 
peptide. The importance of the functional role of the endothelium in the control of 
pulmonary vascular tone, via the release of vasoactive peptides such as NO and ET-1, 
has become increasingly evident. Both these endothelial derived agents have marked 
functional and structural effects on the developing (Kinsella, et at., 1994; Roberts, et a l,
1995) and adult pulmonary circulation (Barnard, et al, 1991; Janakidevi, et a l, 1992). 
The discovery that NO is endothelium derived relaxing factor (EDRF) (Palmer et a l, 
1987) was followed in rapid succession by the use of inhaled NO in humans as therapy 
for pulmonary hypertension (PHT). Many previous studies have demonstrated that NO 
is the first substance capable of selectively reducing PHT, of various etiologies in both 
children and adults, without reducing systemic arterial blood pressure (Pepke-Zaba, et 
a l,  1991; Roberts, et a l, 1992; Rich, et a l,  1993). The role of NO in ET-receptor 
mediated responses in transitional pulmonary circulation of the fetal and neonatal rabbit 
is examined in chapter 8 of this thesis. In the studies described in this chapter, I 
examined the role of NO in ET-receptor mediated responses in the adult rabbit 
pulmonary resistance arteries (PRAs). Furthermore, the effect of PHT secondary to left 
ventricular dysfunction (LVD) was investigated also using a rabbit coronary artery 
ligation model (Deuchar, et al, 1997; Pye, et al, 1996).
A dysfunction of the endothelium has been implicated in the pathophysiology of 
a number of cardiovascular diseases, including PHT (Rabinovitch, et a l,  1986). 
Impairment of NO synthesis, and/or increased ET-1 synthesis, or increased smooth 
muscle sensitivity to ET-1, could account the many features associated with PHT, 
including the increased pulmonary vascular tone and vascular hypertrophy. As I have 
previously stated, ET-1 has been implicated in several pathological conditions including 
heart failure and PHT of various etiologies (Stewart, et a l, 1991). Thus, in chapters 4
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and 5 of this thesis I examined ET-receptor subtypes in small muscular pulmonary 
arteries from the rabbit coronary ligation model of left ventricular dysfunction. The 
involvement of endothelium-derived NO in several pathophysiological states of the 
pulmonary circulation involving PHT has also been reported; including cystic fibrosis, 
Eisenmenger's syndrome and chronic obstmctive lung disease (Dinh-Xuan, et a l, 1989; 
1990; 1991). There is evidence that nitric oxide synthase (NOS) may be upregulated in 
patients with heart failure and inhibition of NOS in these patients increased pulmonary 
vascular resistance (Habib, et al, 1994). Whereas an impairment of NO production was 
reported in isolated pulmonary artery from patients with chronic obstructive lung disease 
(Dinh-Xuan. e ta l,  1993).
The ability of ET to induce the release of EDRF (NO) from the isolated perfused 
mesentery and prostacyclin from the isolated lung has been demonstrated by De Nucci 
et a l (1988). Since previous studies suggest an important role of these endothelial 
derived relaxing factors in the maintenance of low tone in the pulmonary circulation, it 
may be postulated that the potent vasoconstrictor effect of ET-1 on the pulmonary 
vascular smooth muscle is modulated by their concomitant release, with such interaction 
providing a feedback mechanism in vascular control. Indeed, previous studies suggests 
that EDRFs, such as NO, may attenuate ET-1-induced arterial vasoconstriction. 
Raffestin et a l (1991) showed that the rise in pulmonary arteiy pressure in response to 
ET-1 in isolated rat lungs was potentiated by several inhibitors of EDRFs. This was also 
demonstrated in rat aorta by Lang and Lewis (1991) and in pulmonary arteiy branches 
of the rat by MacLean, et al (1994b). Hence, an imbalance between NO and ET-1 may 
contribute to the alteration in vascular tone characteristic of cardiovascular disease.
Therefore in this chapter, I examined the presence of basal and/or agonist- 
induced NO release in sham-operated and coronary ligated PRAs by examining the 
effect of the NOS synthase inhibitor on resting tension and on responses to ET-1 and the 
selective ETg receptor agonist SXS6c. A vascular contraction mediated by NOS 
inhibition could be due to inhibition of basal NO, the presence of endogenous tone, or a 
combination of both effects. To clarify this, I also sought inherent tone in rabbit PRAs
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by determining the response of these vessels, under basal tension, to sodium 
nitroprusside (SNP).
6.2 Methods
Rabbit pulmonaiw resistance arteries
Lungs were obtained from the rabbit coronary ligation model of left ventricular 
dysfunction which has been extensively characterised (Pye et al, 1996) and is described 
in detail in section 2.1.1 of this thesis. In the 8 week and 16 week procedure period 
groups, age matched animals underwent the same methodology as the experimental 
animals (referred to in results and discussion as "ligated") except the ligatures placed 
around the coronary artery were not secured. These are subsequently referred to as 
"sham-operated". Also, age matched animals in which no operational procedures were 
performed were used as controls in the 16 week and 32 week procedure period groups 
These are subsequently referred to as "stock". Measurements of ejection fraction were 
made in all animals and animals were killed by sodium pentabarbitone 8, 16 or 32 weeks 
following the procedure. The lungs were promptly removed and small intralobar 
muscular pulmonary arteries (referred to as pulmonaiy resistance arteries (PRAs) -160 
tim ID; see table 6.1) were dissected out according to the methods stated in section
2.2.3.1. These were mounted as ring preparations (-2mm long) on a wire myograph, 
bathed in Krebs solution at 37°C. Using the normalisation process explained in section 
2.2.5, vessels were tensioned to an equivalent transmural pressure o f -  16 mmHg. This 
pressure was chosen as it is similar to in vivo pressures of rabbit pulmonary arterioles. 
Preliminary studies in our laboratory showed that bubbling with 95% O2 inhibits 
responses to vasoconstrictors in rabbit PRAs so we bubbled with 16% O2/ 5% CO2 
balance N2 . These gas mixtures were chosen as they are similar to those which the 
vessels would be exposed to in vivo.
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Experimental protocol
Vessels were allowed to equilibrate for 1 hour prior to the addition of any drugs. 
The response of the PRAs to 50mM KCl was determined twice; once the contractile 
response had reached a plateau, the vessels were washed out at least 6 times with fresh 
Krebs solution. Following adequate time to reach baseline tension, Cumulative 
concentration-response curves (CCRCs) were constructed to ET-1 or SXS6c (IpM- 
0.3|_lM) following either a 30 minute "rest period" or a 30 minute incubation period with 
100f,iM L-NAME. In a proportion of SXS6c experiments in vessels from 8 week 
procedure groups, 0.1 jiM ET-1 was added to the bath at the end of the SXS6c CCRC, 
before washing, so as to estimate the SXS6c response as a percentage of response to a 
maximal ET-1 concentration. In addition, in a separate group of 8 week rabbit PRAs, 
following equilibration and before the addition of any agents, IfiM SNP was added to 
the bath to examine possible endogenous tone in the vessels.
Data analvsis
Results are expressed graphically as percentage of their own maximum 
contraction, or percentage of reference contraction to second application of 50mM KCL, 
or percentage of contraction to 0.1 p.M ET-1, or absolute response as mg weight tension.. 
A»ECio,/>EC25 and/>EC5o values (where appropriate) were calculated according to the 
methods stated in section 2.5.2, and expressed as -log M concentration. Statistical 
comparison of the means of groups of data were made by Student's unpaired t test when 
two groups were compared, or ANOVA when three or more groups were compared; 
f  <0.05 was considered statistically significant. Throughout, data are expressed as 
mean+SEM and n In = number of ring preparations / number of animals.
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4.3 Results
The ejection fraction of animals from the various experimental groups, from 
which lungs were obtained and PRAs dissected for the studies described in this chapter, 
are shown in table 6.1. The effective pressure to which these vessels were tensioned and 
the resulting estimate of internal diameter are also shown in table 6.1. The ejection 
fraction was markedly reduced in ligated animals compared with sham-operated/stock 
rabbits in 8, 16 and 32 week procedure groups. Also, the reduced ejection fraction was 
significantly lower in 16 week ligated compared to 8 and 32 week ligated rabbits. 
Vessels from all experimental groups were tensioned to a similar effective pressure and 
internal diameter.
(n)
Internal diameter 
(HM)
Effective pressure 
(mmHg)
Ejection fraction 
(%)
8 week
sham-op erated(3 6) 170.1+7.5 18.8+0.8 69.3+1.2
ligated (40) 174.7+7.1 21.2+0.6 45.7+0.9***
16 week
sham-operated(24) 146.7+7.5 20.8+1.3 74.4+0.8
ligated (36) 161.3+6.6 17.8+0.6 40.2+1.2***+
32 week
stock (16) 159.9+7.4 15.8+1.1 74.1+0.9
ligated (20) 156.2+12.5 19.4+1.1 47.5+1.0***
Table 6.1 (1) Ejection fraction of animals from which PRAs were dissected and studied 
in this chapter and (2) internal diameter and effective pressure of PRAs from this cohort 
of rabbits. Statistical comparisons were made by Student's unpaired t-test; ligated vs. 
sham-operated/stock, ***P<0.001; ANOVA: 16 week ligated vs. 8 and 32 week ligated, 
+P<0.001. Values are mean+SEM. n, number of ring preparations.
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SNP (1|liM) had no effect on the baseline tension in PRAs from either 8 week 
sham-operated or coronary-ligated rabbits (n=4/4 in each case). The effect of lOOpM L- 
NAME alone on baseline tension of small pulmonary arteries from the various 
experimental groups was assessed also. This nitric oxide synthase inhibitor evoked 
variable responses. Of the vessels examined in the 8 week procedure group, 23.5% and 
66.7% of the vessel from sham-operated and coronary-ligated rabbits showed a 
vasoconstrictor response, respectively. In the 16 week procedure group, an increase in 
baseline tone was evident in 66.6% and 50% of the vessel from sham-operated and 
coronary-ligated rabbits, respectively. Whilst no response to L-NAME was noted in any 
of the vessels studied from the 32 week procedure group. The magnitude of the increase 
in baseline tension, which was noted in the vessels which responded, is shown in figure
6.1. When this increase in tone was evaluated as a percentage of the reference 
contraction to the second application of 50mM KCl, the response of 8 week sham- 
operated and coronary ligated rabbit vessels was similar, whilst that of the small 
pulmonary arteries from 16 week ligated rabbits was significantly reduced compared 
with corresponding sham-operated tissue (17.4+4.1% vs. 33.0±4.1%, P<0.05; figure 
6.1 A). However, on assessing this vasoconstriction in absolute terms as mg weight 
tension, no significant difference was noted between sham-operated and coronary- 
ligated rabbit PRAs from either group (figure 6. IB). The increase in tension noted in the 
8 week ligated rabbit PRAs tended to be greater than that of control vessels in the same 
group (91.9+21.9 mgwt. vs. 50.0+16.9 mgwt.), however, this did not reach the level of 
statistical significance.
8 week experimental group
Figures 6.2 and 6.3 show the effect of L-NAME on ET-1 responses in PRAs 
from the 8 week procedure group. /?ECio, ^EC%5 andpBCso values are summarised in 
table 6.2. 100|uM L-NAME had no effect on the sensitivity of 8 week sham-operated 
PRAs to ET-1 (figure 6.2 A, table 6.2.) However, in vessels from coronary-ligated
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Figure 6.1 Effect of 100|j,M L-NAME on baseline tension in PRAs from sham-operated 
(open columns) / coronary-ligated (hatched columns) rabbits from 8 week (n=4/4 / 
n=10/10) and 16 week (n=8/8 / n=7/7) procedure groups. A Data are expressed as a 
percentage reference contraction to 50mM KCL B Data are expressed as mg weight 
tension. Each point represents mean±s.e. mean.
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Figure 6.2 Effect of 100|llM L-NAME on ET-1 responses in PRAs from 8 week 
experimental group animals. Data are expressed as a percentage own maximum 
contraction. A sham-operated rabbit PRAs: control (O, n=8/6); +L-NAME ( • ,  n=9/7). 
B coronary-ligated rabbit PRAs: control (O, n=12/7); +L-NAME (#, n=7/6). Each point 
represents mean ± s.e. mean.
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Figure 6.3 Effect of lOOj^ iM L-NAME on ET-1 responses in PRAs from 8 week 
experimental group animals. Data are expressed as a percentage reference contraction to 
50mM KCl. A sham-operated rabbit PRAs: control (O, n=8/6); +L-NAME (# , n-9/7). 
B coronaiy-ligated rabbit PRAs: control (O, n=12/7); +L-NAME ( • ,  n=7/6). Each point 
represents mean ± s.e. mean.
202
rabbits in this group, a marked potentiation was noted in the ET-1-induced 
vasoconstriction. In this preparation, L-NAME caused a leftward shift in the entire 
CCRC, although this effect was more profound over the lower concentrations of ET-1 
(figure 6.2B). An -13 fold and ~8 fold increase was noted in the />EC25 and ^ECgo 
values, respectively, (table 6.2). The magnitude of the contractile responses were 
augmented in vessels from both groups. In sham-operated preparations, this was noted 
particularly to ET-1 concentrations greater than InM (figure 6.3 A), whilst in PRAs from 
coronary-ligated rabbits, the enhancement of vasocontractile responses was more 
pronounced to lower concentration of this peptide (figures 6.3B). However the maximal 
vasoconstriction was not effected in vessels from either group.
Figures 6.4 and 6.5 show the effect of L-NAME on SXS6c responses in PRAs 
from the 8 week procedure group. pEC\Q,pEC25 and^EC^o values are also summarised 
in table 6.2. As was noted in the ET-1 response, inhibition of NOS with lOOjuM L- 
NAME had no effect on sensitivity of sham-operated rabbit PRAs to SXS6c (figure 
6.4A; table 6.2). However the magnitude of the contractile responses to higher SXS6c 
concentrations were greater in the presence of L-NAME and the maximum response was 
significantly increased in this preparation (control 67.9+8.2% vs. presence of L-NAME 
101.8+13.7%, f<0.05; figure 6.5 A). In coronary-ligated rabbit PRAs, L-NAME caused 
a significant potentiation of the responses to SXS6c, causing a leftward shift of the 
entire CCRC (figure 6.4B). This effect was more pronounced over the lower SXS6c 
concentrations, such that a ^ECio value could not be calculated. An -20 fold and -15 
fold increase was noted in the PEC25 and/^EC^o values, respectively (table 6.2). The 
increase in the amplitude of the vasoconstrictions was also more evident at lower SXS6c 
concentrations. The threshold for contraction increased from 3pM to less than IpM and 
the response to lOpM increased 5 fold, however, the maximal contraction to SXS6c was 
not effected in coronary-ligated rabbit vessels (figure 6.5B). The influence of L-NAME 
on the magnitude of the SXS6c vasoconstriction was also assessed in terms of the 
response to 0.1 pM ET-1 in the same preparation. Again, a marked increase was noted in 
the vasoconstriction of PRAs coronary-ligated rabbit to all SXS6c concentration up to
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Figure 6.4 Effect of 100|aM L-NAME on SXS6c responses in PRAs from 8 week 
experimental group animals. Data are expressed as a percentage own maximum 
contraction. A sham-operated rabbit PRAs; control (□, n=10/9); +L-NAME (■, n=5/5). 
B coronary-ligated rabbit PRAs: control (□, n=l 1/7); +L-NAME (■, n=8/6). Each point 
represents mean ± s.e. mean.
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Figure 6.5 Effect of 100|_iM L-NAME on SXS6c responses in PRAs from 8 week 
experimental group animals. Data are expressed as a percentage reference contraction to 
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30nM (results not shown). The maximum contractile response, in terms of percentage of 
response to 0.1 |aM ET-1, tended to be greater in the presence of L-NAME, however this 
was not significant (sham-operated: 87.2+15.8 % vs. 65.4+5.4%; coronary-ligated: 
87.7+9.3% vs. 65.3+8.9%).
n/n ^ECio pEC25
Sham-operated rabbit PRAs
ET-1 control 8/6 9.4+0.6 8.6+0.4 7.9+0.3+100|uM L-NAME 9/7 9.5+0.3 9.3+0.3 8.3+0.2
SXS6c control 10/9 10.6+0.3 9.9+0.3 9.0+0.2+100|liM L-NAME 5/5 10.9+0.3 10.1+0.3 9.2+0.3
Coronarv-lieated rabbit PRAs
ET-1 control 12/7 8.9+0.4 8.3+0.2 7.9+0.2+100pM L-NAME 7/6 10.4+0.3* 9,7+0.3*** 8.7+0.2
SXS6c control 11/7 10.4+0.3 9.4+0.3 8.6+0.2
+100|iM L-NAME 8/6 nc 11.1+0.1*** 10.4+0.3***
Table 6.2 Effect of L-NAME on the sensitivity to ET-1 and SXS6c in PRAs from 8 
week sham-operated and coronary ligated rabbit PRAs. Statistical comparisons were 
made by Students' unpaired t-test: +L-NAME vs. control *R<0.05, ""*^<0.01, 
001. Values are mean ± SEM. ET-1, endothelin-1; SXS6c, sarafotoxin S6c; L- 
NAME, N®-nitro-L-arginine methylester; n/n, number of ring preparations / number of 
animals; nc, not calculated.
16 week experimental group
Figures 6.6 and 6.7 show the effect of L-NAME on ET-1 responses in PRAs 
from the 16 week procedure group. pEC\Q,pEC^s and/>EC5o values are summarised in 
table 6.3. The sensitivity to ET-1 in either 16 week stock or sham-operated PRAs was 
not effected by lOOpM L-NAME (figure 6.6A and B, table 6.3). However, in vessels 
from coronary-ligated rabbits in this group, a marked potentiation was noted in the ET- 
1-induced vasoconstriction. This effect was evident to concentrations of ET-1 greater
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Figure 6.6 Effect of 100p,M L-NAME on ET-1 responses in PRAs from 16 week stock 
and sham-operated rabbits. Data are expressed as a percentage own maximum 
contraction. A stock rabbit PRAs: control (O, n=6/5); +L-NAME (#, n=3/3). B sham- 
operated rabbit PRAs: control (O, n=5/5); +L-NAME (# , n=7/6). Each point represents 
mean + s.e. mean.
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Figure 6.1 Effect of lOOjuM L-NAME on ET-1 responses in PRAs from 16 week 
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208
than InM (figure 6.7A). An ~6 fold increase was noted in the PEC25 and77EC50 values 
(table 6.3). This compares with the results in PRAs from 8 week coronary-ligated rabbits 
where the potentiation effect of L-NAME was most pronounced at lower ET-1 
concentrations. Neither the magnitude of the vasoconstrictions nor the maximum 
response to ET-1 were effected in PRAs from 16 week stock/sham-operated rabbits (not 
shown). In coronary-ligated rabbit PRAs from this group, the magnitude of the 
contractile responses in the second component of the CCRC were augmented, however, 
no significant change occurred in the maximum (Figures 6.7B).
Figures 6.8 and 6.9 show the effect of L-NAME on SXS6c responses in PRAs 
from the 16 week procedure group. ^E C io ,/'E C 25 andpEC^o values are also 
summarised in table 6.3. (The effect of L-NAME on SXS6c responses was not examined 
in vessels from 16 week stock animals). Inhibition of NOS with 100|liM  L-NAME had 
no effect on the sensitivity of sham-operated rabbit PRAs to SXS6c (figure 6.8A; table
6.3). In coronary-ligated rabbit PRAs, a leftward shift in the rising component of the 
SXS6c CCRC was evident (figure 6.8B). This augmentation resulted in a significant 6 
fold increase in the PEC25 (table 6.3). The potentiating effect was more pronounced at 
higher SXS6c concentrations, in teims of the amplitude of the contractile response. The 
threshold for concentration increased from 3pM to less than IpM and a significant 
increase was evident in the contractile response to all SXS6c concentration up to 30nM 
(figure 6.9B). This is in contrast to results in 8 week ligated rabbit arteries, which 
showed the comparatively greater increase to be most pronounced at lower 
concentrations of SXS6c. The magnitude of SXS6c-induced vasoconstrictions were not 
effected in arteries from sham-operated animals and the maximum response was similar 
(figure 6.9A). Whereas in vessels from LVD rabbits, a significant increase was noted in 
the maximum response (control 57.5+11.5% vs. 105.6+13.6%, P<0.05; figure 6.9B).
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Figure 6.8 Effect of 100|iM L-NAME on SXS6c responses in PRAs from 16 week 
experimental group animals. Data are expressed as a percentage of their own maximum 
contraction. A sham-operated rabbit PRAs: control (□, n=6/6); +L-NAME (■, n=4/4). B 
coronary-ligated rabbit PRAs: control (□, n=9/6); +L-NAME (■, n=7/6). Each point 
represents mean ± s.e. mean.
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Figure 6.9 Effect of lOOjuM L-NAME on SXS6c responses in PRAs from 16 week 
experimental group animals. Data are expressed as a percentage reference contraction to 
50mM KCl. A sham-operated rabbit PRAs: control (□, n=6/6); +L-NAME (Vi, n=4/4). 
B coronaiy-ligated rabbit PRAs: control (□, n=9/6); +L-NAME (■, n=7/6). Each point 
represents mean ± s.e. mean.
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n/n pECio /;EC25 i^ECso
Stock rabbit PRAs
ET-1 control 6/5 8.9+0.3 8.4+0.2 7.8+0.2+10C|aM L-NAME 3/3 9.5+0.4 8.5+0.3 7.7+0.3
Sham-operated rabbit PRAs
ET-1 control 5/5 9.7+0.6 10.1+1.0 8.2+0.2+ 100|.iM L-NAME 7/6 9.9+0.6 9.5+0.6 8.5+0.5
SXS6c control 6/6 11.5+0.3 10.8+0.3 9.8+0.2+100pM L-NAME 4/4 11.5+0.4 10.5+0.5 9.7+0.7
Coronarv-ligated rabbit PRAs
ET-1 control 13/7 9.0+0.3 8.2+0.2 7.5+0.1+100tiM L-NAME 6/6 10.0+0.4* 8.9+0.2* 8.0+0.03**
SXS6c control 9/6 9.9+0.2 9.1+0.2 8.6+0.2
+100|iM L-NAME 7/6 9.3+0.3 9.7+0.1* 9.1+0.2
Table 6.3 Effect of L-NAME on the sensitivity to ET-1 and SXS6c in PRAs from 16 
week stock/sham-operated and coronary ligated rabbit PRAs. Statistical comparisons 
were made by Students' unpaired t-test: +L-NAME vs. control *P<0.05, **/^<0.01. 
Values are mean ± SEM. ET-1, endothelin-1; SXS6c, sarafotoxin S6c; L-NAME, N< -^ 
nitro-L-arginine methylester; n/n, number of ring preparations / number of animals.
32 week experimental group
Figures 6.10 and 6.1 lA show the effect of L-NAME on ET-1 responses in PRAs 
from the 32 week procedure group. />ECio,/'EC25 andpECgo values are summarised in 
table 6.4. L-NAME (lOOjuM) had no significant effect on the sensitivity to ET-1 in 
PRAs from either 32 week stock or coronary-ligated rabbits (figure 6.IDA and B, table
6.4). The magnitude of the vasoconstrictions were not effected in vessels from age- 
matched stock animals (not shown); maximum control response 106.7+9.0% vs. 
137.6+41.2%. However, Figure 6.11 A shows, in coronary-ligated rabbit PRAs, that the
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Figure 6.10 Effect of L-NAME on ET-1 responses in PRAs from 32 week
experimental group animals. Data are expressed as a percentage own maximum 
contraction. A stock rabbit PRAs; control (O, ii=5/5); +L-NAME (# , n=3/3). B 
coronary-ligated rabbit PRAs: control (O, n=5/5); +L-NAME (# , n=5/5). Each point 
represents mean ± s.e. mean.
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Figure 6.11 Effect of 100|uM L-NAME on ET-1 and SXS6c responses in PRAs from 32 
week coronary ligated rabbits. Data are expressed as a percentage reference contraction 
to 50mM KCl. A ET-1 control (O, n=5/5); +L-NAME (#, n=5/5). B SXS6c control (□, 
n=6/6); +L-NAME (■, n=5/5). Each point represents mean ± s.e. mean.
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Figure 6.12 Effect of 100|llM  L-NAME on SXS6c responses in PRAs from 32 week 
experimental group animals. Data are expressed as a percentage own maximum 
contraction. A stock rabbit PRAs: control (□, n=5/5); +L-NAME (■, n=3/3). B 
coronary-ligated rabbit PRAs: control (□, n=6/6); +L-NAME (■, n=5/5). Each point 
represents mean ± s.e. mean.
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amplitude of the ET-1 responses tended to be greater in the presence of L-NAME but 
the maximum response was not effected.
Figures 6.12A and B and table 6.4 show the effect of L-NAME on the sensitivity 
of PRAs from the 32 week procedure group. As was noted in the ET-1 response, 
inhibition of NOS with L-NAME had no significant effect on the sensitivity of stock or 
coronaiy-ligated rabbit PRAs to SXS6c (figure 6.12A and B, respectively ; table 6.4). In 
coronary-ligated rabbit PRAs, an -  4 fold increase was noted in the pEC\Q, however this 
was not significant (table 6.4). The magnitude of SXS6c-induced vasoconstrictions were 
not effected in arteries from stock animals (not shown). In vessels from LVD rabbits, the 
amplitude of the vasoconstrictions tended to be greater in the presence of L-NAME, 
particularly to higher peptide concentrations however, the maximum response was not 
significantly increased (control 57.9+10.9% vs. 88.7+12.1%; figure 6.1 IB). These 
results compare with those in PRAs from 8 and 16 week coronary-ligated rabbits, where 
L-NAME was seen to cause a marked potentiation of both ET-1 and SXS6c responses.
n/n /?ECio pECz5 pEC50
Stock rabbit PRAs
ET-1 control 5/5 9.2+0.2 8.5+0.1 7.9+0.1+100p,M L-NAME 3/3 9.5+0.4 8.8+0.3 . 8.0+0.2
SXS6c control 5/5 10.0+0.3 9.4±0.2 8.7+0.1
+100|iM L-NAME 3/3 10.5+0.5 10.0+0.6 8.9+0.3
Coronarv-ligated rabbit PRAs
ET-1 control 5/5 9.3+0.5 8.7+0.4 7.7+0.1+100|aM L-NAME 5/5 9.8+0.4 8.8+0.2 8.1+0.2
SXS6c control 6/6 10.8+0.2 10.3+0.3 9.4+0.2+100tiM L-NAME 5/5 11.2±0.2 10.4+0.3 9.5+0.3
Table 6.4 Effect of L-NAME on the sensitivity to ET-1 and SXS6c in PRAs from 32 
week stock and coronary ligated rabbit PRAs. Values are mean + SEM. ET-1, 
endothelin-1; SXS6c, sarafotoxin S6c; L-NAME, N®-nitro-L-arginine methylester; n/n, 
number of ring preparations / number of animals.
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6.4 Discussion
The results of this chapter demonstrated that the NOS inhibitor, L-NAME, 
potentiates responses to ET-1 and SXS6c in small muscular pulmonary arteries from 
rabbits with LVD, induced by coronary-artery-ligation, but not from age-matched stock 
or sham-operated rabbits. However, the extent of this potentiation varied depending on 
the length of time of the coronary artery ligations. The increase in sensitivity to these 
peptides was most pronounced in the 8 week procedure group, was still evident in 
vessels from 16 week coronaiy-ligated vessels, whereas, in the 32 week procedure 
group, L-NAME had no significant effect on either ET-1- or SXS6c-induced responses. 
These results suggest that there is an increase in NO production associated with the 
development of PHT in these rabbits. This may be basally released NO or NO released 
by the ET-1 and SXS6c via the endothelial ETg receptor. I failed to show vasorelaxatory 
responses to SXS6c in preconstricted rabbit PRAs in the studies of chapter 4 of this 
thesis. However, there is the possibility that the apparent predominance of contractile 
ET-receptor subtypes in this preparation may be preventing the exposure of these 
receptors functionally. The results in PRAs from 8 week coronaiy-ligated rabbits 
demonstrated that the profound potentiation of the responses to SXS6c and ET-1 
following inhibition of NOS was greatest over the first component of the CCRC. The 
results of chapter 5 of this thesis provide several points of evidence for an upregulation 
of endothelial ETp receptors mediating vasodilation in 8 week coronary-ligated rabbit 
PRAs, paiticularly in first component of the CCRC: (1) a potentiating effect of BQ788 
and SB209670 on ET-1-induced responses, particularly to lower concentrations of ET-1, 
was noted in PRAs from 8 week coronary-ligated rabbits; both these antagonists are 
known to inhibit this ETb receptor subtype (Douglas, et aL, 1995; Ohlstein, et a l, 
1994a). Also, (2) SB209670 was comparatively less effective in antagonising SXS6c- 
induced vasoconstrictions in coronary-ligated PRAs compared with the marked 
inhibition noted in sham-operated PRAs. Finally, (3) the contractile response to ET-3 
was significantly reduced in coronary-ligated rabbit PRAs compared with vessels from
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control animals and ET-3 is extremely potent at this receptor (Douglas, et a l, 1995). 
Furthermore, in this chapter, L-NAME caused a comparatively greater increase in the 
contractile response to the ETg selective agonist SXS6c compared to the non-selective 
agonist ET-1. The differential effect of L-NAME on SXS6c and ET-1 suggests a 
heterogeneous population of receptors, differentially influenced by NO. It suggests that 
SXS6c has a high potency for a particular ETg-like receptor. A heterogeneous 
population of receptors in these vessels is also indicated by the results of chapters 4 and 
5 of this thesis.
In addition, results from chapter 3 of this thesis demonstrated that the PRAs 
removed from rabbits with LVD, and increased NOS, demonstrated a decreased 
sensitivity to sodium nitroprusside (SNP); this is an endothelium-independent relaxatory 
agent which activates NO directly. In man, an increase in stimulation of NO by long 
term nitrate administration is also followed by a tolerance to the effects of nitrates 
(Needleman & Johnson, 1973). MacLean & MacMillan (1993) reported that in rats 
chronically treated with L-NAME such that endothelial NOS (eNOS) is depleted, the 
pulmonaiy arteries were hypersensitive to SNP. Hence there is evidence that when there 
is an increased stimulation of NO, either by upregulation of eNOS or administration of 
nitrates, the vascular smooth muscle compensates by a reduction in sensitivity to NO. 
Whereas the findings of MacLean & MacMillan (1993) suggests that when eNOS is 
inhibited, the reverse case holds, with the smooth muscle becoming more sensitive to 
NO.
The nature of the increase in the ET-1- and SXS6c-induced responses produced 
by NOS inhibition varied in 8 and 16 week coronary-ligated rabbit PRAs. As stated, in 
preparations from 8 week LVD animals this augmentation was most pronounced to 
lower concentrations of these peptides; this suggests that this may actually be important 
in in vivo conditions. However in PRAs from 16 week coronary-ligated rabbits, the 
potentiation of both ET-1 and SXS6c responses occurred to higher agonist 
concentrations and this was further demonstrated by the significant increase in the 
maximum vasoconstriction to SXS6c. This suggests that the possible upregulation of
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endothelial ETb receptors, activated by lower concentrations of ET-1 and SXS6c, in 
vessels from 8 week LVD animals (which is suggested by the results of this chapter and 
those of chapter 5), is no longer present in 16 week LVD rabbits. From these findings, 
one could hypothesis that an increase in endothelial ETb receptors mediating 
vasodilation is an early compensatory mechanism which occurs in early stages of 
increased pulmonary pressure induced by LVD. An ET-1 limiting process on 
vasoconstriction mediated by ETB receptors has also been suggested in the systemic 
circulation (Allcock & Warner, 1995). In the cohort of animals used in this chapter, the 
ejection fraction of the 16 week coronary-ligated rabbits was significantly lower than the 
8 week LVD animals but this attenuation did not progress to the 32 week experimental 
groups. Thus it appears unlikely that the rabbits ligated for a longer duration represent a 
more severe LVD condition.
Previous investigators have reported an influence of endothelial derived factors, 
such as NO, on ET receptor-mediated responses in various arterial preparation from 
several species. For example, in the isolated canine liver arterial circuit pressor 
responses to ET-1 and SXS6b were shown to be potentiated by infusion of L-NAME 
(Faro., et a l,  1995). Lang and Lewis (1991) reported that NO inhibited the ET-1- 
induced increase in protein kinase C in rat aorta. Removal of the endothelium was 
shown to increase the maximum effectiveness of both ET-1 and ET-3 on rat pulmonary 
artery and thoracic aorta rings (Rodman, et a l, 1989). Finally, Zellers and co-workers
(1994) reported that ET-1-induced vasoconstrictions in small porcine pulmonary arteries 
and veins were augmented by L-NNA, an L-arginine antagonist, and this was 
enhancement was greater in veins. In addition, my own study showed maximal 
contractile responses to SXS6c to be markedly enhanced in the presence L-NAME in 
"control" PRAs from 8 week procedure animals, thus indicating the involvement of NO 
in responses to SXS6c in this preparation. Also, in chapter 8 of this thesis, I showed that 
L-NAME evokes a marked potentiation of ET-1 and SXS6c responses in neonatal rabbit 
PRAs.
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The "drop o ff  in tension which occurred at higher concentrations in the SXS6c- 
induced vasoconstriction, was still evident in the presence of L-NAME, thus suggesting 
that NO is not involved in its occurrence. The most plausible explanation for this is 
receptor desensitisation. It has previously been shown that the ETb receptor is strongly 
tachyphylactic (Hemy, 1993). In another preparation in which responses were concluded 
to be mediated via ETb receptors, rabbit saphenous vein, SXS6c evoked a 
vasoconstrictor response, however a second application of this peptide was ineffective at 
inducing contraction (Sudjaiwo, et al., 1994). In addition, cumulative addition of SXS6c 
also resulted in a bell-shaped concentration response curve. The authors concluded that 
high concentrations of SXS6c selectively activated the ETb receptor and then 
desensitised this receptor, resulting in a transient contraction or a bell-shaped CCRC. 
Indeed, in my own studies, I was unable to expose the same preparation to more than 
one single application of ET-receptor agonists, due to the lack of response on a second 
application and also the persistence of the contractile response, even after numerous 
washes, when the vessel had been constricted with higher ET-1 concentrations.
In this chapter, I also examined the possible influence of NO on endogenous tone 
in rabbit PRAs from the various experimental groups, by examining the effects of L- 
NAME alone on baseline tension. L-NAME induced a vasoconstriction in only a 
proportion of the PRAs examined. In the 8 week experimental group, a greater number 
of PRAs from coronary-ligated rabbits exhibited a contractile response compared with 
age-matched sham-operated rabbit vessels, whereas approximately half of the total 
number of 16 week group vessels from both LVD and control rabbits contracted in 
response to L-NAME alone. However, none of the vessels from the 32 week procedure 
group exhibited a response. The increase in vascular tone following inhibition of NOS 
tended to be greater in 8 week coronary-ligated PRAs compared with control vessels in 
the same group however, due to variability in the amplitude of the response, this 
increase was not significant. Whereas in vessels from 16 week procedure animals, the 
amplitude of the increase in vascular tone was reduced in vessels from LVD rabbits 
compared with age-matched sham-operated preparations. The possible explanations for
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these findings are that either NO is basally released from PRAs and this is altered in 
coronary-ligated PRAs or the inherent tone in these vessels is altered in LVD animals. 
However, SNP alone was shown to have no effect in baseline tension in PRAs from 
either 8 week sham-operated or coronary ligated rabbits, suggesting a lack of 
endogenous tone in these vessels. Yet the vasoconstrictions to L-NAME may be due to 
an "uncovering" of the inherent tone in these PRAs. I did not examine the influence of 
SNP in vessels from 16 and 32 week experimental group animals, therefore I am unable 
to comment on the possible existence of inherent tone in these vessels. Sheer stress has 
been shown to stimulate NO production (Tesfamariam & Cohen, 1988). However, all 
the vessels in this study were set up at similar transmural pressures, thus the differences 
in the responses to L-NAME alone cannot be accounted for by such an effect. The 
phenomenon of endogenous tone is not often observed in isolated vascular preparations, 
particularly in pulmonary vessels since these are relatively relaxed in situ (see chapter 
1). In the isolated rat lung, Raffestin et a l (1991) demonstrated that baseline perfusion 
pressure was not increased in response to several different EDRF inhibitors, including 
L-NMMA which also inhibits synthesis of NO. Furthermore, these investigators also 
demonstrated a potentiation of the increase in pulmonaiy artery pressure induced by ET- 
1 in the presence of these inhibitors. From these two findings, the authors concluded that 
the potentiation of the ET-1 response was due to an inhibition of ET-1-induced EDRF 
release from the lung, rather than a decrease of basal NO activity. However, previous 
investigators have reported alterations in basal NO and/or inherent tone in the 
pulmonary vasculature in a pulmonaiy hypertensive state. In chronic hypoxic rat models 
of pulmonary hypertension, MacLean et a l (1995) demonstrated that there is an increase 
in endogenous vascular tone in large pulmonary and PRAs from pulmonary 
hypertensive rats compared with controls, and this was shown to be normally attenuated 
by NO production. Barer and co-workers (1993) showed that in isolated blood-perfused 
lungs of rats, L-NAME induced an increase in pulmonary perfusion pressure in chronic 
hypoxic rats but not in controls. A dissociation between basal and stimulated NO release 
has also been suggested to play a pathophysiological role in the early stages of heart
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failure. In a rat model of heart failure, Teerlink et al (1994) showed that ACh-induced 
vasorelaxations were similar in isolated aorta from control and heart failure rats, thus 
suggesting that stimulated NO was not altered. However, the effects of L-NAME and 
measurements of basal cGMP indicated that basal NO was decreased in heart failure 
rats.
In chapter 3 of this thesis, I showed that endothelium-dependant relaxations to 
various agents, including acetylcholine (ACh), could not be demonstrated in 
preconstricted adult PRAs from either stock, sham-operated or coronary-ligated rabbits. 
Furthermore, the ineffectiveness of ACh appears to be an age-related phenomenon in 
this preparation as I demonstrated vasorelaxations to this agent in fetal and neonatal 
rabbit PRAs (chapter 8). However, studies of other investigators show that agonist- 
induced NO release is diminished in pathophysiological states. The ability of ACh to 
relax preconstricted pulmonary arteries was shown to be reduced in vessels from chronic 
hypoxic rats compared with those from control animals (Adnot, et a l, 1991; MacLean, 
et a l, 1995). A decrease in ACh-induced NO release has also been reported in human 
pulmonary arteries from patients with chronic obstractive lung disease (Dinh-Xuan, et 
a l, 1993). The results of these previous studies suggest that agonist-induced release of 
NO is diminished in PHT, whereas the results of this study indicate an enhancement of 
basal NO. This difference in findings may be due to the causative factor of the 
pulmonary hypertensive state. In the aforementioned studies, PHT was induced by an 
hypoxic insult and hypoxia has been shown to reduce NO release (Johns, et. a l, 1989; 
Warren, et a l, 1989). However, the initial change in the pulmonary circulation 
secondary to left-sided cardiac disease is a passive response to a rise in the pulmonary 
venous (left atrial) pressure. Thus hypoxia does not play a major role in the aetiology of 
the PHT model examined in this study.
The results of this chapter are compatible with the results of other studies which 
have demonstrated an increase in NO associated with PHT. For example, there is 
evidence that NOS may be up regulated in patients with heart failure and inhibition of 
NOS increased pulmonary vascular resistance in these patients (Habib, et a l, 1994).
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Pulmonary NO production has also been shown to increase from the lungs of chronically 
hypoxic rats and there is evidence that inducible and endothelial NOS is upregulated in 
the pulmonary resistance arteries from these pulmonaiy hypertensive rats (Isaacson, et 
a l,  1994; Xue, et a l, 1994). In a chronic hypoxic rat model of PHT, MacLean et al
(1995) showed that L-NAME increased the sensitivity to ET-1 in main pulmonary 
arteries from chronic hypoxic rats but not in control vessels.
Similar findings have also been reported in other cardiovascular disease states, 
involving the systemic circulation. Intra-arterial infusions of the inhibitor of NO 
formation, L-NMMA, in human forearm circulation was reported to cause greater 
vasoconstriction in patients with congestive heart failure than in healthy controls 
(Drexler, et a l, 1992). Noll and co-workers (1994) demonstrated in the isolated aorta 
from cardiomyopathic Syrian hamsters with pulmonaiy congestion, that contractions to 
noradrenaline were enhanced in the presence of L-NAME and maximum 
vasorelaxations to ACh were more pronounced compared to control aorta responses. In 
addition, low concentrations of ET-1 were shown to cause stronger contractions in aorta 
from cardiomyopathic hamsters compared with controls, suggesting that this could 
contribute to vasoconstriction in heart failure. The authors concluded that the increased 
agonist-induced release of NO may be a compensatory mechanism in this model.
In conclusion, the results of this study suggest that in rabbit PRAs, secondary 
release of NO may oppose the direct constrictor effect of ET-1 and SXS6c. Inhibition of 
NOS caused a significant potentiation of ET-receptor mediated responses in PRAs from 
rabbits with PHT secondary to LVD, which was induced by 8 weeks and 16 weeks of 
coronaiy artery ligation. However, this was not evident in PRAs from 32 week LVD 
animals; these animals are more likely to represent survivors in this experimental group 
rather than a more severe form of LVD. The increase in basal and/or agonist stimulated 
NO production may be an early compensatoiy mechanism in response to the early 
elevation in pulmonary pressure with LVD in order to maintain responses to ET-1 
constant.
223
Chapter 7
Effects of ET-1 on [125i]e t -1 binding and intracellular 
cyclic nucleotide levels in rabbit pulmonary arteries
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7.1 Introduction
There is unequivocal evidence from pharmacological, biochemical and 
molecular biological studies that the diverse effects of endothelins (ETs) are mediated 
by distinct receptor subtypes (Yanagisawa & Masaki, 1989; Sakurai, et al, 1992b). At 
present the existence of two ET-receptor subtypes has been confirmed (see section 
1.4.5). To briefly recap, the order of affinity of the ETs for the first receptor subtype, 
designated ETa, is ET-1(= ET-2)>ET-3. The second receptor subtype, designated ETg, 
has equal affinity for all three ETs and for sarafotoxins. On the basis of functional 
studies, it has been proposed that multiple ETg receptors exist (Warner, et a i, 1993a; 
Douglas, et at, 1994). ETei-like and ETsi-hke are distinguished by their anatomic 
location and function; the former located on the endothelium, mediating vasodilation, 
whereas the latter is located on the vascular smooth muscle mediating vasoconstriction. 
ET receptor subtypes have also been distinguished by their pharmacological profiles, in 
terms of sensitivity to various antagonists. In addition, there is also evidence for a third 
type, designated ETc, which is selective for ET-3 (Martin, et a l, 1990; Samson, et al, 
1990; Douglas, et al, 1995).
In the studies of chapters 4 and 5 of this thesis, ET-1 was shown to evoke 
biphasic vasoconstrictions over a broad concentration range in small rabbit muscular 
pulmonary arteries. This comprised of a "shallow component" at lower concentrations of 
ET-1 and a steep rising component at ET-1 concentrations above InM. Furthermore, 
these components were differentially influenced by various ET-receptor antagonists. 
These findings were suggestive of negative cooperativity, i.e. an interaction with 
multiple sites, in this preparation. The possible existence of a heterogeneous population 
of ET receptors has been previously reported, including in the rabbit larger pulmonary 
artery and trachea (Hay, et a l, 1996; Yoneyama, et a l,  1995). However this 
interpretation of my data remains speculative. Since the first component of the ET-1 
cumulative concentration response curve was less than 30% of the maximum, curve 
fitting analysis for a biphasic response was not possible and so the theoiy could not be
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mathematically. In this chapter, I describe investigation into the nature of ET-1 induced 
response in rabbit pulmonary arteries by examination of competition radioligand binding 
studies with ET-1 in rabbit pulmonary artery membrane preparations.
In this chapter, I also address regulation of cyclic nucleotide levels. Regulation 
of intracellular cyclic nucleotide levels is one of the important mechanisms in the 
regulation of pulmonary vascular tone (see section 1.1.4.4). Exogenous cyclic 
nucleotides, guanosine 3':5'-cyclic monophosphate (cGMP) and adenosine 3':5'- cyclic 
monophosphate (cAMP) themselves, are potent pulmonary vasodilators (Haynes, et al. 
1992; McMahon, et al., 1992; 1993). cGMP is the key second messenger of nitric oxide 
(NO)-induced pulmonary vasodilation. Pus sard et al (1995) demonstrated that cGMP 
levels were significantly reduced in human pulmonaiy vessels treated with the NO 
synthase inhibitor N®-nitro-L-arginine methyl ester (L-NAME) and indomethacin, 
whereas an elevation was shown in SNP treated vessels. The results of chapter 6 and 8 
demonstrated the involvement of NO in ET-receptor mediated responses in PRAs from 
neonatal and adult rabbits. In particular L-NAME, an agent which acts to decrease 
intracellular concentrations of cGMP, was shown to markedly potentiate ET-receptor 
mediated vasoconstrictions in rabbit PRAs from coronary artery ligated animals but not 
sham-operated rabbits. This finding indicated an increase in basal and/or agonist 
induced NO in vessels from LVD animals.
It has been reported that the expression of ET receptors is regulated by various 
agents, including cAMP (Nambi, e ta l, 1992; Kanno, et a l, 1993). Dibutyryl cAMP, a 
cell-permeable cAMP analogue, was shown to induce an upregulation of ETg receptor 
mRNA in primary rat cultured astrocytes (Hamma, et a l, 1992), whilst a down 
regulation was shown in ROS 17/2 rat osteosarcoma cells (Sakurai, e ta l, 1992a). cAMP 
plays a central role in the vasoactive responses to various agents (Exton, 1985). 
Sumatriptan (GR43175) is a selective 5-hydroxytryptamine Ig/D (5-HTib/d) -like 
receptor agonist which is also believed to evoke vascular smooth muscle contraction 
through inhibition of adenylate cyclase and therefore a decrease in intracellular 
concentrations of cAMP ([cAMPJj) (Humphrey, et a l, 1988; Sumner & Humphrey,
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1990). In the studies of chapter 3 of this thesis, maximal vasoconstrictions to 
sumatriptan were significantly reduced in PRAs from 8 week LVD rabbits compared 
with response of corresponding arteries from sham-operated rabbits. Furthermore, the 
responses to 5HT were shown to be markedly decreased in PRAs from 8 and 32 week 
coronary-ligated rabbits compared with vessels from age matched stock/sham-operated 
animals. Both of these cyclic nucleotides, cAMP and cGMP, have been reported to be 
involved in the second messenger systems of ET-receptor mediated responses. For 
example, Pus sard et a l (1995) reported at ET-1 markedly reduced the cGMP increase in 
SNP-stimulated human pulmonary arteries. This previous finding suggested that ET-1 
may play a role in the control of muscle tone in the human pulmonary vascular bed by 
modifying cGMP levels associated with vasorelaxant agonist stimulation.
In this present study, I also examined the effect of ET-1 on intracellular 
concentrations of cGMP and cAMP within pulmonary arteries from 8 week sham- 
operated and coronary-ligated rabbits. Forskolin was used to activate adenylate cyclase 
directly (Koch, 1982) and the effect of ET-1 on forskolin-induced levels was 
investigated also. Ignarro et a l  (1987) demonstrated regional variation in cGMP levels 
in different sized bovine pulmonary arteries. Similarly, intracellular levels of cAMP and 
cGMP, and the effect of chronic hypoxia on these, were shown to vaiy depending on 
size of pulmonaiy arteries in the rat (MacLean, et a l, 1996b). Therefore in this present 
study I measured the intracellular level of these cyclic nucleotides in vessels of differing 
sizes; namely main intrapulmonary arteiy and pulmonary resistance arteries.
7.2 Methods
Radioligand binding
Membranes from pulmonary arteries, dissected from the main intrapulmonary 
artery to those of diameter of ~100|am, of the lungs from 8 week sham-operated rabbits 
were prepared as described in section 2.4.2 of chapter 2. Briefly, membrane suspensions
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were prepared from the pulmonary arteries from 3-4 lungs and stored at -80^C for use in 
competition assays and protein measurement. Protein content was determined by the 
assay described in section 2.4.3, using bovine serum albumin as a standard.
The protocol for competition assays with unlabelled ET-1 and [H5i]_e T-1 is also 
explained fully in chapter 2, section 2.4.4. Briefly, assay tubes contained final 
concentration of 2 pM [1^^I]-ET-1) and appropriate volume and concentration of 
unlabelled ET-1 (0.01pM-30nM). Final volume of each tube was 250|al, made up with 
assay buffer. The binding reaction was initiated by the addition of the membrane 
preparation (~10|ug protein / tube). After a 2 hour incubation at 22°C, separation of 
bound from free ligand was carried out by rapid vacuum filtration through Whatman 
GF-B filters. Filter were washed 4 times with assay buffer and radioactivity associated 
with the filter was determined with a Gamma counter. Nonspecific binding was 
determined simultaneously in the presence of 200 nM unlabelled ET-1 and specific 
binding was defined as total binding minus non-specific binding.
Assay of intracellular cyclic nucleotide levels
Lungs were obtained from the rabbit coronary ligation model of left ventricular 
dysfunction which has been extensively characterised (Pye, e ta l,  1996) and is described 
in detail in section 2.1.1 of this thesis. 8 weeks following sham-operation or coronary 
artery-ligation rabbits were sacrificed and main intrapulmonary arteries and small 
muscular pulmonary arteries (pulmonary resistance arteries (PRAs)) were dissected out 
(see section 2.2.3.1). Tissue samples were processed and assayed to measure 
intracellular levels of cAMP using modified binding protein technique of Brown et a l 
(1972). [cAMP]i was measured under several different conditions: (1) basal, and in the 
presence of (2) 0.1 p,M ET-1 or (3) 10|,iM forskolin or (4) both simultaneously. Tissue 
samples were also processed and assayed to measure intracellular levels of cGMP levels 
using modified radioimmunoassay technique of Cailla e ta l  (1976). [cGMPJi was 
measured under (1) basal conditions and (2) in the presence of 0.1 tiM ET-1. In both
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cyclic nucleotide assays, all incubations were performed in the presence of ImM 
isobutylmethyIxanthine (IBMX), a non-selective phosphodiesterase inhibitor. A detailed 
description of the tissue preparation and assays is given in the methods sections 2.3.4 
and 2.3.5 of chapter 2 of this thesis.
Data analvsis
Competition binding data was analysed by non-linear least-square curve fitting, 
for a one-site or two-site model, using the Graphpad Prism Program. This provided best 
fit for a two-site model and Ki values for each site were calculated using IC50 values 
provided by the program and the Cheng Prussof equation (Cheng & Prussof, 1973). 
Results are expressed graphically as percentage of the specific binding of the maximum 
and each point represents mean ± SEM. 11= number of animals.
Results for biochemical assays for the measurement of intracellular cyclic 
nucleotide levels are expressed graphically as pmol cAMP/ mg tissue or pmol cGMP/ 
mg tissue. Statistical comparison of the mean groups of data were made by ANOVA 
followed by Tukeys post test; f <0.05 was considered statistically significant. 
Throughout data are expressed as mean ±SEM and n=number of animals.
7,3JR£sults
Competition assay
The specific binding of [^^^I]ET-1 to rabbit pulmonaiy artery membranes was 
completely inhibited by unlabelled ET-1 in a biphasic manner; this is shown in figure 
7.1. Two components were evident; an ultra-high affinity ET binding site at unlabelled 
ET-1 concentrations below IpM and a second high affinity site within the range of IpM 
to 30nM unlabelled ET-1. Curve fitting analysis using the Graphpad Prism program 
revealed a best fit for a two site model. Ki values were 6.43x10 '^M  for the ultra high
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Inhibitory effect of unlabelled ET-Ion the specific binding of 
[125ET-1] to rabbit intrapulmonary artery membranes. Results are 
expressed as a percentage of specific binding of maximum. Each 
point represents the mean+Z- SEM of five experiments.
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affinity first component and 4.83±10"10M for the high affinity second component Bmax 
values of 48.84 fmol/mg of protein and 19.34 fmol/mg of protein were estimated for site 
one and site two, respectively. Thus, approximately 70% of the ET-receptor density was 
represented by the ultra high affinity site.
Intracellular levels of cvclic AMP
The effect of 0.1 |uM ET-1 on basal levels of [cAMPJj in main intrapulmonaiy 
arteries (MIPAs) and pulmonary resistance arteries (PRAs) from sham-operated and 
coronaiy-ligated rabbits are shown in figures 7.2A and 7.2B, respectively. In MIPAs 
from both experimental groups, ET-1 did not significantly alter intracellular cAMP 
levels from basal levels (figure 7.2A). In PRAs from both groups of rabbits, ET-1 
consistently decreased [cAMPJibut again this failed to reach statistical significance 
(figure 7.2B).
Forskolin (lOpM) produced a marked increase in intracellular cAMP levels in all 
arteries from both sham-operated and coronary-ligated rabbits. In MIPAs from sham- 
operated rabbits, forskolin increased [cAMP]i from 0.38+0.1 to 17.47+6.4 pmol/mg 
tissue (P<0.05); in the same vessels from coronary-ligated rabbits, this increase was 
from 0.97+0.3 to 25.42+6.8 pmol/mg (P<0.001). Whilst in PRAs, forskolin increased 
[cAMPJifrom 0.85+0.4 to 27.72+12.3 pmol/mg (P<0.05) and from 2.9+1.2 to 34.8+9.6 
pmol/mg (P<0.01) in sham-operated and coronaiy-ligated preparations, respectively. 
Thus, the stimulatory effect of forskolin was greater in all arteries from coronary-ligated 
compared to sham-operated animals.
The effects of 0.1 pM ET-1 on lOpM forskolin-stimulated intracellular cAMP 
levels in MIPAs and PRAs from sham-operated and coronaiy-ligated rabbits are shown 
in figures 7.3 A and 7.3B, respectively. As can be seen, the combined presence of ET-1 
and forskolin in the incubation solution, resulted in a similar reduction in forskolin- 
stimulated [cAMPjiin MIPAs from sham-operated (52.6+12.2% forskolin plus ET-1 vs. 
100% for paired forskolin alone) and coronary-ligated rabhits (44.6+93.9%; figure
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Figure 7.2 Effect of ET-1 (hatched columns) on control (open columns) intracellular 
cAMP levels in pulmonary arteries from sham-operated (n=6) and coronary artery- 
ligated rabbits (n=8). Results are expressed as pmol cAMP/mg tissue. Levels in (A) 
main intrapulmonary arteries and (B) pulmonary resistance arteries. Each column 
represents the mean ±SEM.
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Figure 7.3 Effect of ET-1 (hatched columns) on forskolin-stimulated (open columns) 
cAMP production in pulmonary arteries from sham-operated (n=6) and coronary artery- 
ligated (n=8) rabbits. Results are expressed as pmol cAMP/mg tissue. Levels in (A) 
main intrapulmonary arteries and (B) pulmonary resistance arteries. Each column 
represents the mean ±SEM.
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Figure 7.4 Effect of ET-1 (hatched columns) on control (open columns) intracellular 
cGMP levels in pulmonaiy arteries from sham-operated (n=4(A)/5(B)) and coronary 
artery-ligated rabbits (n=4(A)/6(B)). Results are expressed as pmol cGMP/mg tissue. 
Levels in (A) main intrapulmonary arteries and (B) pulmonary resistance arteries. Each 
column represents the mean ±SEM.
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7.3 A). Similarly, the presence of ET-1 inhibited forskolin stimulated [cAMPji in PRAs 
from sham-operated (57.1+11.4% of paired forskolin alone) and coronary-ligated rabbits 
(53.1+10.5%; figure 7.3B). However, these apparent reductions were not significantly 
different from forskolin alone levels. ET-1 plus forskolin -stimulated intracellular cAMP 
levels were significantly greater than basal levels in PRAs from sham-operated rabbits 
(P<0.05) and in MIPAs and PRAs from coronary-ligated rabbits (P<0.05).
Intracellular levels of cGMP
Intracellular levels of cyclic GMP in the absence and presence of 0. IjaM ET-1 in 
MIPAs and PRAs from sham-operated and coronary artery-ligated rabbits are shown in 
Figures 7.A and 7.4B, respectively. In MIPAs from coronary artery-ligated animals, 
incubation with 0.1 p.M ET-1 consistently decreased [cGMPJi . However, ET-1 did not 
significantly alter [cGMPJi (figure 7.4A).
In small muscular pulmonary arteries from sham-operated rabbits, incubation 
with ET-1 consistently reduced intracellular cGMP levels (31.47+11.9% compared to 
100% for paired control). In comparison, vessels from the same anatomical location 
from coronary-ligated rabbit lungs, showed a consistent increase in intracellular cGMP 
following incubation with ET-1 (187.6+6.8% compared to 100% for paired control). 
However again, there was great variability between tissues and these alterations failed to 
reach statistical significance.
7.4 Discussion
Effect of ET-1 on rl25i],ET-l binding
In rabbit intrapulmonary artery membranes, unlabelled ET-1 completely 
inhibited [l^^I]ET-l binding in a concentration-dependent, biphasic manner. Curve 
fitting analysis provided a best fit for a two-site model, thus indicating the existence of
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two distinct ET receptor populations in this preparation. This finding is consistent with 
functional studies of isolated rabbit pulmonaiy resistance arteries, discussed in chapters 
4 and 5 of this thesis, in which ET-1 was shown to evoke a potent biphasic 
concentration-dependent vasoconstriction These earlier results showed that cumulative 
concentration response curves to ET-1 included a "shallow component" at lower ET-1 
concentrations (below InM) and a "steeper component" at higher concentrations of ET- 
1. Furthermore, both of these functional components were differentially affected by 
selective antagonists, thus suggesting a heterogeneous population of ET receptors in this 
preparation. The biphasic inhibitory effect of ET-1 demonstrated in the competition 
binding assays of this present chapter provides further evidence for this. This finding 
may correspond with previous binding assay data which showed different populations of 
high- and low-afflnity ETb receptors in brain tissue (Sokolovsky, et a l, 1992). Also 
consistent with this is the report of Perreault and Baribeau (1995). In this previous study 
in separate membrane preparations from pulmonary arteries and veins from the newborn 
piglet, [125i[_eT-1 binding was completely displaced by either ET-1 or ET-3 in a 
concentration dependent manner. ET-1 competition was shown to coixespond to a one- 
site model but computer analysis revealed two binding sites for that of ET-3 : one in the 
picomoiar range, and the other in the nanomolar range. These authors suggested that site 
one and site two corresponded to an ETgi and ETb2 receptor, respectively. Furtheimore, 
the binding characteristic of this ETbi receptor may account for the fact that vasodilator 
responses to ET-receptor agonists are normally only seen at veiy low concentrations, as 
indeed was also shown in the piglet pulmonaiy vasculature.
The existence of an ultra-high affinity ET binding site was evident at unlabelled 
ET-1 concentrations below IpM and a Ki value of 6 .4 3 x 10"14]vi was calculated. The 
second site was evident within the range IpM to 30nM unlabelled ET-1 and also 
displayed high affinity with a Ki value of 4.83x10"10M. This concentration for the Ki for 
site two is the same as K| (0.5+0.InM) demonstrated by Panek et a l (1992) for
competition binding experiments for ET-1 vs. [125JET-1 in membranes also prepared 
from rabbit pulmonary arteries. The Ki for site two is also similar to the nanomolar
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affinities of ET-1 for ET a  and ETb receptors which have been previously defined (Arai, 
et a i, 1990; Sakamoto, et al., 1991, Ohlstein, et a l, 1996). However, the Ki calculated 
for site one is in stark contrast to these values, hence this ultra high affinity receptor 
population appears to be an untypical ETa/ETb receptor. Indeed the findings of other 
investigators also indicate that ET receptor agonists may exert their effects via different 
receptors that do not fit the current classification of ETa and ETb receptors (e.g. 
Sumner, e ta l,  1992; Eglezos, e ta l, 1993; Harrison, eta l, 1992).
Functional studies of ET-receptor mediated responses in rabbit PRAs (chapters 4 
and 5) did not reveal such high affinity receptors. Threshold concentration to elicit a 
vasoconstrictor response was ~12pM and EC50 value was ~ 12nM (chapter 4). Different 
order of potency between binding and functional studies could be explained by the 
exposure of ultra high affinity ET-receptors, using binding techniques, which are not 
functional and therefore cannot be revealed using this latter technique. In addition, the 
EC50 for ET-1 compares more closely with the Kj of 4.8nM calculated for the second 
site. Therefore, the ET-receptors of this second lower affinity population may represent 
those which produce vascular responses following activation. In addition, other 
investigators have proposed that receptors may exist in two conformational states, an 
active state coupled to contraction and an inactive state not coupled to contraction 
(Robertson, et a l, 1994; Beck, et a l, 1995). Thus, one could propose that the apparent 
existence of ultra high affinity ET-receptors in rabbit pulmonary arteries, which cannot 
be exposed in functional assays, may be due to these receptors not being coupled to 
smooth muscle contraction and may be related to a different function within the 
pulmonary vasculature. Disparity between the findings of functional and binding studies 
is also seen in previous studies by other investigators. In functional studies in the rabbit 
saphenous vein, Douglas, et a l (1995) reported that vasoconstrictions to ET-1 were 
resistant to BQ123 (selective ETa antagonist). However, radioligand binding studies 
clearly demonstrated the presence of BQ123-sensitive [l^^I]ET-l binding sites and ETa 
receptor mRNA in this tissue (Webb, et a l,  1993; Gray, et a l , 1993b). As another 
example. Vigne et al (1993) demonstrated in rat brain capillary endothelial cells, that the
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ICso for BQ123 inhibition of ET-1 induced intracellular Ca^ "^  transients was much lower 
than the IC50 determined in binding experiments. The differences in methodology could 
explain the discrepancies between binding studies and other physiological 
/pharmacological studies.
The existence of two distinct ET-1-receptor populations, indicated by the two 
site model of inhibition of [1^^I]-ET-1 binding, is in disagreement with the finding of 
previous ET-receptor binding studies which I have previously referred to, where only a 
single population of receptors was indicated. The Ki values of 0.064pM and 0.48nM 
calculated for site one and site two, respectively, contrasts with values obtained in other 
binding studies in rabbit pulmonary artery preparations. ET-1 was previously shown to 
completely inhibit [l^^I]-ET-l binding in a monophasic manner in membranes prepared 
from endothelium-denuded rabbit pulmonary arteries with IC 50 values of 0.13nM and 
0.38nM (La Douceur, et ah, 1993; Fukuroda, et a l, 1994a). The reasons for theses 
differences in results are unknown. The details of the methods for these previous 
binding assays and my own protocol were as follows. [125i]_eT-1 was present at a 
concentration of 2 pM (this study), lOpM (Fukuroda, et a l, 1994a) and 20 pM (La 
Douceur, et al, 1993); the IC50 is dependent on the concentration of the radioligand 
used and the calculation of Ki involves this value, hence the different radioligand 
concentrations used may be involved in the differences between studies. However other 
parameters were similar. The concentration of unlabelled ET-1 used to define 
nonspecific binding was 100-200 nM for all three studies. La Douceur and co-workers 
(1993) do not give details of protein content of membrane preparation, however a 
similar concentration was employed in the study of this chapter and that of Fukuroda et 
a l  (1994a). Incubations of reaction mixtures were for either 2 or 4 hours at 22-37®C, 
thus adequate conditions for equilibration were allowed in all three studies. Hence, it is 
unlikely that the discrepancy in findings between these studies are due to differences in 
these aspects of methodology.
Fukuroda et a l  (1994b) showed that [1^^I]-ET-1 binding to rabbit pulmonary 
arterial preparations (prepared from arteries of l-5mm outer diameter) was inhibited by
238
BQ3020, with mean IC50 --0.45nM. Similarly, La Douceur et a l (1993) reported that 
SXS6 c inhibited [^^^IJLT-l in this preparation (prepared from secondary branches) with 
an IC50 of 0.32nM Thus the Ki value of 0.48nM calculated for site two in this binding 
study in rabbit arterial membranes demonstrated in this chapter, was similar to that 
previously reported for selective E T b  receptor agonists. In addition, from also 
examining the inhibitory effect of selective ETa receptor antagonist BQ123 on 
inhibition of [^^^I]-ET-1 binding, both these groups demonstrated the predominance of 
ETb receptors in this preparation, as was indicated by the finding of the functional assay 
studies conducted in chapter 5 of this thesis.
Previous binding studies of ET-1 in other species and vascular preparations have 
also reported a monophasic response. In saturation experiments using slide mounted 
sections, [1^^I]-ET-1 bound with high affinity to the media of human pulmonary artery, 
coronaiy artery, aorta and internal mammary arteiy and a one site model was preferred; 
this suggested the presence of either a single population of receptors or a heterogeneous 
population with the same affinity for the peptide (Davenport, et al, 1995). D' Orleans- 
Juste et a l (1992) showed in rat lung membranes that ET-1 inhibited [^^^IJ-ET-l 
binding with an IC50 value of ~0 .2 nM. Marsden et a l (1989) demonstrated that 
unlabelled ET-1 inhibited [1^^I]-ET binding to cultured rabbit aortic smooth muscle 
cells with K j of ~0.4nM.
The reason for this discrepancy in findings is unclear however, several 
possibilities may account for this. In the findings of my study the unusual first site was 
apparent at ET-1 concentrations below IpM whereas, previous binding studies used this 
as the lowest concentration of ET-1 (e.g. Perreault & Baribeau, 1995; Nogughi, et a l, 
1997). Therefore, there is the possibility that the ultra high affinity binding site was not 
revealed in these previous studies because an insufficient range of unlabelled ET-1 was 
used. However this is unlikely as the anomaly remains that in the findings of other 
investigators, the percentage of the specific [1^^I]-ET-1 binding was - 100% (maximum) 
at -IpM  unlabelled ET-1; whereas this percentage was only around 60% at -IpM  and 
- 1 0 0 % was observed at lOOpM unlabelled ET-1 in this present study. On the other
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hand, the divergence of findings may be related to the preparation of the arterial 
membranes. In the binding studies of Fukuroda et al (1994a), La Douceur et al. (1993) 
and Davenport et al (1995) in rabbit and human pulmonaiy arteries, membranes were 
prepared from endothelium-denuded arteries, whereas the membranes used in my own 
study were prepared from arteries in which the endothelium was not removed. 
(Davenport et a l also removed the adventitia). Thus, the previous studies would 
represent binding to receptors which existed on the vascular smooth muscle, whilst those 
present on the endothelium would also be bound in the study of this chapter. 
Furthennore, there is the possibility that the ET receptors of the ultra high affinity site 
were present on the vascular endothelium. This postulate is compatible with the report 
of Perreault and Baribeau (1995) which suggested that the first, high affinity, ET-3 
binding site corresponded to an ETbi receptor subtype.
Additional previous competition binding studies with ET-receptor agonists, other 
than ET-1, have demonstrated the possible existence of multiple, different affinity sites. 
Nakimichi et al. (1992) reported that in porcine bronchus and lung parenchyma 
membranes, ET-3 inhibited [l^^I]ET-l binding with hill coefficients considerably lower 
than unity. This same study also demonstrated in these preparations, that 4AlaET-l and 
BQ123 displaced specific [^^^I]ET-1 binding in a biphasic manner, indicating high and 
low affinity sites. Similar findings for ET-3 have also been reported in lung and tracheal 
preparations (Tschirhart, e ta l,  1991; Takayanagi, e ta l,  1991). Furthermore, previous 
functional studies have demonstrated the existence of distinct ET receptor populations. 
Douglas et a l (1995) demonstrated that contractile responses to ET-1 (SXS6 c and ET-3 
also) were best fitted to a two site model in the rabbit isolated saphenous vein. A high 
affinity (pM) site, showing characteristics of an E T b  receptor, and a low affinity (nM) 
site, showing characteristics of an ETc-like receptor, were reported. Furthermore, this 
study also showed that the two components of the cumulative concentration response 
cuiwes were differentially influenced by selective antagonists, as indeed I also found in 
the functional studies in rabbit pulmonary resistance arteries in chapter 5 of this thesis.
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The heterogeneity in ET-receptors indicated by the biphasic inhibitoiy effect of 
ET-1 on [12^I]-ET-1 binding may be related to the different sized pulmonary arteries 
from which the membrane preparation was produced. Previous functional studies have 
demonstrated differential responses to ET-receptor agonists and antagonists in rat 
pulmonaiy arteries from different anatomical locations, thus demonstrating a diversity in 
the ET-receptor subtype at different levels of the pulmonary circulation (MacLean, et 
a l, 1994a; Higashi, et a l, 1997). In addition, Frid et a l (1994) reported that the bovine 
pulmonary arterial media is composed of multiple phenotypically distinct smooth 
muscle cells; differential ET-receptor subtypes may exist on different smooth muscle 
cells. For the competition binding studies shown in this chapter, I prepared the 
membrane preparation from isolated rabbit pulmonary resistance arteries of various 
diameters which were all dissected out from within the lung. In this thesis, I only studied 
functional responses in isolated pulmonary resistance arteries from the rabbit, however, 
the effects of ET-receptor agonists and antagonists were similar to findings in larger 
rabbit pulmonaiy arteries by other investigators (e.g. Hay, et a l, 1996; see chapter 5). 
Moreover, membrane preparations for the ET-1 vs. [125I]ET-1 competition binding 
studies of Perreault and Baribeau (1995), were prepared from pulmonary arteries 
dissected from the hilum down to 1 0 0 |um diameter, and a one site fit was shown. 
Furthermore, Noguchi et a l  (1997) carried out [1^^I]-ET-1 binding studies 
(autoradiographic technique) separately in elastic and muscular neonatal porcine 
pulmonary arteries and demonstrated similar IC50 and Kd values for these two 
preparations which also differ in size. Therefore, the fact that binding was performed on 
membranes from rabbit pulmonary arteries of different sizes seems unlikely to account 
for the apparent existence of two distinct ET-receptor populations.
In summary, competition binding data from this study suggests the presence of 
two distinct ET receptor populations in rabbit pulmonary arteries; one displaying ultra- 
high affinity and second, also demonstrating high affinity in the nanomolar range. This 
is consistent with the results of functional studies of ET-receptor mediated responses in 
isolated rabbit pulmonary resistance arteries (shown in chapters 4 and 5) in which ET-1
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evoked vasoconstriction in a biphasic manner and the existence of heterogeneous ET 
receptors was suggested by the differential effects of various ET-receptor agonist and 
antagonists. However, confirmation by conventional protein purification/ molecular 
cloning is necessary before their existence can be firmly established.
Effect of ET-1 on intracellular levels of cvclic nucleotides
Although ET-1 has been shown to be a potent vasoconstrictor in pulmonaiy 
arteries from various species, including rabbit and human (chapters 4 and 5 this thesis), 
the second messenger system behind this ET-receptor mediated response is still unclear. 
The findings of this chapter may suggest the ability of ET receptors to interact with 
cyclic nucleotide second messenger systems in rabbit pulmonary arteries.
Although intracellular cAMP levels were not significantly altered by ET-1, 
unidirectional changes were consistent; an increase in main intrapulmonary arteries, 
whilst a decrease was evident in small muscular pulmonary arteries from both groups of 
animals. ET-1 did not significantly change intracellular cGMP levels in either group. 
However in coronary-ligated rabbit vessels, a consistent decrease with ET-1 was evident 
in MIPAs, whilst a consistent increase was evident in PRAs. In sham-operated rabbit 
preparations, [cGMPJi levels were unaltered by ET-1 in MIPAs but, this peptide 
consistently decreased levels in PRAs. Pus sard et a l (1995) also reported that ET-1 had 
no effect on basal cGMP levels in intact human pulmonary arteries or veins.
Forskolin stimulates adenylate cyclase directly (Koch, 1982). As would be 
expected, the presence of forskolin resulted in a marked increase in all pulmonary 
arteries from both groups of animals. This finding is in agreement with previous reports. 
Sweeney e ta l  (1995) demonstrated that forskolin induced a concentration dependent 
increase in [cAMPJi in bovine pulmonaiy arteries. In addition, the results of this chapter 
demonstrated that ET-1 tended to inhibit forskolin-stimulated cAMP production in 
rabbit pulmonary arteries. Such negative coupling to adenylate cyclase would cause 
vasoconstriction via a reduction in intracellular Ca^ "^  levels. Phosphodiesterase (PDE)
242
enzymes are responsible for the breakdown of cyclic nucleotides (Wright, et a l, 1994; 
Eckly & Lugnier, 1994). Since cAMP accumulation was measured in the presence of the 
general PDE inhibitor IBMX, this data should reflect a direct inhibition of adenylate 
cyclase activity rather than degradation of cAMP by increased phosphodiesterase 
activity. This inhibitory effect of ET-1 on forskolin-stimulated cAMP was not 
statistically significant, however other investigators have shown evidence for this. 
Eguchi et a l (1993) demonstrated that ET-1 (and ET-3) dose-dependently inhibited 
cAMP formation stimulated by forskolin and isoproterenol (another adenylate cyclase 
activator) in cultured bovine endothelial cells. In transfected Chinese hamster ovaiy 
cells, inhibition of forskolin-stimulated cAMP was shown to be mediated by ETg 
receptors, whereas ETa receptors were responsible for the accumulation of cAMP. 
Therefore the findings of the study of this chapter may provide yet more evidence for 
the predominance of ETb receptors in rabbit pulmonaiy arteries, which was indicated 
from the results of the functional studies of chapters 4 and 5. In human Girardi heart 
cells expressing ETa and ETb receptors (ratio 4:6), ET-1 was shown to suppress 
forskolin-stimulated cAMP through activation of ETa and ETb receptors (Ozaki, et a l, 
1997). In addition, this reduction in forskolin-stimulated cAMP was only partially 
blocked (2 0 %) by ETa or ETb receptor alone, however was completely inhibited by a 
mixture of these selective antagonists. Thus suggesting intracellular cross-talk between 
ETa and ETb receptor subtypes in these cells. I discussed the possible existence of such 
a cross-talk mechanism in rabbit pulmonary arteries and other preparations in chapter 5 
of this thesis.
Furthermore, the results in this chapter showed that the effect of ET-1 on 
intracellular cAMP and cGMP levels was altered, though not significantly, in pulmonary 
arteries from LVD rabbits compared with those from age-matched sham-operated 
animals. Basal, ET-1-induced and forskolin-stimulated [cAMPJi tended to be greater in 
coronary-ligated rabbit arteries compared to those from sham-operated animals. 
Comparatively greater levels in coronaiy-ligated compared to sham-operated rabbit 
arteries was also apparent for basal and ET-1 induced intracellular cGMP levels. This
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latter tendency may relate to the increased NO levels in coronary-ligated rabbit PRAs 
which was suggested by the results in chapter 6 of this thesis. In this earlier chapter, 
inhibition of NO synthase by L-NAME resulted in a marked potentiation of ET-1 and 
SXS6 c-induced vasoconstrictions of PRAs from coronaiy-ligated but not sham-operated 
rabbits. This contrasts with a previous study of isolated aorta from a rat model of heart 
failure, where NO synthase inhibition with L-NAME, as well as measurements of basal 
cGMP, demonstrated that basal NO release was decreased in chronic heart failure rats, 
however, stimulated NO release was not affected (Teerlink, et a l, 1994b). Similarly, in 
chronic hypoxic rat models, Shaul et a l (1993b) reported a decrease in [cGMPJi in the 
main pulmonary arteries removed from chronic hypoxic rats, and MacLean et al (1996b) 
demonstrated changes in basal cyclic nucleotide levels following hypoxic insult and this 
effect varied depending on vessel size. In this latter study, neither [cAMPJi nor [cGMPJi 
was changed by chronic hypoxia in pulmonaiy resistance arteries, however a decrease in 
the level of both these cyclic nucleotides was demonstrated in both first branch and main 
pulmonary arteries. The result of this previous study reflects further the evidence that 
the phenotype of the vascular smooth muscle cells in the pulmonaiy resistance arteries is 
veiy different from those in the larger arteries and that further changes occur with the 
onset of pulmonary hypertension (Meyrick & Reid, 1978; Sakai, e ta l, 1996).
The studies in this chapter do not provide any insight into mechanism by which 
ET-1 may influence cyclic nucleotide levels. However other studies indicate the 
involvement of guanine nucleotide-binding proteins (G proteins). G proteins serve as the 
transducing communicator between agonist occupation of extracellular receptors and 
their effector systems (Gilman, 1987). In cultured porcine kidney epithelial (LLC-PKl) 
cells, ET-1 enhanced cGMP production but reduced vasopressin- and forskolin- 
stimulated G AMP production (Ozaki, et a l,  1994). Furthermore, both of these effects of 
ET-1 were antagonised by BQ788 but not by BQ123. Pertussis toxin (which results in 
uncoupling of membrane receptors and inhibits certain G protein-dependent receptor- 
mediated responses) inhibited the ET-1-induced cAMP decrease but not the increase in 
cGMP, thus indicating that the cAMP response is mediated by pertussis toxin- sensitive
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Gi protein, whilst the cGMP response is mediated by a peitussis toxin-insensitive G 
protein. These authors concluded therefore that ETg receptors in LLC-PKl cell couple 
to two types of signal transduction cascades to reduce cAMP and stimulate cGMP 
production via distinct G proteins. From studies in cultured bovine endothelial cells, 
Eguchi et al (1993) suggested that endothelial ETg receptors are functionally coupled to 
adenylate cyclase, possibly via Gi protein. It has also been demonstrated that ETs 
stimulate cAMP formation through Gg-protein coupled to ET receptors or through PGE2
production secondaiy to ET-induced intracellular Ca2+mobilisation (Domae, et a i, 
1994; Takigawa, et a l, 1995). However in comparison, in a previous in vivo study in 
canine pulmonary circulation, pretreatment with pertussis toxin was shown to have no 
effect on subsequent ET-1-induced vascular response on resistance or compliance This 
indicated that pertussis toxin sensitive G protein signalling does not mediate ET-1 
induced pulmonary vasoconstriction (Barman & Pauly, 1995).
Many previous studies indicate the involvement of the phosphotidylinositol (4, 
5) “bisphosphate (PIP2) pathway in the mechanism of action of ETs. Both ETa and ETg 
receptors have been described to be coupled to PIP2 hydrolysis via G protein-coupled 
phospholipase C (PLC), and to the generation of inositol phosphates (IP) and 
diacylglycerol (DAG). The actions of IP3 and DAG, via the activation of PKC, then 
result in an increased concentration of intracellular Ca^+ (Emori, et a l, 1990; Eguchi, et 
a l, 1992; see chapter 1). Yoshida e ta l  (1995) reported that in small branches of rabbit 
pulmonary artery, the amplitude of ET-1-induced vasoconstrictions were suppressed by 
pretreatment with Calphostin C, a selective PKC inhibitor, and additional application of 
BQ788 completely abolished it. These authors concluded that stimulation of the ETa 
receptor induces contraction mainly through activation of PKC in this preparation. PKC 
was also reported to involved in ET-receptor mediated contractions in rabbit saphenous 
vein (Sudjarwo & Karaki, 1995). In cultured rabbit vascular smooth muscle cells, ET-1 
induced a rapid (15 sec.) transient formation of IP3 (Marsden, et a l,  1989). The 
rapidness of this alterations suggests that the PIP2  pathway is an initial event following 
ET-receptor activation.
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In this study I investigated the involvement of cyclic nucleotides in rabbit 
pulmonary arteries but not that of the PIP2 pathway. However recent evidence has 
established the phenomenon of cross-talk between distinct signal transduction 
mechanisms to be of importance (Spence, et a l , 1995). Asada et a l (1995) reported that 
ET-1-stimulated cAMP accumulation in ROS 17/2 cells occurred as a secondary effect 
of PIP2 hydrolysis/ Ca^+ transduction cascade. Although the results of this chapter 
suggest a possible involvement of cyclic AMP and cyclic GMP in rabbit pulmonary 
arteries of various sizes, and under both basal and ET-1 stimulated conditions, the 
alterations were not sufficient to be statistically significant due to variability in results 
within the individual groups. This may be related to the limitations of the assay. 
Alternatively, as bovine pulmonary arterial media has been shown to be composed of 
multiple phenotypically distinct smooth muscle cells (Frid, et a l, 1994), if this was also 
the case in the rabbit, then the variability in cyclic nucleotide levels may relate to 
differences in levels/ involvement in different cell types. This possibility is suggested by 
previous evidence which indicates that the complexity, and in many cases even cell- 
specific modulation, of the cyclic nucleotide signalling pathway is related to inputs from 
other classic signal transduction pathways (Muiphy, et a l, 1994; Spence, et a l, 1995). 
A possible site of interaction is at the level of phosphodiesterase (PDE) activity. In 
addition, there is the possibility of interaction between the cAMP and cGMP systems, 
where the most likely point of interaction would be the level of PDEs. However this is 
unlikely to have occurred in this study in rabbit pulmonaiy arteries, as all incubations 
were carried out in the presence of IBMX, a non-selective PDE inhibitor.
The main aim of this study was to assess the involvement of the cyclic 
nucleotides, cAMP and cGMP, in rabbit pulmonary arteries of various sizes. In addition 
to examining the effect of LVD secondaiy to coronary artery ligation, I also attempted to 
relate the intracellular cyclic nucleotide levels to the functional contractile ability of the 
pulmonary resistance arteries. ET-1 was shown to markedly inhibit forskolin-stimulated 
cAMP production in the main pulmonaiy arteries and pulmonary resistance arteries from 
both sham-operated and coronary ligated rabbits. However, despite apparent trends in
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apparent trends in the levels of [cAMPJi ^rid [cGMPJi in pulmonary arteries under basal 
and ET-1-stimulated conditions, no definite conclusions can be drawn from these results 
due to the lack of stastistical evidence. Thus the uncertainty in the role of these cyclic 
nucleotides in ET-1 mediated responses in rabbit pulmonary arteries remains.
Future studies would include analysis of G-proteins involved in ET-receptor 
activation. Components of the PIP2 system would be investigated using various agents 
which interfere in this cascade such as activators or inhibitors of PLC or PKC; this 
second messenger system may have a greater involvement at basal level and / or 
stimulated ET-1 level in this rabbit model. With regard to future radioligand binding 
studies, saturation experiments would provide Kd and values for rabbit pulmonary 
artery membranes and may reveal differences between sham-operated and coronary 
ligated rabbit preparations. Furthermore, additional competition studies using selective 
ET receptor antagonists would provide further information on ET-receptor subtypes 
present.
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Chapter 8
Influence of nitric oxide on ET-receptor mediated 
responses in pulmonary resistance arteries of fetal and
neonatal rabbits.
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8.1 Introduction
As previously introduced in section 1.2 of chapter 1, the pulmonaiy circulation 
undergoes significant structural and functional alterations at birth (Haworth & Hislop, 
1981; Hall & Haworth, 1986, 1987; Dunn et al, 1989). Vasodilation of the small 
pulmonaiy arteries and reduction in the pulmonary arteiy pressure (PAP) and pulmonary 
vascular resistance (PVR) occurs minutes after birth and continues to fall in the 
proceeding hours (Haworth & Hislop, 1981). The marked reduction in PAP and thus 
resistance is vital in order for the pulmonaiy circulation to deal with the 10 fold increase 
in blood flow (PBF) which occurs in the normal transition of the role of gas exchange 
from the placenta to the lungs. However in some newborns, this normal decrease in PVR 
and increase in PBF does not occur and results in persistent pulmonary hypertension of 
the newborn (PPHN) (Hageman et al, 1984; see section 1.3.2). Despite considerable 
study however the mechanisms involved in the pulmonary adaptation to extra-uterine 
life are incompletely understood.
Included in the categories of mediators which may play a role in the normal 
transition of the pulmonary circulation at birth and in the pathophysiology seen in PPHN 
are the peptide endothelin (EX) and the oxidant radical nitric oxide (NO). Both these 
endothelium-derived agents have marked functional effects on the fetal, neonatal and 
adult pulmonary circulation (e.g. Barnard et al, 1991; Perreault & DeMarte, 1991; 
Kinsella et al, 1994). Furthermore, both BT-1 and NO has also been reported to cause 
structural alterations of the developing and adult pulmonary vasculature (e.g. Roberts et 
al, 1995, Thomae etal, 1995; Janakidevi etal, 1992)
Acetylcholine (ACh)-induced vasorelaxations of arteries have been shown to be 
mediated by the release of the endothelium derived relaxing factor (EDRF), NO 
(Furchgott & Zawadski, 1980). Previous investigators have demonstrated alterations in 
ACh-induced relaxation's in pulmonary vasculature from fetus to newborn and during 
the initial days of life. EDRF activity has been shown to be absent or greatly reduced in 
the fetal pulmonary arteries (PA) of the of rabbit and sheep (Zubrow et al, 1989;
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Abman, et ah, 1991). In porcine pulmonary arteries, the vasodilator response to ACh 
was negligible in the newborn and increased to a maximum at 3-10 days of life (Liu et 
al, 1992). Thus in addition to the developmental change in the endothelium-dependent 
response after birth, it may also change at birth when dramatic alterations in pulmonary 
haemodynamics occur.
In this chapter, I examined the vasodilator ability of ACh in fetal, neonatal and 
adult rabbit pulmonary arteries. Effect of developmental age on adrenergic stimulation 
was also investigated using NA. The majority of previous in vitro developmental studies 
on isolated pulmonary arteries have been on conductance vessels however, it is the 
pulmonary resistance arteries (PRAs) which are the important determinants of PVR in 
vivo (Staub, 1985). Hence the responsiveness of these small PRAs were examined 
throughout this study.
Previous reports show reduced endothelium- dependent relaxation's in newborn 
pulmonary vasculature compared with several days after birth ( e.g. Liu et al, 1992). 
This may indicate diminished NO levels at birth. EDRF is inactivated by superoxide 
anions (Rubyani & Vanhoutte, 1986). In this chapter, I also examined the effect of 
superoxide dismutase (SOD), an inhibitor of superoxide anions (Rubyani & Vanhoutte, 
1986), on ACh responses in PRAs from 0-24 hr old rabbits, so as to investigate the 
possibility influence of superoxide anions in the newborn.
Both ET-1 and NO influence the effects mediated by one another. ET production 
is regulated by inhibitory mechanisms such as NO. Agents that increase cyclic 
guanosine monophosphate (cGMP) concentrations, such as nitrovasodilators and 
superoxide dismutase (SOD), all prevent thrombin-induced ET production (Boulanger & 
Lus cher, 1991; Saijonmaa, e ta l ,  1990). Endothelium- derived NO release therefore 
exerts a negative feedback on ET production via a cGMP- dependent mechanism 
(Luscher et al, 1992). Furthermore, ET can stimulate the release of NO when it binds to 
ETb receptors of endothelial cells (Zellers, e ta l,  1994).
Measurement of plasma ET-1 levels in newborn infants show elevated levels at 
birth, which then decrease by day 4 and 5 of life (Endo, et al, 1996; Malamitsi Puchner,
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et al, 1993). Similar changes in plasma levels have also been reported in various 
animals, such as the pig (Levy, et al, 1995). Loesch and Burnstock (1995) showed that 
the endothelial cells of the main pulmonary artery in the newborn rat are rich in ET and 
nitric oxide synthase (NOS), suggesting a substantial involvement in the vasomotor 
control of the pulmonary circulation during the early stages of postnatal development. In 
this chapter I examined the effect of inhibition of nitric oxide synthase (NOS) activity 
on responsiveness of rabbit PRAs, at various developmental ages, to the non-selective 
ETa/b receptor agonist, ET-1, and the selective ETb- receptor agonist, SXS6 c (Williams 
etal, 1991).
8.2 Methods
Rabbit pulmonary resistance arteries
Fetal (2 days preterm) and neonatal New Zealand White rabbit pups were studied 
at 0-24 hrs, 4 days and 7 days after birth. Adult rabbits at ~ 3.5 kg body weight were 
also examined. The pregnant rabbits, fetal and neonatal pups were killed by sodium 
pentabarbitone as described in section 2.1.2. The lungs were promptly removed from the 
animals and small intralobar pulmonary resistance arteries (PRAs ~ 300pm i.d.) were 
dissected out according to the methods stated in section 2.2.3.2. These were mounted as 
ring preparations ( -2 mm long) on a wire myograph, bathed in Krebs solution at 37®C. 
Using the normalisation process explained in section 2.2.5, vessels were tensioned to an 
equivalent transmural pressure of ~ 15 mmHg. This pressure was chosen as it is similar 
to in vivo pressures of rabbit pulmonary arterioles. Preliminaiy studies in our laboratory 
showed that bubbling with 95% 02  inhibits responses to vasoconstrictors in rabbit PRAs 
so we bubbled with 3% 0%/ 5% CO2 balance N% for fetal rabbit vessels and 16% O2/ 5% 
CO2 balance N2 for all others. These gas mixtures were chosen as they are similar to 
those which the vessels would be exposed to in utero and in vivo.
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Experimental protocol
Vessels were allowed to equilibrate for 1 hour prior to the addition of any drugs. 
The response of the PRAs to 50mM KCl was determined twice; once the contractile 
response had reached a plateau, the vessels were washed out at least 6 times with fresh 
Krebs solution. Vessels were then preconstricted with IpM NA and IpM ACh was 
added on top of the induced tone. In PRAs in separate studies, cumulative concentration- 
response curves (CCRCs) to NA (InM-lOpM) were carried out. Following 6 washes 
and at least 20 minutes "resting' time, vessels were preconstricted with 1-1 OpM 5-HT 
and ACh (InM-lOpM) was added cumulatively to the bath on top of the induced 
contraction. The effect of SOD on ACh CCRC was examined in 0-24 hour rabbit PRAs 
only. 50 U/ml was added to the bath 30 minutes prior to the addition of lOnM ET-1 to 
induce tone upon which ACh (lnM-30pM) was added.
Following washout and adequate time to return to baseline tension, CCRCs to 
ET-1 and SXS6 c (lpM-0.3pM) were constructed either in the absence or presence of 
lOOpM L-NAME which was preincubated with the vessels for 30 minutes prior to the 
cumulative addition of peptide.
Note
I investigated the possibility that the previous addition of dings could have an 
affect on the responses to ET-receptor agonists. The preceding exposure of the isolated 
vessels to NA, 5-HT or ACh did not influence these responses. However the 
vasorelaxation studies involving ET-1 as a preconstricting agent and preincubation of 
the preparations with SOD, were carried out on a separate group of preparations, where 
subsequent ET-receptor mediated responses and the influence of L-NAME were not 
examined.
252
Data analysis
CCRCs are expressed either as a percentage of their own maximum contraction 
or as a percentage of the second reference contractile response to 50mM KCl. 
A?ECio,/'EC25 and/?EC5o values.(where appropriate) were calculated by computer 
interpolation from individual CCRCs and expressed as -log M concentration (refer to 
methods in section 2.5.2). Contractions to KCl were expressed as mg weight tension. 
Relaxation's induced by ACh were calculated as a percentage of the level of 
preconstriction to NA or 5-HT, as appropriate, in each preparation. Statistical 
comparison of the means of groups of data were made by Student's unpaired t-test or 
ANOVA; P<0.05 was considered statistically signiEcant. Throughout, data are 
expressed as mean±SEM and n In = number of ring preparations / number of animals..
8.3 Results
Contractile responses to 50mM KCl are shown in figure 8 .1 . PRAs from 7 day 
old and adult rabbits produced a significantly greater response than vessels from fetal 
and newborn rabbits. The average internal diameters (pM) and equivalent transmural 
pressures (mmHg) of PRAs from fetal and neonatal rabbits were as follows: fetal- 
295.5+12.6 pM/ 12.8+0.6 mmHg; 0-24 hr- 329.0+14.3/ 11.8+0.8; 4 day- 343.6+16.5/ 
10.5+0.3; 7 day- 325.5+21.6/ 12.6+0.9 (n= > 10 lungs in each case). Thus PRAs from 
animals at these age points exhibit similar internal diameters when set up at the same 
equivalent internal diameters.
Responses to NA and ACh
Figure 8.2A shows the response to IpM NA in fetal, neonatal and adult rabbit 
PRAs. NA-evoked vasoconstriction was significantly greater in the 0-24 hr preparation 
than in fetal, 4 day, 7 day and adult rabbit PRAs. Rabbit PRAs produced a greater
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Figure 8.1. Contractile response to 50 mM KCl in PRAs from fetal and neonatal rabbits. 
n= >10 lungs for all preparations. Data are expressed as absolute contraction mg weight 
tension. Each column represents the mean ±SEM. Statistical comparisons were made 
using ANOVA followed by Tukey's post test; ^*p< 0.01, ***p<0.001 cf. 7 day 
response.
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Figure 8.2 Responses to NA in rabbit PRAs. A Response to IpM NA; *p<0.05, 
'‘*''''p<0.01 all other age points cf. 0-24 hr. B NA CCRCs in 0-24 hr (O, n=8/8), 4 day (#  
, n-3/3), 1 day (□, n=5/5) and adult (■, n=6/6) rabbit PRAs; ^^f<0.05, ** f  <0.01 0-24 
hr of. 7 day. Data are expressed as reference contraction to 50mM KCl. Each point 
represents mean +SEM. Statistical comparisons were made using ANOVA followed by 
Tukey's post test.
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contractile response to NA following birth; in neonatal vessels, the ability of NA to 
evoke vasoconstriction progressively decreased during the first week after birth such 
that by adulthood no response was noted.
CCRCs to NA are shown in figure 8.2B. As can be seen, this resulted in a 'belf- 
shaped response in vessels from all age points studied except in adult, where again no 
response was noted. The maximum response was noted at 0.3 |llM  NA. Progressively 
greater NA concentrations produced a fall in tension toward or even slightly below 
baseline tension. Again the greatest magnitude of response was noted in 0-24 hour 
vessels; responses to 30nM-l|_iM NA were significantly greater in 0-24 hr compared 
with 7 day rabbit PRAs. (max. 54.9+11.3 c f 13.4+10.4 %, P<0.05). NA had a similar 
sensitivity in all vessels examined. j^ECgo values for NA are shown in table 8.1.
AGE NA
i^ECso n/n
ACh
;^EC50 n/n
0-24 hours 7.7+0.1 8/8 7.4+0.1* 7/7
4 days 7.4+0.2 3/3 7.8+0.1 6/6
7 days 7.9+0.1 5/5 7.8+0.1 6/6
Table 8.1 Sensitivity to NA and ACh in PRAs from 0-24 hour, 4 day and 7 day old 
rabbits. n/n= number of ring preparations from number of animals. Statistical 
comparisons were made by ANOVA followed by Tukey's post test. * P<0.05, 0-24 hr 
pECso vs. 4 day and 7 day.
Figure 8.3A shows the vasodilator effect of IfiM ACh in vessels preconstricted 
with l|iM  NA. Since responses to IpM NA were very small in 7 day old and non­
existent in the adult PRAs, no ACh data is available for these age points. The greatest 
relaxation was observed in 4 day rabbit PRAs, where vessels relaxed to or below 
baseline tension. A substantial relaxation to baseline tension was also noted in fetal
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Figure 8.3 ACh-induced vasorelaxations of rabbit PRAs. A Response to l|iiM ACh 
expressed as percentage of NA (IpM)- induced tone. *f<0.05, **f<0.01 fetal and 4 day 
cf. 0-24 hr response. B ACh CCRCs expressed as a percentage of 5-HT (1-lOjuM)- 
induced tone. * f <0.05 0-24 hr (O, n=7/7) cf. 4 (■, n=6/6) and 7 day (□ , n=6/6); 
+f<0.05 0-24 hr cf. 7 day. Statistical comparisons were made using ANOVA.
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Figure 8.4 Effect of SOD on ACh- Induced vasorelaxations of PRAs from 0-24 hour old 
rabbits. Control ACh CCRC (O, n-=5/5) and in the presence of 50 U/ml SOD (# , 
n=6/6). Data are expressed as percentage of ET-1- induced tone. Each point represents 
mean ± SEM.
vessels. The response at both these age points were significantly greater than that of 0- 
24 hour rabbit PRAs (-40% of NA preconstriction).
Cumulative responses to ACh in vessels preconstricted with 5-HT are shown in 
figure 8.3B. 5-HT induced tone was -100% KCl response in 0-24 hr and 4 day vessels 
and -  60% KCl in PRAs from 7 day old rabbits. PRAs from 0-24 hour rabbits were the 
least sensitive to ACh ( f  <0.05 cf. 4 and 7 days; table 8.1). The magnitude of the
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vasodilatory responses to 0.03 and O.l^iM ACh were significantly less in 0-24 hr 
compared with 4 and 7 day vessels (fig. 8.2B). Vasorelaxation of 0-24 hr and 4 day 
vessels reached a plateau at 0.3pM ACh, however an increasing contractile response 
was noted in 7 day vessels at and beyond this concentrations. ACh evoked a contractile 
response at all concentrations examined in adult rabbit PRAs.
The effect of SOD on ACh-induced relaxations in 0-24 hr rabbit PRAs is shown 
in figure 8.4. Tone was induced with lOnM ET-1; this caused a contraction of -60% of 
the reference KCl response. ACh relaxed the vessels backed to baseline tension and the 
presence of 50u/ml SOD had no effect on sensitivity or magnitude of the response.
The above results demonstrate that the magnitude of the relaxatory response to 
l|_iM ACh in 0-24 hour rabbit PRAs varied depending on the preconstricting agent; this 
is shown in table 8.2. A significantly greater vasorelaxation was seen when tone was 
induced with ET-1 compared to 5-HT. However, the contractile response to ET-1 was 
comparatively smaller than that noted to 5-HT.
Preconstricting
agent Induced tone %50mMKCl)
Relaxatory response to 
1 |.lM ACh (% induced tone)
IpM NA 80.6+21.0 40.2+22.0
l-10|aM5-HT 99.0+10.1 78.7+6.6
lOnM ET-1 63.5+4.6+ 100.0+5.3»
Table 8.2 Relaxatory response of 0-24 hour rabbit PRAs to IpM ACh following 
preconstriction with NA, 5-HT or ET-1. Statistical comparisons were made by ANOVA 
followed by Tukey's post test: relaxatory response following ET-1 cf. 5-HT-induced 
tone, * 7^<0.05; ET-1 cf. 5-HT-induced tone, +f<0.05-
Effect of L-NAME on ET-1 and SXS6c induced responses
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100|o,M L-NAME alone caused an increase in baseline tension in 9% of fetal, 
28% of 0-24 hrs, 23% of 4 day and 38% of 7 day old rabbit PRAs tested. The magnitude 
of this response was very variable.
The response of fetal and neonatal PRAs to ET-1 in the presence and absence of 
lOOpM L-NAME are shown in figures 8.5 -8.8. ^EC^o values and maximum responses 
are shown in table 8.3. L-NAME had no effect on the sensitivity to ET-1 in fetal (figure 
8.5A), 0-24 hour (figure 8.6A) or 4 day old (figure 8.7A) rabbit PRAs (table 8.3). In 
comparison, a significant increase in sensitivity was evident in vessels from 7 day old 
rabbits (figure 8.8A, table 8.3). The magnitude of the maximal ET-1-induced 
vasoconstriction was not affected by L-NAME in fetal preparations (figure 8.5A) 
however an increase by -50 % was noted in 0-24 hr (figure 8.6B) and 7 day old rabbit 
PRAs (figure 8.8B). The greatest effect was seen in 4 day rabbit PRAs, where the 
maximum vasoconstriction was augmented by -150% (figure 8.7B, table 8.3). L-NAME 
markedly increased the magnitude of the response at ET-1 concentrations greater than 
3nM in 0-24 hour vessels. However in 4 and 7 day old rabbit PRAs, a significant 
increase in contractile response was seen from 0. InM ET-1.
ET-1 control
max.
response
n/n ET-1+ L-NAMEpEC^ç) max. 
response
n/n
Fetal 8.7+0.23 95.3+9.0 6/6 8.9+0.3 119.4+20.5 6/6
0-24
hours 8.8+0.23 84.0+14.0 6/6 8.9+0.3 148.5+17.4* 7/7
4
days 8.6+0.13 101.7+16.8 7/6 9.0+0.3 250.0+23.7*^'*6/6
7
days 8.0+0.2 92.7+11.1 6/6 8.9+0.2++ 140.6+10.7* 6/6
Table 8.3 pECsQ values and maximum responses for ET-1 in the presence and absence 
of lOOjLiM L-NAME in fetal and neonatal rabbit PRAs. Maximum response expressed as 
% contraction to 50mM KCl. Statistical comparisons were made by Students unpaired t- 
test: max. response control vs. +L-NAME » E<0.05, *»*E<0.001; control pEC^o vs. +L-
NAME ++E<0.01;and ANOVA 7 day old control ET-1 vs. other age points ^P<0.05. 
ET-1, endothelin-1; L-NAME, L-N® -nitro-L-arginine methyl ester.
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Figure 8.5 Effect of L-NAME (lOOjiM) on responses to ET-1 in PRAs from fetal 
rabbits. ET-1 CCRCs ; control (O, n=6/6) and in the presence of L-NAME (# , n=6/6). 
A Data are expressed as percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50mM KCl. Each point represents mean ± SEM.
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Figure 8.6 Effect of L-NAME (100|_iM) on responses to ET-1 in PRAs from 0-24 hr old 
rabbits. ET-1 CCRCs ; control (O, n=6/6) and in the presence of L-NAME (# , n=7/7). 
A Data are expressed as percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50mM KCL Each point represents mean ± SEM.
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Figure 8.7 Effect of L-NAME (lOOtiM) on responses to ET-1 in PRAs from 4 day old 
rabbits. ET-1 CCRCs ; control (O, n=7/6) and in the presence of L-NAME ( • ,  n=6/6). 
A Data are expressed as percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50mM KCl. Each point represents mean + SEM.
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Figure 8.8 Effect of L-NAME (100|iM) on responses to ET-1 in PRAs from 7 day old 
rabbits. ET-1 CCRCs ; control (O, n=6/6) and in the presence of L-NAME (# , n=6/6). 
A Data are expressed as percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50mM KCl. Each point represents mean ± SEM.
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The response of fetal and neonatal PRAs to SXS6c in the presence and absence 
of 100|liM L-NAME are shown in figures 8.9.-8.12. ^EC^o values and maximum 
responses are shown in table 8.4. L-NAME had no significant effect on sensitivity or 
maximum contractile response to SXS6c in fetal (figure 8.9), 0-24 hour (figure 8.10) or 
4 day old rabbit PRAs (figure 8.11, table 8.4). In 7 day rabbit vessels, a significant 
inhibition of SXS6c-induced response was noted (figure 8.12A, table 8.4). The 
rightward shift in the response was such that the maximum response occurred at 3nM in 
the presence of L-NAME compared with 30pM in control SXS6c CCRC. At this age, no 
influence on the magnitude of the response was noted from IpM-O.lnM however, a 
marked augmentation was evident at concentrations above InM SXS6c (figure.8.12B, 
table 8.4).
SXS6c control
/>EC5o max.
response
n/n SXS6C+ L-NAME^EC5o max.
response
n/n
Fetal 8.64=0.3 39.54=12.2^ 6/6 8.9+0.4 105.2+51.1 4/4
0-24
hours 9.74=0.1 a 97.8±27.7 6/6 9.410.3 198.04=23.6 10/10
4
days 10.8+0.3aa 86.1+8.9 6/6 10.9+0.3 97.5+29.1 6/6
7
days ll.l±0.2aa 41.3+7.lbh 6/6 9.6+0.2+++ 91.7+21.4* 5/5
Table 8.4 joECso values and maximum responses for SXS6c in the presence and absence 
of 100|o,M L-NAME in fetal and neonatal rabbit PRAs. Maximum response expressed as 
% contraction to 50mM KCl Statistical comparisons were made by Students unpaired t- 
test; max. response control vs. +L-NAME * P<0.05; control pEC^o vs. +L-NAME 
+++p<0 001; and ANOVA followed by Tukey's post test: fetal control SXS6c pECsQ vs. 
other age points ^P<0.01, ool; 4 day old control max. vs. other age points,.
hf<0.05, hbp<Q 01 SXS6c, sarafotoxin S6c; L-NAME, L-N®-nitro-L-arginine 
methylester.
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Figure 8.9 Effect of L-NAME (100|,iM) on responses to SXS6c in PRAs from fetal 
rabbits. SXS6c CCRCs ; control (□, n=6/6) and in the presence of L-NAME (■, n=4/4). 
A Data are expressed as percentage own maximum contraction. B Data are expressed as 
percentage reference contraction to 50mM KCl. Each point represents mean ± SEM.
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Figure 8.10 Effect of L-NAME (100|iM) on responses to SXS6c in PRAs from 0-24 hr 
old rabbits. SXS6c CCRCs ; control (□, n=6/6) and in the presence of L-NAME (■, 
n=10/10). A Data are expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50mM KCl. Each point represents 
mean ± SEM.
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Figure 8.11 Effect of L-NAME (lOOjiiM) on responses to SXS6 c in PRAs from 4 day 
old rabbits. SXS6 c CCRCs ; control (O, n=5/5) and in the presence of L-NAME (■ 
11=6/6). A Data are expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50mM KCl.
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Figure 8.12 Effect of L-NAME (100|.iM) on responses to SXS6c in PRAs from 7 day 
old rabbits. SXS6c CCRCs ; control (O, n=6/6) and in the presence of L-NAME ( • ,  
11=5/5). A Data are expressed as percentage own maximum contraction. B Data are 
expressed as percentage reference contraction to 50mM KCl. Each point represents 
mean ± SEM.
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8.4 Discussion
A vast amount of information is available on the reactivity of large diameter 
vessels (> 1 mm) from the neonatal lung (e.g. Davidson & Eldemerdash, 1990; 
Steinhorn et al, 1993; Liu et al, 1992). However, arteries with a diameter greater than 
500|,lM are thought to be relatively unimportant in controlling vascular resistance 
(Andersson et al, 1985). Furthermore, marked structural and functional differences exit 
throughout the vasculature thus making extrapolation of data from larger vessels to 
smaller resistance arteries inappropriate (e.g. Andersson et al, 1985; Buckner et al, 
1982; Somlyo et al, 1965). The results of this chapter demonstrate that PRAs (-300 p.M 
ID) from fetal and neonatal rabbits differ in their responsiveness to the vasoactive 
compounds KCl, NA, 5-HT, ACh, ET-1 and SXS6c in vitro. Furthermore, the influence 
of NO on ET-receptor mediated responses also alters following birth and during the first 
week of extra-uterine life. Thus, these marked changes are seen when the pulmonary 
circulation is in a transitional state as it adapts to perform its vital function of gas 
exchange in vivo (Inselman & Mellins, 1976). These differences indicate that for a 
complete understanding of the postnatal adaptation of the pulmonaiy circulation, it is 
necessaiy to access responses at a level of vascular tree more important in controlling 
pulmonary resistance.
Part of the structural remodelling of the neonatal lung involves the extension of 
vascular smooth muscle into the alveolar region (Inselman & Mellins, 1976). The 
response to KCl, which is mediated through ifs effect on the membrane potential 
(Burnstock et al, 1963) and is therefore receptor independent, indicates the integrity and 
mass of the smooth muscle present. The contractile response of PRAs to KCl 
significantly increased between fetus and birth to 7 days of life. The magnitude of the 
response at 7 days was similar to that observed in adult vessels. These findings suggests 
smooth muscle extension or maturation in pulmonary resistance arteries of the same 
anatomical location within the first week of extra-uterine life. A continued increase in 
the KCl-evoked response of small intrapulmonaiy arteries, of similar diameter to the
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vessels examined here, have also been reported in fetal and neonatal lamb (Dunn et al, 
1989). Furthermore, this study also demonstrated no change in KCl response over time 
in larger diameter intrapulmonary arteries (530-1000|aM i.d.). This finding indicates 
further functional differences between vessels of different sizes in the transitional 
pulmonary circulation.
Responses to NA
Neonatal PRAs had similar sensitivity to NA but differed in magnitude of the 
induced vasoconstriction. The response to NA was veiy variable; all 0-24 hr rabbit 
PRAs examined responded however the percentage of responders then progressively 
decreased such that no adult PRAs studied evoked a response to adrenoceptor 
stimulation. Endogenous NA and adrenaline act on multiple adrenoceptor subtypes. 
Both a i “ and a 2-adrenoceptors mediate vasoconstriction, however endothelial a%- 
adrenoceptors mediating vasodilation through the release of NO have been demonstrated 
in pulmonary vessels (Liu et al, 1991). The presence of a%- and a 2-receptors have been 
demonstrated in isolated pulmonary vessel rings and in the pulmonary vascular bed of 
the rabbit (Docherty & Starke, 1981; MacLean et al, 1993a; 1993b), |3-adrenoceptors, 
mediating vasodilation (Boe & Simonsson, 1980), are exclusively of the (32-receptor 
subtype on the pulmonary vessels of the rabbit (O' Donnell & Wanstall, 1985). NA was 
shown to evoke a "bell"- shaped response in neonatal PRAs; a maximum was reached at 
0.3|,iM and further increments in NA concentrations produced fall in tension toward 
baseline values. This suggests that low concentrations of NA act at a  1-adrenoceptors 
evoking a vasoconstrictor response; whereas p2-receptors are activated by higher NA 
concentrations, producing a relaxatoiy response. a 2-adrenoceptors may also be involved 
in the vasorelaxations observed in the neonatal rabbit PRAs. NO mediates Œ2- 
adrenoceptor agonist- induced pulmonary vasodilation (Liu et al, 1991; Pepke-Zaba et 
al, 1993). Further studies using selective agonists and antagonists would shed further 
light on this.
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In rabbit PRAs, the ability of NA to evoke vasoconstriction was greatest 0-24 
hours after birth, it then decreased during the first week of life and was non-existent in 
adulthood. There are many potential explanations for this. In the newborn pig, plasma 
ET-1 levels were shown to be greater at birth than at 3 days or later and a similar 
situation occurs in the human infant (Levy, et al, 1995; Endo, et al, 1996; Malamitsi 
Puchner, et al, 1993). Low concentrations of ET-1 potentiate the contractions to other 
vasoconstrictor hormones, such as NA (Tabuchi, et a l, 1989). The magnitude of the 
contractile response to NA was significantly greater in PRAs from 0-24 hr old rabbits 
compared to 4 day, 7 day and adult preparations. Thus NA evokes it greatest response at 
a time when plasma ET-1 levels have been shown to be elevated. This observation also 
implies that the functional population of contractile adrenoceptors on rabbit PRAs is at 
its greatest at birth and then begins to decline with increasing age. Alternatively, the 
greater magnitude of vasoconstrictions in the newborn could be related to a reduced 
level of agonist-induced NO level at birth compared to several days old, which is 
suggested by the reduced ACh-induced relaxation in 0-24 hr compared to 4 and 7 day 
vessels (this is discussed later).
NA was shown to be ineffective in small intrapulmonary arteries of adult rabbit 
however larger pulmonaiy arteries have been shown to readily contract in response to 
NA (Mac Lean et al, 1993a; 1993b). Hence there is a possible decrease in adrenergic 
activity with decreases in vessel diameter in the rabbit lung; indeed, this has also been 
demonstrated in the rabbit by Su and co-workers (1978). A significantly smaller 
magnitude of response to NA and adrenaline in smaller diameter pulmonary arteries 
compared with larger diameter vessels has also been reported in the lamb (Dunn et al, 
1989). Differences in sensitivity to adrenergic agonists depending on vessel size has also 
been demonstrated in isolated PAs from guinea pig (Buckner et al, 1982).
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Responses to ACh
Alterations in the response to ACh were also observed at different age points. 
The magnitude of the relaxatory response to ACh was significantly greater at 4 days 
compared to 0-24 hrs old when PRAs were preconstricted with NA. Similarly, on raising 
the tone with 5-HT, ACh-induced vasorelaxation was greater in the 4 and 7 day neonate 
compared to the newborn preparation, which was also significantly less sensitive to 
ACh. These results demonstrate a two phase change in the endothelium-dependent 
vasodilation response to ACh in rabbit PRAs, as has previously been shown in porcine 
intrapulmonary artery (Liu, et a l, 1992). The ACh response of rabbit PRAs increased 
after birth with maximal relaxations at 4 and 7 days of life but by adulthood, ACh was 
unable to evoke vasorelaxations. Similar findings have been reported in neonatal 
isolated pulmonary vessels of other species (Abman, etal, 1991; Steinhorn, et a l,  1993; 
Zellers & Vanhoutte, 1991; Levy e ta l,  1995).
The possibility that the relatively reduced endothelium-dependent relaxation of 
the newborn was due to a reduced NO level was investigated using SOD. Several 
reactants in the plasma milieu cause inactivation of NO, including superoxide anions 
(Moncada, et al., 1991). Rubanyi & Vanhoutte (1986) showed that EDRF half life was 
prolonged in the presence of SOD, a scavenger of superoxide anions. Other studies in 
our laboratory by Morecroft & MacLean (1996) demonstrated that the endothelium- 
dependent response to ACh in large pulmonary arteries of the newborn rabbit was 
restored in the presence of SOD. The preconstricting agent used in the study by 
Morecroft and MacLean was ET-1; I also employed this agent to induce tone in the 
smaller PRAs so that a direct comparison could be made between vessels of different 
diameters. However, in comparison to the findings of Morecroft, the PRAs relaxed to 
baseline tension in response to ACh alone and the presence of SOD had no affect. These 
findings suggest that the presence of superoxide anions inhibits vasorelaxations of larger 
diameter PAs but do not affect the smaller PRAs of the newborn rabbit. The fact that 
ACh- induced a 100% relaxation in PRAs but had negligible affect on larger PAs
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demonstrates functional differences within the same species depending on vessel 
diameter.
ACh has been shown to cause a marked dilation of the pulmonary vascular bed 
of the fetal lamb (Dawes, et al^  1956). Fetal rabbit PRAs demonstrated a 100% 
relaxation to ACh. A substantial relaxation has also been shown in the larger pulmonary 
arteries of the fetal rabbit, also preconstricted with NA (Morecroft & MacLean, 1995a). 
In this previous study the magnitude of the relaxation was shown to depend on the 
vessel size; the response of the extra-1 ohal was significantly greater than that of the main 
pulmonary artery. Furthermore, the ACh-induced response of the fetal PRAs shown in 
this chapter is comparatively greater that the relaxation shown in the larger PAs. This 
suggests that the size of the fetal vessel studied influences the endothelium-dependent 
response, as a greater relaxation is evident with decreasing vessel size.
In comparison, other studies in isolated pulmonary arteries from fetal animals 
have shown diminished basal and stimulated release of endothelial NO in the near- term 
fetus relative to animals a few weeks older (Ahman, et al^  1991; Steinhorn, et ah, 1993; 
Zellers & Vanhoutte, 1991). Although the results of this study show a comparatively 
smaller response of 0-24 hr rabbit PRAs compared to 4 and 7 days old, the relaxations 
obseived in the newborn preparation were still marked. Previous studies however have 
demonstrated a negligible response to ACh at birth (Liu, et al, 1992).
These conflicting findings may be may explained by differences in experimental 
conditions. Conditions in vivo and in vitro differ significantly and between different in 
vitro studies, the size of the vessel studied or the preconstricting agent used prior to 
evoking relaxatory responses varies. Indeed, 1 found that the magnitude of the ACh- 
induced relaxation of 0-24 hr rabbit PRAs depended upon the agent used to induce tone. 
A comparatively greater relaxation was noted following ET-1- induced tone compared 
with 5-HT preconstriction. However, the magnitude of the vasoconstriction to this latter 
compound was markedly greater than that of ET-1 and so the vessel had to relax from a 
greater level of tension. Former reports show that conflicting responses to ACh could be 
explained by the level of pre-existing tone. For example, Hyman & Kadowitz (1988;
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1989) demonstrated, in the feline and rabbit pulmonary vascular bed, that ACh induces a 
pressor response under resting conditions but causes a depressor response under 
conditions of elevated tone. Perez-Vizcaino et al (1996) also demonstrated that 
differences in the relaxant effects of ACh, SNP and ATP in isolated intrapulmonary 
arteries of neonatal piglets, depended upon the vasoconstrictor used. Another factor 
which varies between the experimental conditions of different studies is the percentage 
of O2 used to maintain the preparations. For example Liu et al (1992) and Steinhorn et 
al (1993), when investigating endothelium-dependent vasodilations in neonatal/adult pig 
and newborn/juvenile sheep, aerated the isolated PAs with gas mixture containing 
95%/94% O2, however this level of oxygenation far exceeds that the pulmonaiy arterial 
vasculature is exposed to in vivo . Whereas in the functional studies 1 conducted in this 
chapter and chapter 9 on this thesis, fetal and neonatal preparations were bubbled with 
gas mixture containing 3% and 16% O2, respectively. Previous studies have indicated 
that the functional response to varies agonists varies depending on the p0 2 . to which 
pulmonary vessels are exposed to. For example, Wang and Coceani (1992) showed that 
in isolated pulmonary resistance vessels from fetal lamb, indomethacin per se did not 
alter tone of vessels pre-equilibrated at low p02 (~22 mmHg), whereas it became a 
constrictor at high pÛ2 (-71 mmHg).
Differing results may also be species related. For example, PRAs from the adult 
rat exhibit a relaxatory response to ACh (MacLean, et al, 1994a) whereas, as shown in 
this chapter, the ability of ACh to evoke relaxations is lost in the adult rabbit and a 
contractile response is noted. ACh- mediated vasoconstriction of small pulmonary 
vessels of the rabbit has previously been reported (Sada, et al, 1987). Catravas et a l , 
(1984) also observed vasoconstrictor response to ACh in the rabbit pulmonary 
circulation. This phenomenon has also been shown in isolated pulmonaiy veins; in 
bovine vessels by Ignarro and colleges (1985) and in canine vessels by DeMay and 
Vanhoutte (1982).
Furthermore, in this chapter, the ACh- evoked response was altered from 
vasorelaxation, observed in fetal and neonate, to vasoconstriction, seen in adulthood and
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this contractile response was evident at higher ACh concentrations in PRAs from 7 day 
old PRAs. Similarly, Steinhorn et al (1993) showed that preconstricted isolated 
intralobar pulmonary veins from juvenile sheep (5-6 weeks old) contracted to ACh and 
preparations from newborn animals relaxed to low ACh concentrations and then 
contracted to higher concentrations. These findings suggests an alteration in muscarinic 
receptor subtypes with developmental age. It has been shown in the central nervous 
system that distinct developmental time courses exist for muscarinic receptors (Coyle & 
Yamamura, 1976; Lee, et al, 1990). In addition, muscarinic receptor-mediated cellular 
responses develop overtime (Lee, et al, 1990). Alternatively, the endothelium derived 
factor released in response to ACh from adult pulmonary resistance arteries may 
contractile in nature., e.g. ET, superoxide anions (Vanhoutte & Katusic, 1988).
Influence of NO on ET-receptor mediated responses
ET-1 and SXS6c were potent vasoconstrictors of fetal and neonatal rabbit PRAs. 
Vessels from rabbits at all age points demonstrated a marked contractile response to 
SXS6c, indicating the presence of a significant population of ETb receptors mediating 
vasoconstriction. Similar findings have been documented for the large PA of the adult 
rabbit. (Panek, et al., 1992; LaDouceur, et al., 1993). My results in chapters 4 and 5 also 
indicate this to be the case also in the PRAs of the adult rabbit. Differences in sensitivity 
to these peptides were seen at different developmental ages, suggesting alterations of 
ET- receptor subtypes in the transitional pulmonary circulation. This is investigated 
further in chapter 9 (this thesis) using selective antagonists and is discussed more 
extensively.
Shaul et al (1993) measured NO production, as reflected by cGMP 
accumulation, in pulmonary artery segments of fetal and newborn lambs. They observed 
that pulmonary vascular NO production increased from late gestation until the fourth 
week after birth. Similarly, measurement of constitutive endothelial NOS mRNA in the 
rat showed that the highest levels were detected within 24 hrs after birth and this was
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detected in endothelial cells lining small and medium sized blood vessels (Kawai et al,
1995). These finding suggests that pulmonary vascular NOS enzyme activity increases 
after birth. In this chapter, I investigated this possibility in the PRAs from fetal and 
neonatal rabbits using the NOS enzyme inhibitor L-NAME (Rees, et al, 1990).
L-NAME alone was shown to produce an increase in baseline tension of a 
variable magnitude in a proportion of the PRAs examined. The proportion of vessels 
exhibiting a response increased markedly between fetus and newborn and was greater at 
7 days old. These findings could be due to an increased endogenous tone which is 
normally attenuated by NO. Alternatively they may suggest that an increase in basal 
NOS levels occurs following birth and in the first week of neonatal life in the rabbit. 
These results are also in agreement with previous studies in pig and sheep, where a 
diminished basal and stimulated release of NO from isolated pulmonary arteries of near- 
term fetus relative to animals only a few weeks older was reported (Abman, et al, 1991; 
Liu, etal, 1992; Steinhorn, et al, 1993; Zellers & Vanhoutte, 1991). Thus, the apparent 
increase in NO associated with birth may participate in the postnatal reduction of the 
pulmonaiy vascular resistance. Furthermore, the apparent increment from newborn to 
early neonate could aid the continued decrease in pulmonary vascular resistance which 
occurs during the days and weeks following birth (Rendas, et al, 1978).
Previous investigations suggest an active physiological role for both NO and ET- 
1 in the adaptation of the pulmonary circulation to extra-uterine life. Bndo et al (1996) 
found an increase in serum NO metabolites and decrease in plasma ET-1 between birth 
and 5 days of age in healthy human neonates. In the newborn rat, endothelial cells of the 
pulmonary arteiy were shown, using immunocytochemistry techniques, to be rich in 
NOS and ET (Loesch & Burnstock, 1995). However to date there are few reports on the 
in vitro interaction between NO and ET in the pulmonary artery. Hence, in this chapter, 
I also investigated the possible influence of NO of ET-1 receptor -mediated responses in 
PRAs from fetal and neonatal rabbits using L-NAME.
In fetal rabbit PRAs the presence of L-NAME had no effect on sensitivity or 
magnitude of the maximal response of either ET-1- or SXS6c- evoked vasoconstrictions.
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Vessels from newborn rabbits also demonstrated no change in sensitivity to ET-1 or 
SXS6c following NOS inhibition. The maximal contractile response to SXS6c was also 
unaffected whilst a marked augmentation of the ET-1- induced contractile response was 
noted following birth. Similar effects to those in the 0-24 hr preparation were shown in 4 
day old rabbit vessels except the increase in ET-1-induced contractile response was 
substantially greater. The most pronounced effects of NOS inhibition on ET-receptor 
mediated responses were shown in PRAs from 7 day old rabbits. A marked 
augmentation was noted in both ET-1- and SXS6c- mediated vasoconstriction; the 
relative increase (compared with control maximum for each peptide) was greater in the 
SXS6c response. Furthermore, vessels from this postnatal age demonstrated a. 
significantly increased sensitivity to ET-1, but a marked reduction in SXS6c potency 
following inhibition of NOS. These observation suggest that sensitivity to ET-1 is 
noimally attenuated by NO in 7 day rabbit vessels. I am unable to explain, however, the 
apparent decrease in SXS6c sensitivity following blockade of NO in this preparation. In 
chapter 6 of this thesis I showed that L-NAME had a marked effect on ET-1 and SXS6c- 
induced responses in PRAs from coronary-ligated rabbits but was without effect in 
preparations from sham-operated animals. Other investigators have also reported that 
ET-1 may modulate its vasoconstrictor effect by the release of NO (De Nucci, et al, 
1988; Rodman, et al, 1989). The NOS inhibitor L-NNA was shown to augment 
concentration-dependent contractions to ET-1 in isolated small (2-3 mm) porcine 
pulmonary veins but not arteries (Zellers, et al, 1994).
In comparison to neonatal vessels, the lack of effect of L-NAME on ET-receptor 
mediated responses of fetal PRAs provides further evidence for diminished NO levels in 
the pulmonary vasculature in fetal compared with neonatal life. This does not agree with 
the marked relaxatory response to ACh observed in these vessels however, there could 
be differential effects on control of basal NO (examined by L-NAME studies) and 
agonist-induced NO (studied via the use of ACh). This has also been suggested by 
Cremona et al (1994) after examining inhibition of NO release on vascular tone of 
isolated lungs of pig, sheep, dog and man. In addition, Mian and Martin (1995)
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demonstrated in the rat aorta, that basal activity of NO was more sensitive to 
inactivation by superoxide anion than ACh-stimulated activity. Furthermore, the 
augmentation of ET-1- induced vasoconstriction in neonatal vessels indicates further the 
interaction of these endothelial derived agents in the transitional pulmonary circulation 
Due to the marked effects of NO and ET-1/ SXS6c on the PRAs, the balance of the 
NO/ET system in the adapting neonatal circulation would be crucial in determining 
pulmonary vascular resistance.
These obseiwation suggests in particular that an increase in NO production is 
associated with birth. This may be basally released NO or NO released by agonist 
stimulation by ET-1 via the ETbi receptor or ACh. Indeed, the sensitivity to SXS6c in 
this preparation progressively increased in PRAs from fetal to 7 day old rabbits 
(discussed in chapter 9). This result indicated an alteration in ETb -receptor mediated 
responses and, taking the findings of this chapter into consideration also, a possibly 
increase in agonist-induced release of NO during the first week of life. Furthermore, the 
differential effect of L-NAME on SXS6c and ET-1 responses suggests a heterogeneous 
population of receptors, differentially influenced by NO. I also observed this 
phenomenon in adult rabbit PRAs (chapter 6 this thesis).
At the highest concentration of ET-1 and SXS6c, the response of the fetal and 
neonatal PRAs showed a dramatic "drop off " in tension. This is also evident in the 
SXS6c response in adult rabbit PRAs (chapter 4 this thesis). Endothelins are also known 
to mediate vasodilation via the release of NO from endothelial cells and this is thought 
to be mediated via ETb receptor activation (Carville, et al, 1993, De Nucci, et a i, 1988; 
Eddahibi, et a l, 1991). At all age points, the presence of L-NAME caused the ET-1 
CCRC to appear more biphasic in nature; the responses to higher ET-1 concentrations 
levelled off and the " drop off " in tension was less evident, particularly at 0-24 hours 
following birth. This may be indicative of the involvement of NO in the " drop off " in 
ET-1-evoked response. However, the fall in tension in the SXS6c CCRC at the higher 
concentration range is still observed in the presence of L-NAME. Although the actions 
of other mediators (e.g. PGI2, EDFIF) cannot be mled out, this phenomenon may also be
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due to desensitisation of the response as desensitisation of ETg- receptor mediated 
responses has been demonstrated in the adult rabbit PA (LaDouceur, et a i, 1993) and 
swine pulmonary vein (Sudjarwo, et a l, 1993).
In this chapter I attempted to assess the vascular reactivity of rabbit PRAs at a 
time when marked alterations are occurring in the pulmonaiy circulation as it adapts to 
extra- uterine life. In summary, the contractile responses to KCl increased in magnitude 
with increasing age, implying smooth muscle extension or maturation in pulmonary 
resistance arteries of the same anatomical location at this time. Contractile responses to 
NA were smaller in fetal rabbit PRAs compared to newborn vessels. This may relate to a 
reduced basal NO level in the fetus, as suggested by the relatively lesser effect of L- 
NAME in fetal compared to newborn vessels. However, an augmented agonist-induced 
NO level is indicated before birth by the greater vasorelaxatory response to ACh in fetal 
than in newborn PRAs. Vasoconstrictions to receptor- mediated agents NA and 5-HT 
were comparatively greater in the newborn compared with 7 day old vessels. This may 
be related to the apparent increased level of NO in the 7 day vessels compared with 0-24 
hr rabbit PRAs, which is indicated by (1) the increased vasodilator response to ACh and 
(2) the more pronounced effect of L-NAME on ET-receptor mediate responses in PRAs 
from 7 day old rabbits.
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Chapter 9
Endothelin receptor subtypes in pulmonary resistance 
arteries from fetal and neonatal rabbits
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9.1 Introduction
Endothelin-1 (ET-1) is one of the important endothelial-derived products that has 
been suggested to play an important role in the transition from in utero to postnatal 
pulmonary circulation (Zielger et a l,  1995). Usaki et al (1990) showed evidence of 
increased maternal plasma levels of ET-1 during labour and the presence of large 
amounts of ET-1 in the amniotic fluid. In the newborn pig, the concentration of plasma 
ET-1 was higher at birth than at 3 days or later (Levy et al, 1995). Loesch and Burnstock 
(1995) showed that the endothelial cells of the main pulmonary arteiy in the newborn rat 
are rich in ET (and NOS), suggesting a substantial involvement in the vasomotor control 
of the pulmonary circulation during the early stages of postnatal development. The many 
effects of ET on the pulmonary circulation suggests that it has a role in the transition 
from fetal to neonatal circulation (also see section 1.5.2).
ETs have also been implicated in many pathophysiologic conditions including 
pulmonary hypertension (PHT). The pathophysiological state of persistent pulmonaiy 
hypertension of the newborn (PPHN) can arise when, at birth, the normal decrease in 
PVR and increase in PBF does not occur. This condition results in substantial morbidity 
and mortality in more than 1 in 1000 newborn infants (Reece et al, 1987; Hageman et al, 
1984). Elevated circulating ET-1 levels have been reported in patients with both primary 
and secondaiy PHT and in infants with PPHN (Stewart et al, 1991; Rosenberg et al, 
1993). Kumar et al (1996) have also shown a significant elevation in PPHN and a 
positive correlation with disease severity, suggesting that ET-1 may seive as a marker of 
the disease severity in these infants and in the development of PPHN. Selective 
inhibition of pulmonary ET-receptors may therefore effect pulmonary vasodilation.
In order to fully understand the possible role of endothelin (ET) in the normal 
adaptation of the pulmonary circulation at birth and the pathophysiological state of 
PPHN, it is important to classify which ET receptors are present in the pulmonary 
vasculature at different developmental ages. Two subtypes of mammalian (ET) receptor 
have been cloned and sequenced. The first was denoted ETa and demonstrates
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selectivity for endothelin-1 (ET-1) over ET-3 (Aral et al, 1990). The other receptor, 
ETb, is non-isopeptide selective (Sakurai et al, 1990). Whilst both receptors have been 
shown to mediate contraction, the ETb receptor may also mediate vasorelaxation via 
endothelial release of nitric oxide (Masaki et al, 1991). The following nomenclature was 
suggested to distinguish them: ETb i  for ETb dilator and ETb 2 for ETb constrictor 
receptor (Sokolovsky et al 1992; Warner e/a/, 1993). The ET receptors are discussed in 
chapter 1, section 1.4.5.
However, the types of ET receptor appear to vary with their localisation and 
between species. For example, vasoconstriction is evoked via ETa receptor activation in 
the rat, dog and pig large pulmonary arteries (Douglas et al, 1993, MacLean et al, 1994, 
Nakamiche et a l 1992). However, in the rabbit large pulmonary artery ETb receptors 
mediate vasoconstriction (La Douceur et al, 1993; Fukuroda et al, 1994; Hay et a l,
1996). My results from chapters 4 and 5 suggest that vasoconstrictor ETb receptors also 
predominate in the small pulmonary resistance arteries of the rabbit. In human 
pulmonary resistance arteries ET-1-evoked vasoconstriction also appear to be mediated 
via stimulation of ETb receptors (Chapter 5 this thesis; McCulloch et al, 1996). Studies 
have also demonstrated varied responses between in vivo and in vitro preparations. For 
example, ETb receptor activation has also been shown to have no effect at rest but 
evoke selective pulmonary vasodilation during pulmonary hypertension in intact 
newborn lambs (Wong et a l, 1995). A vasodilator effect was also reported in neonatal 
pig pulmonary circulation (Pinheiro et a l 1993).
In analysing the results from studies in vivo or intact organ preparations in vitro, 
a role of parenchymal or vascular agents cannot be distinguished. Furthermore, the 
majority of in vitro studies on isolated pulmonary arteries have been on conductance 
vessels. However, as previously mentioned, it is the pulmonary resistance arteries 
(PRAs) which are the important determinants of pulmonary vascular resistance, 
hypoxic-induced vasoconstriction and pulmonary hypertension in vivo (Staub, 1985). 
Hence, I examined the responsiveness of PRAs to ET-1 from the fetal and neonatal 
rabbit.
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In chapter 8 I investigated the reactivity of rabbit PRAs at various developmental 
ages. The effect of L-NAME on ET-receptor mediated responses was examined and 
discussed. In this chapter I investigated the ET receptor-subtype(s) responsible for 
vasoconstriction of PRAs before and after birth. Functional responses to ET-receptor 
stimulation in rabbit PRAs from fetal and neonatal rabbits at 3 age points during the first 
week of life were investigated using ET-1 and sarafotoxin S6c (SXS6c; an ETg- 
selective agonist) (Williams et al, 1991). The ET receptor antagonists used to 
characterise the endothelin receptors were the ETa -selective antagonist FR139317 
(Sogabe et al., 1992), BQ788, a potent and selective ETb receptor antagonist (Ishikawa 
et al, 1994) and the non-selective ETa/ETb receptor antagonist SB209670 (Ohlstein et 
al, 1994a; 1994b).
9.2 Methods
Rabbit pulmonary resistance arteries
Fetal (2 days preterm) and neonatal New Zealand White rabbit pups were studied 
at 0-24 hrs, 4 days and 7 days after birth. The pregnant rabbits and fetal and neonatal 
pups were killed by sodium pentabarbitone as described in section 2.1.2. The lungs were 
promptly removed from the animals and small intralobar pulmonary resistance arteries 
(PRAs ~ 300p.m i.d.) were dissected out according to the methods stated in section 
2.2.3.2. These were mounted as ring preparations (-2mm long) on a wire myograph, 
bathed in Krebs solution at 37°C (see section 2.2.5). Using the normalisation process 
explained in section 2.2.5, vessels were tensioned to an equivalent transmural pressure 
of ~ 15 mmHg. This pressure was chosen as it is similar to in vivo pressures of rabbit 
pulmonary arterioles. Preliminary studies in our laboratory showed that bubbling with 
95% 02 inhibits responses to vasoconstrictors in rabbit PRAs so we bubbled with 3% 
O2/ 5% CO2 balance N2 for fetal rabbit vessels and 16% O2/ 5% CO2 balance N2 for all
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others. These gas mixtures were chosen as they are similar to those which the vessels 
would be exposed to in utero and in vivo.
Experimental protocol
Vessels were allowed to equilibrate for 1 hour prior to the addition of any drugs. 
The response of the PRAs to 50mM KCl was determined twice; once the contractile 
response had reached a plateau, the vessels were washed out at least 6 times with fresh 
Krebs solution. Cumulative concentration-response curves (CCRCs) were then 
constructed to ET-1 or SXS6c (IpM - 0.3pM) in PRAs following either a 45 minute 
"rest period" or 45 minute incubation period with the selected concentration of an ET 
receptor antagonist. The antagonists used were FR139317 (at IpM), BQ788 (at IpM) 
and SB209670 (at 0.1 and IpM; examined in 0-24 hr and 4 day old preparations only).
In control SXS6c experiments, 0.1 pM ET-1 was added to the bath at the end of 
the SXS6c CCRC, before washing, so as to estimate the SXS6c response as a percentage 
of response to a maximal ET-1 concentration.
Note
Control responses to ET-1 and SXS6c were carried out, whenever possible, in 
each lung preparation. Due to limitation in equipment and time it was not always 
possible to run a control CCRC to the peptide whilst studying the different antagonists. 
However the control cuives in this study have been updated with each group of 
experiments . No differences were found in the control ET-1 or SXS6c responses when 
tested throughout the period of investigation, thus the data for the control curves which 
are shown have been pooled over many protocols. Unfortunately due to time constraints 
it was not possible to study a range of antagonists concentrations in each tissue. The 
concentrations which were studied, were chosen due to their pA2/pKg values in other 
vascular preparations.
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Data analysis
Results are expressed graphically as percentage of their own maximum 
contraction, or percentage of reference contraction to second application of 50mM KCl. 
pECiQ, pECis and^EC^o values (where appropriate) were calculated according to the 
methods stated in section 2.5.2, and expressed as -log M concentration. Where ever 
possible, />Kg values were estimated for single stated concentration of antagonist 
according to the methods stated in section 2.5.3. Statistical comparison of the means of 
groups of data were made by Student's unpaired t test; p<O.OS was considered 
statistically significant Throughout, data are expressed as mean+SEM and n In = 
number of ring preparations / number of animals.
9.3 Results
The average internal diameters (pm) and equivalent transmural pressures 
(mmHg) of PRAs from fetal and neonatal rabbits examined in this chapter were as 
follows: fetal- 334.1+12.6 pm / 13.0+0.8 mmHg; 0-24 hr- 323.2+55.4 / 12.2+0.6; 4 day- 
333.9+15.6 / 13.0+0.6; 7 day- 315.8+26.9 / 12.5+0.9 (n= > 15 preparations in each 
case). Thus PRAs from animals at these age points exhibited similar internal diameters 
when set up at the same equivalent internal diameters.
Responses to ET-1 and SXS6c
Both ET receptor agonists, ET-1 and SXS6c, were potent vasoconstrictors of 
rabbit pulmonary resistance arteries at all age points studied. Figures 9.1-9.4 show the 
response to both peptides at the various ages and data for />ECio,/>EC25 and ^ EC^o 
values are summarised in table 9.1. ET-1 evoked a phasic response in fetal and neonatal 
preparations. The first component had a gradual slope up to O.lnM in fetal and 0-24 hr 
vessels and liiM ET-1 in 4 and 7 day old vessels. A markedly steeper component up to
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10-30nM ET-1 was then observed, with a fall in the contraction at higher concentrations. 
In a substantial percentage of the experiments, ET-1 and SXS6 c elicited phasic changes 
in tone of variable amplitude and synchronisation, which persisted at times beyond the 
tonic phase of the response.
Similar sensitivity to ET-1 was noted in the PRAs from fetal, 0-24 hour and 4 
day old rabbits, which in turn, were all significantly more sensitive than vessels from 7 
day old animals. 4 day vessels were markedly more sensitive to ET-1 than 7 day rabbit 
PRAs at all levels, i.e. pEC%o^ /'E C 25 and (table 9.1). The values for the
magnitude of the maximal contractile responses are shown on table 9.2. ET-1 evoked a 
similar maximum response at all age points studied (-93% of KCl response).
Endothelin-1 n/n Sarafotoxin S6 n/n
Fetal 95.3+9 6/6 39.5+13.2 ** 6 /6
0-24 hours 84+14 6/6 97.8+27.7 6 /6
4 days 101.7+16.8 7/6 86.1+8.9 6 /6
7 days 92.7+11.1 6/6 41.3+7.1** 6 /6
Table 9.2 Maximal contractile responses to ET-1 and SXS6c in PRAs from fetal and 
neonatal rabbits. Data are expressed as a percentage of reference contraction to second 
application of 50mM KCl. Statistical comparisons were made by Students' unpaired t- 
test; ET-1 vs. SXS6c at same age point, ** p<0.01. Values are mean ± SEM. ET-1, 
endothelin-1; sarafotoxin S6c, SXS6c; n/n, number of ring preparations / number of 
animals.
SXS6 c also evoked a marked contractile response. According to 77EC50 values, 
the order of potency for SXS6c was 7 days = 4 days > 0-24 hours > fetal (table 9.1). 
Like ET-1, SXS6c also produced a phasic response with an eventual fall in the 
contraction. The concentration at which this drop off of the maximum response occurred 
varied with age, being noted over O.lnM in fetal PRAs and then progressively lower 
concentrations with increasing age. Maximal contractions to SXS6c were similar in 0-24
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Figure 9.1 Responses to ET-1 and SXS6 c In PRAs from fetal rabbits. CCRCs to ET-1 
( 0 , 11=6/6) and SXS6 c (□, n=6/6). A Data are expressed as a percentage own maximum 
contraction. B Data are expressed as a percentage reference contraction to 50mM KCl. 
Each point represents mean ± s.e. mean.
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Figure 9.2 Responses to ET-1 and SXS6 c in PRAs from 0-24 hours old rabbits. CCRCs 
to ET-1 (O, 11=6/6 ) and SXS6 c (□, n=6 /6). A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
50mM KCl. Each point represents mean ± s.e. mean.
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Figure 9.3 Responses to ET-1 and SXS6c in PRAs from 4 day old rabbits. CCRCs to 
ET-1 (O, n=7/6) and SXS6c (□, n-6/6). A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
50mM KCl. Each point represents mean ± s.e. mean.
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Figure 9.4 Responses to ET-1 and SXSôc in PRAs from 7 day old rabbits. CCRCs to 
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hour and 4 day old vessels (-90% of KCl response, table 9.2) and were significantly 
greater than that observed in fetal and 7 day old rabbit PRAs (-40%). The maximum 
contractile response to SXS6c when expressed as a percentage of the response to 0.1 |llM  
ET-1 in the same preparation was similar at all age points, being -  57% (47-62%). In 
summary, the potency of SXS6c increased markedly with developmental age and the 
concentration at which the desensitisation occurred markedly decreased with 
developmental age. This indicates a marked alteration in the ETg- receptor mediated 
response during the first week of life.
ET-1 and SXS6c were equipotent in the fetal PRAs (figure 9.1 A) however the 
magnitude of the SXS6c maximum response was markedly smaller (figure 9. IB, table 
9.2). In comparison, SXS6c was significantly more potent than ET-1 at 0-24 hours 
following birth (figure 9.2A) and this greater potency was even more pronounced at 4 
(figure 9.3A) and 7 days old (figure 9.4A). The magnitude of the SXS6c maximum 
response was similar to that noted to ET-1 in the 0-24 hour (figure 9.2B) and 4 day old 
preparation (figure 9.3B) but as was seen in the fetus, was significantly smaller than the 
ET-1 maximum by 7 days following birth (figure 9.4B; table 9.2).
Effect of antagonists on ET receptor mediated responses
FR139317VS.ET-1
pEC25 and ji^ECso values for ET-1 in the presence and absence of FR139317 are 
summarised in table 9.3. Figures 9.5-9.9 illustrate the effect of this antagonist on ET-1- 
induced responses at the different age points. The selective E T a receptor antagonist 
FR139317 failed to inhibit the ET-1-induced vasoconstriction in fetal PRAs (figure 
9.5A). In comparison, ET-1 responses in PRAs from 0-24 hour (figure 9.6A) and 4 day 
old (figure 9.7A) rabbits were significantly inhibited by this antagonist. The estimated 
/»K|) was 6.41+0.16 for 0-24 hour PRAs but this value andpHC values could not be 
calculated for 4 day results since the responses in the presence of the antagonist did not
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Figure 9.5 Responses to ET-1 in fetal rabbit PRAs: effect of selective antagonists. 
CCRCs to ET-1 (O, n-6/6), in the presence of IpM FR139317 (#  n=6/6) and in the 
presence of l|_iM BQ788 (■, n=6/6). A Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
50mM KCl. Each point represents mean ± s.e. mean.
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Figure 9.6 Responses to ET-1 in 0-24 hr old rabbit PRAs; effect of selective antagonists. 
CCRCs to ET-1 (O, 11=6 /6 ), in the presence of l^iM FR139317 (# , n=6 /6 ), l|aM 
BQ788 (■, n=6 /6), 0.1 pM SB209670 (□, n=5/5), and IpM SB209670 (A, n=4/4). A 
Data are expressed as a percentage own maximum contraction. B Data are expressed as 
a percentage reference contraction to 50mM KCl.
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Figure 9.7 Responses to ET-1 in 4 day old rabbit PRAs: effect of selective antagonists. 
CCRCs to ET-1 (O, n=6/6), in the presence of lf.iM FR139317 (# , n=6/6), l|uM 
BQ788 (■, n=6/6), 0.1 ^ iM SB209670 (□, n=6/6), and l|uM SB209670 (A , n=5/5). A 
Data are expressed as a percentage own maximum contraction. B Data are expressed as 
a percentage reference contraction to 50mM KCl. Each point represents mean+SEM.
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Figure 9.8 Responses to ET-1 in 7 day old rabbit PRAs: effect of selective antagonists. 
CCRCs to ET-1 (O, n=6/6), in the presence of 1|liM  FR139317 (#  n~6/6) and in the 
presence of 1|llM  BQ788 (■, n=7/7). A  Data are expressed as a percentage own 
maximum contraction. B Data are expressed as a percentage reference contraction to 
50mM KCl. Each point represents mean ± s.e. mean.
298
reach a maximum. In 7 day old rabbit PRAs, inhibition was not evident at the level of 
/?EC values which were calculated. However as can be seen from figure 9.8A, 
FR139317 caused a shift in the steep component of the ET-1- induced CCRC, which 
occurred at concentrations above 3nM, with an estimated pRg value of 6.76+0.2. This is 
further illustrated by the reduction in the response to 30nM ET-1 from 92.7+11.1% to 
52.8+21.8%.
Furthermore, FR139317 produced a marked reduction in the maximum ET-1 
response of the fetal PRAs (control 95.3+9.0 vs. 47.4+9.9, f<0.01). The magnitude of 
the maximal contraction to ET-1 was not significantly altered in PRAs from 0-24 hr and 
7 day old rabbits. In the presence of FRI39317, the ET-1 response in 4 day old 
preparations did not reach a maximum within the concentration range of peptide studied.
B0788VS. ET-1
Figures 9.5-9.8 show the effect of IpM  BQ788 on ET-1- induced 
vasoconstriction. />EC25 and j^ECgo values and maximal contractile responses for ET-1 
in the presence and absence of BQ788 are illustrated in tables 9.3 and 9.4, respectively. 
This selective ETg receptor antagonist significantly inhibited ET-1 responses in PRAs 
from fetal, 0-24 hour and 4 day old rabbits (figure 9.5A, 9.6A, 9.7A; table 9.3). A 
significant increase in7?ECio value was also noted in the vessels from 0-24 hr (P<0,01) 
and 4 day old rabbits (F<0.05). The estimated ^ Kb value was 6.71+0.13 for 0-24 hour 
rabbit PRAs ant this was significantly greater than the value of 6.23+0.08 calculated for 
4 day old PRAs (P<0.05). A value for /?Kb and pEC values could not be calculated for 
fetal vessel responses since a maximum was not reached within the ET-1 concentration 
range studied. However the rightward shift in the response in fetal PRAs was 
demonstrated further by the significant decrease in the magnitude of the control 
maximum contraction, attained at lOnM ET-1, from 95.3+9.0% to 44.9+14.4% in the 
presence of BQ788 (P<0.05; figure 9.5B). BQ788 failed to inhibit ET-1 CCRCs of 7 day 
old rabbit PRAs and did not significantly alter the maximum contractile response (figure
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9.8; table 9.3, 9.4). In comparison, this selective ETb receptor produced marked increase 
(-70%) in the magnitude of the maximum contraction 0-24 hr and 4 day preparations 
(figure 9.6B, 9.7B; table 9.4).
ET-1 n/n ET-1+ lnMBQ788 n/n
0-24 hours 84.0+14.0 6/6 169.6+17.7 6/6
4 days 101.7+16.8 7/6 163.9+13.4* 6/6
7 days 92.7+11.1 6/6 115.4+19.9 7/7
Table 9.4 Maximal responses to ET-I in the presence and absence of BQ788 in PRAs 
from neonatal rabbits. Data are expressed as a percentage of reference contraction to 
second application of 50mM KCl. Statistical comparisons were made by Students' 
unpaired t- test: ET-1 vs. ET-1+ BQ at same age point; * P<0.05,** E<0.01. Values are 
mean ± SEM. ET-1, endothelin-1; n/n, number of ring preparations / number of animals.
B0788 vs. SXS6C
Figures 9.9-9.12 show the effect of IpM BQ788 on SXS6c induced 
vasoconstrictions. pECis and y^EC^o values for SXS6c in the presence and absence of 
BQ788, which could be calculated, are illustrated in table 9.5. BQ788 produced a 
dramatic rightward shift in the SXS6c- induced responses at all age points studied. 
Inhibition was most pronounced in the neonate PRA response. BQ788 abolished 
responses to lower SXS6c concentrations; the threshold concentration was shifted from 
IpM to lOnM in 0-24 hr vessels (figure 9.10A) and -InM  in 4 day old rabbit PRAs 
(figure 9.11 A). This was further illustrated by the significant decrease in the pEC\Q 
value in 4 day PRA SXS6c response (P<0.01). The maximum SXS6c- induced 
vasoconstriction in 4 day rabbit PRAs was not altered in the presence of BQ788 (figure 
9.1 IB). SXS6c plus BQ788 response failed to reach a maximum within the 
concentration range examined in vessels from fetal (figure 9.9B), 0-24 hr (figure 9.10B)
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Figure 9.9 Responses to SXS6c in PRAs from fetal rabbits; effect of BQ788 CCRCs to 
SXS6c (□, n=6/6) and in the presence of IpM BQ788 (■, n=7/7). A Data are expressed 
as a percentage own maximum contraction. B Data are expressed as a percentage 
reference contraction to 50mM KCl. Each point represents mean ± s.e. mean.
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Figure 9.10 Responses to SXS6c in 0-24 hr old rabbit PRAs; effect of selective 
antagonists. CCRCs to SXS6c (□, n=6/6), in the presence of l|uM BQ788 (■, n=5/5), 
G.ljLiM SB209670 (#  n=3/3), and l|uM SB209670 (A, n=2/2). A Data are expressed as a 
percentage own maximum contraction. B Data are expressed as a percentage reference 
contraction to 50mM KCl. Each point represents mean ± s.e.m.
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Figure 9.11 Responses to SXS6c in 4 day old rabbit PRAs: effect of selective 
antagonists. CCRCs to SXS6c (□, n=6/6), in the presence of lp,M BQ788 (■, n=8/7), 
0.1 tiM SB209670 (#  n=5/5), and IpM SB209670 (A, n=4/4). A Data are expressed as a 
percentage own maximum contraction. B Data are expressed as a percentage reference 
contraction to 50mM KCl. Each point represents mean ± s.e.m.
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and 7 day animals (figure 9.12B), thus preventing calculation of pK ^  and pEC values. 
An estimated/?Kb value of 8.7+0.12 was calculated for PRAs from 4 day old rabbits.
SR2Q9670 vs. ET-1
The effect 0.1 and IfiM SB209670 on ET-1-induced responses in 0-24 hour and 
4 day old rabbit PRAs are shown in figures 9.6 and 9.7, respectively. /»BC25 andpECso 
values which could be calculated are summarised in table 9.3. SB209670 caused a very 
significant inhibition of the entire ET-1 CCRC in PRAs from 0-24 hr and 4 day old 
rabbits. This inhibition was concentration dependent; 0.1|llM SB209670 produced an ~ 
11 fold shift in the ET-1 j^EC^o and a greater shift was apparent in the presence of l^iM 
antagonist. Threshold ET-1 concentration evoking vasoconstriction was shifted from 
lOpM to 0.3-lnM by 0.1 piM SB209670 and to l-30nM by IpM SB209670 (figures 9.6A 
and 9.7A). This pronounced inhibition was further demonstrated by the marked shift in 
the response at the level of the /lECjo value; ET-1 control vs. ET-1 + 0. l|iM  SB209670, 
P<0.01. The maximal contractile response to ET-1 was not altered by 0.1 pM SB209670 
in 0-24 hr or 4 day rabbit vessels. ET-1 response failed to attain a maximum in the 
presence of IpM SB209670 at both neonatal ages (figures 9.6B and 9.7B), thus 
estimations of pEC  and />Kb values unfortunately could not be made. However 
calculated pKB values for 0.1 pM SB 209670 against ET-1 responses in 0-24 hour and 4 
day rabbit PRAs were 8.3+0.1 and 8.0+0.1, respectively.
SR209670 vs. SXS6c
Figure 9.11 shows the effect 0.1 and IpM SB209670 on SXS6c-induced 
responses in 4 day old rabbit PRAs and />EC25 and ^ EC^o values are summarised in 
table 9.5. Preliminary data for PRAs from newborn rabbits are also shown in figures 
9.10. Contractile responses to SXS6c were almost completely abolished by SB209670 in 
PRAs from 4 day old rabbits The threshold concentration evoking vasoconstriction was
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shifted from IpM to InM SXS6c by 0.1 pM SB209670 and to lOnM SXS6c in the 
presence of IpM antagonist (figure 9.11A; control ET-1 />ECio vs. ET-1+ 0.1 pM 
SB209670 /?ECio, P<0.001). An even greater inhibition was noted in SXS6c- evoked 
responses compared to ET-1- induced vasoconstrictions. 0.1 pM SB209670 caused an 
-30 fold shift in the SXS6c and an even greater shift was seen in the presence of
IpM SB209670 (figure 9.11 A). The maximal contractile response was not reached 
within the peptide concentration range studied when IpM SB209670 was present, thus 
agonist potencies in the presence of this antagonist could not be estimated. The 
maximum vasoconstriction was not significantly altered from control SXS6c maximum 
by 0.1 pM SB209670./>Kb values for 0.1 pM SB209670 against SXS6c of 9.2+0.1 and 
10.2+0.2 were calculated for 0-24 hr and 4 day PRAs, respectively. Preliminary data 
indicates a similar degree of inhibition of SXS6c-induced response in PRAs from 0-24 
hr rabbits (figure 9.10, table 9.5).
9.4 Discussion
The results of this chapter demonstrate a marked alteration in ET- receptor 
mediated vasoconstriction in rabbit PRAs between fetal life and birth and during the first 
week of neonatal life. In parallel with the changes in functional responses to ET-1 and 
SXS6c at different developmental ages, variations in the effectiveness of selective 
antagonists were also exhibited. In particular, a hypersensitivity to ETB-receptor 
mediated vasoconstriction is evident within 0-24 hours following birth.
ET-1 and SXS6c were potent vasoconstrictors. Both these peptides contracted all 
vessels in a concentration- dependent manner and a phasic response was elicited at all 
age points studied. The phasic nature of the cumulative response to ET-1 in fetal rabbit 
PRAs is similar to that previously described in isolated small PRAs (-169p,m i.d.) from 
fetal sheep (Wang & Coceani, 1992). This may suggest the involvement of different ET- 
receptor subtypes or indeed may indicate receptor desensitisation. The potency of these 
peptides varied with developmental age. ET-1 was least potent in PRAs from 7 day old
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rabbits whereas sensitivity to SXS6c progressively increased in PRAs from fetal to 7 
day old rabbits. In chapter 4, I studied the effect of ET-1 and SXS6c in adult rabbit 
PRAs and this provided jgEC^o values o f -7.9 for ET-1 and -8.6 for SXS6c. Hence 
PRAs from 7 day neonatal and adult rabbits are similar in sensitivity to ET-1, whereas 
sensitivity to SXS6c in the 7 day old rabbit is markedly greater than that observed in the 
adult rabbit PRAs. It therefore appears that sensitivity to ET-1 decreases over the first 
week of life and is increased compared to that observed in the adult. An attenuation of 
the sensitivity to SXS6c from -11.1 at 7 days to that existing in adult vessels, -8.6, must 
occur at a later age. Measurements of plasma ET-1 in newborn infants demonstrated that 
high levels exist on day one postpartum but by day 4 and 5 of life these levels have 
decreased (MalamitsiPuchner, et al  ^ 1993; Endo, et al, 1996). Similar alterations in 
plasma levels have also been demonstrated in various animals, such as the newborn pig 
(Levy, et al, 1995; Noguchi, et al, 1997). Hence the hypersensitivity to ETg receptor 
stimulation indicated by the results of this chapter appears to exist at a time when 
plasma ET-1 levels have been shown to be elevated. This increased sensitivity may also 
be due to a comparatively greater number of ET receptors present on the pulmonary 
vasculature in the newborn compared to adult lung as Hi slop et al (1995) have 
demonstrated a reduction in [H25]et~1 binding in isolated porcine pulmonaiy arteries 
between birth and adulthood. Giaid et al (1991) reported that immunoreactivity for ET-1 
was substantially decreased in adult human lung compared with the developing fetal 
lung.
ET-1 and SXS6c were equipotent in their ability to evoke vasoconstrictions in 
fetal rabbit PRAs. ET-1 has also been demonstrated as a potent vasoconstrictor in 
isolated small pulmonary arteries and veins from term fetal lambs (Wang & Coceani, 
1992). Also, in a previous in vivo study, Ivy et al (1994) showed that big ET-1 induced 
a rise in total pulmonary resistance of chronically prepared late gestation fetal lambs. 
The lung synthetic system for ET-1 has been reported to develop early in gestation, is 
found in several cell constituents including the endothelium, and is more active in the 
fetus than in the adult (Hemsen, et al, 1990; Giaid, et al, 1991). Furthermore, formation
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of this peptide is accelerated by hypoxia, at least in the adult (Shirakami et al, 1991). 
These previous reports coupled with the results in this chapter, showing ET-1 to be a 
potent vasoconstrictor of fetal PRAs, are in accord with the possibility of this peptide 
contributing directly to the elevated vascular tone of the fetus. However, this concept is 
in apparent contrast with other studies in vivo and the perfused organ in vitro, in which 
ET-1 was shown to be primarily a dilator of the perinatal circulation. In unventilated 
fetal lungs of the sheep, injection of ET-1 into the pulmonaiy artery was shown to dilate 
both large and small pulmonary arteries with no effect on pulmonary veins (Todd & 
Cassin, 1992). Other previous in vivo studies have also demonstrated that the action of 
ET-1 is influenced by the perinatal age and thus, the tone of the vasculature. In 1 day old 
piglet lungs, injection of ET-1 caused vasodilation of the pulmonary arteries, and by 7 
days old, the dilatation was transitory and followed by vasoconstriction (Perreault & 
DeMarte, 1993). In fetal sheep, infusion of ET-1 decreases the PVR, but after the onset 
of ventilation, the vasodilator response decreases and infusions of high concentrations of 
ET-1 cause vasoconstriction (Cassin, et al, 1992). ET-1 did not change pulmonary 
artery pressure in lambs (<1 week old) but markedly increased pulmonary artery 
pressure in 6-12 months old sheep (Wong, et al, 1994b).
Theoretically, several possibilities could explain the apparent inconsistencies in 
findings. The contractile tone in vitro may be inadequate for expression of receptors 
mediating vasodilation (Cassin, et al, 1992). In this chapter I did not examine the effect 
of level of intrinsic tone per se on ET-1-evoked responses. However, ET-1 and SXS6c 
evoked potent contractile response at all developmental age points studied. Furthermore, 
in isolated small PRAs from the fetal lamb lung, even on preconstricting vessels no 
vasodilator response was unmasked and only further contractions were noted (Wang & 
Coceani, 1992). Alternatively, the target for ET-1 vasodilation could be confined to a 
segment of the pulmonary vasculature which is excluded in this isolated in vitro 
preparation. Nevertheless, vessels of the order of magnitude examined in this study 
contribute significantly to the PVR in vivo (Staub, 1985) and have also been shown to be 
the major site of resistance to blood flow in isolated perfused fetal lamb lung (Todd &
309
Cassin, 1992). Hence these vessels would be expected to also function as a target for any 
vasodilator agent. Yet another possibility is that these isolated vessels lack a viable 
endothelium and thus would be unable to produce dilator agents, such as NO and PGI2, 
in response to ET-1 (De Nucci, et al, 1988). However, considering the results of chapter 
8 in this thesis, this explanation seems unlikely as isolated PRAs, from animals at the 
same developmental ages and dissected from the same anatomical location, were shown 
to vasodilate in response to the endothelium-dependent agent ACh and indeed, L~ 
NAME was shown to enhance ET-receptor mediated responses. The most plausible 
explanation is the idea that ET-1 exerts a vasodilator effect in the intact organ both 
directly and through the release of vasoactive agent(s) from the parenchyma. Under 
appropriate conditions, any such agent could override the direct constrictor effect of ET- 
1 on the vasculature. Considering that ET-1 is viewed as a local mediator, being formed 
and acting within the vessel wall (see introduction, chapter 1), then the results of in vitro 
studies, such as those described in this chapter, may provide a better reflection of the 
situation in vivo.
ET-1 caused similar maximal responses at all age points studied (-94% response 
to KCl) but the magnitude of the maximum contractile response to SXS6c was 
significantly greater at 0-24 hours and 4 days (-92%) compared to fetal and 7 days 
(-40%) after birth. These functional differences are most probably not related to 
alterations in the muscularisation of the arteries with postnatal age as previous studies 
show that the rapid decreases in pulmonary pressure, which occurs following birth, to be 
accompanied by a rapid decrease in degree of muscularisation of pulmonary vessels. 
Michel et al, (1991) reported a reduction in percentage muscle thickness and peripheral 
muscularization between <4 days and >2 weeks old in lungs from lambs. In newborn 
piglet lungs a rapid decrease in arterial medial wall thickness to one-half fetal level by 1 
day of age with a further decrease by 3 days of age, with adult wall thickness being 
reached by 7 days old was reported (Haworth & Hislop, 1982). A more likely 
explanation for the variation in the maximal contractile responses to SXS6c shown in 
this chapter is an alteration in ETb receptor between 0-24 hrs and 4 days after birth.
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Hypersensitivity to ETb receptor stimulation following birth was indicated by 
the notably greater potency of SXS6c compared to ET-1 in neonatal PRAs: vessels were 
approximately 10, 20 and 30 times more sensitive to SXS6c compared to ET-1 in 0-24 
hour, 4 day and 7 day old preparations, respectively. These results are indicative of a 
predominant role of vasoconstrictor ETb receptors during the first week of life. Other 
investigators have shown the predominance of this receptor in the larger pulmonary 
artery of the adult rabbit (La Douceur, et al, 1993; Fukuroda, et a l, 1994a; Hay, et al,
1996). Furthermore, results of chapter 4 in this thesis also indicate this to be case in 
adult rabbit small PRAs.
Further evidence for the importance of ETb receptor was provided by the 
observed effects of the selective antagonists. At all age points studied SXS6c- induced 
vasoconstrictions were significantly inhibited by the selective ETb receptor antagonist 
BQ788, thus indicating that this peptide is indeed evoking its responses via the 
activation of ETb receptors. BQ788 had an estimated /»Kb value o f -8.7 against SXS6c 
in the 4 day old rabbit PRAs. However in adult rabbit PRAs, I calculated a/>Kb value of
6.8 for BQ788 vs. SXS6c (chapter 5, this thesis). Hay and co-workers (1996) also 
showed thatBQ788 has a/?Kb value of 6.2 against SXS6c responses in larger rabbit PA. 
Hence this antagonist appears to be extremely potent against SXS6c-induced 
vasoconstrictions in neonatal PRAs. ETb receptors also appear to be involved in ET-1- 
induced vasoconstrictions up to 4 days of age as BQ788 inhibited ET-1-evoked 
responses. The estimated^Kb was significantly greater in 0-24 hr (-6.7) compared with 
4 day old rabbit PRAs (-6.2). This suggests that BQ788 is more potent against ET-1- 
evoked vasoconstrictions 0-24 hrs after birth and provides further evidence for 
hypersensitivity to ETb receptor stimulation at this time. On the other hand, this may 
also reflect structural change in the receptor which could occur with the structural 
alterations in the pulmonary vasculature following birth. Haworth and Hislop (1981) 
reported a progressive loss in pulmonary arterial smooth muscle in the neonatal pig and, 
in the adult and developing bovine pulmonary arterial media, F rid et al (1994) identified 
phenotypic alterations of distinct smooth muscle cell populations with development.
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BQ788 had no significant effect on the magnitude of the maximum responses to 
SXS6c at 4 days. In comparison a significant augmentation in the ET-1 maximum 
contraction was noted; this being most dramatic in newborn rabbit vessels. BQ788 had 
no effect on maximal contractile responses to ET-1 in PRAs from 7 day old rabbits and I 
also showed a similar lack of effect in response of PRAs from adult rabbits (chapter 5 
this thesis). However a marked augmentation of -70 % was evident 0-24 hrs and 4 days 
after birth. The reason for this is unknown but may possibly be due to the blockade of 
ET clearance receptors which have been suggested to be ETb in nature. The ETb 
selective antagonist BQ788 was shown to reduce the uptake of radiolabeled ET by 75% 
in the rat lung (Fukuroda, et al, 1994b). The significant increase in the magnitude of the 
response may also be due to BQ788 inhibition of endothelial ETb receptors mediating 
vasorelaxations in PRAs at 0-24 hours and 4 days after birth.. Moreover, as the 7 day 
PRA SXS6c maximum response was not altered by BQ788, this may indicate that these 
receptors may decrease or disappear by this age. I did not examine these perinatal rabbit 
vessels for the ET-receptor mediated vasodilations however, as previously discussed, 
numerous studies in other species indicate a role for this ETb receptor subtype in the 
perinatal pulmonary vasculature. Furthermore, in keeping with this latter postulate, 
Perreault and DeMarte (1993) demonstrated that ET-1 induced response altered from a 
pulmonary vasodilator response in 1 day old piglets to a vasoconstrictor response by 7 
days of life.
Despite the apparent predominance of contractile ETb receptors, BQ788 failed to 
inhibit ET-1 evoked responses in the 7 day old rabbit vessels. I also showed that ET-1- 
induced vasoconstrictions of adult rabbit PRAs were resistant to BQ788 (chapter 5 this 
thesis). Hay et al (1996) have also reported this phenomenon in the larger rabbit 
pulmonary artery. These authors concluded that the ETb receptors in the rabbit large 
pulmonary arteries are insensitive to BQ788. It would appear, therefore, that on the basis 
of both agonist and antagonist interactions, that the ETb receptor in the large pulmonaiy 
artery of adult rabbits and small pulmonary resistance arteries of 7 day old and adult 
rabbits are pharmacologically similar in terms of insensitivity to BQ788.
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Evidence for a significant role of ET A receptors was provided by the inhibitory 
effect of FR139317 on ET-1 -induced vasoconstriction of PRAs from 0-24 hour and 4 
day old rabbits. A/?Kb o f -6.4 was estimated for the newborn ET-1 responses. This is 
similar to values obtained for FR139317 in typical ET A receptor preparations, e.g. 
guinea-pig pulmonary artery,/;A2 6.65 (Cardell, et a l, 1993). FR139317 did not 
significantly inhibit the fetal and 7 day rabbit PRA responses however a rightward shift 
was apparent at the higher ET-1 concentrations. Furthermore, the presence of FR139317 
caused a significant reduction in ET-1 maximum vasoconstrictions in fetal vessels. This 
is indicative of ET-1 acting via ET a  receptors at high concentrations but at another 
receptor at low concentrations. A similar effect of ETa receptor blockade has been 
observed in human PRAs and larger rabbit PAs where ETa ETb receptors coexist 
(McCulloch, et al, 1996; LaDouceur et al, 1993). Vasoconstriction to ET-1 may follow 
binding to ETa as well as ETb receptors in newborn piglets also (Perreault & Baiibeau, 
1995). Hislop et al (1995) demonstrated, using an in vitro autoradiographic technique, 
the presence of both ETa and ETb receptor subtypes in medial smooth muscle cells in 
pig lungs from birth to adulthood. However, the majority of binding sites in the 
pulmonary arteries were shown to be ETa in nature.
Infusion of the ETa- selective antagonist BQ 123 increased PBF and decreased 
PVR in fetal sheep in utero and in the ovine fetal pulmonary circulation, indicating a 
role of ETa receptor activation in maintaining basal fetal vascular tone (Wong, et al, 
1994a; Ivy, et al, 1994). Also in these previous studies, where agonists were 
administered by intrapulmonary arterial injections, specific ETb receptor activation 
produced a marked pulmonary vasodilation. However our results showed SXS6c as 
being a potent vasoconstrictor in fetal rabbit PRAs. Furthermore ET-1-evoked responses 
were significantly inhibited by the presence of BQ788. These results indicate the 
predominance of ETb receptors which are contractile in nature in the fetal rabbit. 
However as previously stated I did not examine these vessels for ET-receptor mediated 
relaxatory responses. The contrast in findings compared with these previous studies may 
be due to differences in species or with experimental technique, i.e. intact lungs in utero
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with intrapulmonary arterial injections, where parenchymal influences are possible, 
compared with isolated PRAs. This is discussed earlier in this chapter.
The involvement of both ET a and ETg receptors in ET-1-induced 
vasoconstrictions was demonstrated further by the near abolition of the responses in the 
presence of the non-selective ETa/ETb receptor antagonist SB209670 in PRAs from 0- 
24 hour and 4 day old rabbits. A greater inhibition was noted in the presence of this dual 
antagonist compared to either FR139317 or BQ788 alone at the same concentration. For 
example, (IqM) FR139317 and BQ788 resulted in a 6 and 8 fold increase respectively, 
in the ET-1 />EC50 in 0-24 hour old rabbit PRAs, whereas (0.1 pM) SB209670 caused a 
significantly greater 13 fold shift. Synergy between ETa ^nd ETb receptors has been 
reported in the larger rabbit pulmonary artery and human bronchi where administration 
of both an ETa and ETb receptor antagonist is required to inhibit responses to ET-1 
(Fukuroda, et al, 1994c; 1996). My results in chapter 5 showed that in adult rabbit 
PRAs, SB209670 only antagonises ET-1 induced vasoconstrictions at the higher 
concentration range; this further indicates an alteration in the distribution of ET receptor 
subtypes with developmental age. Furthermore, SB209670 was even more potent at 
inhibiting SXS6c- evoked responses compared with ET-1- induced responses in 
neonatal PRAs. This greater potency as an ETb receptor antagonist when SXS6c is the 
agonist rather than ET-1 has also been reported in large pulmonaiy arteiy of the adult 
rabbit (Ohlstein, et al, 1994a). Indeed, the results of chapter 5 in this thesis also suggest 
this to be the case also in small PRAs from adult rabbits.
Neither FR139317 or BQ788 were able to inhibit ET-1-induced responses in 
PRAs from 7 day old rabbits. I also observed this in adult rabbit PRAs (chapter 5 in this 
thesis). Other investigators have also found the necessity to block both ETa and ETb 
receptors in larger rabbit PA (LaDouceur,c/ al, 1993; Fukuroda, et al, 1994c) and human 
bronchi (Fukuroda, et al, 1996) in order to antagonise responses to ET-1 fully. In 
comparison, ET-1 induced vasoconstriction was effectively antagonised by inhibition of 
ETb receptors alone in the fetal to 4 day old rabbit PRAs and by blockade of ETa 
receptors alone in 0-24 hours to 4 day old rabbits. Thus in the newborn, it appears only
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necessary to block either receptor subtype in order to inhibit ET-1 mediated responses 
whereas with increasing age, dual blockade is necessary. Therefore it may be that 
interaction or synergy between ET receptors develops in this preparation. In addition, 
the finding that FR139317 is effective against ET-1-induced responses in PRAs from 0- 
24 hour and 4 day old rabbits but not against those of 7 day and adult rabbit PRAs may 
indicate that as the influence of ETg receptors increases, that of the ET A receptors 
decreases.
The role of ET in the pathogenesis of PPHN is uncertain, but the circulating level 
of ET, which is normally high at birth, remains elevated in this condition (Rosenberg, et 
al, 1993). This has also been demonstrated in animal models of PPHN. In piglets 
exposed to hypoxia from birth, plasma ET-1 was significantly greater than normal for 
age (Noguchi, et al, 1997). In examining the possible role of ET-1 in PPHN, in addition 
to circulating ET-1 levels, it would appear that the balance of ET-receptor subtypes in 
the pulmonary vasculature would also determine the overall functional response to ET- 
1, thus affecting pulmonary vascular resistance. For example, a reduction or lack of 
endothelial ETg receptors mediating vasodilation would presumably heighten responses 
to endogenous ET-1. This latter possibility is demonstrated by previous studies. In the 
newborn piglet lung a transient postnatal increase in endothelial ETb receptor binding is 
evident at 3 days of age (Hislop, et al, 1995). However, these receptors are not evident 
in newborn piglets when pulmonaiy hypertension had been induced by prolonged 
exposure to hypoxia (Noguchi, et al, 1997). Ivy et al (1996) reported that chronic 
intrauterine pulmonary hypertension, induced by partial ligation of ductus arteriosus in 
late gestation fetal lambs, altered ET receptor activity in the ovine fetal lung. In 
particular, this caused a loss of ETb receptor-mediated vasodilation, as indicated by the 
abolition of ET-3-induced increase in PBF. The lungs of rats made pulmonary 
hypertensive by monocrotaline injection showed a reduction in ETb receptor mRNA 
(Miyauchi, et al., 1993). The results of this chapter can not rule out the existence of 
endothelial ETb receptors mediating vasodilation in normal rabbit fetal and newborn 
PRAs. Their possible existence may be masked by the apparent predominance of
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contractile ETb receptors. Indeed, as previously discussed, the presence of BQ788 
caused a marked increase in the maximum contractile response to ET-1 at 0-24 hrs and 4 
days of age and this antagonist also inhibits the endothelial ETb receptor which 
mediates endothelium-dependent relaxation (Douglas, eta l, 1995). Hence a reduction in 
ETb vasodilator receptors might impair the vasodilation directly by reducing the release 
of endothelial derived NO or indirectly by reducing the clearance of ET from the 
circulation (Fukuroda, et al, 1994b). A lack of endothelial ETb receptors in pulmonary 
vasculature in condition of PPHN may therefore contribute to the abnormal maintenance 
of a high pulmonary arterial pressure after birth.
A similar effect would be expected if an increase in relative number of functional 
contractile ETa or ETb receptors was to exist in this condition, as this would heighten 
responses to endogenous ET-1. In the newborn sheep, PHT and increased pulmonary 
blood flow altered the response of ET-1 from pulmonary vasodilation to 
vasoconstriction (Wong, et al, 1995b). Also shown in this study was a lack of effect of 
the ETb receptor agonist 4-Ala ET-1 whereas the selective ETa receptor antagonist 
BQ123 significantly reduced PVR. In a fetal lamb model of intrauterine pulmonary 
hypertension, the response to ET-1 infusion was altered to a predominantly 
vasoconstrictive response. Also, the vasodilator response to BQ123, the ETa receptor 
selective antagonist, was greater following a longer period of ductus arteriosus ligation 
and thus greater pulmonary hypertension (Ivy, et a l, 1996). This suggests a progressive 
ETa receptor-mediated vasoconstriction in this model. More recently these investigators 
demonstrated in this fetal lamb PHT model, that chronic intrauterine ETa receptor 
blockade with BQ123 decreased pulmonary artery pressure in utero, decreased right 
ventricular hypertrophy and distal muscularisation of small pulmonaiy arteries, and 
increased the fall in pulmonaiy vascular resistance at birth (Ivy, et a l, 1997). Hence 
these previous studies indicate an involvement of ETa receptors in the vasoconstrictor 
response, as does the inhibitory effect of FR139317 in PRAs from 0-24 hr and 4 day old 
rabbits which is demonstrated in this chapter.
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In conclusion, the results of this study indicate a rapid alteration in ETb receptor 
mediated contraction in rabbit PRAs during the first week of life. There is a significant 
population of ETb receptors mediating vasoconstriction which coexist alongside ETa 
receptors in fetal and neonatal rabbit PRAs. The contribution of these receptor subtypes 
to the overall ET -induced responses varies with developmental age and a marked 
hypersensitivity to ETb receptor stimulation is apparent in newborn rabbit PRAs. Hence 
alterations in the ETb receptor subtypes present on the vasculature may alter the 
haemodynamic effects of ET-1 in the pulmonary circulation and contribute to it's 
potential roles in (1) maintenance of elevated pulmonary vascular tone in utero, and/or 
(2) control of PVR as the pulmonary circulation adapts to extra-uterine life and/ or (3) 
the pathophysiological state of PPHN.
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Chapter 10 
General Discussion
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10. General Discussion
I have extensively discussed the results of all studies in the relevant chapters. In 
this final chapter, I would like to draw on these findings, discuss them with respect to 
one another, speculate on the significance of the combined results and propose future 
studies. I examined the vascular reactivity of rabbit pulmonary resistance arteries under 
two different transitional states, from fetal to neonatal life and secondary to left 
ventricular dysfunction (LVD). This enabled me to look at changes induced by both 
active (oxygen) and passive (left atrial pressure) influences. Several features are 
common to both situations, including structural and functional alterations and in 
particular, the involvement of the endothelial-derived factors ET-1 and nitric oxide 
(NO).
Before discussing the vascular reactivity of isolated PRAs from the rabbit 
coronary ligation model of left ventricular dysfunction, I attempted to characterise 
particular parameters in this model which are related to the condition of pulmonary 
hypertension (PHT). As discussed in chapter 3, following coronaiy arteiy ligation, 
rabbits exhibited left ventricular hypertrophy, right ventricular hypertrophy, 
augmentation in lung weight and pulmonary vascular remodelling. Previous in vivo 
studies in this model have demonstrated a 44% increase in pulmonary artery pressure in 
8 week coronary-ligated rabbits compared to sham-operated controls (D eu char, et a l,
1997). My own findings, together with these in vivo studies, demonstrate the existence 
of pulmonary hypertension (PHT) secondary to LVD in this model. The possibility that 
heart failure may be the commonest cause of PHT is often overlooked. Heart failure 
following various forms of LVD affects 1-2% of the entire population and associated 
PHT is common (Trell, 1973; Rabinovitch, et al, 1978). Thus the rabbit coronary 
ligation model may act as an ideal model to examine pulmonaiy vascular changes 
occurring in this condition.
It has been proposed that the potent peptide ET-1 plays an important role in 
various pathological conditions including heart disease and PHT, of various aetiologies.
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In addition, there is currently much interest in the development of ET receptor 
antagonists for the treatment of LVD-related conditions. In light of this, I focused the 
functional studies on ET-receptor mediated responses in PRAs. The main findings, 
discussed primarily in chapters 4 and 5, demonstrate the role of contractile ETg^-like 
receptors in mediating vasoconstriction in adult rabbit PRAs. This is consistent with 
previous findings in rabbit isolated larger pulmonary arteries (e.g. Warner, et al, 1993; 
La Douceur, et a l,  1993; Hay, et a l, 1996) and binding studies of membrane 
preparations of rabbit pulmonary arteries (Fukuroda, et a l, 1994b). On comparing 
responses from preparations from 8, 16 and 32 week procedure animals, it was apparent 
that ET-receptor mediated responses were altered by the duration of coronary artery 
ligation. In PRAs from 8 week coronary-ligated rabbits, no change was observed in ET- 
1 or SXS6c responses, whereas sensitivity to both these peptides (at physiological and 
pathophysiological concentration ranges) was significantly reduced in vessels from 16 
week LVD animals. Also, a marked attenuation in the maximal vasoconstrictor response 
to SXS6c was noted in PRAs from the 16 week LVD group compared to age-matched 
stock and sham-operated preparations. In PRAs from 8 week LVD animals, the 
magnitude of ET-3-mediated vasoconstriction was significantly reduced compared to 
sham-operated rabbit PRAs. Whilst in PRAs from 32 week ligated rabbits, no change in 
ET-1 responses but augmented sensitivity to SXS6c was noted. As these alterations 
occurred between IpM-lnM, this suggests that ET-1 may be important in in vivo 
conditions, as in certain pathologies when plasma ET-1 levels equivalent to these 
concentrations have been observed (Cody, et a l, 1992; Kiowski, et a l, 1995). It should 
be noted that in cohorts of animals used for some of the studies, the ejection fraction of 
the 16 week ligated rabbits was markedly lower that of 8 week ligated animals, however 
a progression of this attenuation was not extended to the 32 week LVD animals. Hence 
the rabbits ligated for a longer duration do not appear to represent a more severe form of 
LVD but rather are the "survivors" from this group; this is probably on the basis that 
LVD was not as severe in the first instance. The findings in the 8 and 16 week 
experimental groups may indicate a reduced contribution of constrictor ETg receptors or
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greater involvement of endothelial ETb receptors, mediating vasodilation. In the studies 
of chapter 4 I was unable to demonstrate ET-receptor mediated vasorelaxations in 
preconstricted PRAs, however the existence of these receptors in this preparation cannot 
be ruled out as they may possible be masked by the prevalent vasoconstrictor ETb 
receptor subtype, which was implied by the agonist potency profile of SXS6c > ET-1 = 
ET-3 shown in this preparation (chapter 4). The finding that LVD had differential 
influences on responses to ET-receptor agonists suggests that ETa a.nd ETp receptors 
may be differentially regulated in pathological conditions. Previous reports examining 
the role of ET-1 in heart failure are consistent with this. For example, blunted 
vasoconstriction to ET-1 with concomitant augmentation of vasoconstriction to SXS6c 
has been shown in forearm bloodflow measurements of heart failure patients (Love, et 
al., 1996) and in coronary vessels of a dog model of experimental congestive heart 
failure (Cannan, et a l, 1996). These studies may indicate a greater involvement of 
vasoconstrictor ETb receptors in the systemic and coronary vasculature secondary to 
LVD.
The studies employing the ET-receptor antagonists, discussed in chapter 5, show 
that the pharmacology of the ET-1 receptor in adult rabbit PRAs is extremely complex. 
There may be a quiescent ETa receptor which synergises with a vasoconstrictor ETb 
receptor which is BQ788 sensitive (SB209670 insensitive) and mediates responses to 
lower concentrations of ET-1. There is also a BQ788-insensitive receptor which is 
sensitive to SB209670 and mediates responses to higher ET-1 concentrations. These 
conclusions are indicated by my observations noted in 8 week sham-operated 
preparations. These were as follows: insensitivity to the ETa receptor selective 
antagonist FR139317, which if anything tended to augment the ET-1 induced response; 
sensitivity to BQ788 at low ET-1 concentrations and the sensitivity of the responses to 
higher ET-1 concentrations to SB209670.
In both sham-operated and coronary-ligated rabbit PRAs, 
FR139317 tended to potentiate ET-1-induced responses at higher concentrations and this 
tendency was also observed at lower ET-1 concentrations in the LVD vessels. Tliis
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finding may indicate the presence of a putative inhibitoiy ETa receptor. Evidence for 
such a receptor has been reported in several preparations, including rat fundic strip and 
PRAs (Gray & Clozel, 1993 a; McCulloch & MacLean, 1996). Clearly what would be of 
use to examine this possibility further would be a selective ETa receptor agonist, 
however as mentioned in chapter 1 such a compound has remained elusive. In 8 week 
coronary ligated rabbit PRAs, BQ788 and SB209670 also tended to potentiate responses 
to lower ET-1 concentrations. This suggests that after 8 weeks of coronary artery 
ligation, the BQ788-sensitive ETg receptor mediated response is now potentiated by 
both BQ788 and SB209670. These findings and the tendency of FR139317 to potentiate 
responses to lower ET-1 concentrations, may indicate the presence of inhibitory ETb 
and ETa receptors which may be upregulated in the vessels from LVD rabbits. This 
maybe a physiological compensatory mechanism in response to the early elevation in 
pulmonary pressure to maintain responses to ET-1 constant, particularly at the lower, 
physiological relevant, concentration range.
Results of several of my studies suggest the involvement of a heterogeneous 
population of ET-1 receptors in PRAs from the LVD model. This is indicated by (1) the 
biphasic nature of the cumulative concentration responses to ET-1 (discussed in chapter 
4), (2) the differential effects of selective antagonists on the two components of the ET-1 
cumulative concentration response curve (chapter 5), and (3) the two receptor sites 
demonstrated in competition radioligand binding studies using ET-1 on pulmonaiy 
artery membrane preparations. Regarding this latter finding, which is discussed in 
chapter 7, the first receptor population displayed ultrahigh affinity with the second also 
demonstrating high affinity in the nanomolar range. This may relate to a previous 
binding assay study which demonstrated high and low-affinity ETb receptors in brain 
tissue (Sokolovsky, et al., 1992). An essential and extremely interesting future study 
would be to confirm the presence of two distinct ET receptor populations by 
conventional protein purification and molecular cloning. Also future radioligand binding 
studies would include further competition analysis using selective ET-receptor 
antagonists to provide further insight into the receptor subtypes involved. However, I
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think that first and foremost, saturation studies in this preparation would be essential to 
obtain and Kp values and to answer the intriguing question of whether a difference 
in the number of ET-receptors exists between control and LVD preparations. Indeed 
such a possibility may be related to the apparent differences in the effect of the selective 
antagonists between control and experimental groups which were shown. From the 
binding studies which I did perform, the calculated Ki for site one (~6xlO"U]y[) is much 
lower than previously reported values for ETa and ETb receptors and such high affinity 
receptors were not evident in the functional studies performed. This population therefore 
appears to be of receptor subtype(s) which is not typical of an ETa or ETb receptor and 
which does not appear to mediate functional responses. Consistent with this is the 
findings of other investigators, discussed in chapters 5 and 7, who have also suggested 
the role of other receptor subtypes which do not fit current classification of ETa and 
ETb receptors (e.g. Sumner, et a l, 1992). This demonstrates the growing inadequacy of 
the current cloned ET receptors in accounting for many ET-receptor mediated responses 
which have been shown in this thesis and by other investigators.
Again on examining the vascular reactivity of PRAs from the second model, i.e., 
the transitional pulmonary vasculature from in utero to in vivo, I focused on ET-receptor 
mediated responses and the influence of developmental age. Primarily, a 
hypersensitivity to ETb receptor mediated vasoconstriction was evident within 0-24 
hours of birth. As discussed in chapter 9, PRAs from fetal to 4 day old rabbits are 
e qui sensitive to ET-1 and are 4-8 times more sensitive to this peptide than 7 day old and 
adult rabbit vessels, in which ET-1 is equipotent. Regarding the selective ETb receptor 
agonist, sensitivity to SXS6 c progressively increases in PRAs from fetal to 7 day old 
rabbits, and these have markedly greater sensitivity to SXS6c than PRAs from the adult. 
It therefore appears that sensitivity to ET-1 decreases over the first week of life and is 
increased compared to that obseived in the adult. An attenuation of SXS6c sensitivity to 
that observed in the adult must occur at a later age. The hypersensitivity to ETb receptor 
stimulation demonstrated in this preparation appears to exist at a time when plasma ET- 
1 levels have been shown to be elevated in the human neonate and animal models
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(Endo, et al, 1996; Noguchi, et a l, 1997) and when a comparatively greater number of 
ET receptors on the pulmonary vasculature have been demonstrated (Hislop, et a l,
1995). Maximal vasoconstrictor responses to SXS6 c are markedly greater in PRAs from 
0-24 hour and 4 day old rabbits. These functional differences are unlikely to be related 
to alterations in the mu scolarisation of arteries as previous studies show the rapid 
decrease in pulmonary pressure which occurs following birth, to be accompanied by a 
rapid decrease in the degree of arterial muscularisation (Haworth & Hislop, 1981; 
Michel, et a l, 1991). A more likely explanation is a structural or functional alteration in 
the ETb receptor with change in the vascular smooth muscle phenotype which occurs at 
this time (Frid, et a l, 1994). The findings of my own studies and those performed by 
other investigators in other species are of great importance, as an understanding of the 
role of ET-1 in the normal adaptation of the pulmonary circulation to extrauterine life is 
essential before attempting to examine alterations in pathophysiologic conditions. In 
examining the possible influence of ET-1 in persistent pulmonary hypertension of the 
newborn (PPHN), the potent effects of ET-1 demonstrated in the pulmonary vasculature 
indicates that the balance of ET-receptor subtypes would determine the overall 
functional response. To hypothesise, a lack or reduction of endothelial ETg receptors 
mediating vasodilation would presumably heighten the vasoconstrictor response, and 
this is observed in newborn piglets with hypoxic-induced PHT (Hislop, et a l, 1995). 
Similarly, an increase in functional contractility mediated by ETa or ETg receptors, 
would only add to the abnormal maintenance of a high pulmonary arterial pressure after 
birth which occurs in the pathological state.
In chapter 9, the effect of selective ET-receptor antagonists in the perinatal 
preparations are discussed. Interesting differences were noted between different 
developmental ages. The presence of BQ788 caused a marked increase in the ET-1 
response in PRAs from 0-24 hour and 4 day old rabbits. However, this was not evident 
in vessels from animals at other age points studied and further demonstrates an alteration 
in receptor subtype with age. This reason for this augmentation is unknown but may be 
due to blockade of endothelial ETg receptors mediating vasodilation via the release of
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NO and/or activation of K"  ^ channels, or inhibition of ET clearance receptors. Future 
studies in this model would have to include an examination of the possible existence of 
ET-receptor mediated vasoreiaxations. In addition, activation of ETb receptors has also 
been shown to release adrenomedullin (Jougasaki, et. a l, 1997), a recently discovered 
peptide which can produce pulmonaiy vasorelaxation (Shirai, et a l,  1997). This may 
represent an additional paraciine-autocrine role of the ETb receptor subtype.
Since similar preparations were examined from both the models studies, 
interesting comparisons can be made between them. Despite the apparent predominance 
of vasoconstrictor ETb receptors, BQ788 was unable to antagonise ET-1 mediated 
vasoconstrictions in 7 day old (chapter 9) and adult rabbit (chapter 5) PRAs and this has 
also been demonstrated in the larger pulmonary artery of this species (Hay, et a l, 1996). 
Ineffectiveness of FR139317 in inhibiting responses to ET-1 was also demonstrated in 
PRAs from 7 day old and adult rabbits. However, FR139317 had a significant inhibitory 
effect on ET-1 responses in the same preparation from newborn to 4 day old rabbits and 
BQ788 markedly antagonises ET-1 responses in PRAs from fetal to 4 day old rabbits 
(chapter 9). Also in neonatal preparations, a markedly greater inhibition was seen with 
the non-selective antagonist SB209670 compared with the effect of either ETa receptor 
inhibition (using FR139317) or ETb receptor inhibition (using BQ788) alone. Thus, it 
appears that in the fetus and in newborns younger than 7 days old, antagonism of either 
ETa or ETb receptor alone is sufficient to inhibit ET-1 responses and inhibition of both 
subtypes has a synergistic effect. However in PRAs from the older animal, interaction 
between the two subtypes seem to occur such that inhibition of either subtype alone is 
now insufficient to inhibit the response. The concept of receptor "crosstalk" has 
previously been proposed to explain the observation that dual inhibition of ETa and 
ETb receptors is required to inhibit ET-1 induced vasoconstrictions in various 
preparations, including the rabbit larger pulmonaiy artery (Fukuroda, et al, 1994c; 1996; 
Clozel & Gray, 1995). The mechanism for the plausible receptor crosstalk is not fully 
understood, however interaction at the signal transduction systems between ETa and 
ETb receptors has been suggested (Fukuroda, et a l, 1996; Ozaki, et a l,  1997).
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Comparing the results of the studies with antagonists in the two models (chapters 5 and 
9), the findings suggest that this "crosstalk" does not develop in rabbit PRAs until 
approximately 7 days after birth. One could suggest that this is manifested by a change 
in the smooth muscle phenotype particular to rabbit PRAs.
The altered ET-receptor mediated responses demonstrated here in the rabbit 
LVD model and with developmental age as well as by other investigators in other 
models, may also be due to an alteration in the clearance of ET-1. Numerous reports 
indicate the additional role of ETb receptors as clearance receptors. The pulmonary 
circulation has been shown to be the major site of ET-1 clearance in several animal 
models, including the rabbit (Rimmar & GilUs, et a l, 1989), and ETb receptors are 
exclusively responsible for pulmonary ET-1 removal in the dog in vivo (Dupius, et a l,
1996). Plasma ET-1 levels are elevated in heart failure and PHT of various aetiologies 
including neonatal and secondary to LVD (Noguchi, et a l, 1997; Cody, et al, 1992). 
Thus it is possible that reduced clearance of this peptide contributes to the 
hyperendothelinemia of these pathophysiologies. Hence, it is plausible that alterations in 
the expression or function of this ETb receptor subtype may be involved in the changes 
in ET-receptor mediated responses obseiwed in the perinatal pulmonary vasculature and 
secondary to LVD. As stated, in both these states marked stmctural alterations occur in 
the vascular smooth muscle , particularly at the level of the pulmonary arterial system I 
examined functionally. Thus a stmctural or functional change in the receptor may occur 
with the alteration in vascular smooth muscle. Plasticity of vascular smooth muscle 
expressing ETb receptors in other vascular regions, such as the cerebral circulation, has 
recently been shown in rat and man (Norel, et a l, 1996; Moller, et a l, 1997; Edvinsson, 
et al., 1997). A similar phenomenon may exist in the pulmonary vasculature and may 
relate to the functional results obseiwed.
In the rabbit LVD model, a similar contractile response to KCl was noted in 
PRAs from all stock/sham-operated and coronary-ligated rabbis (chapter 3), indicating 
that the alterations in functional responses were not related to changes the integrity or 
contractility of the vascular smooth muscle. Whilst in fetal and neonatal rabbit PRAs,
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discussed in chapter 8 , vasoconstrictor responses to KCl increased in magnitude with 
developmental age. This has also been shown in similar vessels from fetal and neonatal 
lambs (Dunn, et. al., 1989) and indicates smooth muscle extension or maturation in 
PRAs of the same anatomical location during the first week of extra-uterine life. Also in 
chapter 8 , contractile responses to NA were shown to be smaller in fetal rabbit PRAs 
compared to newborn vessels. This may relate to a reduced basal NO level in the fetus, 
as suggested by the relatively lesser effect of L-NAME in fetal compared to newborn 
vessels. However from examining ACh-induced relaxatory responses in preparations 
from the various developmental ages, an augmented agonist-induced NO level was 
indicated before birth by greater endothelium-dependent relaxations observed in fetal 
compared with newborn PRAs. Vasoconstrictions to receptor-mediated agents NA and 
5-HT were comparatively greater in the newborn compared with 7 day old vessels. This 
may be related to the apparent increased level of NO in the 7 day vessels compared with 
0-24 hr rabbit PRAs, which was indicated by the more pronounced effect of L-NAME 
on ET-receptor mediate responses in PRAs from 7 day old rabbits and the increased 
vasodilator response to ACh. Such an increase in NO would participate in the postnatal 
reduction of the pulmonary vascular resistance. Alternatively, these augmented 
contractile responses may reflect increased local ET-1 levels in the newborn as this 
peptide has previously been shown to potentiate the vasoconstrictor response to other 
agents (Tabuchi, et. a l, 1989) and elevated plasma ET-1 levels are reported in the first 
few days of life, in both human neonate and piglets (Endo, et a l, 1996; Levy, et a l, 
1995).
Again by drawing on the findings in the two different models I examined, and 
focusing on the difference in developmental age, i.e. fetal, neonatal and adult, intriguing 
differences in the vascular reactivity of rabbit PRAs are apparent with this variable. For 
example, in the studies of chapter 3 in adult PRAs, NA was found to be without effect 
and ACh evoked a contractile response. Whereas in fetal and neonatal PRAs, NA was 
able to evoke a contractile response, albeit small in magnitude, and ACh induced a 
concentration-dependent relaxatory response (chapter 8). Moreover a transition in the
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functional effect of ACh in this preparation was apparent with vasoconstriction being 
observed to higher ACh concentrations in 7 day old rabbit PRAs, thus similar to 
situation in the adult preparation. These intriguing findings may be related to alteration 
in receptor subtypes present on the vasculature with developmental age and, as 
previously discussed may be manifested through age-related changes in vascular smooth 
muscle phenotype. In addition, in both models I examined the influence of L-NAME on 
ET-1 and SXS6 c-induced responses. Not only were the nature of the CCRCs to these 
peptides influenced by developmental age, but L-NAME had differential effects on 
these responses depending on this variable. No significant effect on response to either 
peptide was evident in fetal rabbit PRAs, whereas the ET-1 response was markedly 
augmented in newborn rabbit vessels. As discussed in chapter 8 , this augmentation was 
heightened in 4 day old rabbit preparations and was greatest by 7 days after birth. In 
comparison from the studies of chapter 6 in adult PRAs, the ability of L-NAME (NO) to 
modulate ET-receptor mediated responses was only pronounced in LVD animals. This 
comparatively greater role of NO on functional responses in the neonatal PRAs is 
consistent with its putative role in the rapid and progressive reduction of pulmonary 
vascular resistance following birth, as it takes on its low pressure and low resistance 
characteristics.
Habib et al (1994) demonstrated an upregulation of NOS in heart failure patients. 
In the rabbit coronary-ligation model, L-NAME markedly potentiated ET-1- and 
SXS6 c-induced responses in PRAs from LVD rabbits. As discussed in chapter 6 , this 
suggests an increase in NO production associated with the development of PHT in these 
animals. This may be basally released NO as a greater percentage of PRAs from 
coronary-ligated rabbits demonstrated an increase in tone from baseline tension in 
response to L-NAME alone compared to age matched sham-operated animals.
Alternatively, the greater NO production in PRAs from 8 week LVD animals 
could be NO released via stimulation of endothelial ETb receptors. Although such 
receptors could not be shown to induce a vasoreiaxations in this preparation, an 
upregulation of endothelial ETb receptors in 8 week LVD animals is indicated by
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several ET receptor antagonist results in isolated PRAs (discussed in chapter 5). Also, 
PRAs from LVD animals exhibited decreased sensitivity to SNP compared to vessels 
from sham-operated animals. From these findings with L-NAME (chapter 6) and SNP 
(chapter 3) in this model and those of others in man (Needleman & Johnson, 1973), it 
may be postulated when there is increased stimulation of NO, the vascular smooth 
muscle compensates with reduced sensitivity to NO, thus explaining the attenuated SNP 
response observed in LVD animals. A previous study shows that the reverse case may 
hold when eNOS is inhibited, such that pulmonary vascular smooth muscle becomes 
more sensitive to SNP in chronic L-NAME treated rats (MacLean & MacMillan, 1993). 
This increase in NO may act as a compensator mechanism in the early stages of 
increased pulmonaiy arterial pressure. However these findings remain controversial as 
other studies implicate decreased NO in pathological conditions, e.g. an impairment of 
NO production was reported in isolated pulmonary arteries from patients with chronic 
obstructive lung disease (Dinh-Xuan, ei a l, 1993). In addition, in isolated aorta from a 
chronic heart failure rat model, stimulated NO release was unaffected but basal NO 
levels were shown to be decreased compared with control preparations (Teerlink, et al, 
1994b). These latter findings may indicate a lack of NO as being partly responsible for 
the manifestation of the pathological state. However the differential conclusions, that is 
decreased NO implicated in manifestation or increased NO level with possible 
compensatory role, are most probably related to differences in species, the pathological 
state, the vascular bed involved and the nature of the models.
With regard to my own findings, an increased NO production may also account 
for the attenuated vasoconstriction to sumatriptan and 5-HT in PRAs from 8 week 
coronary artery ligated animals compared to sham-operated rabbit vessels which was 
demonstrated in chapter 3. However, as discussed this may also be due to an alteration 
in 5-HT receptors, in particular S-HTjp) receptors, in vessels from LVD animals. Further 
studies using selective antagonists are required to elucidate the receptor subtypes 
involved and to examine further the effect of PHT secondary to LVD. A previous in vivo 
study using this rabbit coronary ligation model demonstrated an increased pulmonary
329
pressor response to i.v. administered 5-HT in 8 week ligated rabbits when compared to 
sham-operated animals (Deuchar, et a l, 1997). Differing results between in vitro and in 
vivo studies of 5-HT have also been shown in the human pulmonary vasculature 
(Raffestin, et a l, 1985; Harris, et al,, 1960). When analysing the results of in vivo 
studies a role of parenchymal and/or vascular agents cannot distinguished, and the 
overall effect will represent the sum of the responses throughout the pulmonary 
vasculature; hence will show the balancing between the vasoconstrictor and vasodilator 
effects of 5-HT. Moreover, in contrast to a previous report in larger pulmonary artery of 
the rabbit where a 5-HT2A type receptor appears to mainly involved in the 
vasoconstriction (Morecroft & MacLean, 1995b), a definite role of 5-HTi-like receptors 
was indicated by my own studies in the PRAs of this species. Again comparing these 
current findings with those previously reported in the larger vessel, these smaller 
muscular arteries have a comparatively greater sensitivity to 5-HT. These findings 
indicate differences in 5-HT responses depending on vessel size, as has been previously 
demonstrated in rat pulmonary arteries (MacLean et al, 1996b).
Another aim of this project was to research the role of intracellular cyclic 
nucleotides in rabbit PRAs and examine the possible effect of LVD using the rabbit 
model, under both basal and ET-1-stimulated conditions. Unfortunately due to the 
variability noted between tissues in the individual groups and thus lack of statistical 
evidence, no definite conclusions can be discussed from the findings shown in chapter 7. 
Measurement of intracellular cyclic nucleotide levels showed that basal levels and ET-1- 
induced levels of cGMP tended to be greater in arteries from coronary-ligated compared 
to sham-operated rabbits. Basal and forskolin-stimulated cAMP levels also tended to be 
greater in LVD rabbit preparations and ET-1 inhibited forskolin-stimulated cAMP in 
vessels from all animals. Further studies are required to elucidate if indeed [cAMPji or 
[cGMPji is altered in the LVD state and if it is involved in the mechanism of action of 
ET-receptor mediated responses in this preparation. Future studies would include 
examination of G-proteins involved and measurement of IP3 levels to assess the 
involvement of the PIP2 system. A study examining the possible interaction of ETa and
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ETb receptors at the intracellular level and possible alterations secondary to LVD and 
with developmental age would prove most interesting. The results of such a study would 
be intriguing, particularly if taken in context with the findings of the studies with ET- 
receptor antagonists discussed in chapter 5, which may suggest the occurrence of 
receptor "crosstalk" in adult rabbit PRAs.
The animal models I used allowed me to examine my particular interests more 
extensively however, obviously all these studies have been perfoimed with their relation 
to the situation in man in mind. Thus it is crucial to compare the responses in animal 
models with those in similar preparations obtained from human tissue. In chapter 5, 
examination of human PRAs demonstrated a similar sensitivity to ET-1 and also exhibit 
a biphasic response to this peptide, as observed in rabbit vessels of similar diameter. 
Due to the infrequency of available human tissue, only limited studies with ET receptor 
antagonists could be carried out, And I again I focused on those compounds examined in 
the animal models. The response to lower ET-1 concentration appeared to be mediated 
by vasoconstrictor ETb receptors, as indicated by the inhibitory effect of BQ788 in this 
range. Whilst previous studies in this preparation demonstrated the involvement of ETa 
receptors in vasoconstrictor responses to higher ET-1 concentrations (McCulloch & 
MacLean, 1995). In my own studies discussed in chapter 5, the non-selective antagonist 
SB209670 is the first compound shown to successfully inhibit the entire ET-1 response 
in this preparation. It is not yet clear if a similar situation occurs in human pulmonaiy 
hypertensive states. Of immense interest for future studies, would be to examine ET- 
receptor mediated responses in pulmonaiy arteries from patients with PHT. This would 
assess any changes in the vascular reactivity to ET-1, and would resolve possible 
alterations in the ET-receptor subtypes present which may occur. As is suggested in 
chapters 5 for rabbit PRAs, the difference in effectiveness of different antagonists may 
be explained by a heterogeneous population of ETb receptors, which are diverse in 
terms of there sensitivity to particular antagonists. Obviously support for this hypothesis 
requires molecular biological evidence of the nature and location of ET-receptor 
subtypes on the pulmonary vasculature.
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The ever growing literature from animal models of PHT indicates that alterations 
of ET-receptor mediated vascular function in heart failure may depend on the 
experimental model, the duration and the severity of the disease, and the type of 
preparation studied. These rapidly accumulating studies imply the possible use of ET 
receptor antagonists as a novel therapy in the treatment of PHT of various aetiologies. 
However the suitability of a non-selective antagonist or one specific for ETa receptors 
remains controversial, as success in ameliorating the features of this condition has been 
reported with both types (e.g. Kiowski, et al., 1995; Sakai, et al., 1996). The 
contribution of ET-receptor subtypes to the overall response varies with developmental 
age and a marked hypersensitivity to vasoconstrictor ETg receptor stimulation is 
apparent in newborn rabbit PRAs. In addition, the results of antagonists studies in the 
rabbit model of LVD highlights the concern that the effectiveness of ET-receptor 
antagonism therapeutically will depend on the level of endothelial ETb receptor 
stimulation and on the relative selectivity for endothelial and smooth muscle ETb 
receptor subtypes.
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